
<html lang="en"     class="pb-page"  data-request-id="f62dbd72-ac9c-46ac-9ade-150dbb9ac53d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;article:article:10.1021/acs.jmedchem.0c01264;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models" /></meta><meta name="dc.Creator" content="Manojkumar R.  Shukla" /></meta><meta name="dc.Creator" content="Sukanya  Patra" /></meta><meta name="dc.Creator" content="Mahip  Verma" /></meta><meta name="dc.Creator" content="Gayathri  Sadasivam" /></meta><meta name="dc.Creator" content="Nirmal  Jana" /></meta><meta name="dc.Creator" content="Sachin J.  Mahangare" /></meta><meta name="dc.Creator" content="Prashant  Vidhate" /></meta><meta name="dc.Creator" content="Dipak  Lagad" /></meta><meta name="dc.Creator" content="Anand  Tarage" /></meta><meta name="dc.Creator" content="Murthy  Cheemala" /></meta><meta name="dc.Creator" content="Chaitanya  Kulkarni" /></meta><meta name="dc.Creator" content="Shankar  Bhagwat" /></meta><meta name="dc.Creator" content="Vinod D.  Chaudhari" /></meta><meta name="dc.Creator" content="Majid  Sayyed" /></meta><meta name="dc.Creator" content="Vipul  Pachpute" /></meta><meta name="dc.Creator" content="Ramesh  Phadtare" /></meta><meta name="dc.Creator" content="Gopal  Gole" /></meta><meta name="dc.Creator" content="Samiron  Phukan" /></meta><meta name="dc.Creator" content="Brahmam  Sunkara" /></meta><meta name="dc.Creator" content="Charudatt  Samant" /></meta><meta name="dc.Creator" content="Manisha  Shingare" /></meta><meta name="dc.Creator" content="Aditya  Naik" /></meta><meta name="dc.Creator" content="Sneha  Trivedi" /></meta><meta name="dc.Creator" content="Ajit Kumar  Marisetti" /></meta><meta name="dc.Creator" content="Madhusudhan  Reddy" /></meta><meta name="dc.Creator" content="Milind  Gholve" /></meta><meta name="dc.Creator" content="Nilesh  Mahajan" /></meta><meta name="dc.Creator" content="Sudeep  Sabde" /></meta><meta name="dc.Creator" content="Vinod  Patil" /></meta><meta name="dc.Creator" content="Dipak  Modi" /></meta><meta name="dc.Creator" content="Maneesh  Mehta" /></meta><meta name="dc.Creator" content="Prashant  Nigade" /></meta><meta name="dc.Creator" content="Kaustubh  Tamane" /></meta><meta name="dc.Creator" content="Swati  Tota" /></meta><meta name="dc.Creator" content="Hemant  Goyal" /></meta><meta name="dc.Creator" content="Harish  Volam" /></meta><meta name="dc.Creator" content="Shashikant  Pawar" /></meta><meta name="dc.Creator" content="Prajakta  Ahirrao" /></meta><meta name="dc.Creator" content="Lal  Dinchhana" /></meta><meta name="dc.Creator" content="Sadanand  Mallurwar" /></meta><meta name="dc.Creator" content="Atul  Akarte" /></meta><meta name="dc.Creator" content="Anand  Bokare" /></meta><meta name="dc.Creator" content="Rupesh  Kanhere" /></meta><meta name="dc.Creator" content="Neetinkumar  Reddy" /></meta><meta name="dc.Creator" content="Sarita  Koul" /></meta><meta name="dc.Creator" content="Manoj  Dandekar" /></meta><meta name="dc.Creator" content="Minakshi  Singh" /></meta><meta name="dc.Creator" content="Peter R.  Bernstein" /></meta><meta name="dc.Creator" content="Lakshmi  Narasimham" /></meta><meta name="dc.Creator" content="Mandar  Bhonde" /></meta><meta name="dc.Creator" content="Jayasagar  Gundu" /></meta><meta name="dc.Creator" content="Rajan  Goel" /></meta><meta name="dc.Creator" content="Sanjeev  Kulkarni" /></meta><meta name="dc.Creator" content="Sharad  Sharma" /></meta><meta name="dc.Creator" content="Rajender Kumar  Kamboj" /></meta><meta name="dc.Creator" content="Venkata P.  Palle" /></meta><meta name="dc.Description" content="PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness agains..." /></meta><meta name="Description" content="PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness agains..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 2, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01264" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01264" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01264" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01264" /></link>
        
    
    

<title>Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01264" /></meta><meta property="og:title" content="Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0019.jpeg" /></meta><meta property="og:description" content="PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties: potency, isoform selectivity, and/or pharmacokinetic profile. To come up with a PI3Kδ inhibitor that overcomes all these deficiencies, a pharmacophoric expansion strategy was employed. Herein, we describe a systematic transformation of a “three-blade propeller” shaped lead, 2,3-disubstituted quinolizinone 11, through a 1,2-disubstituted quinolizinone 20 to a novel “four-blade propeller” shaped 1,2,3-trisubstituted quinolizinone 34. Compound 34 has excellent potency, isoform selectivity, metabolic stability across species, and exhibited a favorable pharmacokinetic profile. Compound 34 also demonstrated a differentiated efficacy profile in human germinal center B and activated B cell-DLBCL cell lines and xenograft models. Compound 34 qualifies for further evaluation as a candidate for monotherapy or in combination with other targeted agents in DLBCLs and other forms of iNHL." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01264"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01264">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01264&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01264&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01264&amp;href=/doi/10.1021/acs.jmedchem.0c01264" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14700-14723</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01242" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01287" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of a Potent and Selective PI3Kδ Inhibitor (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Manojkumar R. Shukla</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manojkumar R. Shukla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#d7bab6b9b8bdbca2bab6a5a4bfa2bcbbb697bba2a7beb9f9b4b8ba"><span class="__cf_email__" data-cfemail="9ef3fff0f1f4f5ebf3ffecedf6ebf5f2ffdef2ebeef7f0b0fdf1f3">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manojkumar+R.++Shukla">Manojkumar R. Shukla</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1735-7965" title="Orcid link">http://orcid.org/0000-0003-1735-7965</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sukanya Patra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sukanya Patra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sukanya++Patra">Sukanya Patra</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mahip Verma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mahip Verma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mahip++Verma">Mahip Verma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gayathri Sadasivam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gayathri Sadasivam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gayathri++Sadasivam">Gayathri Sadasivam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nirmal Jana</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nirmal Jana</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nirmal++Jana">Nirmal Jana</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sachin J. Mahangare</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sachin J. Mahangare</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sachin+J.++Mahangare">Sachin J. Mahangare</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Prashant Vidhate</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Prashant Vidhate</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Prashant++Vidhate">Prashant Vidhate</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dipak Lagad</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dipak Lagad</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dipak++Lagad">Dipak Lagad</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anand Tarage</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anand Tarage</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anand++Tarage">Anand Tarage</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Murthy Cheemala</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Murthy Cheemala</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Murthy++Cheemala">Murthy Cheemala</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chaitanya Kulkarni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chaitanya Kulkarni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chaitanya++Kulkarni">Chaitanya Kulkarni</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shankar Bhagwat</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shankar Bhagwat</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shankar++Bhagwat">Shankar Bhagwat</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vinod D. Chaudhari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vinod D. Chaudhari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vinod+D.++Chaudhari">Vinod D. Chaudhari</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Majid Sayyed</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Majid Sayyed</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Majid++Sayyed">Majid Sayyed</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vipul Pachpute</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vipul Pachpute</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vipul++Pachpute">Vipul Pachpute</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ramesh Phadtare</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ramesh Phadtare</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ramesh++Phadtare">Ramesh Phadtare</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gopal Gole</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gopal Gole</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gopal++Gole">Gopal Gole</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samiron Phukan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samiron Phukan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samiron++Phukan">Samiron Phukan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brahmam Sunkara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brahmam Sunkara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brahmam++Sunkara">Brahmam Sunkara</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charudatt Samant</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charudatt Samant</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charudatt++Samant">Charudatt Samant</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manisha Shingare</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manisha Shingare</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manisha++Shingare">Manisha Shingare</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aditya Naik</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aditya Naik</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aditya++Naik">Aditya Naik</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sneha Trivedi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sneha Trivedi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sneha++Trivedi">Sneha Trivedi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ajit Kumar Marisetti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ajit Kumar Marisetti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ajit+Kumar++Marisetti">Ajit Kumar Marisetti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Madhusudhan Reddy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Madhusudhan Reddy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Madhusudhan++Reddy">Madhusudhan Reddy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Milind Gholve</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Milind Gholve</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Milind++Gholve">Milind Gholve</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nilesh Mahajan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nilesh Mahajan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nilesh++Mahajan">Nilesh Mahajan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sudeep Sabde</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sudeep Sabde</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sudeep++Sabde">Sudeep Sabde</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vinod Patil</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vinod Patil</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vinod++Patil">Vinod Patil</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dipak Modi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dipak Modi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dipak++Modi">Dipak Modi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maneesh Mehta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maneesh Mehta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maneesh++Mehta">Maneesh Mehta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Prashant Nigade</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Prashant Nigade</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Prashant++Nigade">Prashant Nigade</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kaustubh Tamane</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kaustubh Tamane</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kaustubh++Tamane">Kaustubh Tamane</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Swati Tota</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Swati Tota</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Swati++Tota">Swati Tota</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hemant Goyal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hemant Goyal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hemant++Goyal">Hemant Goyal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Harish Volam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harish Volam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harish++Volam">Harish Volam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shashikant Pawar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shashikant Pawar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shashikant++Pawar">Shashikant Pawar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Prajakta Ahirrao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Prajakta Ahirrao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Prajakta++Ahirrao">Prajakta Ahirrao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lal Dinchhana</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lal Dinchhana</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lal++Dinchhana">Lal Dinchhana</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sadanand Mallurwar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sadanand Mallurwar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sadanand++Mallurwar">Sadanand Mallurwar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Atul Akarte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Atul Akarte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Atul++Akarte">Atul Akarte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anand Bokare</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anand Bokare</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anand++Bokare">Anand Bokare</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rupesh Kanhere</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rupesh Kanhere</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rupesh++Kanhere">Rupesh Kanhere</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neetinkumar Reddy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neetinkumar Reddy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neetinkumar++Reddy">Neetinkumar Reddy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarita Koul</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarita Koul</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarita++Koul">Sarita Koul</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manoj Dandekar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manoj Dandekar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manoj++Dandekar">Manoj Dandekar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Minakshi Singh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Minakshi Singh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Minakshi++Singh">Minakshi Singh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter R. Bernstein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter R. Bernstein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter+R.++Bernstein">Peter R. Bernstein</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0407-9150" title="Orcid link">http://orcid.org/0000-0003-0407-9150</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lakshmi Narasimham</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lakshmi Narasimham</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lakshmi++Narasimham">Lakshmi Narasimham</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mandar Bhonde</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mandar Bhonde</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mandar++Bhonde">Mandar Bhonde</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jayasagar Gundu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jayasagar Gundu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jayasagar++Gundu">Jayasagar Gundu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rajan Goel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rajan Goel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rajan++Goel">Rajan Goel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sanjeev Kulkarni</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sanjeev Kulkarni</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sanjeev++Kulkarni">Sanjeev Kulkarni</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sharad Sharma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sharad Sharma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sharad++Sharma">Sharad Sharma</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rajender Kumar Kamboj</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rajender Kumar Kamboj</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rajender+Kumar++Kamboj">Rajender Kumar Kamboj</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Venkata P. Palle</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Venkata P. Palle</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Novel Drug Discovery and Development, Lupin Ltd., Lupin Research Park, Survey No. 46 A/47A, Village Nande, Taluka Mulshi, Pune 412115, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Venkata+P.++Palle">Venkata P. Palle</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01264&amp;href=/doi/10.1021%2Facs.jmedchem.0c01264" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14700–14723</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 1, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 July 2020</li><li><span class="item_label"><b>Published</b> online</span>2 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01264" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01264</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14700%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DManojkumar%2BR.%2BShukla%252C%2BSukanya%2BPatra%252C%2BMahip%2BVerma%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01264%26title%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSelective%2BPI3K%25CE%25B4%2BInhibitor%2B%2528S%2529-2%252C4-Diamino-6-%2528%25281-%25287-fluoro-1-%25284-fluorophenyl%2529-4-oxo-3-phenyl-4H-quinolizin-2-yl%2529ethyl%2529amino%2529pyrimidine-5-carbonitrile%2Bwith%2BImproved%2BPharmacokinetic%2BProfile%2Band%2BSuperior%2BEfficacy%2Bin%2BHematological%2BCancer%2BModels%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14723%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01264"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">996</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01264" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Manojkumar&quot;,&quot;last_name&quot;:&quot;R. Shukla&quot;},{&quot;first_name&quot;:&quot;Sukanya&quot;,&quot;last_name&quot;:&quot;Patra&quot;},{&quot;first_name&quot;:&quot;Mahip&quot;,&quot;last_name&quot;:&quot;Verma&quot;},{&quot;first_name&quot;:&quot;Gayathri&quot;,&quot;last_name&quot;:&quot;Sadasivam&quot;},{&quot;first_name&quot;:&quot;Nirmal&quot;,&quot;last_name&quot;:&quot;Jana&quot;},{&quot;first_name&quot;:&quot;Sachin&quot;,&quot;last_name&quot;:&quot;J. Mahangare&quot;},{&quot;first_name&quot;:&quot;Prashant&quot;,&quot;last_name&quot;:&quot;Vidhate&quot;},{&quot;first_name&quot;:&quot;Dipak&quot;,&quot;last_name&quot;:&quot;Lagad&quot;},{&quot;first_name&quot;:&quot;Anand&quot;,&quot;last_name&quot;:&quot;Tarage&quot;},{&quot;first_name&quot;:&quot;Murthy&quot;,&quot;last_name&quot;:&quot;Cheemala&quot;},{&quot;first_name&quot;:&quot;Chaitanya&quot;,&quot;last_name&quot;:&quot;Kulkarni&quot;},{&quot;first_name&quot;:&quot;Shankar&quot;,&quot;last_name&quot;:&quot;Bhagwat&quot;},{&quot;first_name&quot;:&quot;Vinod&quot;,&quot;last_name&quot;:&quot;D. Chaudhari&quot;},{&quot;first_name&quot;:&quot;Majid&quot;,&quot;last_name&quot;:&quot;Sayyed&quot;},{&quot;first_name&quot;:&quot;Vipul&quot;,&quot;last_name&quot;:&quot;Pachpute&quot;},{&quot;first_name&quot;:&quot;Ramesh&quot;,&quot;last_name&quot;:&quot;Phadtare&quot;},{&quot;first_name&quot;:&quot;Gopal&quot;,&quot;last_name&quot;:&quot;Gole&quot;},{&quot;first_name&quot;:&quot;Samiron&quot;,&quot;last_name&quot;:&quot;Phukan&quot;},{&quot;first_name&quot;:&quot;Brahmam&quot;,&quot;last_name&quot;:&quot;Sunkara&quot;},{&quot;first_name&quot;:&quot;Charudatt&quot;,&quot;last_name&quot;:&quot;Samant&quot;},{&quot;first_name&quot;:&quot;Manisha&quot;,&quot;last_name&quot;:&quot;Shingare&quot;},{&quot;first_name&quot;:&quot;Aditya&quot;,&quot;last_name&quot;:&quot;Naik&quot;},{&quot;first_name&quot;:&quot;Sneha&quot;,&quot;last_name&quot;:&quot;Trivedi&quot;},{&quot;first_name&quot;:&quot;Ajit&quot;,&quot;last_name&quot;:&quot;Kumar Marisetti&quot;},{&quot;first_name&quot;:&quot;Madhusudhan&quot;,&quot;last_name&quot;:&quot;Reddy&quot;},{&quot;first_name&quot;:&quot;Milind&quot;,&quot;last_name&quot;:&quot;Gholve&quot;},{&quot;first_name&quot;:&quot;Nilesh&quot;,&quot;last_name&quot;:&quot;Mahajan&quot;},{&quot;first_name&quot;:&quot;Sudeep&quot;,&quot;last_name&quot;:&quot;Sabde&quot;},{&quot;first_name&quot;:&quot;Vinod&quot;,&quot;last_name&quot;:&quot;Patil&quot;},{&quot;first_name&quot;:&quot;Dipak&quot;,&quot;last_name&quot;:&quot;Modi&quot;},{&quot;first_name&quot;:&quot;Maneesh&quot;,&quot;last_name&quot;:&quot;Mehta&quot;},{&quot;first_name&quot;:&quot;Prashant&quot;,&quot;last_name&quot;:&quot;Nigade&quot;},{&quot;first_name&quot;:&quot;Kaustubh&quot;,&quot;last_name&quot;:&quot;Tamane&quot;},{&quot;first_name&quot;:&quot;Swati&quot;,&quot;last_name&quot;:&quot;Tota&quot;},{&quot;first_name&quot;:&quot;Hemant&quot;,&quot;last_name&quot;:&quot;Goyal&quot;},{&quot;first_name&quot;:&quot;Harish&quot;,&quot;last_name&quot;:&quot;Volam&quot;},{&quot;first_name&quot;:&quot;Shashikant&quot;,&quot;last_name&quot;:&quot;Pawar&quot;},{&quot;first_name&quot;:&quot;Prajakta&quot;,&quot;last_name&quot;:&quot;Ahirrao&quot;},{&quot;first_name&quot;:&quot;Lal&quot;,&quot;last_name&quot;:&quot;Dinchhana&quot;},{&quot;first_name&quot;:&quot;Sadanand&quot;,&quot;last_name&quot;:&quot;Mallurwar&quot;},{&quot;first_name&quot;:&quot;Atul&quot;,&quot;last_name&quot;:&quot;Akarte&quot;},{&quot;first_name&quot;:&quot;Anand&quot;,&quot;last_name&quot;:&quot;Bokare&quot;},{&quot;first_name&quot;:&quot;Rupesh&quot;,&quot;last_name&quot;:&quot;Kanhere&quot;},{&quot;first_name&quot;:&quot;Neetinkumar&quot;,&quot;last_name&quot;:&quot;Reddy&quot;},{&quot;first_name&quot;:&quot;Sarita&quot;,&quot;last_name&quot;:&quot;Koul&quot;},{&quot;first_name&quot;:&quot;Manoj&quot;,&quot;last_name&quot;:&quot;Dandekar&quot;},{&quot;first_name&quot;:&quot;Minakshi&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;R. Bernstein&quot;},{&quot;first_name&quot;:&quot;Lakshmi&quot;,&quot;last_name&quot;:&quot;Narasimham&quot;},{&quot;first_name&quot;:&quot;Mandar&quot;,&quot;last_name&quot;:&quot;Bhonde&quot;},{&quot;first_name&quot;:&quot;Jayasagar&quot;,&quot;last_name&quot;:&quot;Gundu&quot;},{&quot;first_name&quot;:&quot;Rajan&quot;,&quot;last_name&quot;:&quot;Goel&quot;},{&quot;first_name&quot;:&quot;Sanjeev&quot;,&quot;last_name&quot;:&quot;Kulkarni&quot;},{&quot;first_name&quot;:&quot;Sharad&quot;,&quot;last_name&quot;:&quot;Sharma&quot;},{&quot;first_name&quot;:&quot;Rajender&quot;,&quot;last_name&quot;:&quot;Kumar Kamboj&quot;},{&quot;first_name&quot;:&quot;Venkata&quot;,&quot;last_name&quot;:&quot;P. Palle&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14700-14723&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01264&quot;},&quot;abstract&quot;:&quot;PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties: potency, isoform selectivity, and/or pharmacokinetic profile. To come up with a PI3Kδ inhibitor that overcomes all these deficiencies, a pharmacophoric expansion strategy was employed. Herein, we describe a systematic transformation of a “three-blade propeller” shaped lead, 2,3-disubstituted quinolizinone 11, through a 1,2-disubstituted quinolizinone 20 to a novel “four-blade propeller” shaped 1,2,3-trisubstituted quinolizinone 34. Compound 34 has excellent potency, isoform selectivity, metabolic stability across species, and exhibited a favorable pharmacokinetic profile. Compound 34 also demonstrated a differentiated efficacy profile in human germinal center B and activated B cell-DLBCL cell lines and xenograft models. Compound 34 qualifies for further evaluation &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01264&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01264" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01264&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01264" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01264&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01264" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01264&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01264&amp;href=/doi/10.1021/acs.jmedchem.0c01264" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01264" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01264" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01264%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DShukla%26date%3D2020%26atitle%3DDiscovery%2Bof%2Ba%2BPotent%2Band%2BSelective%2BPI3K%25CE%25B4%2BInhibitor%2B%2528S%2529-2%252C4-Diamino-6-%2528%25281-%25287-fluoro-1-%25284-fluorophenyl%2529-4-oxo-3-phenyl-4H-quinolizin-2-yl%2529ethyl%2529amino%2529pyrimidine-5-carbonitrile%2Bwith%2BImproved%2BPharmacokinetic%2BProfile%2Band%2BSuperior%2BEfficacy%2Bin%2BHematological%2BCancer%2BModels%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14700%26epage%3D14723%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (6)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=291241" title="Phenyls">Phenyls</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties: potency, isoform selectivity, and/or pharmacokinetic profile. To come up with a PI3Kδ inhibitor that overcomes all these deficiencies, a pharmacophoric expansion strategy was employed. Herein, we describe a systematic transformation of a “three-blade propeller” shaped lead, 2,3-disubstituted quinolizinone <b>11</b>, through a 1,2-disubstituted quinolizinone <b>20</b> to a novel “four-blade propeller” shaped 1,2,3-trisubstituted quinolizinone <b>34</b>. Compound <b>34</b> has excellent potency, isoform selectivity, metabolic stability across species, and exhibited a favorable pharmacokinetic profile. Compound <b>34</b> also demonstrated a differentiated efficacy profile in human germinal center B and activated B cell-DLBCL cell lines and xenograft models. Compound <b>34</b> qualifies for further evaluation as a candidate for monotherapy or in combination with other targeted agents in DLBCLs and other forms of iNHL.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Targeting key signaling nodes of BCR, RTK, and chemokine receptor signaling, such as Bruton’s tyrosine kinase (BTK) and phosphatidylinositol 3-kinase (PI3K), have led to the approval of drugs for hematological malignancies<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> as well as solid tumors.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Phosphatidylinositol 3-kinases (PI3Ks) are involved in the signal transduction of numerous cellular functions and known to play a central role in regulating a wide range of cellular processes including metabolism, survival, motility, differentiation, and cell activation.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Dysfunctional regulation of the PI3K pathway results in a variety of disease states including several cancers, autoimmune disorders, and inflammation.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Class 1 PI3Ks comprise of four isoforms: PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ. PI3Kα and -β are expressed ubiquitously in all tissues, whereas the expression of isoforms PI3Kδ and -γ is restricted to leukocytes.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Pan PI3K inhibitors have demonstrated efficacy in cancer patients in clinical trials.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> However, the utility of such compounds was limited by side effects such as hyperglycemia, maculopapular rash, and gastrointestinal intolerance.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10 ref11">(7−11)</a> In an attempt to mitigate dose-limiting toxicity, recent efforts have focused upon isoform-selective PI3K inhibitors. PI3Kδ overexpression and hyperactivation have been observed in patients with CLL, NHL, and multiple myeloma.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Thus, targeting of PI3Kδ emerged as a novel therapeutic strategy for the treatment of B-cell proliferative disorders.</div><div class="NLM_p">PI3K inhibitors that have been approved or are in clinical development can be classified based on their selectivity profile toward various PI3K isoforms. Idelalisib (<b>1</b>) (Gilead Sciences, Inc.), a prototypical PI3Kδ inhibitor, is approved for relapsed cancers such as CLL, small lymphocytic lymphoma (SLL), and follicular lymphoma (FL).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Emergence of respiratory infections and increased rates of death led to halting of 6 clinical trials with idelalisib in CLL, SLL, and iNHL, warranting review of strategies to mitigate class specific toxicities and further advocating the development of safer PI3Kδ inhibitors.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Dual PI3Kγδ inhibitors [<i>e.g.</i>, IPI-145 (<b>2</b>)] with narrow potency margins between PI3Kδ and PI3Kγ isoforms are reported to have higher incidences of ≥grade 3 adverse events and dose-limiting toxicities.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> A structurally distinct dual PI3Kδ and CK1 inhibitor umbralisib (<b>3</b>), despite higher dose levels of 800 mg, q.d., reported good tolerability and much lower incidence of autoimmune mediated toxicities.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Tenalisib, another dual PI3Kγδ inhibitor from Rhizen Pharmaceuticals, received Orphan designation, and clinical trials are ongoing as monotherapy and in combination with pembrolizumab for the treatment of Hodgkin’s lymphoma.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> AMG-319, a compound structurally similar to idelalisib, has also entered phase II testing against CLL and HNSCC.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, the trial against HNSCC has been terminated for safety reasons. These findings collectively show strong structural dependencies in delineating on-target activity versus off-target toxicity profiles for PI3Kδ inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of known PI3Kδ inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Restricted indications for PI3Kδ inhibitors and relegation to third-line use prompt the development of newer PI3Kδ inhibitors with better differentiated efficacy and toxicity profiles.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> Emerging research indicates the desirability of maintaining high isoform (PI3Kδ) selectivity at systemic concentration to differentiate between adequate target-engagement and display of toxicity.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Thus, we envisaged to identify a potent and selective PI3Kδ inhibitor, which would also have superior pharmacokinetic properties to allow a once daily dosing regimen.</div><div class="NLM_p">Selective PI3Kδ inhibitors reported thus far structurally resemble a “three-blade propeller” maintaining approximately 120° angle with respect to each other. Typically, these blades consist of a bicyclic central core, a hinge binding moiety, and an aromatic ring.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25−27)</a> The protein tolerates only small or no substituent on the C-3-aryl group and has limited scope for hinge group modifications, posing further challenges to achieve good selectivity and optimal pharmacokinetic profiles. Thus, we wanted to redefine the pharmacophoric features to further optimize isoform selectivity and pharmacokinetic profile. We performed multiple iterations of structure activity relationship analysis to obtain compound <b>34</b> as a novel PI3Kδ inhibitor with good potency, selectivity, favorable PK properties, robust efficacy, and safety profile.</div><div class="NLM_p last">Compound <b>34</b> has a novel “four-blade propeller” shape that is responsible for the selective inhibition of the PI3Kδ subunit over other PI3K subunits in biochemical and cell-based assays and has potent anticancer activity in human DLBCL cell lines. We further demonstrate robust antitumor efficacy in preclinical xenograft models of both germinal center B (GCB)- and activated B cell (ABC)-DLBCL at once daily dosing regimens.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Design and Evaluation of Initial PI3Kδ Inhibitors</h3><div class="NLM_p">Medicinal chemistry design and modelling efforts focused on designing compounds with additional anchoring points as compared to existing PI3Kδ inhibitors (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). These efforts led to the identification of the structurally novel quinolizin-4-one scaffold, which showed selective PI3Kδ inhibition. Our initially designed compound <b>4</b> showed an adequate inhibition of PI3Kδ (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Further SAR studies showed that the 9<i>H</i>-purine and 4-aminopyrimidine-5-carbonitrile, hinge binding regions, were equally well tolerated upon replacing -H with -methyl at C-6 (R<sub>2</sub> = H, Me), as evident by good cellular potency of compounds <b>5</b> and <b>6</b>. However, the introduction of the methyl group at C-6 led to poor stability in mouse liver microsomes and reduced selectivity over other PI3K isoforms. The importance of substitution at C-6 was revealed when methyl substitution (R<sub>1</sub> = Me) led to a drastic decrease in potency for compounds <b>7</b> and <b>8</b>, indicating that a hydrophobic group at C-7 may not be tolerated. Compound <b>9</b> with a methyl group at C-6 and a fluorine atom at C-7 retained potency; however, its stability in mouse liver microsomes was compromised.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial SAR of 3-Phenyl-4<i>H</i>-quinolizin-4-one<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0009.gif" alt="" id="GRAPHIC-d7e736-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0010.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">--: not tested.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> determined by the extent of inhibition of cellular pAKT levels.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">MLM, RLM, HLM: mouse, rat, and human liver microsomes; % remaining of the test compound, after 30 min, in the presence of NADPH at 1 μM concentration.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Inactive: no activity at 10 μM.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">GSK-2636771: +ve control for the PI3Kβ isoform.</p></div></div><div></div></div><div class="NLM_p">Removal of the C-6 methyl group from compound <b>9</b> led to significant improvement in metabolic stability as shown by compound <b>10</b>. Moreover, compound <b>10</b> also showed potent inhibition of cellular PI3Kδ activity (IC<sub>50</sub> 9.8 nM). The replacement of the purine hinge binder by 2,4 diaminopyrimidine-5-carbonitrile in compound <b>11</b> led to the improvement of cellular potency by 6.6-fold (IC<sub>50</sub> against PI3Kδ = 1.49 nM) as compared to compound <b>10</b>. Furthermore, the removal of the 4-amino group from the hinge binder, 2,4 diaminopyrimidine-5-carbonitrile region of compound <b>11</b> led to compound <b>12</b> with similar potency (IC<sub>50</sub> against PI3Kδ = 7 nM). However, it had reduced stability in mouse and rat liver microsomes. The removal of the 5-nitrile group from the hinge binder region in compound <b>13</b> resulted in a loss of activity against PI3Kδ, thus demonstrating the importance of the nitrile functional group at that position. The incorporation of a 2-methyl group between the two nitrogens of the pyrimidine was not tolerated (as shown in compound <b>14</b>). However, swapping the methyl and amine groups at R<sub>4</sub> generated compound <b>15</b> (IC<sub>50</sub> = 0.89 nM), which was more potent than compound <b>11</b>. This compound, however, was associated with drastically reduced metabolic stability in rat and mouse liver microsomes. Next, we explored different substitutions on the phenyl ring of the hydrophobic pocket. Introducing a <i>meta</i>-methyl phenyl group as R<sub>3</sub> in compound <b>16</b> increased potency against PI3Kδ and exhibited good PI3K isoform selectivity; however, metabolic stability in mouse liver microsomes was severely compromised. Replacing the <i>meta</i>-methyl phenyl group of compound <b>16</b> with a <i>para</i>-fluoro phenyl group and hinge binder with 2,4 diaminopyrimidine-5-carbonitrile in compound <b>17</b> showed moderate inhibition only. The hybridization of <b>16</b> and <b>17</b><i>via</i> a 3-methyl, 5-fluoro-disubstituted phenyl resulted in <b>18,</b> which retained good PI3Kδ potency but had poor metabolic stability. Replacing the methyl group in R<sub>3</sub> of compound <b>18</b> by the fluorine atom in compound <b>19</b> retained the cellular potency against PI3Kδ with concomitant improvement in metabolic stability in mouse liver microsomes, indicating the role of the methyl group in limiting mouse liver microsomal stability. The data obtained so far imply that fluoro or methyl substitution on the phenyl group led to the decrease in potency and loss of metabolic stability in mouse liver microsomes, respectively.</div><div class="NLM_p">The <i>in vivo</i> pharmacokinetic properties strengthened the above observation further, as compound <b>11</b> administered at 1.0 mg/kg intravenously in mice, demonstrated low systemic clearance (25 mL/min/kg), moderate AUC<sub>last</sub> of 1.6 h*μM, <i>T</i><sub>1/2</sub> of 1.2 h, and oral bioavailability of 22%. Conversely, compounds <b>10</b> and <b>17</b> had a poor pharmacokinetic profile with high clearance and low oral bioavailability (data not shown).</div><div class="NLM_p">Our docking studies with compound <b>11</b> exhibited that the 2,4 diaminopyrimidine-5-carbonitrile formed three hydrogen bonds with the hinge residues [backbone of Val828 (C═O and NH) and Glu826 (C═O)] (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a). The 7-fluoro-4<i>H</i>-quinolizin-4-one ring assumed a conformation which is perpendicular to the hinge region. The overall orientation of compound <b>11</b>, along with its interactions within the ATP binding site of the protein, revealed that the hydrophobic pocket near C-1 could be accessed with hydrophobic groups. This led to the identification of an unexplored site in between the P-loop and the activation loop within the ATP binding pocket. We hypothesized that when the phenyl ring is moved from the C-3 to C-1 position in compound <b>20</b>, the phenyl group at the C-1 position would be accommodated in the unexplored hydrophobic space (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b). This hydrophobic interaction consists of the C-1 phenyl ring with PRO758, ILE777, MET752, and TRP760 of the protein. As expected, these hydrophobic interactions helped to retain potency of compound <b>20</b> against PI3Kδ. The addition of another phenyl as the other arm at the C-3 position in compound <b>20</b> to completely occupy the ATP binding site gave rise to four-blade propeller-shaped compound <b>34</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c). The binding orientation of compound <b>34</b> is similar to that of compound <b>20</b> except that the docking orientation of the quinolizine-4-one group makes a surprising 180° turn, positioning <i>p</i>-fluoro phenyl similar to the C-3 position of compound <b>11</b>. The newly introduced C-3 phenyl ring of compound <b>34</b> makes additional hydrophobic interaction with ILE777, MET752, and PRO758. Additionally, fluorine has the potential to function as a halogen bond donor and/or would prefer stabilization with the electron rich site (formed by COO– of ASP832 and C═O of SER831) of the protein surface, thus favoring the 180° turn.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking studies of compounds <b>11</b>, <b>20</b>, and <b>34</b> with PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a>). (a) Compound <b>11</b> docked to the ATP site of PI3Kδ. (b) Docking mode of compound <b>20</b> with C-1 phenyl substituent depicting the occupancy of the unexplored hydrophobic area of the protein. (c) Binding mode of compound <b>34</b> exhibiting the complete occupancy of the ATP binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compounds <b>21</b>, <b>22</b>, and <b>24</b> had comparable potency and moderate stability in mouse liver microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The substituent at C-1 in general displayed moderate stability in liver microsomes. The addition of one more amino group between the two ring-nitrogens of the hinge binder segment of compound <b>24</b> generated compound <b>25</b> with slightly better cellular potency (IC<sub>50</sub> = 9.42 nM) and exhibited a significant improvement in percentage remaining in mouse liver microsome (57 <i>vs</i> 90%). Interestingly, the methyl group at C-3 of compound <b>26</b> decreased the potency by 12-fold, as compared to compound <b>25</b>. However, the somewhat bigger cyclopropyl group present in compounds <b>27</b> and <b>28</b> retained cellular potency against PI3Kδ (IC<sub>50</sub> = 16 and 3.39 nM, respectively), indicating a bigger hydrophobic group can be tolerated at C-3. However, such aliphatic substituents had a negative impact on liver microsomal stability.</div><div class="NLM_p">The above observation encouraged us to increase the bulk further from the cyclopropyl to phenyl group at C-3. Also, based on learnings from our earlier SAR  (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), an alkyl substituent on phenyl usually led to poor metabolic or pharmacokinetic profile. Thus, a C-3 phenyl group as the hydrophobic substituent at C-1 and the hinge binding group 2,4-diaminopyrimidine-5-carbonitrile as R<sub>4</sub> was fixed in a series of compounds (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). As depicted in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, compounds such as <b>29</b> and <b>30</b>, with 2,4-diaminopyrimidine-5-carbonitrile as the hinge-binding group R<sub>4</sub>, were more potent inhibitors of PI3Kδ (with cellular IC<sub>50</sub> = 5.6 and 5.9 nM, respectively) and had good liver microsomal stability.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Optimization of the Hydrophobic Pocket at the C-3 Position and Hinge Binder on 7-Fluoro-4<i>H</i>-quinolizin-4-one<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0011.gif" alt="" id="GRAPHIC-d7e1054-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0012.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">--: not tested.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> determined by the extent of inhibition of cellular pAKT levels.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">MLM, RLM, and HLM: mouse, rat, and human liver microsomes; % remaining of the test compound, after 30 min, in the presence of NADPH at 1 μM concentration.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Inactive: no activity at 10 μM.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t2fn6"><sup><sup>f</sup></sup><p class="last">% inhibition reported is a representative of two independent experiments.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Exploring Hydrophobic Pocket at C-1, C-3 Positions, and Hinge Binders<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0013.gif" alt="" id="GRAPHIC-d7e1099-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0014.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">--: not tested.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> determined by the extent of inhibition of cellular pAKT levels.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">MLM, RLM, and HLM: mouse, rat, and human liver microsomes; % remaining of the test compound, after 30 min, in the presence of NADPH at 1 μM concentration.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Inactive: no activity at 10 μM.</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last"><i>n</i> = 1.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Optimization of Substitution at the C-1 Position with 2,4-Diaminopyrimidine-5-carbonitrile as a Hinge Binder<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0015.gif" alt="" id="GRAPHIC-d7e1143-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0016.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">--: not tested.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> determined by the extent of inhibition of cellular pAKT levels.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">MLM, RLM, and HLM: mouse, rat, and human liver microsomes; % remaining of the test compound, after 30 min, in the presence of NADPH at 1 μM concentration.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Inactive: no activity at 10 μM.</p></div><div class="footnote" id="t4fn5"><sup><sup>e</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t4fn6"><sup><sup>f</sup></sup><p class="last">% inhibition reported is a representative of two independent experiments.</p></div></div><div></div></div><div class="NLM_p">The introduction of a phenyl group at the C-1 of compound <b>11</b> generated compound <b>31</b>, which had reduced cellular PI3Kδ potency (IC<sub>50</sub> = 14 nM) and inferior mouse microsomal stability. The introduction of more bulk at C-1, for example, a <i>p</i>-benzamide group as R<sub>5</sub> (compound <b>32</b>), resulted in the loss of isoform selectivity against PI3Kα significantly (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The introduction of electron-donating substitution at the para position of the C-1 phenyl group, like methoxy, in compound <b>33</b> resulted in regaining isoform selectivity. Compound <b>34</b> with a <i>para</i> fluorophenyl gave good cellular potency and isoform selectivity. Microsomal stability was also better for this compound. Compound <b>34</b> is more potent for PI3Kδ than compound <b>23</b>, indicating that phenyl at C-3 brings in hydrophobic interactions as predicted by docking studies. The para fluoro phenyl substitution at the C-1 position of compound <b>34</b> plays an important role in improving its microsomal stability as compared to the unsubstituted phenyl group in compound <b>31</b>.</div><div class="NLM_p">Compounds with the 2-amino-4-methylpyrimidine-5-carbonitrile group in the hinge binder region are depicted in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. The incorporation of a methyl group at the C-1 position of compound <b>15</b> resulted in compound <b>35</b>, which had reduced cellular PI3Kδ potency (IC<sub>50</sub> = 54 nM). Replacement of the methyl group by a <i>para</i> fluorophenyl group in compound <b>35</b> led to compound <b>36</b>, which was less potent as well as less selective compared to compound <b>34</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Optimization of Substitution at the C-1 Position and 2-Amino-4-methylpyrimidine-5-carbonitrile as a Hinge Binder<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0017.gif" alt="" id="GRAPHIC-d7e1263-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0018.gif" alt="" id="gr12" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">--: not tested.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> determined by the extent of inhibition of cellular pAKT levels.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">MLM, RLM, and HLM: mouse, rat, and human liver microsomes; % remaining of the test compound, after 30 min, in the presence of NADPH at 1 μM concentration.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Inactive: no activity at 10 μM.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last"><i>n</i> = 1.</p></div></div><div></div></div><div class="NLM_p">Compounds <b>11</b>, <b>25</b>, <b>29</b>, <b>30</b>, and <b>34</b>, which have different quinolizin-4-one substitution patterns, were evaluated for <i>in vivo</i> pharmacokinetic properties in mice following intravenous and oral administration (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compounds <b>11</b>, <b>25</b>, <b>29</b>, and <b>30</b> exhibited low AUC and high clearance. Compound <b>34</b> displayed the lowest clearance, moderate oral bioavailability, adequate plasma exposure, and had a suitable half-life to enable its evaluation in the preclinical xenograft models. Favorable physicochemical properties exhibited by compounds <b>11</b>, <b>25</b>, <b>31</b>, <b>34</b>, and <b>36</b> are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. Compound <b>34</b> has sufficiently a high LipE of 5.64, we recognized that we lost some “efficiency” in order to achieve the selectivity, while still being in acceptable physical property space. Additionally, compound <b>34</b> displayed marginally high PFI of 7.38; however, it has a reasonably good solubility of 68.5 (μM).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Profile of Standards and Lead Compounds in Male BALB/c Mice<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">ROA<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>last</sub><a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> (h*μM)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a> (h)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t6fn7" aria-label="g">g</a> (L/kg)</th><th class="colsep0 rowsep0" align="center">% <i>F</i><a class="ref internalNav" href="#t6fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IPI-145<a onclick="showRef(event, 'cit30a'); return false;" href="javascript:void(0);" class="ref cit30a">(30a)</a></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.083</td><td class="colsep0 rowsep0" align="char" char=".">13.34</td><td class="colsep0 rowsep0" align="char" char=".">4.55</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">87.5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.083</td><td class="colsep0 rowsep0" align="char" char=".">0.93</td><td class="colsep0 rowsep0" align="char" char=".">0.328</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAL-101<a onclick="showRef(event, 'cit30b'); return false;" href="javascript:void(0);" class="ref cit30b">(30b)</a></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">7.43</td><td class="colsep0 rowsep0" align="char" char=".">0.43</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="left">0.73</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">6.98</td><td class="colsep0 rowsep0" align="char" char=".">9.25</td><td class="colsep0 rowsep0" align="char" char=".">0.83</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">37.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">18.0</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.08</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Vehicle: IV: DMA (10%): PEG 300 (20%): Captisol (20%) in NS (q.s.), PO: Tween 80 (1%): TPGS (10%): water (q.s.). Dosing volume: IV: 5 mL/kg and PO: 10 mL/kg.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">ROA, route of administration.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Time to reach maximum peak conc.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Maximum peak plasma observed conc achieved.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Area under the curve from time 0 to last measurable conc.</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last">Terminal elimination plasma half-life.</p></div><div class="footnote" id="t6fn7"><sup><sup>g</sup></sup><p class="last">Steady-state volume of distribution.</p></div><div class="footnote" id="t6fn8"><sup><sup>h</sup></sup><p class="last">% oral bioavailability.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Determined and calculated Physicochemical Parameters of Key Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char=".">MW</th><th class="colsep0 rowsep0" align="center">(δ) cellular IC<sub>50</sub> nM</th><th class="colsep0 rowsep0" align="center" char="."><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a>log <i>D</i><sub>7.4</sub></th><th class="colsep0 rowsep0" align="center" char=".">LipE<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a> (δ)</th><th class="colsep0 rowsep0" align="center" char=".">PFI<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">solubility (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">415.43</td><td class="colsep0 rowsep0" align="left">1.49</td><td class="colsep0 rowsep0" align="char" char=".">1.26</td><td class="colsep0 rowsep0" align="char" char=".">7.57</td><td class="colsep0 rowsep0" align="char" char=".">5.26</td><td class="colsep0 rowsep0" align="char" char=".">691.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char=".">451.41</td><td class="colsep0 rowsep0" align="left">9.42</td><td class="colsep0 rowsep0" align="char" char=".">1.88</td><td class="colsep0 rowsep0" align="char" char=".">6.15</td><td class="colsep0 rowsep0" align="char" char=".">5.88</td><td class="colsep0 rowsep0" align="char" char=".">368.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="char" char=".">491.53</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="char" char=".">2.49</td><td class="colsep0 rowsep0" align="char" char=".">5.36</td><td class="colsep0 rowsep0" align="char" char=".">7.49</td><td class="colsep0 rowsep0" align="char" char=".">50.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">509.52</td><td class="colsep0 rowsep0" align="left">9.5 ± 1.4</td><td class="colsep0 rowsep0" align="char" char=".">2.38</td><td class="colsep0 rowsep0" align="char" char=".">5.64</td><td class="colsep0 rowsep0" align="char" char=".">7.38</td><td class="colsep0 rowsep0" align="char" char=".">68.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">508.53</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="char" char=".">3.26</td><td class="colsep0 rowsep0" align="char" char=".">4.56</td><td class="colsep0 rowsep0" align="char" char=".">8.26</td><td class="colsep0 rowsep0" align="char" char=".">44.94</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Log <i>D</i><sub>7.4</sub> the experimentally determined parameter log <i>D</i><sub>7.4</sub>.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">LipE(δ) = pIC<sub>50</sub>(δ) – log <i>D</i><sub>7.4</sub>.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">Property forecast index (PFI) is the sum of the log <i>D</i><sub>7.4</sub> and the number of aromatic rings.</p></div></div></div><div class="NLM_p">Anticancer activity of key compounds <b>11</b>, <b>25</b>, <b>31</b>, <b>34</b>, and <b>36</b> was studied in DLBCL cell lines <i>in vitro</i>. These cell lines represent B cell receptor-based hematological malignancies, which are dependent on downstream proteins of BCR signaling. Compound <b>34</b> showed excellent potency against representative DLBCL cell lines, of either GCB (SUDHL-6), or ABC subtype (OCI-Ly10 and TMD-8) as evident from the <i>in vitro</i> anticancer activity results (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>, <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). As observed in the cell-free assays, the potency of compound <b>34</b> was superior to CAL-101 even in the anticancer activity assays.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Interestingly, the compound was potent against both ABC-DLBCL and GCB-DLBCL cell lines. Sensitivity against the GCB-DLBCL cell line SuDHL-6 may be attributed to the increased prevalence of PTEN loss, leading to activation and dependence on PI3K-AKT signaling.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Bar graphs showing % inhibition ± SEM of cell viability achieved by compound <b>34</b> and CAL-101 in SUDHL-6, OCI-Ly10, and TMD-8 cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Anticancer Activity of Key Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">anticancer activity (IC<sub>50</sub>, nM)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t8fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">SUDHL-6</th><th class="colsep0 rowsep0" align="center">OCI-Ly10</th><th class="colsep0 rowsep0" align="center">TMD-8</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAL-101</td><td class="colsep0 rowsep0" align="left">22.5 ± 2.1</td><td class="colsep0 rowsep0" align="left">31.9 ± 5.1</td><td class="colsep0 rowsep0" align="left">7.3 ± 1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">1.8 ± 0.5</td><td class="colsep0 rowsep0" align="left">1.8 ± 0.6</td><td class="colsep0 rowsep0" align="left">0.09 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b><a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">11.9</td><td class="colsep0 rowsep0" align="left">7.02</td><td class="colsep0 rowsep0" align="left">15.91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b><a class="ref internalNav" href="#t8fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">160.1</td><td class="colsep0 rowsep0" align="left">50.4% inhibition at 0.01 nM<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left"><0.1 nM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><1 nM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><0.1 nM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">11.6 ± 8</td><td class="colsep0 rowsep0" align="left">42% at 1 nM<a class="ref internalNav" href="#t8fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">0.08 ± 0.01</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Anticancer activity is measured based on % inhibition of cellular ATP, IC<sub>50</sub> determined using GraphPad Prism (4 parameter analysis).</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">IC<sub>50</sub> mentioned based on the bar graph (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">Data reported are average ± SEM value of at least 2 independent experiments.</p></div><div class="footnote" id="t8fn4"><sup><sup>d</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t8fn5"><sup><sup>e</sup></sup><p class="last">% inhibition reported as IC<sub>50</sub> could not be determined.</p></div></div></div><div class="NLM_p">Because of its superior anticancer activity and pharmacokinetic profile, compound <b>34</b> was chosen for detailed PK studies in rodent and nonrodent species, followed by <i>in vivo</i> efficacy studies. Half-life of compound <b>34</b> was found to be considerably higher in dogs as compared to rodents. Pharmacokinetic properties demonstrated by compound <b>34</b> were found to be consistently superior to CAL-101 and IPI-145 based on the published data<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Pharmacokinetic Profile for Compound <b>34</b><i>vs</i> Reference Compounds in Rat and Dog<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">ROA<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub><a class="ref internalNav" href="#t9fn3" aria-label="c">c</a> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub><a class="ref internalNav" href="#t9fn4" aria-label="d">d</a> (μM)</th><th class="colsep0 rowsep0" align="center">AUC<sub>last</sub><a class="ref internalNav" href="#t9fn5" aria-label="e">e</a> (h*μM)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t9fn6" aria-label="f">f</a> (h)</th><th class="colsep0 rowsep0" align="center">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub><a class="ref internalNav" href="#t9fn7" aria-label="g">g</a> (L/kg)</th><th class="colsep0 rowsep0" align="center">% <i>F</i><a class="ref internalNav" href="#t9fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IPI-145<a onclick="showRef(event, 'cit30a'); return false;" href="javascript:void(0);" class="ref cit30a">(30a)</a></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">3.64</td><td class="colsep0 rowsep0" align="left">2.77</td><td class="colsep0 rowsep0" align="left">0.73</td><td class="colsep0 rowsep0" align="left">30.50</td><td class="colsep0 rowsep0" align="left">1.66</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.88</td><td class="colsep0 rowsep0" align="left">7.03</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4.33</td><td class="colsep0 rowsep0" align="left">14.1</td><td class="colsep0 rowsep0" align="left">1.83</td><td class="colsep0 rowsep0" align="left">3.23</td><td class="colsep0 rowsep0" align="left">0.49</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">1.33</td><td class="colsep0 rowsep0" align="left">5.68</td><td class="colsep0 rowsep0" align="left">26.25</td><td class="colsep0 rowsep0" align="left">3.15</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAL-101<a onclick="showRef(event, 'cit30c'); return false;" href="javascript:void(0);" class="ref cit30c">(30c)</a></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">3.46 ± 0.53</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.89</td><td class="colsep0 rowsep0" align="left">47.8 ± 19</td><td class="colsep0 rowsep0" align="left">2.49</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">0.31 ± 0.18</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.52</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">39 ± 13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">2.35 ± 0.76</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.31 ± 0.43</td><td class="colsep0 rowsep0" align="left">0.76 ± 0.25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.50 ± 0.16</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.99 ± 0.1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">48 ± 23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">0.08 ± 0</td><td class="colsep0 rowsep0" align="left">1.7 ± 0.2</td><td class="colsep0 rowsep0" align="left">11 ± 3</td><td class="colsep0 rowsep0" align="left">3.8 ± 1</td><td class="colsep0 rowsep0" align="left">2.9 ± 0.7</td><td class="colsep0 rowsep0" align="left">1.0 ± 0.2</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">PO</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">2.0 ± 0</td><td class="colsep0 rowsep0" align="left">4.8 ± 0.5</td><td class="colsep0 rowsep0" align="left">36 ± 5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">IV</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6.4 ± 2</td><td class="colsep0 rowsep0" align="left">0.8 ± 0.1</td><td class="colsep0 rowsep0" align="left">0.4 ± 0.1</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Vehicle: IV (rat & dog): DMA (10%):PEG 300: (20%): 20% w/v Captisol NS (qs); PO (rat): Tween 80 (1%): TPGS (10%): water (q.s.); dosing volume: IV rat: 4 mL/kg and dog: 2 mL/kg (15 min infusion); PO (rats): 10 mL/kg.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">ROA, route of administration.</p></div><div class="footnote" id="t9fn3"><sup><sup>c</sup></sup><p class="last">Time to reach maximum peak plasma conc.</p></div><div class="footnote" id="t9fn4"><sup><sup>d</sup></sup><p class="last">Maximum peak plasma conc achieved.</p></div><div class="footnote" id="t9fn5"><sup><sup>e</sup></sup><p class="last">Area under the plasma concentration–time curve from time 0 to last measurable conc.</p></div><div class="footnote" id="t9fn6"><sup><sup>f</sup></sup><p class="last">Terminal elimination plasma half-life.</p></div><div class="footnote" id="t9fn7"><sup><sup>g</sup></sup><p class="last">Steady-state volume of distribution.</p></div><div class="footnote" id="t9fn8"><sup><sup>h</sup></sup><p class="last">% oral bioavailability.</p></div></div></div><div class="NLM_p">Compound <b>34</b> showed potent inhibition of PI3Kδ and also demonstrated selectivity in biochemical assays (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). It was also tested for cellular inhibition of PI3K activity by measuring PI3K-induced AKT phosphorylation in cell lines expressing specific PI3K isoforms. The data show that the potency of compound <b>34</b> in biochemical assays was commensurate with reduction in the AKT activity in the appropriate cell lines. Compound <b>34</b> showed potent reduction in AKT activation (IC<sub>90</sub>, 37.6 nM; as measured by AKT phosphorylation at S473) in anti-IgM stimulated Raji cells and displayed selectivity of 16.3 and 214-folds over PI3Kγ and PI3Kβ isoforms, respectively. Furthermore, compound <b>34</b> displayed excellent selectivity for PI3Kδ over PI3Kα (as no inhibition of AKT phosphorylation was observed in the PI3Kα-driven MDA-MB-453 cells).</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. <i>In Vitro</i> Profile for Compound <b>34</b> in Biochemical and Cell-Based Assays<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="8" align="center">inhibitory concentration [IC<sub>50, 90</sub> (nM)]<a class="ref internalNav" href="#t10fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">PI3Kα</th><th class="rowsep1 colsep0" colspan="2" align="center">PI3Kβ</th><th class="rowsep1 colsep0" colspan="2" align="center">PI3Kδ</th><th class="rowsep1 colsep0" colspan="2" align="center">PI3Kγ</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound <b>34</b></th><th class="colsep0 rowsep0" align="center">biochemical</th><th class="colsep0 rowsep0" align="center">cell based</th><th class="colsep0 rowsep0" align="center">biochemical</th><th class="colsep0 rowsep0" align="center">cell-based</th><th class="colsep0 rowsep0" align="center">biochemical<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cell based<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">biochemical<a class="ref internalNav" href="#t10fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">cell-based</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub></td><td class="colsep0 rowsep0" align="left">377.2</td><td class="colsep0 rowsep0" align="left">inactive</td><td class="colsep0 rowsep0" align="left">241.6</td><td class="colsep0 rowsep0" align="left">208</td><td class="colsep0 rowsep0" align="left">3.3 ± 1.2</td><td class="colsep0 rowsep0" align="left">9.5 ± 1.4</td><td class="colsep0 rowsep0" align="left">17.9 ± 3</td><td class="colsep0 rowsep0" align="left">177</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>90</sub></td><td class="colsep0 rowsep0" align="left">2357</td><td class="colsep0 rowsep0" align="left">inactive</td><td class="colsep0 rowsep0" align="left">12194</td><td class="colsep0 rowsep0" align="left">8050</td><td class="colsep0 rowsep0" align="left">28.1 ± 14.9</td><td class="colsep0 rowsep0" align="left">37.6 ± 15.1</td><td class="colsep0 rowsep0" align="left">159.8 ± 26.6</td><td class="colsep0 rowsep0" align="left">614</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">positive control IC<sub>50</sub></td><td class="colsep0 rowsep0" colspan="2" align="center">BYL-719</td><td class="colsep0 rowsep0" colspan="2" align="center">GSK-2636771</td><td class="colsep0 rowsep0" colspan="2" align="center">IPI_145</td><td class="colsep0 rowsep0" colspan="2" align="center">IPI-145</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">28.6</td><td class="colsep0 rowsep0" align="left">13.2</td><td class="colsep0 rowsep0" align="left">21.7</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">0.9 ± 0.3</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.2</td><td class="colsep0 rowsep0" align="left">20.5 ± 4.5</td><td class="colsep0 rowsep0" align="left">39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">Biochemical assays were conducted with purified p110α, p110β, p110γ, and p110δ proteins, cell-based assays were conducted with cell lines and MDA-MB-453 (p110α), 786-O (p110β), Raji (p110δ), and RAW 264.7(p110γ).</p></div><div class="footnote" id="t10fn2"><sup><sup>b</sup></sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t10fn3"><sup><sup>c</sup></sup><p class="last">Data reported are average ± SEM value of at least 2 independent experiments.</p></div></div></div><div class="NLM_p">Subsequently, we evaluated compound <b>34</b> in the xenograft models of human ABC-DLBCL (OCI-Ly10 and TMD-8) and GCB-DLBCL (SUDHL-6). A dose-dependent reduction in the tumor volume was observed upon 24 days of once daily oral treatment in the OCI-Ly10 xenograft with a calculated ED<sub>50</sub> (based on % TGI) of 6.47 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>). Tumor growth inhibition of 81.95% was seen with a highly significant (<i>P</i> < 0.001) reduction in both tumor volume and tumor weight. At a similar dose-level of 3 mg/kg, compound <b>34</b> displayed a marginally superior tumor growth inhibition in comparison to CAL-101. Concentrations of compound <b>34</b> in the tumors (0.38 μM) were nearly twofold higher than that of CAL-101 (0.15 μM) at same dose level (3 mg/kg). In contrast to CAL-101 which showed significant body weight reduction (<i>P</i> < 0.05, day-24), compound <b>34</b> did not result in any significant reduction in body weight at the tested doses. Comparative evaluation with CAL-101 at doses beyond 3 mg/kg could not be done because of the higher incidence of toxicity and mortality associated specifically with CAL-101 in NOD scid mice (data not shown).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vivo</i> efficacy of compound 34 in xenograft models of OCI-Ly10 (A), TMD-8 (B), and SUDHL-6 (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Efficacy of Compound <b>34</b> in the OCI-Ly10 Xenograft Model<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±">tumor volume day-24 (mm<sup>3</sup>)</th><th class="colsep0 rowsep0" align="center">tumor growth Inhibition day-24 (% TGI)</th><th class="colsep0 rowsep0" align="center" char="±">tumor weight day-24 (g)</th><th class="colsep0 rowsep0" align="center" char="±">body weight day-24 (g)</th><th class="colsep0 rowsep0" align="center">tumor Conc. day-24 (μM)</th><th class="colsep0 rowsep0" align="center">plasma Conc. day-24 (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vehicle</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">1430.74 ± 363.89</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">0.86 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">22.60 ± 0.34</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAL-101</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char="±">828.42 ± 77.12<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">47.33 ± 5.21</td><td class="colsep0 rowsep0" align="char" char="±">0.48 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">20.68 ± 0.42<a class="ref internalNav" href="#t11fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.15 ± 0.16</td><td class="colsep0 rowsep0" align="left">0.04 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char="±">838.21 ± 105.92<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">46.13 ± 6.59</td><td class="colsep0 rowsep0" align="char" char="±">0.50 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">21.79 ± 0.21</td><td class="colsep0 rowsep0" align="left">0.13 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.18 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char="±">756.43 ± 118.01<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">52.49 ± 7.38</td><td class="colsep0 rowsep0" align="char" char="±">0.43 ± 0.11<a class="ref internalNav" href="#t11fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char="±">20.85 ± 0.38</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.71 ± 0.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="±">507.84 ± 68.67<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">72.03 ± 3.80</td><td class="colsep0 rowsep0" align="char" char="±">0.27 ± 0.05<a class="ref internalNav" href="#t11fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char="±">21.84 ± 0.35</td><td class="colsep0 rowsep0" align="left">0.96 ± 0.24</td><td class="colsep0 rowsep0" align="left">1.72 ± 0.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char="±">383.56 ± 45.03<a class="ref internalNav" href="#t11fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">81.95 ± 2.65</td><td class="colsep0 rowsep0" align="char" char="±">0.22 ± 0.06<a class="ref internalNav" href="#t11fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="±">21.51 ± 0.61</td><td class="colsep0 rowsep0" align="left">3.25 ± 0.74</td><td class="colsep0 rowsep0" align="left">5.22 ± 1.08</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">Vehicle: Tween 80 (1%), Gelucire 44/14 (15%) and Milli-Q water (84%), in a dose volume of 10 mL/kg, q.d., p.o. Data shown as mean ± SEM of <i>n</i> = 8. Two-way ANOVA followed by the Bonferroni’s post-hoc comparisons test.</p></div><div class="footnote" id="t11fn2"><sup><sup>b</sup></sup><p class="last"><i>P</i> < 0.05.</p></div><div class="footnote" id="t11fn3"><sup><sup>c</sup></sup><p class="last"><i>P</i> < 0.001 compared to vehicle control. One-way ANOVA followed by the Dunnett’s post-hoc comparisons test.</p></div><div class="footnote" id="t11fn4"><sup><sup>d</sup></sup><p class="last"><i>P</i> < 0.05.</p></div><div class="footnote" id="t11fn5"><sup><sup>e</sup></sup><p class="last"><i>P</i> < 0.01.</p></div><div class="footnote" id="t11fn6"><sup><sup>f</sup></sup><p class="last"><i>P</i> < 0.001 compared to the vehicle control. Concentration (conc.).</p></div></div></div><div class="NLM_p">Efficacy of compound <b>34</b> was further confirmed in another ABC-DLBCL xenograft model established with the TMD-8 cell line. Similar to the OCI-Ly10 xenograft, treatment with compound <b>34</b> resulted in a dose-dependent reduction in tumor volume and tumor weight with an ED<sub>50</sub> (based on % TGI) of 5.45 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B and <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). At the highest tested dose of 30 mg/kg, a significant (<i>p</i> < 0.001) reduction in tumor weight and a maximum tumor growth inhibition of 73.13% was seen on day-19. Effects on the tumor growth and body weight were comparable between CAL-101 and compound <b>34</b> in the TMD-8 xenograft at a dose of 3 mg/kg, although the concentrations reached by compound <b>34</b> (0.63 μM) was higher in comparison to CAL-101 (0.14 μM).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Efficacy of Compound <b>34</b> in the TMD-8 Xenograft Model<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±">tumor volume day-19 (mm<sup>3</sup>)</th><th class="colsep0 rowsep0" align="center">tumor growth inhibition day-19 (% TGI)</th><th class="colsep0 rowsep0" align="center" char="±">tumor weight day-19 (g)</th><th class="colsep0 rowsep0" align="center" char="±">body weight day-19 (g)</th><th class="colsep0 rowsep0" align="center">tumor conc. day-19 (μM)</th><th class="colsep0 rowsep0" align="center">plasma conc. day-19 (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vehicle</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">1811.14 ± 301.55</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">1.30 ± 0.30</td><td class="colsep0 rowsep0" align="char" char="±">28.66 ± 0.83</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAL-101</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char="±">1312.58 ± 236.05<a class="ref internalNav" href="#t12fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">29.28 ± 13.14</td><td class="colsep0 rowsep0" align="char" char="±">1.07 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">25.03 ± 0.82<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.14 ± 0.05</td><td class="colsep0 rowsep0" align="left">0.02 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char="±">1299.76 ± 129.73<a class="ref internalNav" href="#t12fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">29.76 ± 7.35</td><td class="colsep0 rowsep0" align="char" char="±">1.30 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">24.85 ± 0.53<a class="ref internalNav" href="#t12fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.17 ± 0.04</td><td class="colsep0 rowsep0" align="left">0.21 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char="±">1214.92 ± 114.29<a class="ref internalNav" href="#t12fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">35.13 ± 6.67</td><td class="colsep0 rowsep0" align="char" char="±">1.05 ± 0.22</td><td class="colsep0 rowsep0" align="char" char="±">25.66 ± 0.56</td><td class="colsep0 rowsep0" align="left">0.63 ± 0.27</td><td class="colsep0 rowsep0" align="left">0.70 ± 0.17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char="±">657.85 ± 103.18<a class="ref internalNav" href="#t12fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">67.88 ± 5.86</td><td class="colsep0 rowsep0" align="char" char="±">0.62 ± 0.12<a class="ref internalNav" href="#t12fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char="±">24.48 ± 0.84<a class="ref internalNav" href="#t12fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">1.65 ± 1.06</td><td class="colsep0 rowsep0" align="left">2.67 ± 2.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char="±">564.71 ± 56.37<a class="ref internalNav" href="#t12fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">73.13 ± 3.06</td><td class="colsep0 rowsep0" align="char" char="±">0.62 ± 0.11<a class="ref internalNav" href="#t12fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char="±">23.86 ± 0.55<a class="ref internalNav" href="#t12fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">4.08 ± 1.31</td><td class="colsep0 rowsep0" align="left">5.50 ± 1.59</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">Vehicle: Tween 80 (1%), Gelucire 44/14 (15%) and Milli-Q water (84%), in a dose volume of 10 mL/kg, q.d., p.o. Data shown as mean ± SEM of <i>n</i> = 7–8. Two-way ANOVA followed by Bonferroni’s post-hoc comparisons test.</p></div><div class="footnote" id="t12fn2"><sup><sup>b</sup></sup><p class="last"><i>P</i> < 0.05.</p></div><div class="footnote" id="t12fn3"><sup><sup>c</sup></sup><p class="last"><i>P</i> < 0.01.</p></div><div class="footnote" id="t12fn4"><sup><sup>d</sup></sup><p class="last"><i>P</i> < 0.001 compared to the vehicle control. One-way ANOVA followed by the Dunnett’s post-hoc comparisons test.</p></div><div class="footnote" id="t12fn5"><sup><sup>e</sup></sup><p class="last"><i>P</i> < 0.05 compared to the vehicle control. Concentration (conc.).</p></div></div></div><div class="NLM_p">In a SUDHL-6 (GCB-DLBCL) xenograft study, 15 days treatment with compound <b>34</b> showed superior tumor growth inhibition (55%) in comparison to CAL-101 (38.52%) at a common dose of 5 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C, <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a></a>). Consistent with the observations in OCI-Ly10 and TMD-8 studies, the tumor concentrations of compound <b>34</b> (0.20 μM) in this study were found to be higher than CAL-101 (0.08 μM).</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. Efficacy of Compound <b>34</b> in the SUDHL-6 Xenograft Model<a class="ref internalNav" href="#t13fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compounds</th><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±">tumor volume day-15 (mm<sup>3</sup>)</th><th class="colsep0 rowsep0" align="center">tumor growth inhibition day-15 (% TGI)</th><th class="colsep0 rowsep0" align="center" char="±">tumor weight day-15 (g)</th><th class="colsep0 rowsep0" align="center" char="±">body weight day-15 (g)</th><th class="colsep0 rowsep0" align="center">tumor conc. day-15 (μM)</th><th class="colsep0 rowsep0" align="center">plasma conc. day-15 (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">vehicle</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char="±">1982.0 ± 289.04</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char="±">1.69 ± 0.32</td><td class="colsep0 rowsep0" align="char" char="±">28.13 ± 0.65</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAL-101</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char="±">1276.78 ± 192.24<a class="ref internalNav" href="#t13fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">38.52 ± 9.50</td><td class="colsep0 rowsep0" align="char" char="±">1.25 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">23.84 ± 0.79<a class="ref internalNav" href="#t13fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.08 ± 0.03</td><td class="colsep0 rowsep0" align="left">0.03 ± 0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char="±">964.54 ± 225.49<a class="ref internalNav" href="#t13fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">55.14 ± 11.45</td><td class="colsep0 rowsep0" align="char" char="±">0.87 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">23.63 ± 1.11<a class="ref internalNav" href="#t13fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.20 ± 0.06</td><td class="colsep0 rowsep0" align="left">0.38 ± 0.11</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t13fn1"><div class="footnote" id="t13fn1"><sup><sup>a</sup></sup><p class="last">Vehicle: Tween 80 (1%), Gelucire 44/14 (15%) and Milli-Q water (84%), in a dose volume of 10 mL/kg, q.d., p.o. Data shown as mean ± SEM of <i>n</i> = 7–8. Two-way ANOVA followed by the Bonferroni’s post-hoc comparisons test.</p></div><div class="footnote" id="t13fn2"><sup><sup>b</sup></sup><p class="last"><i>P</i> < 0.01.</p></div><div class="footnote" id="t13fn3"><sup><sup>c</sup></sup><p class="last"><i>P</i> < 0.001 compared to the vehicle control. Concentration (conc.).</p></div></div></div><div class="NLM_p">Strikingly, compound <b>34</b> maintained selectivity toward the PI3Kδ isoform even at the IC<sub>90</sub> concentration (IC<sub>90</sub>, 28.1 nM for PI3Kδ <i>vs</i> 159.8 nM for PI3Kγ) with ∼6-fold selectivity against PI3Kγ and >80-fold selectivity against PI3Kα and PI3Kβ (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). In the cell-based assays, compound <b>34</b> maintained even higher selectivity, 16-fold for PI3Kδ over PI3Kγ at the IC<sub>90</sub> concentrations. Compound <b>34</b> showed excellent selectivity against a panel of 196 kinases at a concentration of 10 μM (<30%) inhibition against 5 kinases and <20% inhibition against the remaining 191 kinases (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_001.pdf" class="ext-link">Table S2</a>). Compound <b>34</b> showed plasma protein bindings of 96.98, 96.92, and 98.86 for mouse, rat, and human, respectively. Based on the plasma protein binding profile seen in mouse, free drug concentrations at the highest tested dose of 30 mg/kg, p.o., in OCI-LY10 and TMD8 xenograft models are 157.6 and 166.1 nM, respectively. At these concentrations, compound <b>34</b> will engage PI3Kδ (IC<sub>90</sub> of 37.6 nM in the PI3Kδ cell-based assay) while still sparing PI3Kγ (IC<sub>90</sub> 614 nM in the PI3Kγ cell-based assay), thereby increasing tolerability and therapeutic index as compared to other available PI3K inhibitors. Conversely, less potent compounds with inferior pharmacokinetic properties had to be administered in higher doses for effective target engagement. This, however, is expected to lower the therapeutic index and reduce tolerability.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Our findings may have important implications as we demonstrate herein, for the first time, that it is feasible to design a safer and efficacious PI3Kδ selective inhibitor. Compound <b>34</b> is capable of blocking >90% of PI3Kδ, without significantly blocking the other PI3K isoforms, a profile that is expected to limit PI3Kγ-mediated toxicities. Consistent with this concept, compound <b>34</b> demonstrated robust efficacy in preclinical models of DLBCLs with minimal effects on animal health and survival even at high dose levels.</div><div class="NLM_p last">Our data suggest that it may be relevant to evaluate compound <b>34</b> clinically in both GCB and ABC-DLBCL patients, stratified based on mutational and molecular markers. Apart from PI3Kγδ, several other therapeutic targets like BTK are being explored for the clinical management of DLBCLs with mixed results and limited success. We also envisage testing rational combinations of our compounds with chemoimmunotherapy and targeted therapies to achieve complete and durable remissions in DLBCLs with best-in-class safety margins.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemistry</h3><div class="NLM_p">The synthetic pathway for the analogues <b>4–19</b> is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The quinolizin-4-one scaffold in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> was prepared from commercially available, differently substituted, picolinaldehydes. The quinolizin-4-one core <b>40c–e</b> was constructed in 3 steps, wherein a Wittig reaction was performed between a substituted picolinaldehyde and ethyl 3-(diethoxyphosphoryl)-4-oxopentanoate to obtain <b>38a–e</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The intermediates <b>38c–e</b> were hydrolyzed to acids <b>39c–e</b> and subsequent cyclization of these intermediates <b>39c–e</b> in the presence of EDC·HCl produced the quinolizin-4-one scaffolds <b>40c–e</b>. Compounds <b>40a–b</b> were prepared by cyclization of compounds <b>38a–b</b> using <i>p</i>TsOH.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The variations at the C-3 position were introduced by the bromination of quinolizin-4-one followed by Suzuki coupling with differently substituted aryl or aliphatic boronic acids.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33,34)</a> These ketone intermediates <b>42a–j</b> were converted into ketimine intermediates <b>43a–j</b> in the presence of Ellman’s sulfinamide and titanium isopropoxide. The reduction of these ketimines gave a mixture of two diastereomers, the required isomer (<i>S</i>,<i>S</i><sub>s</sub>) being the major diastereomer.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> The intermediates <b>44a–d</b> were used in the next step without diastereomeric separation, whereas, diastereomers <b>44e–j</b> were separated by crystallization in ethanol and water. The sulfinamide intermediates <b>44a–j</b> were deprotected in methanolic HCl and the resulted amines <b>45a–j</b> were treated with varying halo heterocycles, like purines and pyrimidines, to afford final compounds <b>4–19</b>. Compounds <b>4–9</b> were purified by chiral HPLC, whereas, compounds <b>10–19</b> were synthesized by using chirally pure amines <b>45e–j</b>.</div><figure id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>4–19</b>, <b>46</b>, and <b>26</b>, <b>30–34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) K<sub>2</sub>CO<sub>3</sub>, ethyl 3-(diethoxyphosphoryl)-4-oxopentanoate, THF, and water, 45 °C, 4 h; (ii) <i>p</i>-TsOH and xylene, 140 °C; (iii) LiOH, THF/methanol/water (2:2:1), RT, 2 h; (iv) EDC·HCl, TEA and DMF, RT, 18 h; (v) NBS and DMF, 0 °C, 1 h; (vi) arylboronic acid, Na<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub> and ethanol/toluene/water (2:2:1), 85 °C, 12 h; (vii) (<i>S</i>)-2-methylpropane-2-sulfinamide, Ti(O<i>i</i>Pr)<sub>4</sub> and toluene, 95 °C, 9 h; (viii) NaBH<sub>4</sub> and THF, 45 °C, 1.5 h; (ix) methanolic HCl and methanol, RT, 0.5 h; (x) halo heterocycle, DIPEA and DMF, 100 °C, 30 h. (xi) NBS, DMF, 0 °C, 1 h; and (xii) aliphatic or aryl boronic acid, Pd(amphos)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> and dioxane, 90 °C, 36 h.</p></p></figure><div class="NLM_p">The synthesis of the aryl substituent at the C-1 position of the quinolizin-4-one core for analogues <b>20–25</b> is described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Substitution at the C-1 position was achieved by blocking the C-3 position by iodination of <b>40e</b> by NIS. Further treatment of compound <b>48</b> with Ellman’s sulfinamide and titanium isopropoxide afforded compound <b>49</b>. The ketimine intermediate <b>49</b> was reduced by NaBH<sub>4</sub> to afford the mixture of two diastereomers, which were crystallized in ethanol and water to give the desired diastereomer (<i>S,S</i><sub>s</sub>) as sulfinamide intermediate <b>50</b>.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Compound <b>50</b> was deprotected in methanolic HCl to give amine as in compound <b>51</b>. Protection of compound <b>51</b> by <i>tert</i>-butoxycarbonyl group, followed by its bromination afforded compound <b>53</b>.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The de-iodination at the C-3 position was performed by NaBH<sub>4</sub> in IPA. The treatment of compound <b>54</b> with aryl boronic acid under Suzuki coupling conditions afforded compounds <b>55a–c</b>. The deprotection of the Boc group gave chiral amine, which reacts with various halo heterocycles to afford compounds <b>20–25</b>.</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>20–25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NIS and DMF, RT, 2.5 h; (ii) (<i>S</i>)-2-methylpropane-2-sulfinamide, Ti(O<i>i</i>Pr)<sub>4</sub>, and toluene, 95 °C, 9 h; (iii) NaBH<sub>4</sub> and THF, 45 °C, 1.5 h; (iv) methanolic HCl and methanol, RT, 0.5 h; (v) Na<sub>2</sub>CO<sub>3</sub>, Boc-anhydride, and THF/water (12:2), 40 °C, 2 h; (vi) NBS and DMF, 0 °C, 1 h; (vii) NaBH<sub>4</sub> and IPA, 45 °C, 30 min; (viii) arylboronic acid, Na<sub>2</sub>CO<sub>3,</sub>Pd(PPh<sub>3</sub>)<sub>4</sub>, and ethanol/toluene/water (2:2:1), 90 °C, 8 h; (ix) TFA, 60 °C, 30 min; and (x) halo heterocycle, DIPEA, and DMF, 80 °C, 8 h.</p></p></figure><div class="NLM_p">The synthesis of analogues of compound <b>26</b> (compounds <b>30–34</b>) is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Substitution at the quinolizin-4-one C-1 position is achieved by bromination followed by the Suzuki coupling reaction. Compounds <b>27–29</b> and compounds <b>35–36</b> were synthesized as described in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Variation at the C-3 position of compounds <b>59a–b</b> were done by the Suzuki coupling reaction and variation at the C-1 position (R<sub>5</sub>) before the nucleophilic substitution reaction with halo heterocycles.</div><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>27–29</b> and <b>35–36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions; (i) aliphatic or arylboronic acid, Pd(amphos)Cl<sub>2</sub>, NaOtBu, CsF, and dioxane, 85 °C, 15 h; (ii) NBS and DMF, 0–25 °C, 30 min; (iii) aryl boronic acid, Na<sub>2</sub>CO<sub>3</sub>, Pd(amphos)Cl<sub>2</sub>, CsF, and dioxane, 85 °C, 4 h; (iv) TFA and DCM, 50 °C, 1 h. (v) Halo heterocycle, DIPEA and DMF, 80 °C, 12 h.</p></p></figure><div class="NLM_p last">The absolute stereochemistry of intermediate <b>50</b> was initially determined to be <i>S</i>,<i>S</i><sub>s</sub> using vibrational circular dichroism (VCD), and it was later confirmed through single crystal X-ray crystallography studies (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_003.csv" class="ext-link">Supporting Information</a>). Stereochemistry of intermediate <b>44e</b> was confirmed to be <i>S</i>,<i>S</i><sub>s</sub> through independent synthesis by coupling intermediate <b>50</b> with phenyl boronic acid. Later, intermediate <b>44e</b> was converted to the lead compounds, as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78452" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78452" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Our efforts toward designing a structurally distinct PI3Kδ inhibitor led to the redefinition of the pharmacophore. This was achieved by introducing another arm to make a four-blade propeller structure. This novel design, in addition to being potent and selective, also showed superior cellular PI3Kδ inhibition. It also imparted a better PK profile as compared to CAL-101 and IPI-145. Compound <b>34</b> was optimized for better isoform selectivity at therapeutically relevant dose levels. We feel that it is suitable for further evaluation as a potential development candidate for monotherapy or in combination with other targeted agents, in DLBCLs and other forms of iNHL.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51123" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51123" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Methods</h3><div class="NLM_p last">All reagents were purchased from commercial suppliers and used without purification unless otherwise specified. All anhydrous reactions were performed under a nitrogen atmosphere using dry solvents. Silica gel column chromatography was carried out on ISCO CombiFlash Companion with prepacked columns. Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded on a Bruker AVANCE V-III 400 MHz spectrometer. All spectra were determined in the solvents indicated and chemical shifts are reported in δ units downfield from the internal standard tetramethylsilane (TMS) with interproton coupling constants reported in hertz (Hz). Multiplicity patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad; dd, doublet of doublet; dt, doublet of triplet; dq, and doublet of quartet. All NMR spectra were analyzed using MestReNova 10.0 program software. Liquid chromatography (LC)/mass spectrometry (MS) analyses were performed on either an Agilent 1200 series LC instrument coupled to an Agilent Ion Trap MS instrument or a Thermo Scientific Accela LC instrument coupled to a Thermo Scientific MSQ Plus instrument. Gas chromatography (GC)/MS analyses were performed on a Thermo Scientific focus GC instrument coupled to a Thermo Scientific ISQ instrument. HRMS spectra were acquired by direct infusion of samples in positive ESI (electrospray ionization) mode on Thermo Q Exactive HRMS at 140000 resolution. Compound purity was determined by reverse-phase HPLC performed on an Agilent 1290 Infinity equipped with either a ZORBAX Eclipse Plus C18, 50 mm × 2.1 mm, 1.8 μm or an Acquity Beh C18, 50 mm × 2.1 mm, 1.7 μm column using either acid (0.1% formic acid) or base (0.1% NH<sub>4</sub>OH)-modified MeCN–H<sub>2</sub>O gradients. Preparative HPLC was performed on a Gilson GX 281 series using a YMC ODS-A column or YMC Triat column (50 mm × 250 mm, 10 μm) using either acid (0.1% formic acid) or base-(0.1% NH<sub>4</sub>OH) modified MeCN–H<sub>2</sub>O gradients. Few final compounds were prepared as a racemic mixture and separated using preparative chiral HPLC at the final stage. Preparative chiral separations were carried out using a Knauer Azura 2.1 L purification system with CHIRALPAK IA column and different mobile phases. Methods and conditions for chiral separation of all of the relevant compounds are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_003.csv" class="ext-link">Supporting Information</a>. The analytical data for the final compounds are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_003.csv" class="ext-link">Supporting Information</a>. All tested compounds were determined to be >95% purity by HPLC. Optical rotations were measured at the sodium D line, using a Rudolph autopol IV automatic polarimeter and a 100 mm cell. VCD spectra of the compounds were recorded on a BioTools/Bomem Dual PEM chiral IR spectrometer (Biotools, Inc., Jupiter, FL) using a 100 μm liquid cell equipped with BaF<sub>2</sub> windows.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure for the Wittig Reaction</h3><div class="NLM_p">To a stirred solution of 5-fluoropicolinaldehyde (38 g, 304 mmol) and ethyl 3-(diethoxyphosphoryl)-4-oxopentanoate (85 g, 304 mmol) in THF (190 mL) was added dropwise K<sub>2</sub>CO<sub>3</sub> solution (42 g, 304 mmol in 56 mL water) at room temperature and heated at 45 °C for 4 h. The reaction mixture was slowly poured into stirred ice-cold water (500 mL). The precipitated solid was filtered and dried under vacuum to obtain the desired compound.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> Ethyl 4-Oxo-3-(pyridin-2-ylmethylene)pentanoate (<b>38a</b>)</h4><div class="NLM_p last">Yield: 68%. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.70–8.66 (m, 1H), 7.78–7.71 (m, 1H), 7.58 (s, 1H), 7.45–7.41 (m, 1H), 7.27–7.23 (m, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 4.06 (s, 2H), 2.54 (s, 3H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). GCMS (EI) <i>m</i>/<i>z</i>: 233.12 [M]<sup>+</sup></div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Ethyl 3-((5-Methylpyridin-2-yl)methylene)-4-oxopentanoate (<b>38b</b>)</h4><div class="NLM_p last">Yield: 34% <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.51 (d, <i>J</i> = 2.3 Hz, 1H), 7.58–7.50 (m, 2H), 7.32 (d, <i>J</i> = 7.9 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 4.05 (s, 2H), 2.52 (s, 3H), 2.37 (s, 3H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 248.33 [M + H]<sup>+</sup></div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Ethyl 3-((6-Methylpyridin-2-yl)methylene)-4-oxopentanoate (<b>38c</b>)</h4><div class="NLM_p last">Yield: 74%. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.62 (t, <i>J</i> = 7.7 Hz, 1H), 7.56 (s, 1H), 7.24 (d, <i>J</i> = 7.7 Hz, 1H), 7.11 (d, <i>J</i> = 7.7 Hz, 1H), 4.14 (q, <i>J</i> = 7.1 Hz, 2H), 4.02 (s, 2H), 2.57 (s, 3H), 2.53 (s, 3H), 1.25 (t, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 248.39 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Ethyl 3-((5-Fluoro-6-methylpyridin-2-yl)methylene)-4-oxopentanoate (<b>38d</b>)</h4><div class="NLM_p last">Yield: 55%. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.52 (s, 1H), 7.39–7.28 (m, 2H), 4.14 (q, <i>J</i> = 7.2 Hz, 2H), 4.01 (s, 2H), 2.54 (d, <i>J</i> = 3.0 Hz, 3H), 2.52 (s, 3H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 266 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Ethyl 3-((5-Fluoropyridin-2-yl)methylene)-4-oxopentanoate (<b>38e</b>)</h4><div class="NLM_p last">Yield: 71%. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.54 (t, <i>J</i> = 1.7 Hz, 1H), 7.55 (s, 1H), 7.51–7.40 (m, 2H), 4.15 (q, <i>J</i> = 7.1 Hz, 2H), 4.04 (s, 2H), 2.53 (s, 3H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 252.39 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure for Hydrolysis</h3><div class="NLM_p">To a stirred solution of <b>38e</b> (19 g, 76 mmol) in THF/MeOH (200 mL, 1:1), solution of lithium hydroxide (4.68 g, 113 mmol in water 50 mL) was added. The reaction mixture was stirred at room temperature for 2 h. Organic solvents were removed under vacuum. The mixture was diluted with water (100 mL) and neutralized by using aq HCl. The resulting precipitate solid was filtered, dried under vacuum to obtain the desired product.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-((6-Methylpyridin-2-yl)methylene)-4-oxopentanoic Acid (<b>39c</b>)</h4><div class="NLM_p last">Yield: 94%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.30 (br s, 1H), 7.79 (t, <i>J</i> = 7.7 Hz, 1H), 7.71 (s, 1H), 7.48 (d, <i>J</i> = 7.6 Hz, 1H), 7.26 (d, <i>J</i> = 7.7 Hz, 1H), 3.94 (s, 2H), 2.50 (s, 3H), 2.46 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 220.64 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-((5-Fluoro-6-methylpyridin-2-yl)methylene)-4-oxopentanoic Acid (<b>39d</b>)</h4><div class="NLM_p last">Yield: 90%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.65 (s, 1H), 7.59 (t, <i>J</i> = 8.4 Hz, 1H), 7.45 (dd, <i>J</i> = 8.5, 3.9 Hz, 1H), 3.74 (s, 2H), 2.65 (d, <i>J</i> = 2.8 Hz, 3H), 2.56 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 238.39 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-((5-Fluoropyridin-2-yl)methylene)-4-oxopentanoic Acid (<b>39e</b>)</h4><div class="NLM_p last">Yield: 88%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.10 (s, 1H), 8.69 (d, <i>J</i> = 2.9 Hz, 1H), 7.91–7.74 (m, 3H), 3.94 (s, 2H), 2.46 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 224.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> General Procedure for Cyclization</h3><div class="NLM_p">(a) A stirred solution of <b>38a</b> (1.7 g, 7.29 mmol) and <i>p</i>TsOH (0.139 g, 0.729 mmol) in xylene (75 mL) was heated at 140 °C for 2 h and then cooled to room temperature. The solvent was removed under vacuum, the resultant residue was diluted with cold water and extracted with DCM (2 × 200 mL). The combined organic layer was washed with water (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography using 50% ethyl acetate in hexane as an eluent to obtain the desired product.</div><div class="NLM_p">(b) To a stirred solution of <b>39e</b> (65 g, 291 mmol) in DMF (200 mL) was added EDC·HCl (67.0 g, 349 mmol) at 0–5 °C. The reaction mixture was stirred for 10 min, and then triethylamine (60.9 mL, 437 mmol) was added at the same temperature. This reaction mixture was stirred at room temperature for 18 h. The reaction mixture was poured into ice cold water and stirred for 30 min at 0–5 °C. The precipitated solid was filtered, dried to obtain the desired product.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-Acetyl-4<i>H</i>-quinolizin-4-one (<b>40a</b>)</h4><div class="NLM_p last">Yield: 71%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.20–9.12 (m, 1H), 7.69–7.61 (m, 1H), 7.50–7.41 (m, 1H), 7.19–7.06 (m, 3H), 2.67 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 188.64 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-Acetyl-7-methyl-4<i>H</i>-quinolizin-4-one (<b>40b</b>)</h4><div class="NLM_p last">Yield: 84%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.03–8.97 (m, 1H), 7.59 (d, <i>J</i> = 8.9 Hz, 1H), 7.34 (dd, <i>J</i> = 8.9, 1.7 Hz, 1H), 7.18–7.12 (m, 1H), 7.06 (d, <i>J</i> = 1.8 Hz, 1H), 2.66 (s, 3H), 2.44 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 201.9 [M]<sup>+</sup>.</div></div><div id="sec4_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-Acetyl-6-methyl-4<i>H</i>-quinolizin-4-one (<b>40c</b>)</h4><div class="NLM_p last">Yield: 70%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.36–7.29 (m, 1H), 7.15–7.06 (m, 1H), 6.93 (d, <i>J</i> = 2.0 Hz, 1H), 6.89 (d, <i>J</i> = 2.1 Hz, 1H), 6.63–6.55 (m, 1H), 3.06 (s, 3H), 2.62 (s, 3H). GCMS (EI) <i>m</i>/<i>z</i>: 201.07.</div></div><div id="sec4_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-Acetyl-7-fluoro-6-methyl-4<i>H</i>-quinolizin-4-one (<b>40d</b>)</h4><div class="NLM_p last">Yield: 60%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.33 (dd, <i>J</i> = 9.7, 5.8 Hz, 1H), 7.13 (dd, <i>J</i> = 9.7, 7.5 Hz, 1H), 6.97 (d, <i>J</i> = 2.0 Hz, 1H), 6.91 (d, <i>J</i> = 2.0 Hz, 1H), 2.96 (d, <i>J</i> = 4.3 Hz, 3H), 2.62 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 220 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-Acetyl-7-fluoro-4<i>H</i>-quinolizin-4-one (<b>40e</b>)</h4><div class="NLM_p last">Yield: 78%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.05 (dd, <i>J</i> = 5.6, 2.5 Hz, 1H), 7.66 (dd, <i>J</i> = 9.7, 5.5 Hz, 1H), 7.41–7.32 (m, 1H), 7.24–7.19 (m, 1H), 7.10 (d, <i>J</i> = 1.7 Hz, 1H), 2.65 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 205.91 [M]<sup>+</sup>.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> General Procedure for Bromination</h3><div class="NLM_p">To a stirred solution of <b>40e</b> (16.5 g, 80 mmol) in DMF (60 mL) was added a solution of NBS (13.6 g, 735 mmol) in DMF (30 mL) at 0 °C. This reaction mixture was stirred at 0–5 °C for 1 h. The reaction mixture was diluted by cold water (250 mL) and extracted with ethyl acetate (2 × 150 mL). The combined organic layer was washed with water (2 × 100 mL) and dried over anhydrous sodium sulfate. The organic layer was concentrated under vacuum. The crude product was purified by flash column chromatography using 25% ethyl acetate in hexane as an eluent to obtain the desired product.</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-Acetyl-3-bromo-4<i>H</i>-quinolizin-4-one (<b>41a</b>)</h4><div class="NLM_p last">Yield: 65%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.23–9.15 (m, 1H), 7.61–7.53 (m, 1H), 7.53–7.46 (m, 1H), 7.21–7.12 (m, 1H), 6.59 (s, 1H), 2.69 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 266.2/268.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 2-Acetyl-3-bromo-7-methyl-4<i>H</i>-quinolizin-4-one (<b>41b</b>)</h4><div class="NLM_p last">Yield: 71%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.04–8.98 (m, 1H), 7.50 (d, <i>J</i> = 8.9 Hz, 1H), 7.37 (dd, <i>J</i> = 8.9, 1.7 Hz, 1H), 6.58 (s, 1H), 2.68 (s, 3H), 2.46 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 279.9/281.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-Acetyl-3-bromo-6-methyl-4<i>H</i>-quinolizin-4-one (<b>41c</b>)</h4><div class="NLM_p last">Yield: 72%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.28–7.22 (m, 1H), 7.21–7.13 (m, 1H), 6.71–6.63 (m, 1H), 6.39 (s, 1H), 3.07 (s, 3H), 2.65 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 280.21/282.27 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-Acetyl-3-bromo-7-fluoro-6-methyl-4<i>H</i>-quinolizin-4-one (<b>41d</b>)</h4><div class="NLM_p last">Yield: 61%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.31–7.22 (m, 1H), 7.22–7.13 (m, 1H), 6.44 (s, 1H), 2.96 (d, <i>J</i> = 4.2 Hz, 3H), 2.66 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 298.27/300.15 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-Acetyl-3-bromo-7-fluoro-4<i>H</i>-quinolizin-4-one (<b>41e</b>)</h4><div class="NLM_p last">Yield: 77%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.09 (dd, <i>J</i> = 5.5, 2.4 Hz, 1H), 7.61 (dd, <i>J</i> = 9.6, 5.4 Hz, 1H), 7.47–7.39 (m, 1H), 6.66 (s, 1H), 2.68 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 283.9/285.88 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> General Procedure for the Suzuki Coupling Reaction</h3><div class="NLM_p">To a stirred mixture of <b>41e</b> (1.6 g, 5.63 mmol), phenylboronic acid (0.75 g, 6.2 mmol), and Na<sub>2</sub>CO<sub>3</sub> (1.79 g, 16.9 mmol) in water/ethanol/toluene (50 mL, 1:2:2) was added tetrakis(triphenylphosphine)-palladium(0) (0.39 g, 0.34 mmol) under a nitrogen atmosphere. The reaction mixture was purged by nitrogen for 5 min and then heated at 85 °C for 12 h. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified by flash column chromatography using 25% ethyl acetate in hexane as an eluent to obtain the desired product.</div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 2-Acetyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>42a</b>)</h4><div class="NLM_p last">Yield: 92%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.26–9.20 (m, 1H), 7.62–7.55 (m, 1H), 7.51–7.38 (m, 6H), 7.14–7.07 (m, 1H), 6.75–6.70 (m, 1H), 1.95 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 264 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 2-Acetyl-7-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>42b</b>)</h4><div class="NLM_p last">Yield: 91%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.10–9.0 (m, 1H), 7.56–7.34 (m, 6H), 7.31 (dd, <i>J</i> = 8.9, 1.7 Hz, 1H), 6.71 (s, 1H), 2.44 (s, 3H), 1.94 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 278.40 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 2-Acetyl-6-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>42c</b>)</h4><div class="NLM_p last">Yield: 89%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.54–7.33 (m, 5H), 7.31–7.23 (m, 1H), 7.14–7.05 (m, 1H), 6.63–6.57 (m, 1H), 6.53 (s, 1H), 3.05 (s, 3H), 1.92 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 278.01 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 2-Acetyl-7-fluoro-6-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>42d</b>)</h4><div class="NLM_p last">Yield: 69%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.50–7.35 (m, 5H), 7.31–7.22 (m, 1H), 7.16–7.07 (m, 1H), 6.57 (s, 1H), 2.94 (d, <i>J</i> = 4.3 Hz, 3H), 1.91 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 296.05 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 2-Acetyl-7-fluoro-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>42e</b>)</h4><div class="NLM_p last">Yield: 91%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.14 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 7.65–7.57 (m, 1H) 7.52–7.41 (m, 5H), 7.41–7.31 (m, 1H), 6.81 (s, 1H), 1.95 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 282.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-Acetyl-7-fluoro-3-(<i>m</i>-tolyl)-4<i>H</i>-quinolizin-4-one (<b>42f</b>)</h4><div class="NLM_p last">Yield: 93%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.0 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 8.08–7.99 (m, 1H), 7.85–7.74 (m, 1H), 7.37–7.29 (m, 1H), 7.23–7.18 (m, 2H), 7.14–7.09 (m, 1H), 7.07 (s, 1H), 2.34 (s, 3H), 2.02 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 296.04 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-Acetyl-7-fluoro-3-(3-fluoro-5-methylphenyl)-4<i>H</i>-quinolizin-4-one (<b>42g</b>)</h4><div class="NLM_p last">Yield: 84%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.16–9.11 (m, 1H), 7.62 (dd, <i>J</i> = 9.6, 5.5 Hz, 1H), 7.42–7.35 (m, 1H), 7.08–6.99 (m, 2H), 6.99–6.89 (m, 1H), 6.80 (s, 1H), 2.40 (s, 3H), 2.01 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 314.34 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-Acetyl-7-fluoro-3-(4-fluorophenyl)-4<i>H</i>-quinolizin-4-one (<b>42h</b>)</h4><div class="NLM_p last">Yield: 83%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.12 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 7.64–7.58 (m, 1H) 7.49–7.44 (m, 2H), 7.41–7.35 (m, 1H), 7.19–7.13 (m, 2H), 6.80 (s, 1H), 1.99 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 300.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-Acetyl-3-(3,5-difluorophenyl)-7-fluoro-4<i>H</i>-quinolizin-4-one (<b>42i</b>)</h4><div class="NLM_p last">Yield: 91%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.04 (dd, <i>J</i> = 5.9, 2.5 Hz, 1H), 8.11–8.03 (m, 1H), 7.92–7.84 (m, 1H), 7.68–7.52 (m, 1H), 7.32–7.23 (m, 1H), 7.11–7.03 (m, 2H), 2.28 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 318.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-Acetyl-7-fluoro-3-methyl-4<i>H</i>-quinolizin-4-one (<b>42j</b>)</h4><div class="NLM_p last">Yield: 26%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.87 (dd, <i>J</i> = 6.1, 2.4 Hz, 1H), 7.95–7.87 (m, 1H), 7.71–7.62 (m, 1H), 7.18 (s, 1H), 2.59 (s, 3H), 2.22 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 220.15 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> General Procedure for the Ketimine Synthesis</h3><div class="NLM_p">To a stirred solution of <b>42e</b> (50.1 g, 178 mmol) and titanium(IV) isopropoxide (209 mL, 712 mmol) in toluene (25 mL) was added (<i>S</i>)-2-methylpropane-2-sulfinamide (23.75 g, 196 mmol) at room temperature. The reaction mass was heated at 95 °C for 9 h. The reaction mass was diluted with DCM (2 L), satd. sodium chloride (1 L), and water (1 L). The reaction mass was stirred for 10 min at room temperature. The organic layer was separated and aqueous layer washed with DCM (2 × 1 L). The combined organic layer was filtered through Celite bed and concentrated under vacuum. The crude product was purified by flash column chromatography by using 50% ethyl acetate in hexane as an eluent to give the desired product.</div><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (<i>S</i>,<i>E</i>)-2-Methyl-<i>N</i>-(1-(4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethylidene)propane-2-sulfinamide (<b>43a</b>)</h4><div class="NLM_p last">Yield: 46%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.20 (d, <i>J</i> = 7.4 Hz, 1H), 7.62–7.54 (m, 1H), 7.51–7.32 (m, 6H), 7.12–7.06 (m, 1H), 6.76 (s, 1H), 2.17 (s, 3H), 1.30 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 367.35 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>S</i>,<i>E</i>)-2-Methyl-<i>N</i>-(1-(7-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethylidene)propane-2-sulfinamide (<b>43b</b>)</h4><div class="NLM_p last">Yield: 54%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.92–8.84 (m, 1H), 7.91–7.80 (m, 1H), 7.56–7.51 (m, 1H), 7.43–7.31 (m, 5H), 6.91 (s, 0.8H), 6.79 (s, 0.2H), 2.40 (d, <i>J</i> = 1.3 Hz, 3H), 2.18 (s, 2.2H), 1.89 (s, 0.8H), 1.21 (s, 2.2H), 1.09 (s, 6.8H). LCMS (ESI) <i>m</i>/<i>z</i>: 381.29 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (<i>S</i>,<i>E</i>)-2-Methyl-<i>N</i>-(1-(6-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethylidene)propane-2-sulfinamide (<b>43c</b>)</h4><div class="NLM_p last">Product was not isolated and the reaction mixture was used for subsequent step.</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (<i>S</i>,<i>E</i>)-<i>N</i>-(1-(7-Fluoro-6-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethylidene)-2-methylpropane-2-sulfinamide (<b>43d</b>)</h4><div class="NLM_p last">Yield: 51%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.43–7.39 (m, 4H), 7.37–7.32 (m, 1H), 7.28–7.22 (m, 1H), 7.15–7.05 (m, 1H), 6.59 (s, 1H), 2.93 (d, <i>J</i> = 4.4 Hz, 3H), 2.12 (s, 3H), 1.27 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 399.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (<i>S</i>,<i>E</i>)-<i>N</i>-(1-(7-Fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethylidene)-2-methylpropane-2-sulfinamide (<b>43e</b>)</h4><div class="NLM_p last">Yield: 66%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.12 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 7.64–7.57 (m, 1H), 7.48–7.41 (m, 4H), 7.39–7.33 (m, 2H), 6.84 (s, 1H), 2.16 (s, 3H), 1.30 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 385.28 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>S</i>,<i>E</i>)-<i>N</i>-(1-(7-Fluoro-4-oxo-3-(<i>m</i>-tolyl)-4<i>H</i>-quinolizin-2-yl)ethylidene)-2-methylpropane-2-sulfinamide (<b>43f</b>)</h4><div class="NLM_p last">Yield: 59%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.10 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 7.62–7.56 (m, 1H), 7.37–7.30 (m, 3H), 7.23–7.17 (m, 2H), 6.84 (s, 1H), 2.38 (s, 3H), 2.15 (s, 3H), 1.30 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 399.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (<i>S</i>,<i>E</i>)-<i>N</i>-(1-(7-Fluoro-3-(3-fluoro-5-methylphenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethylidene)-2-methylpropane-2-sulfinamide (<b>43g</b>)</h4><div class="NLM_p last">Yield: 32%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.11 (dd, <i>J</i> = 5.7, 2.5 Hz, 1H), 7.65–7.57 (m, 1H), 7.43–7.32 (m, 1H), 7.06–6.97 (m, 2H), 6.94–6.86 (m, 1H), 6.82 (s, 1H), 2.38 (s, 3H), 2.21 (s, 3H), 1.30 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 416.35 [M]<sup>+</sup>.</div></div><div id="sec4_7_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>S</i>,<i>E</i>)-<i>N</i>-(1-(7-Fluoro-3-(4-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethylidene)-2-methylpropane-2-sulfinamide (<b>43h</b>)</h4><div class="NLM_p last">Yield: 57%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.14–9.07 (m, 1H), 7.64–7.58 (m, 1H), 7.49–7.42 (m, 2H), 7.40–7.34 (m, 1H), 7.16–7.10 (m, 2H), 6.83 (s, 1H), 2.20 (s, 3H), 1.30 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 403.23 [M + H]<sup>+</sup>.</div></div><div id="sec4_7_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>S</i>,<i>E</i>)-<i>N</i>-(-(3-(3,5-Difluorophenyl)-7-fluoro-4-oxo-4<i>H</i>-quinolizin-2-yl)ethylidene)-2-methylpropane-2-sulfinamide (<b>43i</b>)</h4><div class="NLM_p last">Yield: 64%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.12–8.91 (m, 1H), 8.10–7.96 (m, 1H), 7.90–7.79 (m, 1H), 7.69–7.51 (m, 1H), 7.30–7.20 (m, 1H), 7.17–7.04 (m, 2H), 2.39 (s, 2H), 2.0 (s, 1H), 1.23 (s, 2H), 1.07 (s, 7H). LCMS (ESI) <i>m</i>/<i>z</i>: 420.92 [M]<sup>+</sup>.</div></div><div id="sec4_7_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>S</i>,<i>E</i>)-<i>N</i>-(1-(7-Fluoro-3-methyl-4-oxo-4<i>H</i>-quinolizin-2-yl)ethylidene)-2-methylpropane-2-sulfinamide (<b>43j</b>)</h4><div class="NLM_p last">Yield: 45%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.03–8.94 (m, 1H), 7.53–7.44 (m, 1H), 7.28–7.19 (m, 1H), 6.65–6.58 (m, 1H), 2.72 (s, 2H), 2.50 (s, 1H), 2.36 (s, 2H), 2.24 (s, 1H), 1.32 (s, 5H), 1.25 (s, 4H). LCMS (ESI) <i>m</i>/<i>z</i>: 322.93 [M]<sup>+</sup>.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> General Procedure for the Ketimine Reduction</h3><div class="NLM_p">To a stirred suspension of NaBH<sub>4</sub> (6.35 g, 17 1.8 mmol) in THF (500 mL) was added <b>43e</b> (66 g, 17 1.8 mmol) at room temperature, and the reaction mixture was heated at 45 °C for 1.5 h. The reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate (3 × 500 mL), the combined organic layer was washed with the brine solution (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain (<i>S</i>)-<i>N</i>-1-((7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide.</div><div class="NLM_p">In a round bottom flask suspension of (<i>S</i>)-<i>N</i>-1-(7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (66 g, 171 mmol) in ethanol/water (660 mL, 1:1) was heated at 80 °C for 10 min. The clear solution was allowed to come at room temperature and then cooled at 0–5 °C for 1 h. The solid product was filtered, washed with a chilled water/ethanol (330 mL, 4:1), and dried under high vacuum to obtain pure (<i>S</i>)-<i>N</i>-(<i>S</i>)-1-(7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide <b>44e</b> (36 g, 54.5% yield, 96.26% HPLC purity, 96.7% chiral purity).</div><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (<i>S</i>)-2-Methyl-<i>N</i>-(1-(4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)propane-2-sulfinamide (<b>44a</b>)</h4><div class="NLM_p last">Yield: 47%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.08 (d, <i>J</i> = 7.4 Hz, 1H), 7.55–7.45 (m, 3H), 7.45–7.30 (m, 4H), 7.04–6.94 (m, 1H), 6.83 (s, 1H), 4.60–4.49 (m, 1H), 3.55 (s, 1H), 1.42 (d, <i>J</i> = 6.7 Hz, 3H), 1.23 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 369.25 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (<i>S</i>)-2-Methyl-<i>N</i>-(1-(7-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)propane-2-sulfinamide (<b>44b</b>)</h4><div class="NLM_p last">Yield: 54%, LCMS (ESI) <i>m</i>/<i>z</i>: 383.29 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (<i>S</i>)-2-Methyl-<i>N</i>-(1-(6-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)propane-2-sulfinamide (<b>44c</b>)</h4><div class="NLM_p last">Yield: 46%, LCMS (ESI) <i>m</i>/<i>z</i>: 383.85 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (<i>S</i>)-<i>N</i>-(1-(7-Fluoro-6-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (<b>44d</b>)</h4><div class="NLM_p last">Yield: 70%, LCMS (ESI) <i>m</i>/<i>z</i>: 401.09 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(7-Fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (<b>44e</b>)</h4><div class="NLM_p last">Yield: 67%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.0 (dd, <i>J</i> = 5.8, 2.4 Hz, 1H), 7.58–7.45 (m, 3H), 7.45–7.38 (m, 1H), 7.32–7.22 (m, 3H), 6.91 (s, 1H), 4.59–4.48 (m, 1H), 3.53 (d, <i>J</i> = 5.2 Hz, 1H), 1.41 (d, <i>J</i> = 6.7 Hz, 3H), 1.22 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 387.08 [M + H]<sup>+</sup>. [α]<sub>D</sub> 53.091° (<i>c</i> 0.990, CHCl<sub>3</sub>).</div></div><div id="sec4_8_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(7-Fluoro-4-oxo-3-(<i>m</i>-tolyl)-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (<b>44f</b>)</h4><div class="NLM_p last">Yield: 63%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 7.91–7.75 (m, 1H), 7.70–7.54 (m, 1H), 7.45–7.28 (m, 1H), 7.29–7.15 (m, 2H), 7.08 (br s, 2H), 5.73 (d, <i>J</i> = 7.1 Hz, 1H), 4.27–4.13 (m, 1H), 2.35 (s, 3H), 1.29 (d, <i>J</i> = 6.8 Hz, 3H), 1.08 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 401.08 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(7-Fluoro-3-(3-fluoro-5-methylphenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (<b>44g</b>)</h4><div class="NLM_p last">Yield: 37%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.99 (dd, <i>J</i> = 5.7, 2.4 Hz, 1H), 7.58–7.50 (m, 1H), 7.33–7.28 (m, 1H), 7.0–6.82 (m, 4H), 4.54–4.45 (m, 1H), 3.54 (s, 1H), 2.41 (s, 3H), 1.43 (d, <i>J</i> = 6.6 Hz, 3H), 1.23 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 418.35 [M]<sup>+</sup>.</div></div><div id="sec4_8_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(7-Fluoro-3-(4-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (<b>44h</b>)</h4><div class="NLM_p last">Yield: 47%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.99 (dd, <i>J</i> = 5.8, 2.4 Hz, 1H), 7.61–7.49 (m, 1H), 7.33–7.23 (m, 3H), 7.23–7.14 (m, 2H), 6.89 (s, 1H), 4.55–4.47 (m, 1H), 3.53 (s, 1H), 1.41 (d, <i>J</i> = 6.6 Hz, 3H), 1.23 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 405.67 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(3-(3,5-Difluorophenyl)-7-fluoro-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (<b>44i</b>)</h4><div class="NLM_p last">Yield: 40%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.01–8.93 (m, 1H), 7.55 (dd, <i>J</i> = 9.7, 5.4 Hz, 1H), 7.36–7.26 (m, 1H), 6.92 (s, 1H), 6.90–6.82 (m, 3H), 4.51–4.40 (m, 1H), 3.63 (d, <i>J</i> = 5.7 Hz, 1H), 1.42 (d, <i>J</i> = 6.7 Hz, 3H), 1.22 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 423.10 [M + H]<sup>+</sup>.</div></div><div id="sec4_8_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (<i>S</i>)-<i>N</i>-((<i>S</i>)-1-(7-Fluoro-3-methyl-4-oxo-4H-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (<b>44j</b>)</h4><div class="NLM_p last">Yield: 21%, <sup>1</sup>H NMR (400 MHz), 9 (DMSO-<i>d</i><sub>6</sub>): δ 8.79 (dd, <i>J</i> = 6.2, 2.4 Hz, 1H), 7.84–7.76 (m, 1H), 7.56–7.46 (m, 1H), 7.09 (s, 1H), 5.86 (d, <i>J</i> = 6.7 Hz, 1H), 4.73–4.61 (m, 1H), 2.26 (s, 3H), 1.40 (d, <i>J</i> = 6.8 Hz, 3H), 1.11 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 324.95 [M]<sup>+</sup>.</div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Synthesis of Intermediate <b>44e</b> from Intermediate <b>50</b></h3><div class="NLM_p">To the stirred solution of <b>50</b> (80 mg, 0.183 mmol), phenylboronic acid (25.7 mg, 0.211 mmol), and Na<sub>2</sub>CO<sub>3</sub> (38.9 mg, 0.367 mmol) in water/ethanol/toluene (6 mL, 1:2:2) was added tetrakis(triphenylphosphine)-palladium(0) (5.30 mg, 4.58 μmol) under a nitrogen atmosphere. The reaction mixture was purged by nitrogen for 5 min and then heated at 85 °C for 1.5 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified by flash column chromatography using 25% ethyl acetate in hexane as an eluent to obtain the desired product <b>44e</b> (46.2 mg, 65.2%% yield, 99.23% HPLC purity, 99.35% chiral purity).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.82 (dd, <i>J</i> = 6.1, 2.4 Hz, 1H), 7.90–7.81 (m, 1H), 7.68–7.58 (m, 1H), 7.54–7.43 (m, 2H), 7.43–7.35 (m, 1H), 7.33–7.25 (m, 2H), 7.24 (s, 1H), 5.73 (d, <i>J</i> = 7.2 Hz, 1H), 4.28–4.16 (m, 1H), 1.30 (d, <i>J</i> = 6.7 Hz, 3H), 1.08 (s, 9H). [α]<sub>D</sub> 55.682° (<i>c</i> 0.471, CHCl<sub>3</sub>). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>21</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 387.1543; found, 387.1533.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Deprotection of <i>tert</i>-Butylsulfinyl Auxiliary</h3><div class="NLM_p">To a stirred solution of <b>44e</b> (1.7 g, 4.40 mmol) in methanol (5 mL) was added methanolic HCl (5.86 mL, 17.59 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 30 min. The solvent was evaporated under vacuum. The reaction mixture was basified by saturated sodium bicarbonate solution and extracted with ethyl acetate (4 × 200 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum to obtain the desired product.</div><div id="sec4_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 2-(1-Aminoethyl)-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>45a</b>)</h4><div class="NLM_p last">Yield: 81%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.07 (d, <i>J</i> = 7.4 Hz, 1H), 7.53–7.43 (m, 3H), 7.42–7.36 (m, 1H), 7.36–7.26 (m, 3H), 6.99 (s, 1H), 6.98–6.90 (m, 1H), 4.22–4.12 (m, 1H), 1.30 (d, <i>J</i> = 6.6 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 264.98 [M]<sup>+</sup>.</div></div><div id="sec4_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 2-(1-Aminoethyl)-7-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>45b</b>)</h4><div class="NLM_p last">Yield: 91%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.72–8.66 (m, 1H), 7.66 (d, <i>J</i> = 9.0 Hz, 1H), 7.46–7.39 (m, 2H), 7.38–7.29 (m, 2H), 7.26 (d, <i>J</i> = 7.5 Hz, 2H), 7.14 (s, 1H), 3.90–3.80 (m, 1H), 2.33 (s, 3H), 1.95 (br s, 2H), 1.10 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 279.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_10_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 2-(1-Aminoethyl)-6-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>45c</b>)</h4><div class="NLM_p last">Yield: 70%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.44–7.28 (m, 4H), 7.28–7.21 (m, 2H), 7.13–7.04 (m, 1H), 6.93 (s, 1H), 6.62–6.54 (m, 1H), 3.80–3.70 (m, 1H), 2.79 (s, 3H), 1.78 (s, 2H), 1.08 (d, <i>J</i> = 6.6 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 279.05 [M + H]<sup>+</sup>.</div></div><div id="sec4_10_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 2-(1-Aminoethyl)-7-fluoro-6-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>45d</b>)</h4><div class="NLM_p last">Yield: 71%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 7.50–7.40 (m, 2H), 7.40–7.34 (m, 1H), 7.31–7.25 (m, 2H), 7.19 (dd, <i>J</i> = 9.7, 5.9 Hz, 1H), 7.03–6.96 (m, 1H), 6.81 (s, 1H), 4.09–3.99 (m, 1H), 2.88 (d, <i>J</i> = 4.4 Hz, 3H) 1.26 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 297.34 [M + H]<sup>+</sup>.</div></div><div id="sec4_10_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>45e</b>)</h4><div class="NLM_p last">Yield: 91%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.80 (dd, <i>J</i> = 6.2, 2.5 Hz, 1H), 7.91–7.82 (m, 1H), 7.65–7.55 (m, 1H), 7.49–7.40 (m, 2H), 7.40–7.34 (m, 1H), 7.34–7.25 (m, 3H), 3.93–3.81 (m, 1H), 2.05 (br s, 2H), 1.12 (d, <i>J</i> = 6.6 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 283.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_10_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-3-(<i>m</i>-tolyl)-4<i>H</i>-quinolizin-4-one (<b>45f</b>)</h4><div class="NLM_p last">Yield: 80%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.78 (dd, <i>J</i> = 6.1, 2.5 Hz, 1H), 7.93–7.78 (m, 1H), 7.68–7.51 (m, 1H), 7.38–7.25 (m, 2H), 7.22–7.13 (m, 1H), 7.13–6.99 (m, 2H), 3.96–3.79 (m, 1H), 2.35 (s, 3H), 1.87 (br s, 2H), 1.11 (d, <i>J</i> = 6.6 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 297.05 [M + H]<sup>+</sup>.</div></div><div id="sec4_10_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-3-(3-fluoro-5-methylphenyl)-4<i>H</i>-quinolizin-4-one (<b>45g</b>)</h4><div class="NLM_p last">Yield: 89%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.01–8.94 (m, 1H), 7.56–7.47 (m, 1H), 7.27–7.23 (m, 1H), 7.10 (s, 1H), 6.98–6.86 (m, 2H), 6.83 (d, <i>J</i> = 9.3 Hz, 1H), 4.22–4.12 (m, 1H), 2.40 (s, 3H), 1.31 (d, <i>J</i> = 6.6 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 315.34 [M + H]<sup>+</sup>.</div></div><div id="sec4_10_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-3-(4-fluorophenyl)-4<i>H</i>-quinolizin-4-one (<b>45h</b>)</h4><div class="NLM_p last">Yield: 79%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.79 (dd, <i>J</i> = 6.2, 2.4 Hz, 1H), 7.91–7.82 (m, 1H), 7.65–7.55 (m, 1H), 7.37–7.22 (m, 5H), 3.92–3.82 (m, 1H), 1.93 (br s, 2H), 1.12 (d, <i>J</i> = 6.6 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 301.16 [M + H]<sup>+</sup>.</div></div><div id="sec4_10_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> (<i>S</i>)-2-(1-Aminoethyl)-3-(3,5-difluorophenyl)-7-fluoro-4<i>H</i>-quinolizin-4-one (<b>45i</b>)</h4><div class="NLM_p last">Yield: 71%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81 (dd, <i>J</i> = 6.0, 2.4 Hz, 1H), 7.94–7.85 (m, 1H), 7.71–7.61 (m, 1H), 7.33 (s, 1H), 7.30–7.17 (m, 1H), 7.11–7.0 (m, 2H), 3.92–3.82 (m, 1H), 1.98 (s, 2H), 1.13 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 319.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_10_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-3-methyl-4<i>H</i>-quinolizin-4-one (<b>45j</b>)</h4><div class="NLM_p last">Yield: 91%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.77 (dd, <i>J</i> = 6.3, 2.5 Hz, 1H), 7.83–7.74 (m, 1H), 7.53–7.43 (m, 1H), 7.24 (s, 1H), 4.35–4.25 (m, 1H), 2.23 (s, 3H), 1.23 (d, <i>J</i> = 8.7 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 221.64 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> General Procedure for Nucleophilic Aromatic Substitution</h3><div class="NLM_p">To a stirred solution of <b>45e</b> (6.4 g, 22.67 mmol) and 2,4-diamino-6-chloropyrimidine-5-carbonitrile (3.84 g, 22.67 mmol) in DMF (100 mL) was added DIPEA (7.92 mL, 45.3 mmol) at 25 °C. The reaction mixture was heated at 100 °C for 30 h. The reaction mixture was diluted with water (300 mL) and extracted with ethyl acetate (3 × 300 mL). The organic layer was isolated and washed with water (2 × 150 mL), dried over anhydrous sodium sulfate, and evaporated under vacuum. The crude product was purified by flash column chromatography using 65% ethyl acetate in hexane as an eluent to obtain the desired product.</div><div class="NLM_p">Compounds <b>4–9</b> were purified on chiral prep HPLC to obtain the enantiomer by using a CHIRALPAK IA column.</div><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> (<i>S</i>)-2-(1-((9<i>H</i>-Purin-6-yl)amino)ethyl)-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>4</b>)</h4><div class="NLM_p last">Yield: 19%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.94–8.84 (m, 1H), 8.29–8.09 (m, 3H), 7.75–7.54 (m, 2H), 7.54–7.29 (m, 5H), 7.16–7.06 (m, 1H), 7.02 (s, 1H), 5.30–5.13 (m, 1H), 1.33 (d, <i>J</i> = 6.7 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 383 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> (<i>S</i>)-2-(1-((9<i>H</i>-Purin-6-yl)amino)ethyl)-6-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>5</b>)</h4><div class="NLM_p last">Yield: 10%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.94 (br s, 1H), 8.14 (br s, 3H), 7.62–7.41 (m, 4H), 7.40–7.30 (m, 1H), 7.25 (d, <i>J</i> = 8.9 Hz, 1H), 7.11–7.01 (m, 1H), 6.81 (s, 1H), 6.58 (d, <i>J</i> = 6.7 Hz, 1H), 5.25–5.06 (m, 1H), 2.80 (s, 3H), 1.31 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 397.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (<i>S</i>)-4-Amino-6-((1-(6-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>6</b>)</h4><div class="NLM_p last">Yield: 16%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.94 (s, 1H), 7.59 (d, <i>J</i> = 7.0 Hz, 1H), 7.49–7.29 (m, 6H), 7.24 (br s, 2H), 7.13–7.07 (m, 1H), 6.78 (s, 1H), 6.61 (d, <i>J</i> = 6.7 Hz, 1H), 5.03–4.94 (m, 1H), 2.80 (s, 3H), 1.25 (d, <i>J</i> = 7.7 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 397.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> (<i>S</i>)-2-(1-((9<i>H</i>-Purin-6-yl)amino)ethyl)-7-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>7</b>)</h4><div class="NLM_p last">Yield: 18%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.87 (br s, 1H), 8.71 (s, 1H), 8.32–8.05 (m, 3H), 7.58–7.29 (m, 6H), 6.99 (s, 1H), 5.43–5.08 (m, 1H), 2.31 (s, 3H), 1.32 (d, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 397.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> (<i>S</i>)-4-Amino-6-((1-(7-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>8</b>)</h4><div class="NLM_p last">Yield: 25%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.71 (s, 1H), 7.93 (s, 1H), 7.70–7.60 (m, 2H), 7.57–7.30 (m, 6H), 7.24 (br s, 2H), 6.97 (s, 1H), 5.12–5.02 (m, 1H), 2.33 (s, 3H), 1.27 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 397.04 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> (<i>S</i>)-4-Amino-6-((1-(7-fluoro-6-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>9</b>)</h4><div class="NLM_p last">Yield: 28%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.11 (s, 1H), 7.52–7.43 (m, 3H), 7.43–7.33 (m, 2H), 7.21–7.13 (m, 1H), 7.09–6.99 (m, 1H), 6.49 (s, 1H), 5.66 (br s, 2H), 5.49 (d, <i>J</i> = 6.4 Hz, 1H), 5.22–5.12 (m, 1H), 2.89 (d, <i>J</i> = 4.3 Hz, 3H), 1.39 (d, <i>J</i> = 6.9 Hz, 3H). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>19</sub>FN<sub>6</sub>O [M + H]<sup>+</sup>, 415.1683; found, 415.1676.</div></div><div id="sec4_11_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> (<i>S</i>)-2-(1-((9<i>H</i>-Purin-6-yl)amino)ethyl)-7-fluoro-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>10</b>)</h4><div class="NLM_p last">Yield: 18%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.80 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 8.30–8.03 (m, 3H), 7.82–7.73 (m, 1H), 7.69–7.29 (m, 6H), 7.14 (s, 1H), 5.31–5.12 (m, 1H), 1.33 (d, <i>J</i> = 6.9 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 401.04 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>11</b>)</h4><div class="NLM_p last">Yield: 47%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.82 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 7.88–7.79 (m, 1H), 7.67–7.54 (m, 2H), 7.54–7.42 (m, 3H), 7.41–7.32 (m, 1H), 7.10 (s, 1H), 6.97 (d, <i>J</i> = 7.0 Hz, 1H), 6.57 (s, 2H), 5.15–5.02 (m, 1H), 1.20 (d, <i>J</i> = 7.1 Hz, 3H). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>19</sub>FN<sub>6</sub>O [M + H]<sup>+</sup>, 416.1635; found, 416.1631. [α]<sub>D</sub> 663.9° (<i>c</i> 0.002, CHCl<sub>3</sub>).</div></div><div id="sec4_11_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> (<i>S</i>)-2-Amino-4-((1-(7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>12</b>)</h4><div class="NLM_p last">Yield: 31%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.87–8.80 (m, 1H), 8.18 (s, 1H), 7.91–7.83 (m, 1H), 7.72–7.57 (m, 3H), 7.52–7.32 (m, 4H), 7.24–7.07 (m, 2H), 6.47 (br s, 1H), 5.18–5.06 (m, 1H), 1.23 (d, <i>J</i> = 6.8 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 401 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> (<i>S</i>)-2-(1-((2-Aminopyrimidin-4-yl)amino)ethyl)-7-fluoro-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>13</b>)</h4><div class="NLM_p last">Yield: 24%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 7.88–7.80 (m, 1H), 7.79–7.56 (m, 3H), 7.55–7.19 (m, 5H), 6.98 (s, 1H), 5.72 (br s, 3H), 5.04–4.68 (m, 1H), 1.24 (d, <i>J</i> = 4.6 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 376.09 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (<i>S</i>)-4-Amino-6-((1-(7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)-2-methylpyrimidine-5-carbonitrile (<b>14</b>)</h4><div class="NLM_p last">Yield: 44%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.87–8.78 (m, 1H), 7.86–7.76 (m, 1H), 7.73–7.55 (m, 3H), 7.54–7.28 (m, 4H), 7.18 (s, 1H), 7.12 (br s, 2H), 5.28–5.06 (m, 1H), 2.13 (s, 3H), 1.30 (d, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 415.11 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> (<i>S</i>)-2-Amino-4-((1-(7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)-6-methylpyrimidine-5-carbonitrile (<b>15</b>)</h4><div class="NLM_p last">Yield: 36%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.83 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 7.94–7.81 (m, 1H), 7.81–7.20 (m, 7H), 7.10 (br s, 2H), 6.37 (br s, 1H), 5.23–5.0 (m, 1H), 2.25 (s, 3H), 1.23 (d, <i>J</i> = 7.1 Hz, 3H). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>23</sub>H<sub>19</sub>FN<sub>6</sub>O [M + H]<sup>+</sup>, 415.1683; found, 415.1676. [α]<sub>D</sub> 332.976° (<i>c</i> 0.504, CHCl<sub>3</sub>).</div></div><div id="sec4_11_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-4-oxo-3-(<i>m</i>-tolyl)-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>16</b>)</h4><div class="NLM_p last">Yield: 6%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 7.89–7.80 (m, 1H), 7.65–7.55 (m, 1H), 7.40–7.31 (m, 2H), 7.20–7.09 (m, 3H), 6.94 (d, <i>J</i> = 6.9 Hz, 1H), 6.57 (s, 2H), 6.11 (br s, 2H), 5.12–5.04 (m, 1H), 2.35 (s, 3H), 1.23 (d, <i>J</i> = 3.6 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 430.09 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-3-(4-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>17</b>)</h4><div class="NLM_p last">Yield: 20%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.82 (d, <i>J</i> = 5.7 Hz, 1H), 7.94–7.80 (m, 1H), 7.71–7.52 (m, 2H), 7.36–7.19 (m, 2H), 7.10 (s, 1H), 7.0 (d, <i>J</i> = 7.0 Hz, 1H), 6.57 (s, 2H), 6.16 (br s, 2H), 5.20–4.91 (m, 1H), 4.15–3.91 (m, 1H), 1.20 (d, <i>J</i> = 6.5 Hz, 3H). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>17</sub>F<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup>, 434.1541; found, 434.1534.</div></div><div id="sec4_11_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-3-(3-fluoro-5-methylphenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>18</b>)</h4><div class="NLM_p last">Yield: 38%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.82 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 7.94–7.84 (m, 1H), 7.69–7.56 (m, 1H), 7.18–6.98 (m, 3H), 6.93 (d, <i>J</i> = 6.8 Hz, 1H), 6.57 (br s, 2H), 5.09–4.99 (m, 1H), 2.36 (s, 3H), 1.23 (d, <i>J</i> = 2.4 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 448.07 [M + H]<sup>+</sup>.</div></div><div id="sec4_11_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> (<i>S</i>)-2,4-Diamino-6-((1-(3-(3,5-difluorophenyl)-7-fluoro-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>19</b>)</h4><div class="NLM_p last">Yield: 10%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.85 (dd, <i>J</i> = 5.9, 2.4 Hz, 1H), 7.98–7.88 (m, 1H), 7.73–7.61 (m, 1H), 7.37–7.19 (m, 3H), 7.16–7.0 (m, 2H), 6.67 (br s, 2H), 6.23 (br s, 1H), 5.11–4.95 (m, 1H), 1.25 (d, <i>J</i> = 7.1 Hz, 3H). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>16</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup>, 452.1447; found, 452.1442.</div></div><div id="sec4_11_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> (<i>S</i>)-4-Amino-6-((1-(7-fluoro-3-methyl-4-oxo-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>46</b>)</h4><div class="NLM_p last">Yield: 48%, 1H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.77 (dd, <i>J</i> = 6.4, 2.4 Hz, 1H), 7.93 (s, 1H), 7.89–7.70 (m, 2H), 7.57–7.42 (m, 1H), 7.28 (br s, 2H), 7.03 (s, 1H), 5.50–5.38 (m, 1H), 2.31 (s, 3H), 1.47 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 339.47 [M]<sup>+</sup>.</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Synthesis of Compound <b>47a–b</b></h3><div class="NLM_p">These compounds were prepared by the procedure described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> bromination reaction.</div><div id="sec4_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> (<i>S</i>)-2,4-Diamino-6-((1-(1-bromo-7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>47a</b>)</h4><div class="NLM_p last">Yield: 67%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.98 (dd, <i>J</i> = 5.6, 2.5 Hz, 1H), 8.34–8.25 (m, 1H), 7.91–7.81 (m, 1H), 7.64–7.49 (m, 3H), 7.49–7.39 (m, 2H), 7.14 (br s, 1H), 6.70 (br s, 2H), 5.38–5.26 (m, 1H), 1.53 (d, <i>J</i> = 7.2 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 494.11/496.05 [M + H]<sup>+</sup>.</div></div><div id="sec4_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> (<i>S</i>)-4-Amino-6-((1-(1-bromo-7-fluoro-3-methyl-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>47b</b>)</h4><div class="NLM_p last">Yield: 67%, LCMS (ESI) <i>m</i>/<i>z</i>: 416.87/418.86 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> General Procedure for the Suzuki Coupling Reaction</h3><div class="NLM_p">To a stirred solution of <b>47a</b> (200 mg, 0.405 mmol) in dioxane/water 10 mL (4:1) was added (4-fluorophenyl)boronic acid (56.6 mg, 0.405 mmol) and Na<sub>2</sub>CO<sub>3</sub> (107 mg, 1.011 mmol) under nitrogen. The reaction mixture was purged by nitrogen for 10 min, then Pd(amphos)Cl<sub>2</sub> (14.32 mg, 0.020 mmol) was added. The reaction mixture was heated at 90 °C for 36 h. The solvent was evaporated under reduced pressure and extracted with ethyl acetate (3 × 25 mL) and washed with water (25 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative HPLC to afford the desired product.</div><div id="sec4_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> (<i>S</i>)-4-Amino-6-((1-(7-fluoro-1-(4-fluorophenyl)-3-methyl-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>26</b>)</h4><div class="NLM_p last">Yield: 36%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 7.94 (s, 1H), 7.70–7.61 (m, 1H), 7.51–7.15 (m, 6H), 6.97–6.82 (m, 1H), 4.95–4.83 (m, 1H), 2.42 (s, 3H), 1.44 (d, <i>J</i> = 7.4 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 432.98 [M]<sup>+</sup>.</div></div><div id="sec4_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> (<i>S</i>)-2,4-Diamino-6-((1-(1-cyclopropyl-7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>30</b>)</h4><div class="NLM_p last">Yield: 44%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.86 (dd, <i>J</i> = 6.1, 2.6 Hz, 1H), 8.53–8.39 (m, 1H), 7.77–7.67 (m, 1H), 7.51–7.38 (m, 3H), 7.30 (d, <i>J</i> = 7.5 Hz, 1H), 7.09–7.01 (m, 1H), 6.59 (br s, 2H), 6.37 (br s, 2H), 6.17–6.07 (m, 1H), 4.97 (d, <i>J</i> = 7.1 Hz, 1H), 2.31–2.20 (m, 1H), 1.33 (d, <i>J</i> = 7.3 Hz, 3H), 1.29–1.25 (m, 2H), 0.83–0.73 (m, 1H), 0.69–0.59 (m, 1H). LCMS (ESI) <i>m</i>/<i>z</i>: 456.11 [M + H]<sup>+</sup>.</div></div><div id="sec4_13_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-4-oxo-1,3-diphenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>31</b>)</h4><div class="NLM_p last">Yield: 63%,<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.92 (dd, <i>J</i> = 5.8, 2.6 Hz, 1H), 8.14 (s, 1H), 7.67–7.55 (m, 2H), 7.57–7.45 (m, 5H), 7.44–7.35 (m, 2H), 7.27–7.22 (m, 1H), 7.09–7.04 (m, 1H), 6.99–6.90 (m, 1H), 6.54 (s, 2H), 4.97–4.85 (m, 1H), 4.18 (d, <i>J</i> = 7.1 Hz, 1H), 1.26 (d, <i>J</i> = 7.3 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 492.24 [M + H]<sup>+</sup>.</div></div><div id="sec4_13_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> (<i>S</i>)-4-(2-(1-((2,6-Diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-1-yl)benzamide (<b>32</b>)</h4><div class="NLM_p last">Yield: 14%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.92 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 8.12–7.97 (m, 3H), 7.75 (d, <i>J</i> = 8.0 Hz, 1H), 7.56–7.43 (m, 4H), 7.43–7.31 (m, 3H), 7.08–6.99 (m, 1H), 6.99–6.89 (m, 1H), 6.54 (s, 2H), 6.13 (br s, 2H), 4.91–4.81 (m, 1H), 4.20 (d, <i>J</i> = 7.0 Hz, 1H), 1.27 (d, <i>J</i> = 7.2 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 534.94 [M + H]<sup>+</sup>.</div></div><div id="sec4_13_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-1-(4-methoxyphenyl)-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>33</b>)</h4><div class="NLM_p last">Yield: 37.9%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.91 (d, <i>J</i> = 5.5 Hz, 1H), 7.98–7.33 (m, 6H), 7.23–6.96 (m, 5H), 6.82–6.46 (m, 2H), 5.08–4.86 (m, 1H), 4.21 (d, <i>J</i> = 7.3 Hz, 1H), 3.86 (s, 3H), 1.27 (d, <i>J</i> = 7.3 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 522.03 [M + H]<sup>+</sup>.</div></div><div id="sec4_13_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>34</b>)</h4><div class="NLM_p last">Yield: 34%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.92 (dd, <i>J</i> = 5.9, 2.5 Hz, 1H), 7.70–7.61 (m, 1H), 7.57–7.45 (m, 3H), 7.45–7.36 (m, 3H), 7.36–7.22 (m, 2H), 7.07 (s, 1H), 7.02–6.93 (m, 1H), 6.54 (s, 2H), 4.94–4.83 (m, 1H), 4.22 (d, <i>J</i> = 7.0 Hz, 1H), 1.27 (d, <i>J</i> = 7.3 Hz, 3H). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>28</sub>H<sub>21</sub>F<sub>2</sub>N<sub>7</sub>O [M + H]<sup>+</sup>, 510.1854; found, 510.1848. [α]<sub>D</sub> 426.537° (<i>c</i> 1.031, CHCl<sub>3</sub>).</div></div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> General Procedure for the Iodination Reaction</h3><div class="NLM_p">To a stirred solution of <b>40e</b> (1 g, 4.87 mmol) in DMF (4 mL) was added NIS (1.096 g, 4.87 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2.5 h. The reaction mixture was diluted by cold water and extracted with ethyl acetate (3 × 40 mL). The combined organic layer was washed with water (2 × 50 mL), dried over anhydrous sodium sulfate, and concentrated under vacuum to obtain the crude product. The crude product was purified by flash column chromatography by using 25–30% ethyl acetate in hexane as an eluent to obtain (<b>48</b>) (1.2 g, yield 74.4%).</div><div class="NLM_p"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.11 (d, <i>J</i> = 5.0 Hz, 1H), 7.65–7.56 (m, 1H), 7.49–7.39 (m, 1H), 6.62 (s, 1H), 2.68 (s, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 332.03 [M + H]<sup>+</sup>.</div><div id="sec4_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> (<i>S</i>,<i>E</i>)-<i>N</i>-(1-(7-Fluoro-3-iodo-4-oxo-4<i>H</i>-quinolizin-2-yl)ethylidene)-2-methylpropane-2-sulfinamide (<b>49</b>)</h4><div class="NLM_p">Compound <b>49</b> was synthesized by using a procedure the same as the ketimine synthesis described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><div class="NLM_p last">Yield 38.1%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.22–8.96 (m, 1H), 7.65–7.50 (m, 1H), 7.47–7.33 (m, 1H), 6.66 (s, 0.5H), 6.65 (s, 0.5H), 2.77 (s, 1.5H), 2.55 (s, 1.5H), 1.35 (s, 5H), 1.29 (s, 4H). LCMS (ESI) <i>m</i>/<i>z</i>: 434.88 [M]<sup>+</sup>.</div></div><div id="sec4_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> (<i>S</i>)-<i>N</i>-(<i>S</i>)-1-((7-Fluoro-3-iodo-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)-2-methylpropane-2-sulfinamide (<b>50</b>)</h4><div class="NLM_p">Compound <b>50</b> was synthesized by using procedure same as ketimine reduction described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><div class="NLM_p last">Yield 52.3%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88 (dd, <i>J</i> = 6.0, 2.4 Hz, 1H), 7.96–7.88 (m, 1H), 7.77–7.67 (m, 1H), 7.14 (s, 1H), 6.19 (d, <i>J</i> = 7.3 Hz, 1H), 4.77–4.66 (m, 1H), 1.37 (d, <i>J</i> = 6.9 Hz, 3H), 1.11 (s, 9H). [α]<sub>D</sub> −0.858° (<i>c</i> 0.862, CHCl<sub>3</sub>). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>15</sub>H<sub>18</sub>FIN<sub>2</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 437.0196; found, 437.0186.</div></div><div id="sec4_14_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-3-iodo-4<i>H</i>-quinolizin-4-one (<b>51</b>)</h4><div class="NLM_p">Compound <b>51</b> was synthesized by using procedure same as de-protection of <i>tert</i>-butylsulfinyl auxiliary described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><div class="NLM_p last">Yield 85%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.91–8.83 (m, 1H), 7.96–7.87 (m, 1H), 7.74–7.65 (m, 1H), 7.31 (s, 1H), 4.28–4.19 (m, 1H), 2.16 (br s, 2H), 1.23 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 332.9 [M + H]<sup>+</sup>.</div></div><div id="sec4_14_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> (<i>S</i>)-<i>tert</i>-Butyl (1-(7-Fluoro-3-iodo-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>52</b>)</h4><div class="NLM_p">To a stirred solution of <b>51</b> (0.700 g, 2.108 mmol) in THF/water (14 mL, 12:2) were added sodium carbonate (0.212 g, 2.53 mmol) and Boc-anhydride (0.538 mL, 2.318 mmol). Reaction mixture was heated at 40 °C for 2 h. The reaction mixture was diluted with water and extracted with ethyl acetate (2 × 100 mL). Combined organic layer washed with water (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give crude product. This crude product was washed with hexane (20 mL) and dried to obtain pure solid product <b>52</b>.</div><div class="NLM_p last">Yield 78%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.97–8.79 (m, 1H), 7.97–7.88 (m, 1H), 7.81 (d, <i>J</i> = 7.1 Hz, 1H), 7.76–7.68 (m, 1H), 6.95 (s, 1H), 4.90–4.75 (m, 1H), 1.37 (s, 9H), 1.28 (d, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 432.94 [M + H]<sup>+</sup>.</div></div><div id="sec4_14_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> <i>tert</i>-Butyl (<i>S</i>)-(1-(1-Bromo-7-fluoro-3-iodo-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>53</b>)</h4><div class="NLM_p">Compound <b>53</b> was prepared by procedure described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> for bromination reaction.</div><div class="NLM_p last">Yield 88%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.07–9.01 (m, 1H), 8.34–8.25 (m, 1H), 7.95–7.86 (m, 1H), 7.69 (br s, 1H), 5.38–5.25 (m, 1H), 1.42 (d, <i>J</i> = 7.2 Hz, 3H), 1.33 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 510.85/512.92 [M + H]<sup>+</sup>.</div></div><div id="sec4_14_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> <i>tert</i>-Butyl (<i>S</i>)-(1-(1-Bromo-7-fluoro-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>54</b>)</h4><div class="NLM_p">To a stirred solution of compound <b>53</b> (3.1 g, 6.07 mmol) in IPA (40 mL) was added NaBH<sub>4</sub> (0.207 g, 5.46 mmol) at room temperature and reaction mixture was heated at 45 °C for 30 min. The reaction mixture was diluted with saturated ammonium chloride solution (100 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layer was washed with water (2 × 50 mL), dried over anhydrous sodium sulfate and concentrated under vacuum to obtain crude compound. Crude product was purified by flash column chromatography using 30% ethyl acetate in hexane as eluent to yield compound <b>54</b> (2.1 g, 90%).</div><div class="NLM_p last"><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.12–8.92 (m, 1H), 8.19 (dd, <i>J</i> = 10.1, 5.4 Hz, 1H), 7.95–7.85 (m, 1H), 7.82 (d, <i>J</i> = 7.8 Hz, 1H), 6.60 (s, 1H), 5.02–4.90 (m, 1H), 1.37 (s, 9 H), 1.31 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 385.16/387.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_14_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> (<i>S</i>)-<i>tert</i>-Butyl (1-(7-Fluoro-4-oxo-1-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>55a</b>)</h4><div class="NLM_p">Compound <b>55a</b> was synthesized by using procedure same as Suzuki reaction described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><div class="NLM_p last">Yield 84%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.0–8.93 (m, 1H), 7.66–7.50 (m, 5H), 7.42 (d, <i>J</i> = 7.6 Hz, 1H), 7.33 (d, <i>J</i> = 7.3 Hz, 1H), 7.13–7.04 (m, 1H), 6.68 (s, 1H), 4.43–4.32 (m, 1H), 1.35 (s, 9H), 1.07 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 383.19 [M + H]<sup>+</sup>.</div></div><div id="sec4_14_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> <i>tert</i>-Butyl (<i>S</i>)-(1-(7-Fluoro-1-(3-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>55b</b>)</h4><div class="NLM_p last">Yield: 90%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.05–8.90 (m, 1H), 7.71–7.48 (m, 3H), 7.44–7.31 (m, 1H), 7.30–7.23 (m, 1H), 7.23–7.1 8 (m, 1H), 7.18–7.08 (m, 1H), 6.67 (d, <i>J</i> = 2.8 Hz, 1H), 4.45–4.24 (m, 1H), 1.35 (s, 9H), 1.10 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 401.16 [M + H]<sup>+</sup>.</div></div><div id="sec4_14_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> <i>tert</i>-Butyl (<i>S</i>)-(1-(1-(3,5-Difluorophenyl)-7-fluoro-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>55c</b>)</h4><div class="NLM_p last">Yield: 72%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.02–8.97 (m, 1H), 7.67–7.58 (m, 2H), 7.48–7.39 (m, 1H), 7.26–7.17 (m, 2H), 7.12 (d, <i>J</i> = 9.0 Hz, 1H), 6.67 (s, 1H), 4.40–4.28 (m, 1H), 1.35 (s, 9H), 1.13 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 419.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> General Procedure of Boc Deprotection</h3><div class="NLM_p">To a stirred trifluoroacetic acid (3.1 mL, 50.7 mmol) was added <b>55a</b> (0.97 g, 2.54 mmol) at 0–5 °C. The reaction mixture was heated at 60 °C for 30 min. Trifluoroacetic acid was evaporated under vacuum, and the reaction mixture was diluted by cold water and basified with saturated sodium carbonate solution. The crude product was extracted with ethyl acetate (3 × 30 mL). The organic layer was dried over anhydrous sodium sulfate and evaporated under vacuum to obtain compound <b>56a</b>.</div><div id="sec4_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-1-phenyl-4<i>H</i>-quinolizin-4-one (<b>56a</b>)</h4><div class="NLM_p last">Yield 91%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.06–8.83 (m, 1H), 7.63–7.44 (m, 4H), 7.40–7.25 (m, 2H), 7.07 (dd, <i>J</i> = 10.0, 5.7 Hz, 1H), 6.91 (s, 1H), 3.75–3.60 (m, 1H), 1.06 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 283.04 [M + H]<sup>+</sup>.</div></div><div id="sec4_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-1-(3-fluorophenyl)-4<i>H</i>-quinolizin-4-one (<b>56b</b>)</h4><div class="NLM_p last">Yield: 76%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.98 (dd, <i>J</i> = 5.9, 2.6 Hz, 1H), 7.65–7.50 (m, 2H), 7.40–7.30 (m, 1H), 7.30–7.23 (m, 1H), 7.23–7.14 (m, 1H), 7.14–7.07 (m, 1H), 6.91 (s, 1H), 3.73–3.63 (m, 1H), 1.96 (s, 2H), 1.08 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 301.4 [M + H]<sup>+</sup>.</div></div><div id="sec4_15_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> (<i>S</i>)-2-(1-Aminoethyl)-1-(3,5-difluorophenyl)-7-fluoro-4<i>H</i>-quinolizin-4-one (<b>56c</b>)</h4><div class="NLM_p last">Yield: 76%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.98 (dd, <i>J</i> = 5.9, 2.5 Hz, 1H), 7.62–7.52 (m, 1H), 7.47–7.36 (m, 1H), 7.24–7.13 (m, 3H), 6.90 (s, 1H), 3.72–3.62 (m, 1H), 1.95 (s, 2H), 1.09 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 319.16 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> Synthesis of Compounds <b>20–25</b></h3><div class="NLM_p">These compounds were prepared by the nucleophilic aromatic substitution as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.</div><div id="sec4_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-4-oxo-1-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>20</b>)</h4><div class="NLM_p last">Yield: 7%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.93 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 7.79–7.46 (m, 5H), 7.34 (d, <i>J</i> = 7.4 Hz, 1H), 7.29–7.08 (m, 2H), 6.70 (s, 1H), 6.56 (s, 2H), 6.19 (br s, 2H), 5.01–4.87 (m, 1H), 1.17 (d, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 416.13 [M + H]<sup>+</sup>. [α]<sub>D</sub> 70.907° (<i>c</i> 1.014, CHCl<sub>3</sub>). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>18</sub>FN<sub>7</sub>O [M + H]<sup>+</sup>, 416.1635; found, 416.1622.</div></div><div id="sec4_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> (<i>S</i>)-4-Amino-6-((1-(7-fluoro-4-oxo-1-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>21</b>)</h4><div class="NLM_p last">Yield:49%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.94 (dd, <i>J</i> = 5.9, 2.6 Hz, 1H), 7.94 (s, 1H), 7.82 (d, <i>J</i> = 7.2 Hz, 1H), 7.64–7.47 (m, 5H), 7.35 (d, <i>J</i> = 7.4 Hz, 1H), 7.26 (br s, 2H), 7.17–7.07 (m, 1H), 6.76 (s, 1H), 4.99–4.85 (m, 1H), 1.27 (d, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 401.30 [M + H]<sup>+</sup>.</div></div><div id="sec4_16_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> (<i>S</i>)-4-Amino-6-((1-(7-fluoro-1-(3-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>22</b>)</h4><div class="NLM_p last">Yield: 42%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.95 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 7.92 (d, <i>J</i> = 6.1 Hz, 1H), 7.89–7.79 (m, 1H), 7.66–7.52 (m, 2H), 7.46–7.38 (m, 1H), 7.38–7.19 (m, 4H), 7.19–7.11 (m, 1H), 6.77 (d, <i>J</i> = 7.1 Hz, 1H), 4.95–4.85 (m, 1H), 1.30 (d, <i>J</i> = 6.8 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 419.79 [M + H]<sup>+</sup>.</div></div><div id="sec4_16_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>23</b>)</h4><div class="NLM_p last">Yield: 31.6%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.94 (dd, <i>J</i> = 5.8, 2.6 Hz, 1H), 7.76–7.69 (m, 1H), 7.58–7.51 (m, 1H), 7.47–7.36 (m, 3H), 7.19–7.11 (m, 2H), 6.70 (s, 1H), 6.56 (s, 2H), 4.94–4.85 (m, 1H), 1.18 (d, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 434.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_16_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> (<i>S</i>)-4-Amino-6-((1-(7-fluoro-1-(3-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>24</b>)</h4><div class="NLM_p last">Yield: 51%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.96 (dd, <i>J</i> = 5.7, 2.6 Hz, 1H), 7.91 (s, 1H), 7.83 (d, <i>J</i> = 7.3 Hz, 1H), 7.64–7.54 (m, 1H), 7.44–7.33 (m, 1H), 7.31–7.17 (m, 5H), 6.78 (s, 1H), 4.95–4.84 (m, 1H), 1.33 (d, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 437.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_16_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> (<i>S</i>)-2,4-Diamino-6-((1-(1-(3,5-difluorophenyl)-7-fluoro-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>25</b>)</h4><div class="NLM_p last">Yield: 29%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.96 (dd, <i>J</i> = 5.6, 2.5 Hz, 1H), 7.71–7.54 (m, 1H), 7.46 (d, <i>J</i> = 9.3 Hz, 1H), 7.43–7.33 (m, 1H), 7.33–7.16 (m, 2H), 7.12 (d, <i>J</i> = 7.3 Hz, 1H), 6.71 (s, 1H), 6.58 (s, 2H), 6.14 (br s, 1H), 4.91–4.75 (m, 1H), 1.24 (d, <i>J</i> = 6.9 Hz, 3H). [α]<sub>D</sub> 77.642° (<i>c</i> 0.475, CHCl<sub>3</sub>). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>22</sub>H<sub>16</sub>F<sub>3</sub>N<sub>7</sub>O [M + H]<sup>+</sup>, 452.1447; found, 452.1434.</div></div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> General Procedure for the Suzuki Coupling Reaction</h3><div class="NLM_p">To a stirred solution of <b>52</b> (0.800 g, 1.851 mmol) in dioxane (15 mL), cyclopropylboronic acid (0.477 g, 5.55 mmol), CsF (1.125 g, 7.40 mmol), and NaO<i>t</i>Bu (0.356 g, 3.70 mmol) were added under nitrogen. The reaction mixture was purged by nitrogen for 10 min, then Pd(amphos)Cl<sub>2</sub> (0.262 g, 0.370 mmol) was added. The reaction mixture was heated at 85 °C for 15 h. The reaction mass was diluted with water (50 mL) and extracted with ethyl acetate (2 × 50 mL). The organic layer was washed with water (2 × 50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude. This crude product was purified by flash column chromatography using 45% ethyl acetate in hexane as an eluent to obtain product <b>57a</b> (500 mg, 78% yield).</div><div id="sec4_17_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> <i>tert</i>-Butyl (<i>S</i>)-(1-(3-Cyclopropyl-7-fluoro-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl) Carbamate (<b>57a</b>)</h4><div class="NLM_p last">Yield: 78%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.99 (dd, <i>J</i> = 6.0, 2.4 Hz, 1H), 7.49–7.40 (m, 1H), 7.26–7.16 (m, 1H), 6.79 (s, 1H), 5.56 (br s, 1H), 5.02–4.82 (m, 1H), 1.88–1.74 (m, 1H), 1.53–1.36 (m, 12H), 1.22–1.08 (m, 3H), 0.99–0.94 (m, 1H). LCMS (ESI) <i>m</i>/<i>z</i>: 347.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_17_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> <i>tert</i>-Butyl (<i>S</i>)-(1-(7-Fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>57b</b>)</h4><div class="NLM_p last">Yield: 85%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 8.85–8.78 (m, 1H), 7.87 (dd, <i>J</i> = 9.8, 5.8 Hz, 1H), 7.67–7.58 (m, 1H), 7.56 (d, <i>J</i> = 7.2 Hz, 1H), 7.49–7.43 (m, 2H), 7.42–7.30 (m, 3H), 7.03 (s, 1H), 4.62–4.50 (m, 1H), 1.35 (s, 9H), 1.09 (d, <i>J</i> = 6.5 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 383.29 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i144" class="anchor-spacer"></div><h3 class="article-section__title" id="_i144"> Synthesis of Compounds <b>58a–b</b></h3><div class="NLM_p">These compounds were prepared by using the procedure described in step-5, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> for bromination reaction.</div><div id="sec4_18_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> <i>tert</i>-Butyl (<i>S</i>)-(1-(1-Bromo-3-cyclopropyl-7-fluoro-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>58a</b>)</h4><div class="NLM_p last">Yield:81%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.10 (dd, <i>J</i> = 5.7, 2.5 Hz, 1H), 8.24–8.11 (m, 1H), 7.39–7.30 (m, 1H), 6.13 (br s, 1H), 5.78–5.71 (m, 1H), 2.07–2.02 (m, 1H), 1.68 (d, <i>J</i> = 7.3 Hz, 3H) 1.43 (s, 9H), 1.24–1.16 (m, 2H), 1.07–1.02 (m, 1H), 0.79–0.74 (m, 1H). LCMS (ESI) <i>m</i>/<i>z</i>: 425.05/427.06 [M + H]<sup>+</sup>.</div></div><div id="sec4_18_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> <i>tert</i>-Butyl (<i>S</i>)-(1-(1-Bromo-7-fluoro-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>58b</b>)</h4><div class="NLM_p last">Yield: 92%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.10 (dd, <i>J</i> = 5.5, 2.4 Hz, 1H), 8.33–8.22 (m, 1H), 7.61–7.38 (m, 4H), 7.34–7.21 (m, 2H), 5.56–5.12 (m, 1H), 1.49 (d, <i>J</i> = 7.3 Hz, 3H), 1.38 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 461.2/463.17 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i147" class="anchor-spacer"></div><h3 class="article-section__title" id="_i147"> Synthesis of Compounds <b>59a–c</b></h3><div class="NLM_p">Compounds <b>59a–c</b> were synthesized by using the same procedure as the Suzuki reaction described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> for compound <b>26</b>.</div><div id="sec4_19_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> <i>tert</i>-Butyl (<i>S</i>)-(1-(3-Cyclopropyl-7-fluoro-1-(4-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>59a</b>)</h4><div class="NLM_p last">Yield: 63%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.07 (dd, <i>J</i> = 5.9, 2.4 Hz, 1H), 7.35–7.16 (m, 4H), 7.06–6.96 (m, 1H), 6.90–6.81 (m, 1H), 5.61 (br s, 1H), 4.42–4.32 (m, 1H), 1.96–1.86 (m, 1H), 1.43–1.34 (m, 12H), 1.33–1.24 (m, 2H), 1.20–1.05 (m, 2H). LCMS (ESI) <i>m</i>/<i>z</i>: 441.08 [M + H]<sup>+</sup>.</div></div><div id="sec4_19_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> <i>tert</i>-Butyl (<i>S</i>)-(1-(7-Fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>59b</b>)</h4><div class="NLM_p last">Yield: 50.9%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.10 (dd, <i>J</i> = 5.8, 2.4 Hz, 1H), 7.63–7.55 (m, 1H), 7.54–7.46 (m, 2H), 7.46–7.18 (m, 6H), 7.16–7.08 (m, 1H), 7.08–6.99 (m, 1H), 4.80–4.67 (m, 1H), 3.83 (d, <i>J</i> = 8.6 Hz, 1H), 1.38 (s, 9H), 1.20 (d, <i>J</i> = 7.3 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 477.15 [M + H]<sup>+</sup>.</div></div><div id="sec4_19_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> <i>tert</i>-Butyl (<i>S</i>)-(1-(7-Fluoro-1-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)carbamate (<b>59c</b>)</h4><div class="NLM_p last">Yield: 42%, <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>): δ 9.10 (dd, <i>J</i> = 5.9, 2.5 Hz, 1H), 7.88–7.78 (m, 1H), 7.53–7.46 (m, 2H), 7.46–7.38 (m, 1H), 7.34–7.29 (m, 2H), 5.22–5.07 (m, 1H), 4.27–4.16 (m, 1H), 2.59 (s, 3H), 1.44 (d, <i>J</i> = 7.3 Hz, 3H), 1.38 (s, 9H). LCMS (ESI) <i>m</i>/<i>z</i>: 397.13 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i151" class="anchor-spacer"></div><h3 class="article-section__title" id="_i151"> Synthesis of Compounds <b>60a–c</b></h3><div class="NLM_p">Compounds <b>60a–c</b> were synthesized by using the same procedure as Boc de-protection described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><div id="sec4_20_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> (<i>S</i>)-2-(1-Aminoethyl)-3-cyclopropyl-7-fluoro-1-(4-fluorophenyl)-4<i>H</i>-quinolizin-4-one (<b>60a</b>)</h4><div class="NLM_p last">Yield: 98%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.89 (dd, <i>J</i> = 6.2, 2.5 Hz, 1H), 7.49–7.35 (m, 5H), 6.93–6.85 (m, 1H), 5.03 (br s, 2H), 4.40–4.30 (m, 1H), 1.70–1.61 (m, 1H), 1.57–1.43 (m, 2H), 1.36 (d, <i>J</i> = 7.0 Hz, 3H), 1.30–1.21 (m, 2H). LCMS (ESI) <i>m</i>/<i>z</i>: 341.18 [M + H]<sup>+</sup>.</div></div><div id="sec4_20_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-1-(4-fluorophenyl)-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>60b</b>)</h4><div class="NLM_p last">Yield: 95%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.93 (dd, <i>J</i> = 5.7, 2.7 Hz, 1H), 7.52–7.36 (m, 8H), 7.34–7.28 (m, 2H), 7.02–6.93 (m, 1H), 3.87–3.77 (m, 1H), 1.30 (s, 2H), 0.93 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 377.28 [M + H]<sup>+</sup>.</div></div><div id="sec4_20_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> (<i>S</i>)-2-(1-Aminoethyl)-7-fluoro-1-methyl-3-phenyl-4<i>H</i>-quinolizin-4-one (<b>60c</b>)</h4><div class="NLM_p last">Yield: 94%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.90 (dd, <i>J</i> = 6.2, 2.5 Hz, 1H), 8.11–8.01 (m, 1H), 7.69–7.62 (m, 1H), 7.46–7.40 (m, 2H), 7.37 (d, <i>J</i> = 7.3 Hz, 1H), 7.33–7.26 (m, 1H), 7.20 (d, <i>J</i> = 7.5 Hz, 1H), 4.15–4.08 (m, 1H), 2.74 (s, 3H), 2.29 (br s, 2H), 1.26 (d, <i>J</i> = 7.0 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 297.23 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i155" class="anchor-spacer"></div><h3 class="article-section__title" id="_i155"> Synthesis of Compounds <b>27–29</b> and <b>35–36</b></h3><div class="NLM_p">These compounds were prepared by using the procedure described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, as a nucleophilic aromatic substitution reaction for the synthesis of compound <b>4–19</b>.</div><div id="sec4_21_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> (<i>S</i>)-4-Amino-6-((1-(3-cyclopropyl-7-fluoro-1-(4-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>27</b>)</h4><div class="NLM_p last">Yield: 29.7%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.84 (dd, <i>J</i> = 6.2, 2.5 Hz, 1H), 7.94 (s, 1H), 7.66–7.54 (m, 1H), 7.49–7.34 (m, 2H), 7.34–7.17 (m, 3H), 6.93–6.76 (m, 1H), 5.44–5.24 (m, 1H), 2.28–2.14 (m, 1H), 1.83–1.72 (m, 1H), 1.51 (d, <i>J</i> = 7.3 Hz, 3H), 1.22–1.11 (m, 1H), 1.0–0.77 (m, 2H). LCMS (ESI) <i>m</i>/<i>z</i>: 458.93 [M]<sup>+</sup>.</div></div><div id="sec4_21_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> (<i>S</i>)-2,4-Diamino-6-((1-(3-cyclopropyl-7-fluoro-1-(4-fluorophenyl)-4-oxo-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>28</b>)</h4><div class="NLM_p last">Yield: 14.4%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88 (dd, <i>J</i> = 6.1, 2.5 Hz, 1H), 7.67–7.53 (m, 1H), 7.49–7.35 (m, 2H), 7.35–7.21 (m, 2H), 6.88–6.79 (m, 1H), 6.58 (br s, 2H), 5.59 (s, 2H), 2.20–2.09 (m, 1H), 1.41 (d, <i>J</i> = 7.1 Hz, 3H), 1.31–1.17 (m, 1H), 1.07–0.89 (m, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 473.93 [M]<sup>+</sup>.</div></div><div id="sec4_21_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> (<i>S</i>)-2,4-Diamino-6-((1-(7-fluoro-1-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (<b>29</b>)</h4><div class="NLM_p last">Yield: 14%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.89 (dd, <i>J</i> = 6.1, 2.5 Hz, 1H), 8.16–8.07 (m, 1H), 7.77–7.60 (m, 1H), 7.60–7.28 (m, 5H), 7.12 (d, <i>J</i> = 7.3 Hz, 1H), 6.56 (s, 2H), 5.98 (br s, 1H), 5.23–5.12 (m, 1H), 2.59 (s, 3H), 1.44 (d, <i>J</i> = 7.3 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 430.23 [M + H]<sup>+</sup>.</div></div><div id="sec4_21_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> (<i>S</i>)-2-Amino-4-((1-(7-fluoro-1-methyl-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)-6-methylpyrimidine-5-carbonitrile (<b>35</b>)</h4><div class="NLM_p last">Yield: 26%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.04–8.88 (m, 1H), 8.23–8.08 (m, 1H), 7.72–7.62 (m, 1H), 7.58–7.32 (m, 5H), 7.10 (br s, 2H), 6.46 (br s, 1H), 5.24–5.07 (m, 1H), 2.58 (s, 3H), 2.21 (s, 3H), 1.47 (d, <i>J</i> = 7.3 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 429.12 [M + H]<sup>+</sup>.</div></div><div id="sec4_21_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> (<i>S</i>)-2-Amino-4-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4<i>H</i>-quinolizin-2-yl)ethyl)amino)-6-methylpyrimidine-5-carbonitrile (<b>36</b>)</h4><div class="NLM_p last">Yield: 44.8%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.93 (dd, <i>J</i> = 5.8, 2.5 Hz, 1H), 7.70–7.63 (m, 1H), 7.56–7.46 (m, 3H), 7.45–7.36 (m, 3H), 7.36–7.05 (m, 3H), 7.05–6.93 (m, 2H), 6.49 (s, 1H), 4.89–4.80 (m, 1H), 4.75 (s, 1H), 2.20 (s, 3H), 1.30 (d, <i>J</i> = 7.1 Hz, 3H). LCMS (ESI) <i>m</i>/<i>z</i>: 509.19 [M + H]<sup>+</sup>. [α]<sub>D</sub> 162.0° (<i>c</i> 0.450, CHCl<sub>3</sub>).</div></div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i161" class="anchor-spacer"></div><h3 class="article-section__title" id="_i161"> Biology Protocols</h3><div id="sec4_22_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> PI3Kα, -β, -γ, and -δ Homogenous Time Resolved Fluorescence Biochemical Assay</h4><div class="NLM_p last">Inhibition of kinase activity of the 4 isoforms of the PI3K enzyme was demonstrated using a homogenous time-resolved fluorescence (HTRF)-based assay kit provided by Millipore. The assay procedure was carried out as per manufacturer’s instructions. Particular isoform of the PI3K enzyme was incubated with a PIP<sub>2</sub> substrate in the presence of ATP and in the presence of the PI3K inhibitor or 2.5% DMSO, and the reaction was allowed to proceed at 25 °C for 45 min. Stop mix (provided by the HTRF kit) was added to stop the reaction followed by a brief mixing. Finally, the detection mix (provided by the HTRF kit Millipore/Eurofins, Cat#33-017) was added, the reaction mixture was vortexed and incubated at RT for an additional 2 h. The assay plate was read in the PHERAstar instrument at preset conditions for time-resolved fluorescence measurement (FRET). Non-biotinylated PIP<sub>3</sub> generated in the kinase reaction competed with the biotinylated PIP<sub>3</sub> and reduced FRET signal. The FRET signal further increased dose dependently upon the presence of increasing concentration of PI3K inhibitor(s). IC<sub>50</sub> values were generated from % inhibition using GraphPad Prism software.</div></div><div id="sec4_22_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> Cellular PI3K Inhibition Assay</h4><div class="NLM_p last">Inhibition of cellular PI3K activity was measured by the reduction of pAKT (phosphorylation at S473) levels using alpha screen surefire <i>p</i>-AKT1/2/3 (Ser473) assay kit from PerkinElmer. Adherent cells (MDA-MB-453 for PI3Kα, 786-O for PI3Kβ, and RAW 264.7 for PI3Kγ) were seeded at an optimized seeding density (40,000 cells/well) in 96 well cell culture grade plates in media containing 10% fetal bovine serum, and incubated overnight, whereas suspension cells (Raji for PI3Kδ, 1 million cells/well) were seeded on the day of the experiment. One hour compound treatment was performed with or without serum starvation (2 h serum starvation for RAW 264.7 and Raji). For PI3Kα and PI3Kβ, MDA-MB-453 and 786-O cells, respectively, were lysed after the completion of treatment. For PI3Kγ and PI3Kδ, RAW 264.7 and Raji cells, respectively, were stimulated for a particular time (10 nM C5A stimulation for 3 min in RAW 264.7 and 3 μg/mL of anti-IgM for 30 min in Raji cells) after 1 h compound treatment. Post stimulation, lysis buffer was added and the plate was shaken on an orbital plate shaker at approximately 300 rpm for 10 min. Using the cell lysate, AlphaScreen SureFire assay was performed to measure phosphorylation of AKT in the cells according to the manufacturer’s instructions. Fluorescence was measured using an alpha technology-compatible plate reader (PHERAstar) at 520–620 nm. IC<sub>50</sub> values were generated from % inhibition using GraphPad Prism software.</div></div><div id="sec4_22_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> Anticancer Assay</h4><div class="NLM_p last">GCB-DLBCL cells (SU-DHL-6; CRL-2959, ATCC) and ABC-DLBCL cells (OCI-Ly10 obtained from UHN, Canada and TMD-8 obtained from Tokyo Medical and Dental University) were seeded at an optimized seeding density (5000 cells/well for SU-DHL-6, 10000 cells/well for OCI-Ly10 and 2500 cells/well for TMD-8) in 96-well cell culture grade opaque plates, on the day of the experiment. Cells were then treated with increasing concentrations of compounds, and plates were incubated for 96 h under normal cell culture conditions (37 °C with 5% CO<sub>2</sub>). Some wells were kept as DMSO control wells (treated with only DMSO, final DMSO concentration: 0.1%). At the completion of treatment time, 100 μL/well of the CellTiter-Glo reagent was added and plates were wrapped in aluminum foil and kept on a shaker at room temperature for 3 min. Plates were further incubated for 10 min in the dark. Plates were then read on PHERAstar. RLUs (relative light inits) were directly proportional to the cell number. Average RLU of the vehicle was considered as 100% growth, and % inhibition at various concentrations of compound treatment was calculated accordingly. IC<sub>50</sub> values were generated from % inhibition using GraphPad Prism software.</div></div><div id="sec4_22_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> Efficacy Evaluation in Mouse Xenograft Models</h4><div class="NLM_p last">Male and female NOD scid mice (NOD.CB17-Prkdcscid/J, 6–9 weeks old) were procured from The Jackson Laboratory, USA. Mice were housed under standard laboratory conditions (22–25 °C temperature and 50–70% relative humidity) in individually ventilated cages and fed autoclaved rodent laboratory chow and purified water ad libitum; mice were acclimatized for a duration of 14 days prior to experimentation. Ectopic xenografts of the tumors were established by subcutaneous injection of 20 million cells (OCI-Ly10) in female NOD scid mice or 10 million cells (TMD-8 and SUDHL-6) in male NOD scid mice. Tumor cells were suspended in a solution (1:1) of phosphate buffered saline-Matrigel (Product #356234: Corning Matrigel Basement Membrane Matrix), and injected in the right-flanks of the mice in a volume of 200 μL/mouse. Animals were randomized into treatment groups when the mean tumor volume reached in the range of 130–160 mm<sup>3</sup>. In the dose–response studies with OCI-Ly10 and TMD-8 xenografts, tumor-bearing animals were randomized into six treatment groups each (<i>n</i> = 8) and administered orally with a vehicle (1% Tween 80 + 15% Gelucire-44/14 + 84% Milli-Q water, 10 mL/kg), CAL-101 (idelalisib, 3 mg/kg), and compound <b>34</b> (1, 3, 10, and 30 mg/kg), once daily. In the SUDHL-6 xenograft study, the mice were randomized into three treatment groups (<i>n</i> = 8) and treated orally with a vehicle, CAL-101 (5 mg/kg) and compound <b>34</b> (5 mg/kg), once daily. Compounds were administered in a study duration ranging from 15 to 24 days, during which the animal body weight was recorded daily and tumor size was measured twice weekly. At the study termination, blood samples and tumor samples were collected 1.5 h after last dose and tumor weight for each treatment group was recorded. Tumor volume was calculated using the formula: Tumor volume in mm<sup>3</sup> = (length × width × width)/2. Percent tumor growth inhibition was calculated to be 1 – (<i>T</i><sub>f</sub> – <i>T</i><sub>i</sub>)/(<i>C</i><sub>f</sub> – <i>C</i><sub>i</sub>) × 100, where <i>T</i><sub>i</sub> and <i>T</i><sub>f</sub> are the initial (pre-treatment) and final tumor volumes, and <i>C</i><sub>i</sub> and <i>C</i><sub>f</sub> are the initial and final tumor volumes of the vehicle group, respectively. Percentage change in body weight was calculated as (final body weight – initial body weight)/(initial body weight) × 100. All the procedures conducted on the animals were in accordance to the provisions of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) and approved by the Institutional Animal Ethics Committee of Lupin Research Park.</div></div><div id="sec4_22_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i166" class="anchor-spacer"></div><h4 class="article-section__title" id="_i166"> Metabolic Stability, Plasma Protein Binding, and Pharmacokinetic Studies</h4><div id="sec4_22_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i167" class="anchor-spacer"></div><h5 class="article-section__title" id="_i167"> Metabolic Stability</h5><div class="NLM_p last">Stock solutions of test compounds were spiked at 1 μM concentration into 0.25 mg/mL liver microsomes (mouse, rat, and human) and pre-incubated for 5 min at 37 °C. The reaction was initiated by adding NADPH in potassium phosphate buffer (50 mM, pH 7.4). Reactions were quenched with 100 μL of the quenching solvent at 0, 10, 20, and 30 min. A positive control reaction was performed similarly with nicardipine (1 μM) at 0.25 mg mL<sup>–1</sup> of microsomal protein concentration. A NADPH negative control was performed in a similar manner except that, in this case, NADPH was absent from the incubation mixture, and the samples were collected at 0 and 30 min. All the samples were analyzed by LCMS/MS. % parent remaining at 10, 20, and 30 min was quantified. The log of transformed % parent remaining was plotted as a function of time, and slope of the regression line was used to calculate the metabolic rate. The metabolic rate of the test compounds were calculated as <i>K</i>[<i>S</i>]/[<i>P</i>], where <i>K</i> is the slope of % parent remaining versus time plot, [<i>S</i>] is the substrate concentration, 1 μM, and [<i>P</i>] is the protein concentration, 0.25 mg/mL. The percent remaining of test compounds or positive control in each sample was determined by considering the levels in the 0 min sample as 100%.</div></div><div id="sec4_22_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i168" class="anchor-spacer"></div><h5 class="article-section__title" id="_i168"> Plasma Protein Binding</h5><div class="NLM_p last">Plasma protein binding was carried out using the equilibrium dialysis method in a high throughput dialysis (HTD) device containing a dialysis membrane with a molecular weight cutoff of 6–8k. The plasma was spiked with test compounds or reference control to obtain a final concentration of 5 μM in the reaction mixture and final DMSO concentration of 0.5%. For the protein binding study, a 150 μL aliquot of the test item-spiked plasma was added to a plasma chamber and 150 μL of buffer was added to the buffer chamber of the HTD device. Dialysis was carried out in a shaking water bath (50 rpm) at 37 °C for 16 h. Following dialysis, an aliquot of 100 μL was removed from each well (plasma and buffer side) and diluted with an equal volume of the opposite matrix to nullify the matrix effect and was submitted for LCMS/MS analysis. Warfarin at 5 μM was used as a reference standard under the same experimental conditions. The sample extraction was performed by the protein precipitation method. Cross-matrixed samples were terminated with ice-cold acetonitrile containing nicardipine (0.05 μM) as an internal standard. The terminated samples were vortexed and centrifuged for 10 min at 4000 rpm. Supernatants were separated, transferred to 96-well plate, and submitted for bioanalysis. A fit-for-purpose LCMS/MS method was used for the quantification of test compounds and warfarin.</div></div><div id="sec4_22_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i169" class="anchor-spacer"></div><h5 class="article-section__title" id="_i169"> Pharmacokinetic Studies</h5><div class="NLM_p">Laboratory preclinical rodents were housed under standard laboratory conditions (22–25 °C temperature and 50–70% relative humidity) in polycarbonate cages and fed autoclaved rodent laboratory chow except when fasted overnight for oral groups and purified water ad libitum. All the study procedures were conducted as per CPCSEA guidelines and pre-approved IAEC protocols. Male BALB/c mice or male Sprague Dawley rats were administered intravenously as a slow bolus injection <i>via</i> tail vein at a dose of 1 mg/kg or dosed orally through stomach intubation cannula at a dose of 10 mg/kg. Dosing volume was 5 and 10 mL/kg for i.v. and p.o. groups for the mouse, and 4 and 10 mL/kg for rats, respectively. Blood samples were collected from retro-orbital plexus of a set of three mice each at 0.083 (only for i.v.) 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h in microcentrifuge tubes containing K<sub>2</sub>EDTA as an anticoagulant. In the case of the rat study, blood samples were collected serially from each rat at 0.083 (only for i.v.) 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h. All the samples were stored below −70 °C until bioanalysis.</div><div class="NLM_p">Male Beagle dogs were administered intravenously as an infusion (15 min) <i>via</i> a cephalic vein at a dose of 1 mg/kg in a dose volume of 2 mL/kg. Blood samples were collected from the cephalic vein of each dog at 0.083, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 h in microcentrifuge tubes containing K<sub>2</sub>EDTA as an anticoagulant. Plasma samples were harvested by centrifugation of whole blood at 7000 rpm and 4 ± 2 °C for 5 min. Plasma concentrations were determined by the LCMS/MS method using an internal standard.</div><div class="NLM_p last">The plasma concentration–time data were subjected to noncompartmental analysis using Phoenix WinNonlin software (version 8.0) to assess the pharmacokinetics parameters. Peak plasma concentrations (<i>C</i><sub>max</sub>) and time for the peak plasma concentrations (<i>T</i><sub>max</sub>) were the observed values. The area under the concentration time curve (AUC) was calculated by the linear trapezoidal rule. The terminal elimination rate constant (<i>k</i><sub>el</sub>) was determined by regression analysis of the linear terminal portion of the log plasma concentration–time curve. The terminal half-life (<i>T</i><sub>1/2</sub>) estimated as 0.693/<i>k</i><sub>el</sub>. CLiv was calculated as dose/AUC and <i>V</i><sub>ss</sub> as CL<sub>iv</sub> × MRT. Oral bioavailability was the ratio of dose normalized (AUC<sub>po</sub>/AUC<sub>iv</sub>) × 100.</div></div></div><div id="sec4_22_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i170" class="anchor-spacer"></div><h4 class="article-section__title" id="_i170"> Molecular Modeling</h4><div class="NLM_p last">The docking process was carried out using the Protein preparation, LigPrep, and Glide modules of the Schrodinger Discovery suite. Protein preparation: the protein structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a>) was downloaded and prepared through the protein preparation modules keeping the default parameters to add the required hydrogens and correct the bond length and angles including removing of all the water molecules. The restrained minimization was carried out using an OPLS2005 force field. Ligand preparation: the compounds were initially prepared using the LigPrep modules keeping the required stereochemistry in place. Ligand docking: the prepared ligands were subjected to molecular docking using the Glide module using the Xtra precession mode using the default parameters.</div></div><div id="sec4_22_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i171" class="anchor-spacer"></div><h4 class="article-section__title" id="_i171"> Kinase Selectivity Profiling</h4><div class="NLM_p last">Compound <b>34</b> comprehensive kinase profile assays were performed by Eurofins Pharma Discovery Services according to the well-known methods. Further methodological details are available on the company Web site (<a href="http://www.eurofinsdiscoveryservices.com" class="extLink">www.eurofinsdiscoveryservices.com</a>).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i172"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01264" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01264?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01264</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Analytical data; methods and conditions for separation of enantiomers (compounds <b>4–9</b>) by preparative chiral HPLC and comprehensive kinase profile of compound <b>34</b> (Table S2) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) that are the subject of this publication (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_003.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>) that are the subject of this publication (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_004.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) that are the subject of this publication (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_005.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) that are the subject of this publication (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_006.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>) that are the subject of this publication (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_007.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_001.pdf">jm0c01264_si_001.pdf (7.73 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_003.csv">jm0c01264_si_003.csv (1.42 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_004.csv">jm0c01264_si_004.csv (1.67 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_005.csv">jm0c01264_si_005.csv (1.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_006.csv">jm0c01264_si_006.csv (1.29 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_007.csv">jm0c01264_si_007.csv (0.72 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01264" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manojkumar R. Shukla</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1735-7965" title="Orcid link">http://orcid.org/0000-0003-1735-7965</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#315c505f5e5b5a445c50434259445a5d50715d4441585f1f525e5c"><span class="__cf_email__" data-cfemail="f19c909f9e9b9a849c90838299849a9d90b19d8481989fdf929e9c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sukanya Patra</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mahip Verma</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gayathri Sadasivam</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nirmal Jana</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sachin J. Mahangare</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Prashant Vidhate</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dipak Lagad</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anand Tarage</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Murthy Cheemala</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chaitanya Kulkarni</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shankar Bhagwat</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vinod D. Chaudhari</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Majid Sayyed</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vipul Pachpute</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramesh Phadtare</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gopal Gole</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samiron Phukan</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brahmam Sunkara</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charudatt Samant</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manisha Shingare</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aditya Naik</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sneha Trivedi</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ajit Kumar Marisetti</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Madhusudhan Reddy</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Milind Gholve</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nilesh Mahajan</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sudeep Sabde</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vinod Patil</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dipak Modi</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maneesh Mehta</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Prashant Nigade</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kaustubh Tamane</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Swati Tota</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hemant Goyal</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harish Volam</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shashikant Pawar</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Prajakta Ahirrao</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lal Dinchhana</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sadanand Mallurwar</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Atul Akarte</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anand Bokare</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rupesh Kanhere</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neetinkumar Reddy</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarita Koul</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manoj Dandekar</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Minakshi Singh</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter R. Bernstein</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0407-9150" title="Orcid link">http://orcid.org/0000-0003-0407-9150</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lakshmi Narasimham</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mandar Bhonde</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jayasagar Gundu</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajan Goel</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sanjeev Kulkarni</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharad Sharma</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rajender Kumar Kamboj</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Venkata P. Palle</span> - <span class="hlFld-Affiliation affiliation">Novel Drug Discovery and Development,
Lupin Ltd., Lupin Research
Park, Survey No. 46 A/47A, Village Nande, Taluka
Mulshi, Pune 412115, India</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i173">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38731" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38731" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to acknowledge the contributions of scientists belonging to PI3Kδ project team from the following departments: Medicinal Chemistry, CADD, Analytical Chemistry, Pre-clinical Pharmacology, DMPK, Process Chemistry, Drug Safety Assessment, Clinical Research, and IPMG.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ABC-DLBCL</td><td class="NLM_def"><p class="first last">activated B cell-like (ABC) type of diffuse large B cell lymphoma</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve from time zero to the last measurable concentration</p></td></tr><tr><td class="NLM_term">BCR</td><td class="NLM_def"><p class="first last">B-cell receptor</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">systemic clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">CsF</td><td class="NLM_def"><p class="first last">cesium fluoride</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">EDC·HCl</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term">GCB-DLBCL</td><td class="NLM_def"><p class="first last">germinal center B cell-like type of diffuse large B cell lymphoma</p></td></tr><tr><td class="NLM_term">IPA</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">NaBH<sub>4</sub></td><td class="NLM_def"><p class="first last">sodium borohydride</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">μM</td><td class="NLM_def"><p class="first last">micromolar</p></td></tr><tr><td class="NLM_term">Pd(amphos)Cl<sub>2</sub></td><td class="NLM_def"><p class="first last">bis(di-<i>tert</i>-butyl(4-dimethylaminophenyl)phosphine)dichloropalladium(II)</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphatidylinositol-3-kinase</p></td></tr><tr><td class="NLM_term">RTKs</td><td class="NLM_def"><p class="first last">receptor tyrosine kinases</p></td></tr><tr><td class="NLM_term">SU-DHL-6</td><td class="NLM_def"><p class="first last">Stanford University-diffuse histiocytic lymphoma</p></td></tr><tr><td class="NLM_term">TCR</td><td class="NLM_def"><p class="first last">T-cell receptor</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethyl amine</p></td></tr><tr><td class="NLM_term">Ti(O<i>i</i>Pr)<sub>4</sub></td><td class="NLM_def"><p class="first last">titanium(IV) isopropoxide</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">time after administration of a drug when the maximum plasma concentration is reached</p></td></tr><tr><td class="NLM_term">TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>ss</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i175">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Koehrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span> <span> </span><span class="NLM_article-title">B-cell Receptor Signaling in Chronic Lymphocytic Leukemia and other B-cell Malignancies</span>. <i>Clin. Adv. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">65</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=27057669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BC28fotFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=55-65&author=S.+Koehrerauthor=J.+A.+Burger&title=B-cell+Receptor+Signaling+in+Chronic+Lymphocytic+Leukemia+and+other+B-cell+Malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies</span></div><div class="casAuthors">Koehrer Stefan; Burger Jan A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-65</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">B-cell receptor (BCR) signaling has emerged as a key pathway for the expansion of neoplastic B-cell clones in several B-cell malignancies.  The mechanisms that activate BCR signaling differ substantially among subtypes of B-cell lymphoma and leukemia.  These include BCR stimulation by foreign or self-antigens, or the acquisition of mutations in components of the BCR pathway that result in autonomous or enhanced antigen-induced BCR signaling.  Targeting BCR signaling with selective inhibitors of the BCR-associated kinases Bruton's tyrosine kinase, spleen tyrosine kinase, and phosphoinositide 3-kinase delta induces high response rates in patients with chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia, and diffuse large B-cell lymphoma of the activated B-cell-like subtype and is currently transforming the therapeutic landscape in these diseases.  Here we review the mechanisms of BCR activation that govern growth and survival of malignant B cells.  We also summarize recent clinical trials of BCR inhibitors, with a focus on the most clinically advanced agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk0cFTqP-4v8zK395ZObgVfW6udTcc2eZIpC0dYjDRMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fotFCnsA%253D%253D&md5=e4c1cffc4441352f099de4bf034b3f10</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoehrer%26aufirst%3DS.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26atitle%3DB-cell%2520Receptor%2520Signaling%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%2520and%2520other%2520B-cell%2520Malignancies%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D14%26spage%3D55%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Myklebust, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brody, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrt, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolstad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wälchli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trøen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liestøl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beiske, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irish, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span> <span> </span><span class="NLM_article-title">Distinct Patterns of B-cell Receptor Signaling in Non-Hodgkin Lymphomas Identified by Single-cell Profiling</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-05-718494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2016-05-718494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=28011673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFaqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=759-770&author=J.+H.+Myklebustauthor=J.+Brodyauthor=H.+E.+Kohrtauthor=A.+Kolstadauthor=D.+K.+Czerwinskiauthor=S.+W%C3%A4lchliauthor=M.+R.+Greenauthor=G.+Tr%C3%B8enauthor=K.+Liest%C3%B8lauthor=K.+Beiskeauthor=R.+Houotauthor=J.+Delabieauthor=A.+A.+Alizadehauthor=J.+M.+Irishauthor=R.+Levy&title=Distinct+Patterns+of+B-cell+Receptor+Signaling+in+Non-Hodgkin+Lymphomas+Identified+by+Single-cell+Profiling&doi=10.1182%2Fblood-2016-05-718494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling</span></div><div class="casAuthors">Myklebust, June H.; Brody, Joshua; Kohrt, Holbrook E.; Kolstad, Arne; Czerwinski, Debra K.; Walchli, Sebastien; Green, Michael R.; Troeen, Gunhild; Liestoel, Knut; Beiske, Klaus; Houot, Roch; Delabie, Jan; Alizadeh, Ash A.; Irish, Jonathan M.; Levy, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">759-770</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Kinases downstream of B-cell antigen receptor (BCR) represent attractive targets for therapy in non-Hodgkin lymphoma (NHL).  As clin. responses vary, improved knowledge regarding activation and regulation of BCR signaling in individual patients is needed.  Here, using phosphospecific flow cytometry to obtain malignant B-cell signaling profiles from 95 patients representing 4 types of NHL revealed a striking contrast between chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) tumors.  Lymphoma cells from diffuse large B cell lymphoma patients had high basal phosphorylation levels of most measured signaling nodes, whereas follicular lymphoma cells represented the opposite pattern with no or very low basal levels.  MCL showed large inter patient variability in basal levels, and elevated levels for the phosphorylated forms of AKT, extra cellular signal-regulated kinase, p38, STAT1, and STAT5 were assocd. with poor outcome.  CLL tumors had elevated basal levels for the phosphorylated forms of BCR-signaling nodes (Src family tyrosine kinase, spleen tyrosine kinase [SYK], phospholipase Cγ), but had low α-BCR-induced signaling.  This contrasted MCL tumors, where α-BCR-induced signalling was variable, but significantly potentiated as compared with the other types.  Over expression of CD79B, combined with a gating strategy where by signalling output was directly quantified per cell as a function of CD79B levels, confirmed a direct relationship between surface CD79B, IgM (IgM), and IgM-induced signaling levels.  Furthermore, α-BCR-induced signaling strength was variable across patient samples and correlated with BCR subunit CD79B expression, but was inversely correlated with susceptibility to Bruton tyrosine kinase (BTK) and SYK inhibitors in MCL.  These individual differences in BCR levels and signaling might relate to differences in therapy responses to BCR-pathway inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswmOzY3Fn_bVg90H21EOLACvtfcHk0lhHEB3k_8KrLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFaqtLk%253D&md5=d0ee3513296a6120148c107755f32188</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-05-718494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-05-718494%26sid%3Dliteratum%253Aachs%26aulast%3DMyklebust%26aufirst%3DJ.%2BH.%26aulast%3DBrody%26aufirst%3DJ.%26aulast%3DKohrt%26aufirst%3DH.%2BE.%26aulast%3DKolstad%26aufirst%3DA.%26aulast%3DCzerwinski%26aufirst%3DD.%2BK.%26aulast%3DW%25C3%25A4lchli%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DM.%2BR.%26aulast%3DTr%25C3%25B8en%26aufirst%3DG.%26aulast%3DLiest%25C3%25B8l%26aufirst%3DK.%26aulast%3DBeiske%26aufirst%3DK.%26aulast%3DHouot%26aufirst%3DR.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DIrish%26aufirst%3DJ.%2BM.%26aulast%3DLevy%26aufirst%3DR.%26atitle%3DDistinct%2520Patterns%2520of%2520B-cell%2520Receptor%2520Signaling%2520in%2520Non-Hodgkin%2520Lymphomas%2520Identified%2520by%2520Single-cell%2520Profiling%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D759%26epage%3D770%26doi%3D10.1182%2Fblood-2016-05-718494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbach-Weese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0liuVJ_OfTPOnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatenay-Rivauday, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Novel and Specific PI3Kalpha Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-13-0865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1158%2F1535-7163.MCT-13-0865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=24608574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1117-1129&author=C.+Fritschauthor=A.+Huangauthor=C.+Chatenay-Rivaudayauthor=C.+Schnellauthor=A.+Reddyauthor=M.+Liuauthor=A.+Kauffmannauthor=D.+Guthyauthor=D.+Erdmannauthor=A.+De+Poverauthor=P.+Furetauthor=H.+Gaoauthor=S.+Ferrettiauthor=Y.+Wangauthor=J.+Trappeauthor=S.+M.+Brachmannauthor=S.-M.+Mairaauthor=C.+Wilsonauthor=M.+Boehmauthor=C.+Garcia-Echeverriaauthor=P.+Cheneauthor=M.+Wiesmannauthor=R.+Cozensauthor=J.+Leharauthor=R.+Schlegelauthor=G.+Caravattiauthor=F.+Hofmannauthor=W.+R.+Sellers&title=Characterization+of+the+Novel+and+Specific+PI3Kalpha+Inhibitor+NVP-BYL719+and+Development+of+the+Patient+Stratification+Strategy+for+Clinical+Trials&doi=10.1158%2F1535-7163.mct-13-0865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span></div><div class="casAuthors">Fritsch, Christine; Huang, Alan; Chatenay-Rivauday, Christian; Schnell, Christian; Reddy, Anupama; Liu, Manway; Kauffmann, Audrey; Guthy, Daniel; Erdmann, Dirk; De Pover, Alain; Furet, Pascal; Gao, Hui; Ferretti, Stephane; Wang, Youzhen; Trappe, Joerg; Brachmann, Saskia M.; Maira, Sauveur-Michel; Wilson, Christopher; Boehm, Markus; Garcia-Echeverria, Carlos; Chene, Patrick; Wiesmann, Marion; Cozens, Robert; Lehar, Joseph; Schlegel, Robert; Caravatti, Giorgio; Hofmann, Francesco; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1117-1129</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects assocd. with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family.  Here, we report the biol. properties of the 2-aminothiazole deriv. NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms.  The compd. selectivity combined with excellent drug-like properties translates to dose- and time-dependent inhibition of PI3Kα signaling in vivo, resulting in robust therapeutic efficacy and tolerability in PIK3CA-dependent tumors.  Novel targeted therapeutics such as NVP-BYL719, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients.  Here, we also describe the application of the Cancer Cell Line Encyclopedia as a preclin. platform to refine the patient stratification strategy for NVP-BYL719 and found that PIK3CA mutation was the foremost pos. predictor of sensitivity while revealing addnl. pos. and neg. assocns. such as PIK3CA amplification and PTEN mutation, resp.  These patient selection determinants are being assayed in the ongoing NVP-BYL719 clin. trials.  Mol Cancer Ther; 13(5); 1117-29. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBW6u023PF7Vg90H21EOLACvtfcHk0liuVJ_OfTPOnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D&md5=58d9132052dd9d430361021b0f877475</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0865%26sid%3Dliteratum%253Aachs%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DChatenay-Rivauday%26aufirst%3DC.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DErdmann%26aufirst%3DD.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520Novel%2520and%2520Specific%2520PI3Kalpha%2520Inhibitor%2520NVP-BYL719%2520and%2520Development%2520of%2520the%2520Patient%2520Stratification%2520Strategy%2520for%2520Clinical%2520Trials%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1117%26epage%3D1129%26doi%3D10.1158%2F1535-7163.mct-13-0865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demanse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase a–Selective Inhibition with Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1200/jco.2017.72.7107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1200%2FJCO.2017.72.7107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=29401002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1291-1299&author=D.+Juricauthor=J.+Rodonauthor=J.+Taberneroauthor=F.+Jankuauthor=H.+A.+Burrisauthor=J.+H.+M.+Schellensauthor=M.+R.+Middletonauthor=J.+Berlinauthor=M.+Schulerauthor=M.+Gil-Martinauthor=H.+S.+Rugoauthor=R.+Seggewiss-Bernhardtauthor=A.+Huangauthor=D.+Bootleauthor=D.+Demanseauthor=L.+Blumensteinauthor=C.+Coughlinauthor=C.+Quadtauthor=J.+Baselga&title=Phosphatidylinositol+3-Kinase+a%E2%80%93Selective+Inhibition+with+Alpelisib+%28BYL719%29+in+PIK3CA-Altered+Solid+Tumors%3A+Results+From+the+First-in-Human+Study&doi=10.1200%2Fjco.2017.72.7107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study</span></div><div class="casAuthors">Juric, Dejan; Rodon, Jordi; Tabernero, Josep; Janku, Filip; Burris, Howard A.; Schellens, Jan H. M.; Middleton, Mark R.; Berlin, Jordan; Schuler, Martin; Gil-Martin, Marta; Rugo, Hope S.; Seggewiss-Bernhardt, Ruth; Huang, Alan; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Coughlin, Christina; Quadt, Cornelia; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1291-1299</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose We report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the max. tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)-selective inhibitor.  Patients and Methods In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule.  In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer received alpelisib 400 mg once daily.  Results One hundred thirty-four patients received treatment.  Alpelisib max. tolerated doses were established as 400mg once daily and 150mg twice daily.  Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1).  Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%).  Alpelisib was rapidly absorbed; half-life was 7.6 h at 400 mg once daily with minimal accumulation.  Objective tumor responses were obsd. at doses ≥ 270 mg once daily; overall response ratewas 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses).  Stable disease was achieved in 70 (52.2%) patients and was maintained . 24 wk in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%.  In patients with estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer, median progression-free survival was 5.5 mo.  Frequently mutated genes (≥ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%).  Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps0P3SQLaDT7Vg90H21EOLACvtfcHk0ljafhS-MnNOvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO&md5=e95593fa4359b0ae552c92f909387f5b</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.72.7107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.72.7107%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DGil-Martin%26aufirst%3DM.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBootle%26aufirst%3DD.%26aulast%3DDemanse%26aufirst%3DD.%26aulast%3DBlumenstein%26aufirst%3DL.%26aulast%3DCoughlin%26aufirst%3DC.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520a%25E2%2580%2593Selective%2520Inhibition%2520with%2520Alpelisib%2520%2528BYL719%2529%2520in%2520PIK3CA-Altered%2520Solid%2520Tumors%253A%2520Results%2520From%2520the%2520First-in-Human%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1291%26epage%3D1299%26doi%3D10.1200%2Fjco.2017.72.7107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leevers, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woscholski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfield, M. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Function of 3-Phosphorylated Inositol Lipids</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.70.1.535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1146%2Fannurev.biochem.70.1.535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=11395417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=535-602&author=B.+Vanhaesebroeckauthor=S.+J.+Leeversauthor=K.+Ahmadiauthor=J.+Timmsauthor=R.+Katsoauthor=P.+C.+Driscollauthor=R.+Woscholskiauthor=P.+J.+Parkerauthor=M.+D.+Waterfield&title=Synthesis+and+Function+of+3-Phosphorylated+Inositol+Lipids&doi=10.1146%2Fannurev.biochem.70.1.535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and function of 3-phosphorylated inositol lipids</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Leevers, Sally J.; Ahmadi, Khatereh; Timms, John; Katso, Roy; Driscoll, Paul C.; Woscholski, Rudiger; Parker, Peter J.; Waterfield, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">535-602</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with 443 refs.  The 3-phosphorylated inositol lipids fulfill roles as second messengers by interacting with the lipid binding domains of a variety of cellular proteins.  Such interactions can affect the subcellular localization and aggregation of target proteins, and through allosteric effects, their activity.  Generation of 3-phosphoinositides has been documented to influence diverse cellular pathways and hence alter a spectrum of fundamental cellular activities.  This review is focused on the 3-phosphoinositide lipids, the synthesis of which is acutely triggered by extracellular stimuli, the enzymes responsible for their synthesis and metab., and their cell biol. roles.  Much knowledge has recently been gained through structural insights into the lipid kinases, their interaction with inhibitors, and the way their 3-phosphoinositide products interact with protein targets.  This field is now moving toward a genetic dissection of 3-phosphoinositide action in a variety of model organisms.  Such approaches will reveal the true role of the 3-phosphoinositides at the organismal level in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpChv_q4q6cLVg90H21EOLACvtfcHk0ljafhS-MnNOvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVehtL0%253D&md5=9905473d362ef35b512d038efb901d3e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.70.1.535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.70.1.535%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DLeevers%26aufirst%3DS.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DTimms%26aufirst%3DJ.%26aulast%3DKatso%26aufirst%3DR.%26aulast%3DDriscoll%26aufirst%3DP.%2BC.%26aulast%3DWoscholski%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DP.%2BJ.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26atitle%3DSynthesis%2520and%2520Function%2520of%25203-Phosphorylated%2520Inositol%2520Lipids%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2001%26volume%3D70%26spage%3D535%26epage%3D602%26doi%3D10.1146%2Fannurev.biochem.70.1.535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriskantharajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span> <span> </span><span class="NLM_article-title">PI3K Inhibitors in Inflammation, Autoimmunity and Cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2015.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.coph.2015.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=26093105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=82-91&author=A.-K.+Starkauthor=S.+Sriskantharajahauthor=E.+M.+Hesselauthor=K.+Okkenhaug&title=PI3K+Inhibitors+in+Inflammation%2C+Autoimmunity+and+Cancer&doi=10.1016%2Fj.coph.2015.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K inhibitors in inflammation, autoimmunity and cancer</span></div><div class="casAuthors">Stark, Anne-Katrien; Sriskantharajah, Srividya; Hessel, Edith M.; Okkenhaug, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-91</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues.  Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer.  Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research.  In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small mol. inhibitors, of which several are currently in clin. trials for the treatment of immune-related disorders and cancer.  The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clin. and clin. development of PI3K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNWPQZuO9fE7Vg90H21EOLACvtfcHk0ljnzu8-BaSGdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7%252FM&md5=382eb159c8ec5e3a4bc14f71f54dd295</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DA.-K.%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26aulast%3DOkkenhaug%26aufirst%3DK.%26atitle%3DPI3K%2520Inhibitors%2520in%2520Inflammation%252C%2520Autoimmunity%2520and%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D82%26epage%3D91%26doi%3D10.1016%2Fj.coph.2015.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulhati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampy, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychahou, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B. M.</span></span> <span> </span><span class="NLM_article-title">Novel Expression Patterns of PI3K/AKT/mTOR Signaling Pathway</span>. <i>J. Am. Coll. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1016/j.jamcollsurg.2009.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.jamcollsurg.2009.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=20421047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ptV2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2010&pages=767-778&author=S.+M.+Johnsonauthor=P.+Gulhatiauthor=B.+A.+Rampyauthor=Y.+Hanauthor=P.+G.+Rychahouauthor=H.+Q.+Doanauthor=H.+L.+Weissauthor=B.+M.+Evers&title=Novel+Expression+Patterns+of+PI3K%2FAKT%2FmTOR+Signaling+Pathway&doi=10.1016%2Fj.jamcollsurg.2009.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer</span></div><div class="casAuthors">Johnson Sara M; Gulhati Pat; Rampy Bill A; Han Yimei; Rychahou Piotr G; Doan Hung Q; Weiss Heidi L; Evers B Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Surgeons</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">767-76, 776-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway plays a critical role in the growth and progression of colorectal cancer (CRC).  The purpose of our study was 2-fold: (1) to determine the expression levels of several key components of this pathway, including p85alpha, Akt1, Akt2, p-mTOR(Ser2448), and p-p70S6K(Thr389) in CRCs; and (2) to correlate the expression of these proteins with cancer stage and location (left versus right side).  STUDY DESIGN:  Immunohistochemistry for p85alpha, Akt1, Akt2, p-mTOR(Ser2448), and p-p70S6K(Thr389) was performed on normal colon and CRCs from 154 patients.  RESULTS:  All proteins investigated were significantly overexpressed in CRCs compared with matched normal colonic tissue from the same patient (p < 0.0001).  PI3K pathway component proteins were moderately correlated across normal and malignant colon tissues; correlations tended to be stronger in normal tissues as compared with the same correlations in cancers.  Expression levels of p85alpha were significantly higher in stage IV cancers than in stage I to III cancers (p = 0.0005). p85alpha expression was also significantly increased in the adjacent normal colonic mucosa of patients with stage IV CRC compared with earlier stages (p = 0.003).  Finally, expression of Akt1, Akt2, and p-p70S6K(Thr389) was higher in left-sided CRCs compared with CRCs in the right colon (p = 0.007, p = 0.0008, and p = 0.04, respectively).  CONCLUSIONS:  The PI3K/Akt/mTOR pathway components, p85alpha, Akt1, Akt2, p-mTOR(Ser2448), and p-p70S6K(Thr389) are highly overexpressed in CRCs, providing the rationale for targeting this pathway therapeutically in CRC patients.  The increased expression of p85alpha in the adjacent normal mucosa of stage IV patients suggests an important field defect, which may contribute to the growth and progression of these cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB4mmWCyEtHfh3YQQtAhNufW6udTcc2ebciK_qK0GaErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ptV2mtw%253D%253D&md5=d9589b687ab20567c42ade1869da7fc1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.jamcollsurg.2009.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jamcollsurg.2009.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DS.%2BM.%26aulast%3DGulhati%26aufirst%3DP.%26aulast%3DRampy%26aufirst%3DB.%2BA.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DRychahou%26aufirst%3DP.%2BG.%26aulast%3DDoan%26aufirst%3DH.%2BQ.%26aulast%3DWeiss%26aufirst%3DH.%2BL.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DNovel%2520Expression%2520Patterns%2520of%2520PI3K%252FAKT%252FmTOR%2520Signaling%2520Pathway%26jtitle%3DJ.%2520Am.%2520Coll.%2520Surg.%26date%3D2010%26volume%3D210%26spage%3D767%26epage%3D778%26doi%3D10.1016%2Fj.jamcollsurg.2009.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">591, A Novel Specific Pan-PI3K Inhibitor, Preferentially Targets Cancer Stem Cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3371</span>– <span class="NLM_lpage">3386</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0674-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1038%2Fs41388-018-0674-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30635656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVGgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=3371-3386&author=H.+Zhouauthor=C.+Yuauthor=L.+Kongauthor=X.+Xuauthor=J.+Yanauthor=Y.+Liauthor=T.+Anauthor=L.+Gongauthor=Y.+Gongauthor=H.+Zhuauthor=H.+Zhangauthor=X.+Yangauthor=Y.+Li&title=591%2C+A+Novel+Specific+Pan-PI3K+Inhibitor%2C+Preferentially+Targets+Cancer+Stem+Cells&doi=10.1038%2Fs41388-018-0674-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells</span></div><div class="casAuthors">Zhou, Hongyu; Yu, Chunlei; Kong, Lingmei; Xu, Xiaoliang; Yan, Juming; Li, Yingchao; An, Tao; Gong, Liang; Gong, Yaxiao; Zhu, Huifang; Zhang, Hongbin; Yang, Xiaodong; Li, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3371-3386</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) have been implicated in metastasis, relapse, and therapeutic resistance of cancer, so successful cancer therapy may therefore require the development of drugs against CSCs or combining anti-CSCs drugs with conventional therapies.  The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most frequently activated signaling pathways in human cancer, playing a central role in tumorigenesis as well as the maintenance of CSCs.  Here, we designed and identified B591, a dihydrobenzofuran-imidazolium salt, as a novel specific pan-PI3K inhibitor with potent inhibitory activity against class I PI3K isoforms, which showed effective inhibition of cellular PI3K/mTOR signaling pathway and robust antitumor activity in a set of cancer cell lines.  Notably, compared with bulk tumor cell populations, B591 exhibited more potency in suppressing CSCs survival and inducing CSCs apoptosis, and presence of B591 effectively eliminated paclitaxel-enriched CSCs.  B591 diminished self-renewal capacity and decreased the expression of epithelial-mesenchymal transition (EMT) markers of CSCs.  In vivo, B591 preferentially decreased CSCs levels in mouse xenograft model of human breast cancer as evidenced esp. by remarkable redn. of tumor-initiating ability.  Consistent with the preferential targeting of CSCs, B591 effectively inhibited breast tumor metastasis and delayed tumor regrowth following paclitaxel treatment.  Taken together, our findings establish B591, a novel PI3K inhibitor, as a strong candidate for clin. evaluation as a CSCs targeting agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgpgRnXOUhGrVg90H21EOLACvtfcHk0lhnpkfVDpIWOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVGgsb4%253D&md5=33f993c90d89c82d0d42554dde49afcd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0674-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0674-5%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26atitle%3D591%252C%2520A%2520Novel%2520Specific%2520Pan-PI3K%2520Inhibitor%252C%2520Preferentially%2520Targets%2520Cancer%2520Stem%2520Cells%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D3371%26epage%3D3386%26doi%3D10.1038%2Fs41388-018-0674-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-0954-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1186%2Fs12943-019-0954-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30782187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=26&author=J.+Yangauthor=J.+Nieauthor=X.+Maauthor=Y.+Weiauthor=Y.+Pengauthor=X.+Wei&title=Targeting+PI3K+in+Cancer%3A+Mechanisms+and+Advances+in+Clinical+Trials&doi=10.1186%2Fs12943-019-0954-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span></div><div class="casAuthors">Yang Jing; Nie Ji; Ma Xuelei; Wei Yuquan; Peng Yong; Wei Xiawei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer.  Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of which are currently employed in clinical trials evaluation, and it is becoming increasingly clear that PI3K inhibitors are effective in inhibiting tumor progression.  PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and isoform-specific inhibitors.  In this review, we performed a critical review to summarize the role of the PI3K pathway in tumor development, recent PI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGm3fFMcHFSMScOqQTSkOffW6udTcc2eYiaJZYzxkzBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D&md5=4267e4df49544ebe11ab4255e69e5bbe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-0954-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-0954-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DX.%26atitle%3DTargeting%2520PI3K%2520in%2520Cancer%253A%2520Mechanisms%2520and%2520Advances%2520in%2520Clinical%2520Trials%26jtitle%3DMol.%2520Canc.%26date%3D2019%26volume%3D18%26spage%3D26%26doi%3D10.1186%2Fs12943-019-0954-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P.</span></span> <span> </span><span class="NLM_article-title">Review For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI3-Kinase Inhibitors</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">402</span>, <span class="refDoi"> DOI: 10.3390/biom9090402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.3390%2Fbiom9090402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCis73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=402&author=C.+Buchananauthor=K.+Leeauthor=P.+Shepherd&title=Review+For+Better+or+Worse%3A+The+Potential+for+Dose+Limiting+the+On-Target+Toxicity+of+PI3-Kinase+Inhibitors&doi=10.3390%2Fbiom9090402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">For better or worse: the potential for dose limiting the on-target toxicity of PI 3-kinase inhibitors</span></div><div class="casAuthors">Buchanan, Christina M.; Lee, Kate L.; Shepherd, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">402</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The hyper-activation of the phosphoinositide (PI) 3-kinase signaling pathway is a hallmark of many cancers and overgrowth syndromes, and as a result, there has been intense interest in the development of drugs that target the various isoforms of PI 3-kinase.  Given the key role PI 3-kinases play in many normal cell functions, there is significant potential for the disruption of essential cellular functions by PI 3-kinase inhibitors in normal tissues; so-called on-target drug toxicity.  It is, therefore, no surprise that progress within the clin. development of PI 3-kinase inhibitors as single-agent anti-cancer therapies has been slowed by the difficulty of identifying a therapeutic window.  The aim of this review is to place the cellular, tissue and whole-body effects of PI 3-kinase inhibition in the context of understanding the potential for dose limiting on-target toxicities and to introduce possible strategies to overcome these.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQp6wQLF91B7Vg90H21EOLACvtfcHk0lg6pWIDHN1ArA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCis73L&md5=ec582298d9e45e53f1fd839b63108cc9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3390%2Fbiom9090402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom9090402%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DShepherd%26aufirst%3DP.%26atitle%3DReview%2520For%2520Better%2520or%2520Worse%253A%2520The%2520Potential%2520for%2520Dose%2520Limiting%2520the%2520On-Target%2520Toxicity%2520of%2520PI3-Kinase%2520Inhibitors%26jtitle%3DBiomolecules%26date%3D2019%26volume%3D9%26spage%3D402%26doi%3D10.3390%2Fbiom9090402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faia, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brophy, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lussier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillotson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDougall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span> <span> </span><span class="NLM_article-title">PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Supresses Activity in Autoimmune and Inflammatory Disease Models</span>. <i>Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1364</span>– <span class="NLM_lpage">1374</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.chembiol.2013.09.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1364-1374&author=D.+G.+Winklerauthor=K.+L.+Faiaauthor=J.+P.+DiNittoauthor=J.+A.+Aliauthor=K.+F.+Whiteauthor=E.+E.+Brophyauthor=M.+M.+Pinkauthor=J.+L.+Proctorauthor=J.+Lussierauthor=C.+M.+Martinauthor=J.+G.+Hoytauthor=B.+Tillotsonauthor=E.+L.+Murphyauthor=A.+R.+Limauthor=B.+D.+Thomasauthor=J.+R.+MacDougallauthor=P.+Renauthor=Y.+Liuauthor=L.-S.+Liauthor=K.+A.+Jessenauthor=C.+C.+Fritzauthor=J.+L.+Dunbarauthor=J.+R.+Porterauthor=C.+Rommelauthor=V.+J.+Palombellaauthor=P.+S.+Changelianauthor=J.+L.+Kutok&title=PI3K-%CE%B4+and+PI3K-%CE%B3+Inhibition+by+IPI-145+Abrogates+Immune+Responses+and+Supresses+Activity+in+Autoimmune+and+Inflammatory+Disease+Models&doi=10.1016%2Fj.chembiol.2013.09.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DFaia%26aufirst%3DK.%2BL.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BF.%26aulast%3DBrophy%26aufirst%3DE.%2BE.%26aulast%3DPink%26aufirst%3DM.%2BM.%26aulast%3DProctor%26aufirst%3DJ.%2BL.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BG.%26aulast%3DTillotson%26aufirst%3DB.%26aulast%3DMurphy%26aufirst%3DE.%2BL.%26aulast%3DLim%26aufirst%3DA.%2BR.%26aulast%3DThomas%26aufirst%3DB.%2BD.%26aulast%3DMacDougall%26aufirst%3DJ.%2BR.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DFritz%26aufirst%3DC.%2BC.%26aulast%3DDunbar%26aufirst%3DJ.%2BL.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26atitle%3DPI3K-%25CE%25B4%2520and%2520PI3K-%25CE%25B3%2520Inhibition%2520by%2520IPI-145%2520Abrogates%2520Immune%2520Responses%2520and%2520Supresses%2520Activity%2520in%2520Autoimmune%2520and%2520Inflammatory%2520Disease%2520Models%26jtitle%3DComput.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1364%26epage%3D1374%26doi%3D10.1016%2Fj.chembiol.2013.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahana, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaresan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberwein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-08-1253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1158%2F1078-0432.CCR-08-1253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=19118049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1ektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=217-225&author=M.-C.+Crouthamelauthor=J.+A.+Kahanaauthor=S.+Korenchukauthor=S.-Y.+Zhangauthor=G.+Sundaresanauthor=D.+J.+Eberweinauthor=K.+K.+Brownauthor=R.+Kumar&title=Mechanism+and+Management+of+AKT+Inhibitor-Induced+Hyperglycemia&doi=10.1158%2F1078-0432.ccr-08-1253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia</span></div><div class="casAuthors">Crouthamel, Ming-Chih; Kahana, Jason A.; Korenchuk, Susan; Zhang, Shu-Yun; Sundaresan, Gobalakrishnan; Eberwein, Derek J.; Brown, Kathleen K.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">217-225</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I receptor and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathways are among the most active areas of drug discovery in cancer research.  However, due to their integral roles in insulin signaling, inhibitors targeting these pathways often lead to hyperglycemia and hyperinsulinemia.  We investigated the mechanism of hyperglycemia induced by GSK690693, a pan-AKT kinase inhibitor in clin. development, as well as methods to ameliorate these side effects.  The effect of GSK690693 on blood glucose, insulin, and glucagon levels was characterized in mice.  We then evaluated the effects of commonly prescribed antidiabetic agents on GSK690693-induced hyperglycemia.  The mechanism of blood glucose increase was evaluated using fasting and tracer uptake studies and by measuring liver glycogen levels.  Finally, approaches to manage AKT inhibitor-induced hyperglycemia were designed using fasting and low carbohydrate diet.  We report that treatment with antidiabetic agents does not significantly affect GSK690693-induced hyperglycemia in rodents.  However, administration of GSK690693 in mice significantly reduces liver glycogen (∼90%), suggesting that GSK690693 may inhibit glycogen synthesis and/or activate glycogenolysis.  Consistent with this observation, fasting before drug administration reduces baseline liver glycogen levels and attenuates hyperglycemia.  Further, GSK690693 also inhibits peripheral glucose uptake and introduction of a low-carbohydrate (7%) or 0% carbohydrate diet after GSK690693 administration effectively reduces diet-induced hyperglycemia in mice.  The mechanism of GSK690693-induced hyperglycemia is related to peripheral insulin resistance, increased gluconeogenesis, and/or hepatic glycogenolysis.  A combination of fasting and low carbohydrate diet can reduce the magnitude of hyperglycemia induced by an AKT inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrleTZ-otQBbrVg90H21EOLACvtfcHk0lg6pWIDHN1ArA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1ektQ%253D%253D&md5=ae0e0287caad7b6d4de979a73dc3cc2d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1253%26sid%3Dliteratum%253Aachs%26aulast%3DCrouthamel%26aufirst%3DM.-C.%26aulast%3DKahana%26aufirst%3DJ.%2BA.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.-Y.%26aulast%3DSundaresan%26aufirst%3DG.%26aulast%3DEberwein%26aufirst%3DD.%2BJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DMechanism%2520and%2520Management%2520of%2520AKT%2520Inhibitor-Induced%2520Hyperglycemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D217%26epage%3D225%26doi%3D10.1158%2F1078-0432.ccr-08-1253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rihawi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span> <span> </span><span class="NLM_article-title">Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2015-0248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1634%2Ftheoncologist.2015-0248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=27151652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGnur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=855-860&author=K.+H.+Khanauthor=M.+Wongauthor=K.+Rihawiauthor=S.+Bodlaauthor=D.+Morgansteinauthor=U.+Banerjiauthor=L.+R.+Molife&title=Hyperglycemia+and+Phosphatidylinositol+3-Kinase%2FProtein+Kinase+B%2FMammalian+Target+of+Rapamycin+%28PI3K%2FAKT%2FmTOR%29+Inhibitors+in+Phase+I+Trials%3A+Incidence%2C+Predictive+Factors%2C+and+Management&doi=10.1634%2Ftheoncologist.2015-0248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management</span></div><div class="casAuthors">Khan, Khurum H.; Wong, Mabel; Rihawi, Karim; Bodla, Shankar; Morganstein, Daniel; Banerji, Udai; Molife, Lulama R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">855-860</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Dysregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is implicated in human cancer growth and progression.  Agents targeting this pathway are assocd. with hyperglycemia due to interaction with the insulin-glucose regulatory axis.  Identifying the predictive factors for hyperglycemia in patients treated with these agents may help direct future management.  Clin. characteristics and outcomes of patients treated consecutively with PI3K, AKT, or mTOR inhibitors in the Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, between 2007 and 2012 were recorded.  Baseline variables and their assocn. with grade 3 hyperglycemia (Common Terminol. Criteria for Adverse Events, version 3.0) were analyzed by using the chi-square test and Fisher exact test for categorical variables and binary logistic regression for continuous variables.  A total of 341 patients were treated in 12 phase I trials of PI3K/AKT/mTOR inhibitors, and 298 patients (87.4%) developed hyperglycemia.  Hyperglycemia was grade 1 in 217 (72.8%) and grade 2 in 61 (20.5%) patients, resp.  Grade ≥3 hyperglycemia was seen in 6.7% of patients (n = 20).  According to the chi-square test, age <65 years (p =.03), history of diabetes (p =.003), and treatment with AKT and dual PI3K/mTOR inhibitors (p <.0005) predicted the occurrence of grade 3 hyperglycemia.  Of 24 patients requiring intervention, 20 received metformin, 2 dietary advice, 1 insulin, and 1 both metformin and insulin.  One patient required dose redn.  There were no permanent drug discontinuations, and no hyperglycemia-related dose-limiting toxicities were obsd.; thus, the recommended phase II dose was not affected by the hyperglycemia obsd. in our cohort.  Hyperglycemia is common in patients treated with PI3K/AKT/mTOR inhibitors; however, it is manageable with conventional treatment.  Predictive factors of age, history of diabetes, and administration of AKT and dual PI3K/mTOR inhibitors warrant prospective validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp82LfubcEXBrVg90H21EOLACvtfcHk0lgyqhcyEsyJ7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGnur7M&md5=3adadb9070a419e2179c830dbc711390</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2015-0248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2015-0248%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DK.%2BH.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DRihawi%26aufirst%3DK.%26aulast%3DBodla%26aufirst%3DS.%26aulast%3DMorganstein%26aufirst%3DD.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26atitle%3DHyperglycemia%2520and%2520Phosphatidylinositol%25203-Kinase%252FProtein%2520Kinase%2520B%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528PI3K%252FAKT%252FmTOR%2529%2520Inhibitors%2520in%2520Phase%2520I%2520Trials%253A%2520Incidence%252C%2520Predictive%2520Factors%252C%2520and%2520Management%26jtitle%3DOncologist%26date%3D2016%26volume%3D21%26spage%3D855%26epage%3D860%26doi%3D10.1634%2Ftheoncologist.2015-0248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafarge, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landego, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. J.</span></span> <span> </span><span class="NLM_article-title">The Phosphoinositide 3-Kinase Signaling Pathway in Normal and Malignant B Cells: Activation Mechanisms, Regulation and Impact on Cellular Functions</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">224</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2012.00224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.3389%2Ffimmu.2012.00224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=22908014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BC38fpvFaqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=224&author=S.+D.+Paulsauthor=S.+T.+Lafargeauthor=I.+Landegoauthor=T.+Zhangauthor=A.+J.+Marshall&title=The+Phosphoinositide+3-Kinase+Signaling+Pathway+in+Normal+and+Malignant+B+Cells%3A+Activation+Mechanisms%2C+Regulation+and+Impact+on+Cellular+Functions&doi=10.3389%2Ffimmu.2012.00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions</span></div><div class="casAuthors">Pauls Samantha D; Lafarge Sandrine T; Landego Ivan; Zhang Tingting; Marshall Aaron J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">224</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K) pathway is a central signal transduction axis controlling normal B cell homeostasis and activation in humoral immunity.  The p110δ PI3K catalytic subunit has emerged as a critical mediator of multiple B cell functions.  The activity of this pathway is regulated at multiple levels, with inositol phosphatases PTEN and SHIP both playing critical roles.  When deregulated, the PI3K pathway can contribute to B cell malignancies and autoantibody production.  This review summarizes current knowledge on key mechanisms that activate and regulate the PI3K pathway and influence normal B cell functional responses including the development of B cell subsets, antigen presentation, immunoglobulin isotype switch, germinal center responses, and maintenance of B cell anergy.  We also discuss PI3K pathway alterations reported in select B cell malignancies and highlight studies indicating the functional significance of this pathway in malignant B cell survival and growth within tissue microenvironments.  Finally, we comment on early clinical trial results, which support PI3K inhibition as a promising treatment of chronic lymphocytic leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6PU49jJBvRNyzdcP07UmufW6udTcc2eaQri-ZgJ0ke7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpvFaqtg%253D%253D&md5=2521d7033f7bc2781aeee853ec033e5f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2012.00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2012.00224%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DS.%2BD.%26aulast%3DLafarge%26aufirst%3DS.%2BT.%26aulast%3DLandego%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DMarshall%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520Phosphoinositide%25203-Kinase%2520Signaling%2520Pathway%2520in%2520Normal%2520and%2520Malignant%2520B%2520Cells%253A%2520Activation%2520Mechanisms%252C%2520Regulation%2520and%2520Impact%2520on%2520Cellular%2520Functions%26jtitle%3DFront.%2520Immunol.%26date%3D2012%26volume%3D3%26spage%3D224%26doi%3D10.3389%2Ffimmu.2012.00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przepiorka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Claro, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shord, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrotra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma</span>. <i>Clin. Canc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1529</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-14-2522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1158%2F1078-0432.CCR-14-2522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1525-1529&author=B.+W.+Millerauthor=D.+Przepiorkaauthor=R.+A.+de+Claroauthor=K.+Leeauthor=L.+Nieauthor=N.+Simpsonauthor=R.+Gudiauthor=H.+Saberauthor=S.+Shordauthor=J.+Bullockauthor=D.+Maratheauthor=N.+Mehrotraauthor=L.+S.+Hsiehauthor=D.+Ghoshauthor=J.+Brownauthor=R.+C.+Kaneauthor=R.+Justiceauthor=E.+Kaminskasauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+Approval%3A+Idelalisib+Monotherapy+for+the+Treatment+of+Patients+with+Follicular+Lymphoma+and+Small+Lymphocytic+Lymphoma&doi=10.1158%2F1078-0432.ccr-14-2522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma</span></div><div class="casAuthors">Miller, Barry W.; Przepiorka, Donna; Angelo de Claro, R.; Lee, Kyung; Nie, Lei; Simpson, Natalie; Gudi, Ramadevi; Saber, Haleh; Shord, Stacy; Bullock, Julie; Marathe, Dhananjay; Mehrotra, Nitin; Hsieh, Li Shan; Ghosh, Debasis; Brown, Janice; Kane, Robert C.; Justice, Robert; Kaminskas, Edvardas; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1525-1529</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On July 23, 2014, the FDA granted accelerated approval to idelalisib (Zydelig tablets; Gilead Sciences, Inc.) for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma or relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.  In a multicenter, single-arm trial, 123 patients with relapsed indolent non-Hodgkin lymphomas received idelalisib, 150 mg orally twice daily.  In patients with follicular lymphoma, the overall response rate (ORR) was 54%, and the median duration of response (DOR) was not evaluable; median follow-up was 8.1 mo.  In patients with SLL, the ORR was 58% and the median DOR was 11.9 mo.  One-half of patients experienced a serious adverse reaction of pneumonia, pyrexia, sepsis, febrile neutropenia, diarrhea, or pneumonitis.  Other common adverse reactions were abdominal pain, nausea, fatigue, cough, dyspnea, and rash.  Common treatment-emergent lab. abnormalities were elevations in alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, abs. lymphocytes, and triglycerides.  Continued approval may be contingent upon verification of clin. benefit in confirmatory trials.  Clin Cancer Res; 21(7); 1525-9. cpr2015 AACR.  See related article by Gandhi et al., p.  1537.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbi_gkmWnf7rVg90H21EOLACvtfcHk0lgyqhcyEsyJ7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahsro%253D&md5=1c8a5a577c05e3ff995368c55fd7607d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2522%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DB.%2BW.%26aulast%3DPrzepiorka%26aufirst%3DD.%26aulast%3Dde%2BClaro%26aufirst%3DR.%2BA.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DNie%26aufirst%3DL.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DGudi%26aufirst%3DR.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DShord%26aufirst%3DS.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DMarathe%26aufirst%3DD.%26aulast%3DMehrotra%26aufirst%3DN.%26aulast%3DHsieh%26aufirst%3DL.%2BS.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520Approval%253A%2520Idelalisib%2520Monotherapy%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Follicular%2520Lymphoma%2520and%2520Small%2520Lymphocytic%2520Lymphoma%26jtitle%3DClin.%2520Canc.%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1525%26epage%3D1529%26doi%3D10.1158%2F1078-0432.ccr-14-2522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylors, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liem, A. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLntyre, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abella-Dominicis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreiling, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedberg, J. W.</span></span> <span> </span><span class="NLM_article-title">Phase 2 Study of Idelalisib and Entospletinib: Pneumonitis Limits Combination Therapy in Relapsed Refractory CLL and NHL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2411</span>– <span class="NLM_lpage">2415</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-12-683516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2015-12-683516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=26968534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ent7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2411-2415&author=P.+M.+Barrauthor=G.+B.+Saylorsauthor=S.+E.+Spurgeonauthor=B.+D.+Chesonauthor=D.+R.+Greenwaldauthor=S.+M.+O%E2%80%99Brienauthor=A.+K.+D.+Liemauthor=R.+E.+McLntyreauthor=A.+Joshiauthor=E.+Abella-Dominicisauthor=M.+J.+Hawkinsauthor=A.+Reddyauthor=J.+Di+Paoloauthor=H.+Leeauthor=J.+Heauthor=J.+Huauthor=L.+K.+Dreilingauthor=J.+W.+Friedberg&title=Phase+2+Study+of+Idelalisib+and+Entospletinib%3A+Pneumonitis+Limits+Combination+Therapy+in+Relapsed+Refractory+CLL+and+NHL&doi=10.1182%2Fblood-2015-12-683516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL</span></div><div class="casAuthors">Barr, Paul M.; Saylors, Gene B.; Spurgeon, Stephen E.; Cheson, Bruce D.; Greenwald, Daniel R.; O'Brien, Susan M.; Liem, Andre K. D.; Mclntyre, Rosemary E.; Joshi, Adarsh; Abella-Dominicis, Esteban; Hawkins, Michael J.; Reddy, Anita; Paolo, Julie Di; Lee, Hank; He, Joyce; Hu, Jing; Dreiling, Lyndah K.; Friedberg, Jonathan W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2411-2415</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Although agents targeting B-cell receptor signaling have provided practice-changing results in relapsed chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), they require prolonged administration and provide incomplete responses.  Given synergis- tic preclin. activity with phosphatidylinositol 3-kinase d and spleen tyrosine kinase inhibition, this phase 2 study evaluated the safety and efficacy of the combination of idelalisib and entospletinib.  Eligible patients with relapsed or refractory CLL or NHL under- went intrapatient dose escalation with each agent.  With a median treatment exposure of 10 wk, 60% and 36% of patients with CLL or follicular lymphoma, resp., achieved objective responses.  However, the study was terminated early because of treatment- emergent pneumonitis in 18% of patients (severe in 11 of 12 cases).  Although most patients recovered with supportive measures and systemic steroids, 2 fatalities occurred and were attributed to treatment-emergent pneumonitis.  Increases of interferon-g and interleukins 6, 7, and 8 occurred over time in patients who developed pneumonitis.  Future studies of novel combinations should employ conservative designs that incorporate pharmacodynamics/biomarker monitoring.  These investigations should also prospectively evaluate plasma cytokine/chemokine levels in an attempt to validate biomarkers predictive of response and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGlEOcr0eY7Vg90H21EOLACvtfcHk0livmcdRwcGtzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ent7jP&md5=46d9b9095074f93cb5e8a743b05316e5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-12-683516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-12-683516%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DSaylors%26aufirst%3DG.%2BB.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DCheson%26aufirst%3DB.%2BD.%26aulast%3DGreenwald%26aufirst%3DD.%2BR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DLiem%26aufirst%3DA.%2BK.%2BD.%26aulast%3DMcLntyre%26aufirst%3DR.%2BE.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DAbella-Dominicis%26aufirst%3DE.%26aulast%3DHawkins%26aufirst%3DM.%2BJ.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DDreiling%26aufirst%3DL.%2BK.%26aulast%3DFriedberg%26aufirst%3DJ.%2BW.%26atitle%3DPhase%25202%2520Study%2520of%2520Idelalisib%2520and%2520Entospletinib%253A%2520Pneumonitis%2520Limits%2520Combination%2520Therapy%2520in%2520Relapsed%2520Refractory%2520CLL%2520and%2520NHL%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2411%26epage%3D2415%26doi%3D10.1182%2Fblood-2015-12-683516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matos, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassenti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnason, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Idelalisib given Front-line for Treatment of Chronic Lymphocytic Leukemia causes Frequent Immune-mediated Hepatotoxicity</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-03-707133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2016-03-707133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=27247136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=195-203&author=B.+L.+Lampsonauthor=S.+N.+Kasarauthor=T.+R.+Matosauthor=E.+A.+Morganauthor=L.+Rassentiauthor=M.+S.+Davidsauthor=D.+C.+Fisherauthor=A.+S.+Freedmanauthor=C.+A.+Jacobsonauthor=P.+Armandauthor=J.+S.+Abramsonauthor=J.+E.+Arnasonauthor=T.+J.+Kippsauthor=J.+Feinauthor=S.+Fernandesauthor=J.+Hannaauthor=J.+Ritzauthor=H.+T.+Kimauthor=J.+R.+Brown&title=Idelalisib+given+Front-line+for+Treatment+of+Chronic+Lymphocytic+Leukemia+causes+Frequent+Immune-mediated+Hepatotoxicity&doi=10.1182%2Fblood-2016-03-707133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity</span></div><div class="casAuthors">Lampson, Benjamin L.; Kasar, Siddha N.; Matos, Tiago R.; Morgan, Elizabeth A.; Rassenti, Laura; Davids, Matthew S.; Fisher, David C.; Freedman, Arnold S.; Jacobson, Caron A.; Armand, Philippe; Abramson, Jeremy S.; Arnason, Jon E.; Kipps, Thomas J.; Fein, Joshua; Fernandes, Stacey; Hanna, John; Ritz, Jerome; Kim, Haesook T.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Idelalisib is a small-mol. inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).  To evaluate idelalisib as front-line therapy, we enrolled 24 subjects in a phase 2 study consisting of 2 mo of idelalisib monotherapy followed by 6 mo of combination therapy with idelalisib and the anti-CD20 antibody ofatumumab.  After a median follow-up period of 14.7 mo, hepatotoxicity was found to be a frequent and often severe adverse event.  A total of 19 subjects (79%) experienced either grade ≥1 ALT or AST elevation during the study, and 13 subjects (54%) experienced grade ≥3 transaminitis.  The median time to development of transaminitis was 28 days, occurring before ofatumumab introduction.  Younger age and mutated Ig heavy chain status were significant risk factors for the development of hepatotoxicity.  Multiple lines of evidence suggest that this hepatotoxicity was immune mediated.  A lymphocytic infiltrate was seen on liver biopsy specimens taken from 2 subjects with transaminitis, and levels of the proinflammatory cytokines CCL-3 and CCL-4 were higher in subjects experiencing hepatotoxicity.  All cases of transaminitis resolved either by holding the drug, initiating immunosuppressants, or both, and rates of recurrent toxicity were lower in patients taking steroids when idelalisib was reinitiated.  A decrease in peripheral blood regulatory T cells was seen in patients experiencing toxicity on therapy, which is consistent with an immune-mediated mechanism.  These results suggest that caution should be taken as drugs within this class are developed for CLL, particularly in younger patients who have not received prior disease-specific therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFWd0SBaN9E7Vg90H21EOLACvtfcHk0lhxycwZVxDEMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrfK&md5=eec3c52d470b0b70266f7ecc3f7d8de0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-03-707133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-03-707133%26sid%3Dliteratum%253Aachs%26aulast%3DLampson%26aufirst%3DB.%2BL.%26aulast%3DKasar%26aufirst%3DS.%2BN.%26aulast%3DMatos%26aufirst%3DT.%2BR.%26aulast%3DMorgan%26aufirst%3DE.%2BA.%26aulast%3DRassenti%26aufirst%3DL.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DFisher%26aufirst%3DD.%2BC.%26aulast%3DFreedman%26aufirst%3DA.%2BS.%26aulast%3DJacobson%26aufirst%3DC.%2BA.%26aulast%3DArmand%26aufirst%3DP.%26aulast%3DAbramson%26aufirst%3DJ.%2BS.%26aulast%3DArnason%26aufirst%3DJ.%2BE.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DFein%26aufirst%3DJ.%26aulast%3DFernandes%26aufirst%3DS.%26aulast%3DHanna%26aufirst%3DJ.%26aulast%3DRitz%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIdelalisib%2520given%2520Front-line%2520for%2520Treatment%2520of%2520Chronic%2520Lymphocytic%2520Leukemia%2520causes%2520Frequent%2520Immune-mediated%2520Hepatotoxicity%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D195%26epage%3D203%26doi%3D10.1182%2Fblood-2016-03-707133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S.</span></span> <span> </span><span class="NLM_article-title">Duvelisib, a Novel Oral Dual Inhibitor of PI3K-delta, Gamma, is Clinically Active in Advanced Hematologic Malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-786566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2017-05-786566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=29191916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12ks7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=877-887&author=I.+W.+Flinnauthor=S.+O%E2%80%99Brienauthor=B.+Kahlauthor=M.+Patelauthor=Y.+Okiauthor=F.+F.+Fossauthor=P.+Porcuauthor=J.+Jonesauthor=J.+A.+Burgerauthor=N.+Jainauthor=V.+M.+Kellyauthor=K.+Allenauthor=M.+Douglasauthor=J.+Sweeneyauthor=P.+Kellyauthor=S.+Horwitz&title=Duvelisib%2C+a+Novel+Oral+Dual+Inhibitor+of+PI3K-delta%2C+Gamma%2C+is+Clinically+Active+in+Advanced+Hematologic+Malignancies&doi=10.1182%2Fblood-2017-05-786566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies</span></div><div class="casAuthors">Flinn, Ian W.; O'Brien, Susan; Kahl, Brad; Patel, Manish; Oki, Yasuhiro; Foss, Francine F.; Porcu, Pierluigi; Jones, Jeffrey; Burger, Jan A.; Jain, Nitin; Kelly, Virginia M.; Allen, Kerstin; Douglas, Mark; Sweeney, Jennifer; Kelly, Patrick; Horwitz, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">877-887</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-δ (PI3K-δ) and PI3K-γ in late stage clin. development for hematol. malignancy treatment.  This phase 1 study evaluated max. tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib in 210 patients with advanced hematol. malignancies.  In the dose escalation phase (n531), duvelisib 8 to 100 mg twice daily was administered, with MTD detd. as 75 mg twice daily.  In the expansion phase (n 5 179), patients with indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL), or T-cell lymphoma(TCL) were treated with 25 or 75 mg duvelisib twice daily continuously.  Single-dose duvelisib was rapidly absorbed (time to max. concn., 1-2 h), with a half-life of 5.2 to 10.9 h.  PD results showed inhibition of phospho-AKT (S473) in CLL tumor cells following a single dose and near-complete inhibition of CLL proliferation (Ki-67) by cycle 2.  Clin. responses were seen across a range of doses and disease subtypes: iNHL overall response rate, 58% (n 5 31) with 6 complete responses (CRs); relapsed/refractory CLL, 56% (n 5 55) with 1 CR; peripheral TCL, 50%(n5 16)with 3 CR; and cutaneous TCL, 32% (n 5 19).  Median time to response was ∼1.8 mo.  Severe (grade ≥3) adverse events occurred in 84% of patients: neutropenia (32%), alanine transaminase increase (20%), aspartate transaminase increase (15%), anemia and thrombocytopenia (each 14%), diarrhea (11%), and pneumonia (10%).  These data support further investigation of duvelisib in phase 2 and 3 studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIqIxR4vd3fbVg90H21EOLACvtfcHk0lhxycwZVxDEMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12ks7rL&md5=74e4dd8f900cbd0a29dcfc0eae9689a9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786566%26sid%3Dliteratum%253Aachs%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DKahl%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DOki%26aufirst%3DY.%26aulast%3DFoss%26aufirst%3DF.%2BF.%26aulast%3DPorcu%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DKelly%26aufirst%3DV.%2BM.%26aulast%3DAllen%26aufirst%3DK.%26aulast%3DDouglas%26aufirst%3DM.%26aulast%3DSweeney%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DP.%26aulast%3DHorwitz%26aufirst%3DS.%26atitle%3DDuvelisib%252C%2520a%2520Novel%2520Oral%2520Dual%2520Inhibitor%2520of%2520PI3K-delta%252C%2520Gamma%252C%2520is%2520Clinically%2520Active%2520in%2520Advanced%2520Hematologic%2520Malignancies%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D877%26epage%3D887%26doi%3D10.1182%2Fblood-2017-05-786566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nastoupil, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunning, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vose, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreeder, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sportelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purdom, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span> <span> </span><span class="NLM_article-title">Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-hodgkin Lymphoma: a Phase 1 Dose Escalation and Expansion Trial</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e100</span>– <span class="NLM_lpage">e109</span>, <span class="refDoi"> DOI: 10.1016/s2352-3026(18)30216-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2FS2352-3026%2818%2930216-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30709431" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=e100-e109&author=L.+J.+Nastoupilauthor=M.+A.+Lunningauthor=J.+M.+Voseauthor=M.+T.+Schreederauthor=T.+Siddiqiauthor=C.+R.+Flowersauthor=J.+B.+Cohenauthor=J.+A.+Burgerauthor=W.+G.+Wierdaauthor=S.+O%E2%80%99Brienauthor=P.+Sportelliauthor=H.+P.+Miskinauthor=M.+A.+Purdomauthor=M.+S.+Weissauthor=N.+H.+Fowler&title=Tolerability+and+Activity+of+Ublituximab%2C+Umbralisib%2C+and+Ibrutinib+in+Patients+with+Chronic+Lymphocytic+Leukaemia+and+Non-hodgkin+Lymphoma%3A+a+Phase+1+Dose+Escalation+and+Expansion+Trial&doi=10.1016%2Fs2352-3026%2818%2930216-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2818%2930216-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252818%252930216-3%26sid%3Dliteratum%253Aachs%26aulast%3DNastoupil%26aufirst%3DL.%2BJ.%26aulast%3DLunning%26aufirst%3DM.%2BA.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DSchreeder%26aufirst%3DM.%2BT.%26aulast%3DSiddiqi%26aufirst%3DT.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DCohen%26aufirst%3DJ.%2BB.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DSportelli%26aufirst%3DP.%26aulast%3DMiskin%26aufirst%3DH.%2BP.%26aulast%3DPurdom%26aufirst%3DM.%2BA.%26aulast%3DWeiss%26aufirst%3DM.%2BS.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26atitle%3DTolerability%2520and%2520Activity%2520of%2520Ublituximab%252C%2520Umbralisib%252C%2520and%2520Ibrutinib%2520in%2520Patients%2520with%2520Chronic%2520Lymphocytic%2520Leukaemia%2520and%2520Non-hodgkin%2520Lymphoma%253A%2520a%2520Phase%25201%2520Dose%2520Escalation%2520and%2520Expansion%2520Trial%26jtitle%3DLancet%2520Haematol.%26date%3D2019%26volume%3D6%26spage%3De100%26epage%3De109%26doi%3D10.1016%2Fs2352-3026%2818%2930216-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lunning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vose, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nastoupil, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreeder, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sportelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Ublituximab and Umbralisib in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1811</span>– <span class="NLM_lpage">1820</span>, <span class="refDoi"> DOI: 10.1182/blood.2019002118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood.2019002118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=31558467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BB3MnisVyksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2019&pages=1811-1820&author=M.+Lunningauthor=J.+Voseauthor=L.+Nastoupilauthor=N.+Fowlerauthor=J.+A.+Burgerauthor=W.+G.+Wierdaauthor=M.+T.+Schreederauthor=T.+Siddiqiauthor=C.+R.+Flowersauthor=J.+B.+Cohenauthor=P.+Sportelliauthor=H.+P.+Miskinauthor=M.+S.+Weissauthor=S.+O%E2%80%99Brien&title=Ublituximab+and+Umbralisib+in+Relapsed%2FRefractory+B-cell+Non-Hodgkin+Lymphoma+and+Chronic+Lymphocytic+Leukemia&doi=10.1182%2Fblood.2019002118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia</span></div><div class="casAuthors">Lunning Matthew; Vose Julie; Nastoupil Loretta; Fowler Nathan; Burger Jan A; Wierda William G; Schreeder Marshall T; Siddiqi Tanya; Flowers Christopher R; Cohen Jonathon B; Sportelli Peter; Miskin Hari P; Weiss Michael S; O'Brien Susan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1811-1820</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeting both CD20 and phosphatidylinositol 3-kinase (PI3K), a protein that is critically involved in B-cell maturation, could be an efficacious strategy for treating B-cell malignancies.  The safety of the next-generation compounds umbralisib, a PI3K-δ inhibitor, plus ublituximab, an anti-CD20 monoclonal antibody (combination referred to as U2), was evaluated in patients with chronic lymphocytic lymphoma (CLL) or non-Hodgkin lymphoma (NHL) in this phase 1/1b study.  Phase 1 dose escalation was performed with a 3 + 3 design to establish the maximum tolerated dose.  In this portion, ublituximab was given intravenously (NHL, 900 mg; CLL, 600 or 900 mg) for 12 cycles.  Umbralisib was given orally once daily at 800 or 1200 mg (initial formulation) or 400 to 1200 mg (micronized formulation) in the phase 1 dose escalation portion, and at 800 to 1200 mg in the phase 1b portion until progression, toxicity, or study removal.  The maximum tolerated dose was not reached in either the CLL or NHL cohort, and only 1 dose-limiting toxicity was observed.  U2 had low instances of grade 3 or higher diarrhea (8%), pneumonia (8%), or hepatic toxicity (4%).  Treatment discontinuation due to adverse events occurred in 13% of patients, and umbralisib dose reductions occurred in 15% of patients.  The overall response rate for all patients was 46% with 17% complete responses.  The median duration of response was 20 months (95% confidence interval, 11.3-not reached).  U2 was well tolerated, and no new safety signals were observed over single-agent umbralisib.  Preliminary efficacy with this combination is promising and warrants further investigation.  This study was registered at www.clinicaltrials.gov as #NCT02006485.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8ka8B-cMxyEwlCcfExbvbfW6udTcc2eacNBYdLSJQsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnisVyksg%253D%253D&md5=f2984ca33f2a3690331ab1c0a79966a4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood.2019002118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.2019002118%26sid%3Dliteratum%253Aachs%26aulast%3DLunning%26aufirst%3DM.%26aulast%3DVose%26aufirst%3DJ.%26aulast%3DNastoupil%26aufirst%3DL.%26aulast%3DFowler%26aufirst%3DN.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DSchreeder%26aufirst%3DM.%2BT.%26aulast%3DSiddiqi%26aufirst%3DT.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DCohen%26aufirst%3DJ.%2BB.%26aulast%3DSportelli%26aufirst%3DP.%26aulast%3DMiskin%26aufirst%3DH.%2BP.%26aulast%3DWeiss%26aufirst%3DM.%2BS.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DUblituximab%2520and%2520Umbralisib%2520in%2520Relapsed%252FRefractory%2520B-cell%2520Non-Hodgkin%2520Lymphoma%2520and%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DBlood%26date%3D2019%26volume%3D134%26spage%3D1811%26epage%3D1820%26doi%3D10.1182%2Fblood.2019002118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Careddu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consonni, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakkalanka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagna, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allavena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlo-Stella, C.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K δ / γ Inhibitor RP6530</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1112</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-18-1133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1158%2F1078-0432.CCR-18-1133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30352904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Kntr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=1098-1112&author=S.+L.+Locatelliauthor=G.+Caredduauthor=S.+Serioauthor=F.+M.+Consonniauthor=A.+Maedaauthor=S.+Viswanadhaauthor=S.+Vakkalankaauthor=L.+Castagnaauthor=A.+Santoroauthor=P.+Allavenaauthor=A.+Sicaauthor=C.+Carlo-Stella&title=Targeting+Cancer+Cells+and+Tumor+Microenvironment+in+Preclinical+and+Clinical+Models+of+Hodgkin+Lymphoma+Using+the+Dual+PI3K+%CE%B4+%2F+%CE%B3+Inhibitor+RP6530&doi=10.1158%2F1078-0432.ccr-18-1133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530</span></div><div class="casAuthors">Locatelli, Silvia L.; Careddu, Giuseppa; Serio, Simone; Consonni, Francesca M.; Maeda, Akihiro; Viswanadha, Srikant; Vakkalanka, Swaroop; Castagna, Luca; Santoro, Armando; Allavena, Paola; Sica, Antonio; Carlo-Stella, Carmelo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1098-1112</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Tumor-assocd. macrophages (TAMs) and the hyperactivation of the PI3K/AKT pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease outcome.  Because the δ and γ isoforms of PI3K are overexpressed in Hodgkin/Reed-Sternberg (HRS) cells and the tumor microenvironment (TME), we propose that the PI3Kδ/γ inhibitor RP6530 might affect both HRS cells and TME, ultimately leading to an enhanced antitumor response.  Exptl. Design: Hodgkin lymphoma cell lines (L-540, KM-H2, and L-428) and primary human macrophages were used to investigate the activity of RP6530 in vitro and in vivo in Hodgkin lymphoma cell line xenografts.  Results:In vitro, RP6530 besides killing and inhibiting the proliferation of Hodgkin lymphoma cells, downregulated lactic acid metab., switching the activation of macrophages from an immunosuppressive M2-like phenotype to a more inflammatory M1-like state.  By RNA sequencing, we define tumor glycolysis as a specific PI3Kδ/γ-dependent pathway implicated in the metabolic reprogramming of cancer cells.  We identify the metabolic regulator pyruvate kinase M2 as the main mediator of tumor-induced immunosuppressive phenotype of macrophages.  Furthermore, we show in human tumor xenografts that RP6530 repolarizes TAMs into proinflammatory macrophages and inhibits tumor vasculature, leading to tumor regression.  Interestingly, patients with Hodgkin lymphoma experiencing objective responses (complete response and partial response) in a phase I trial using RP6530 showed a significant inhibition of circulating myeloid-derived suppressor cells and an av. mean redn. in serum thymus and activation-regulated chemokine levels of 40% (range, 4%-76%).  Conclusions: Our results support PI3Kδ/γ inhibition as a novel therapeutic strategy that targets both malignant cells and the TME to treat patients with Hodgkin lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAqk8NCT8DkbVg90H21EOLACvtfcHk0lh6CEaOWNvdVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Kntr7E&md5=9f612e6aa256af3ef9c542855312d6b9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1133%26sid%3Dliteratum%253Aachs%26aulast%3DLocatelli%26aufirst%3DS.%2BL.%26aulast%3DCareddu%26aufirst%3DG.%26aulast%3DSerio%26aufirst%3DS.%26aulast%3DConsonni%26aufirst%3DF.%2BM.%26aulast%3DMaeda%26aufirst%3DA.%26aulast%3DViswanadha%26aufirst%3DS.%26aulast%3DVakkalanka%26aufirst%3DS.%26aulast%3DCastagna%26aufirst%3DL.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DAllavena%26aufirst%3DP.%26aulast%3DSica%26aufirst%3DA.%26aulast%3DCarlo-Stella%26aufirst%3DC.%26atitle%3DTargeting%2520Cancer%2520Cells%2520and%2520Tumor%2520Microenvironment%2520in%2520Preclinical%2520and%2520Clinical%2520Models%2520of%2520Hodgkin%2520Lymphoma%2520Using%2520the%2520Dual%2520PI3K%2520%25CE%25B4%2520%252F%2520%25CE%25B3%2520Inhibitor%2520RP6530%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D1098%26epage%3D1112%26doi%3D10.1158%2F1078-0432.ccr-18-1133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobinai, K.</span></span> <span> </span><span class="NLM_article-title">Development of New Agents for Peripheral T-cell Lymphoma</span>. <i>Expet Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1080/14712598.2019.1572746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1080%2F14712598.2019.1572746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30658046" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=197-209&author=Y.+Itoauthor=S.+Makitaauthor=K.+Tobinai&title=Development+of+New+Agents+for+Peripheral+T-cell+Lymphoma&doi=10.1080%2F14712598.2019.1572746"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F14712598.2019.1572746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2019.1572746%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DY.%26aulast%3DMakita%26aufirst%3DS.%26aulast%3DTobinai%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520New%2520Agents%2520for%2520Peripheral%2520T-cell%2520Lymphoma%26jtitle%3DExpet%2520Opin.%2520Biol.%2520Ther.%26date%3D2019%26volume%3D19%26spage%3D197%26epage%3D209%26doi%3D10.1080%2F14712598.2019.1572746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzasa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and In Vivo Evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG 319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1021/jm501624r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501624r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=480-511&author=T.+D.+Cushingauthor=X.+Haoauthor=Y.+Shinauthor=K.+Andrewsauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=J.+Duquetteauthor=B.+Fisherauthor=F.+Gonzalez-Lopez%0Ade+Turisoauthor=X.+Heauthor=K.+R.+Henneauthor=Y.-L.+Huauthor=R.+Hungateauthor=M.+G.+Johnsonauthor=R.+C.+Kellyauthor=B.+Lucasauthor=J.+D.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=T.+San+Miguelauthor=D.+Mohnauthor=V.+Pattaropongauthor=L.+H.+Pettusauthor=A.+Reicheltauthor=R.+M.+Rzasaauthor=J.+Seganishauthor=A.+S.+Taskerauthor=R.+C.+Wahlauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=D.+Zhangauthor=D.+P.+Metz&title=Discovery+and+In+Vivo+Evaluation+of+%28S%29-N-%281-%287-fluoro-2-%28pyridin-2-yl%29quinolin-3-yl%29ethyl%29-9H-purin-6-amine+%28AMG+319%29+and+Related+PI3K%CE%B4+Inhibitors+for+Inflammation+and+Autoimmune+Disease&doi=10.1021%2Fjm501624r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span></div><div class="casAuthors">Cushing, Timothy D.; Hao, Xiaolin; Shin, Youngsook; Andrews, Kristin; Brown, Matthew; Cardozo, Mario; Chen, Yi; Duquette, Jason; Fisher, Ben; Gonzalez-Lopez de Turiso, Felix; He, Xiao; Henne, Kirk R.; Hu, Yi-Ling; Hungate, Randall; Johnson, Michael G.; Kelly, Ron C.; Lucas, Brian; McCarter, John D.; McGee, Lawrence R.; Medina, Julio C.; San Miguel, Tisha; Mohn, Deanna; Pattaropong, Vatee; Pettus, Liping H.; Reichelt, Andreas; Rzasa, Robert M.; Seganish, Jennifer; Tasker, Andrew S.; Wahl, Robert C.; Wannberg, Sharon; Whittington, Douglas A.; Whoriskey, John; Yu, Gang; Zalameda, Leeanne; Zhang, Dawei; Metz, Daniela P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">480-511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochem. properties are described.  This medicinal chem. effort led to the identification of I (AMG319), a compd. with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt3BtsoY7G2rVg90H21EOLACvtfcHk0lhMmbFF9vN1OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegur%252FL&md5=08af48a5c6208d6f61bea77e9ad840aa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReichelt%26aufirst%3DA.%26aulast%3DRzasa%26aufirst%3DR.%2BM.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520and%2520In%2520Vivo%2520Evaluation%2520of%2520%2528S%2529-N-%25281-%25287-fluoro-2-%2528pyridin-2-yl%2529quinolin-3-yl%2529ethyl%2529-9H-purin-6-amine%2520%2528AMG%2520319%2529%2520and%2520Related%2520PI3K%25CE%25B4%2520Inhibitors%2520for%2520Inflammation%2520and%2520Autoimmune%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D480%26epage%3D511%26doi%3D10.1021%2Fjm501624r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.-h.</span></span> <span> </span><span class="NLM_article-title">PI3K Isoform-selective Inhibitors: Next-generation Targeted Cancer Therapies</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1038/aps.2015.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1038%2Faps.2015.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=26364801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wls7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1170-1176&author=X.+Wangauthor=J.+Dingauthor=L.-h.+Meng&title=PI3K+Isoform-selective+Inhibitors%3A+Next-generation+Targeted+Cancer+Therapies&doi=10.1038%2Faps.2015.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K isoform-selective inhibitors: next-generation targeted cancer therapies</span></div><div class="casAuthors">Wang, Xiang; Ding, Jian; Meng, Ling-hua</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1170-1176</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pivotal roles of phosphatidylinositol 3-kinases (PI3Ks) in human cancers have inspired active development of small mols. to inhibit these lipid kinases.  However, the first-generation pan-PI3K and dual-PI3K/mTOR inhibitors have encountered problems in clin. trials, with limited efficacies as a monotherapeutic agent as well as a relatively high rate of side effects.  It is increasingly recognized that different PI3K isoforms play non-redundant roles in particular tumor types, which has prompted the development of isoform-selective inhibitors for pre-selected patients with the aim for improving efficacy while decreasing undesirable side effects.  The success of PI3K isoform-selective inhibitors is represented by CAL101 (Idelalisib), a first-in-class PI3Kδ-selective small-mol. inhibitor that has been approved by the FDA for the treatment of chronic lymphocytic leukemia, indolent B-cell non-Hodgkin's lymphoma and relapsed small lymphocytic lymphoma.  Inhibitors targeting other PI3K isoforms are also being extensively developed.  This review focuses on the recent progress in development of PI3K isoform-selective inhibitors for cancer therapy.  A deeper understanding of the action modes of novel PI3K isoform-selective inhibitors will provide valuable information to further validate the concept of targeting specific PI3K isoforms, while the identification of biomarkers to stratify patients who are likely to benefit from the therapy will be essential for the success of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwF2MuL2qax7Vg90H21EOLACvtfcHk0lhMmbFF9vN1OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wls7jN&md5=1cad476e2913a827be1d9c4a0294e519</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Faps.2015.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2015.71%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DL.-h.%26atitle%3DPI3K%2520Isoform-selective%2520Inhibitors%253A%2520Next-generation%2520Targeted%2520Cancer%2520Therapies%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2015%26volume%3D36%26spage%3D1170%26epage%3D1176%26doi%3D10.1038%2Faps.2015.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenwell, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. B.</span></span> <span> </span><span class="NLM_article-title">PI3K Inhibitors: Understanding Toxicity Mechanisms and Management</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">828</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=29179250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ltlGntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=821-828&author=I.+B.+Greenwellauthor=A.+Ipauthor=J.+B.+Cohen&title=PI3K+Inhibitors%3A+Understanding+Toxicity+Mechanisms+and+Management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K Inhibitors: Understanding Toxicity Mechanisms and Management</span></div><div class="casAuthors">Greenwell I Brian; Ip Andrew; Cohen Jonathon B</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">821-8</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) pathway has attracted immense interest as a therapeutic target for cancer treatment.  Idelalisib was the first PI3K inhibitor approved by the US Food and Drug Administration and is utilized in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma.  Copanlisib has subsequently been approved for relapsed follicular lymphoma in patients who have received at least two prior systemic therapies.  There are multiple other PI3K agents currently in development; these target various combinations of PI3K isoforms.  Despite the therapeutic benefit, there have been concerns about the severe and sometimes fatal adverse effects of this class of drug.  Several side effects are unusual and have poorly understood mechanisms; these include autoimmune dysfunction, opportunistic infections, skin toxicity, hypertension, and hyperglycemia.  An understanding of these unusual toxicities, as well as a good grasp of management principles, will be important as more PI3K inhibitors are approved and become incorporated into routine practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5yvT6h5ErjpQHPYJuLg8TfW6udTcc2eYYCe26OtRDVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ltlGntA%253D%253D&md5=6c477dd4ae70ee2393283cd0b43ec885</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwell%26aufirst%3DI.%2BB.%26aulast%3DIp%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DJ.%2BB.%26atitle%3DPI3K%2520Inhibitors%253A%2520Understanding%2520Toxicity%2520Mechanisms%2520and%2520Management%26jtitle%3DOncology%26date%3D2017%26volume%3D31%26spage%3D821%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Identification of GNE-293, a Potent and Selective PI3K delta Inhibitor: Navigating In Vitro Genotoxicity while Improving Potency and Selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4953</span>– <span class="NLM_lpage">4959</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.bmcl.2013.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=23867164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4953-4959&author=B.+S.+Safinaauthor=Z.+K.+Sweeneyauthor=J.+Liauthor=B.+K.+Chanauthor=A.+Bisconteauthor=D.+Carreraauthor=G.+Castanedoauthor=M.+Flagellaauthor=R.+Healdauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=K.+Reifauthor=L.+Salphatiauthor=E.+M.+Sewardauthor=B.+Weiauthor=D.+P.+Sutherlin&title=Identification+of+GNE-293%2C+a+Potent+and+Selective+PI3K+delta+Inhibitor%3A+Navigating+In+Vitro+Genotoxicity+while+Improving+Potency+and+Selectivity&doi=10.1016%2Fj.bmcl.2013.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GNE-293, a potent and selective PI3Kδ inhibitor: Navigating in vitro genotoxicity while improving potency and selectivity</span></div><div class="casAuthors">Safina, Brian S.; Sweeney, Zachary K.; Li, Jun; Chan, Bryan K.; Bisconte, Angelina; Carrera, Diane; Castanedo, Georgette; Flagella, Michael; Heald, Robert; Lewis, Cristina; Murray, Jeremy M.; Nonomiya, Jim; Pang, Jodie; Price, Steve; Reif, Karin; Salphati, Laurent; Seward, Eileen M.; Wei, Binqing; Sutherlin, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4953-4959</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an effort to identify potent and isoform selective inhibitors of PI3Kδ, GNE-293 was identified.  Inhibitor 2 was found to induce micronuclei formation in both the MNT and HCA in vitro assays.  Compds. testing neg. for genotoxicity were successfully identified through modifications of the 2-benzimidazole substituent and the methylene moiety to disrupt planarity.  A variety of heteroatom linkers were explored to examine their effect on potency and isoform selectivity by restricting torsional angles to favor ligand interactions with PI3Kδ's Trp 760.  These modifications also resulted in an improved in vivo pharmacokinetic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeYyeZOKH5CrVg90H21EOLACvtfcHk0ljo3c8hU5Ei6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltLbO&md5=c1aac13409cb5f33390cf98d689dabc3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DCarrera%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DIdentification%2520of%2520GNE-293%252C%2520a%2520Potent%2520and%2520Selective%2520PI3K%2520delta%2520Inhibitor%253A%2520Navigating%2520In%2520Vitro%2520Genotoxicity%2520while%2520Improving%2520Potency%2520and%2520Selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4953%26epage%3D4959%26doi%3D10.1016%2Fj.bmcl.2013.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forseth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppenol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Orally Efficacious Phosphoinositide 3-Kinaseδ Inhibitors with Improved Metabolic Stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9228</span>– <span class="NLM_lpage">9242</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGrs7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9228-9242&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=K.+Forsethauthor=A.+C.+Haranauthor=C.+Ipauthor=A.+Kashishianauthor=M.+Kimauthor=D.+Koditekauthor=S.+Koppenolauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=S.+Perreaultauthor=K.+D.+Puriauthor=A.+G.+Villase%C3%B1orauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=J.+Therrienauthor=J.+Treibergauthor=G.+Phillips&title=Discovery+of+Orally+Efficacious+Phosphoinositide+3-Kinase%CE%B4+Inhibitors+with+Improved+Metabolic+Stability&doi=10.1021%2Facs.jmedchem.6b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability</span></div><div class="casAuthors">Patel, Leena; Chandrasekhar, Jayaraman; Evarts, Jerry; Forseth, Kristen; Haran, Aaron C.; Ip, Carmen; Kashishian, Adam; Kim, Musong; Koditek, David; Koppenol, Sandy; Lad, Latesh; Lepist, Eve-Irene; McGrath, Mary E.; Perreault, Stephane; Puri, Kamal D.; Villasenor, Armando G.; Somoza, John R.; Steiner, Bart H.; Therrien, Joseph; Treiberg, Jennifer; Phillips, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9228-9242</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of phosphoinositide-3-kinase delta (PI3K-delta) has been implicated in numerous pathologies including hematol. malignancies and rheumatoid arthritis.  Described in this manuscript is the discovery, optimization and in vivo evaluation of a novel series of pyridine-contg. PI3K-delta inhibitors.  This work led to the discovery of I, a highly selective inhibitor of PI3K-delta which displays an excellent pharmacokinetic profile and is efficacious in a rodent model of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LgrP9YV8frVg90H21EOLACvtfcHk0ljo3c8hU5Ei6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGrs7rF&md5=6d9dff0ec5270aab250fcb4800d8635a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01169%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DForseth%26aufirst%3DK.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DKoppenol%26aufirst%3DS.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Orally%2520Efficacious%2520Phosphoinositide%25203-Kinase%25CE%25B4%2520Inhibitors%2520with%2520Improved%2520Metabolic%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9228%26epage%3D9242%26doi%3D10.1021%2Facs.jmedchem.6b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3532</span>– <span class="NLM_lpage">3548</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1CgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3532-3548&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=A.+C.+Haranauthor=C.+Ipauthor=J.+A.+Kaplanauthor=M.+Kimauthor=D.+Koditekauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=N.+Novikovauthor=S.+Perreaultauthor=K.+D.+Puriauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=J.+Therrienauthor=J.+Treibergauthor=A.+G.+Villase%C3%B1orauthor=A.+Yeungauthor=G.+Phillipsauthor=A.+Yeungauthor=G.+Phillips&title=2%2C4%2C6-Triaminopyrimidine+as+a+Novel+Hinge+Binder+in+a+Series+of+PI3K%CE%B4+Selective+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors</span></div><div class="casAuthors">Patel, Leena; Chandrasekhar, Jayaraman; Evarts, Jerry; Haran, Aaron C.; Ip, Carmen; Kaplan, Joshua A.; Kim, Musong; Koditek, David; Lad, Latesh; Lepist, Eve-Irene; McGrath, Mary E.; Novikov, Nikolai; Perreault, Stephane; Puri, Kamal D.; Somoza, John R.; Steiner, Bart H.; Stevens, Kirk L.; Therrien, Joseph; Treiberg, Jennifer; Villasenor, Armando G.; Yeung, Arthur; Phillips, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3532-3548</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) is an appealing target for several hematol. malignancies and inflammatory diseases.  Herein, we describe the discovery and optimization of a series of propeller shaped PI3Kδ inhibitors comprising a novel triaminopyrimidine hinge binder.  Combinations of electronic and structural strategies were employed to mitigate aldehyde oxidase mediated metab.  This medicinal chem. effort culminated in the identification of 52, a potent and highly selective inhibitor of PI3Kδ that demonstrates efficacy in a rat model of arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpygPlHbWp_TLVg90H21EOLACvtfcHk0lhsOmCZQZVa0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1CgtL4%253D&md5=9e01fff097eccd127a9b9284d725d7e1</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00213%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKaplan%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DYeung%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26aulast%3DYeung%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3D2%252C4%252C6-Triaminopyrimidine%2520as%2520a%2520Novel%2520Hinge%2520Binder%2520in%2520a%2520Series%2520of%2520PI3K%25CE%25B4%2520Selective%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3532%26epage%3D3548%26doi%3D10.1021%2Facs.jmedchem.6b00213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdulai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valastro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span> <span> </span><span class="NLM_article-title">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4783</span>– <span class="NLM_lpage">4814</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOrsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4783-4814&author=M.+W.+D.+Perryauthor=R.+Abdulaiauthor=M.+Mogemarkauthor=J.+Petersenauthor=M.+J.+Thomasauthor=B.+Valastroauthor=A.+Westin+Eriksson&title=Evolution+of+PI3K%CE%B3+and+%CE%B4+Inhibitors+for+Inflammatory+and+Autoimmune+Diseases&doi=10.1021%2Facs.jmedchem.8b01298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases</span></div><div class="casAuthors">Perry, Matthew W. D.; Abdulai, Raolat; Mogemark, Mickael; Petersen, Jens; Thomas, Matthew J.; Valastro, Barbara; Westin Eriksson, Annika</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4783-4814</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositol 3-kinases (PI3Ks) γ and δ are key enzymes in hematopoietic cells and have been seen as high-value targets for the treatment of diseases with inflammatory and immunomodulatory components since their discovery and the identification of their roles.  In this Perspective we review progress in the application of inhibitors of PI3Kγ and δ to inflammatory and immunol. conditions over the past 6 years.  We consider progress in the understanding of the roles of PI3Kγ and PI3Kδ in immunol. and inflammation, the experience from clin. trials where inhibitors have been tested, and what has been learned about the safety of their use.  The extensive medicinal chem. efforts to discover both isoform selective and dual PI3Kγδ inhibitors are analyzed and detailed.  Developments in understanding the structural chem. of the PI3K enzymes and the factors that govern isoform selectivity are discussed.  The effects obsd. with the known inhibitor compds. in animal models are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5tJy6u73_7bVg90H21EOLACvtfcHk0lhsOmCZQZVa0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOrsr7O&md5=2b5cdec8135ee6ebd94624b9a675c889</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01298%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DAbdulai%26aufirst%3DR.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DM.%2BJ.%26aulast%3DValastro%26aufirst%3DB.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26atitle%3DEvolution%2520of%2520PI3K%25CE%25B3%2520and%2520%25CE%25B4%2520Inhibitors%2520for%2520Inflammatory%2520and%2520Autoimmune%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4783%26epage%3D4814%26doi%3D10.1021%2Facs.jmedchem.8b01298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span> <span> </span><span class="NLM_article-title">Research Advances on Selective Phosphatidylinositol 3 Kinase δ (PI3Kδ) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127457</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.bmcl.2020.127457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=32755681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Cqs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127457&author=J.+Sunauthor=Y.+Fengauthor=Y.+Huangauthor=S.-Q.+Zhangauthor=M.+Xin&title=Research+Advances+on+Selective+Phosphatidylinositol+3+Kinase+%CE%B4+%28PI3K%CE%B4%29+Inhibitors&doi=10.1016%2Fj.bmcl.2020.127457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors</span></div><div class="casAuthors">Sun, Jiajia; Feng, Yifan; Huang, Yuan; Zhang, San-Qi; Xin, Minhang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">127457</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PI3Kδ in B cells mediates antigen receptor signaling and promote neutrophil chemotaxis.  The activation of PI3Kδ can cause mast cell maturation and degranulation, myeloid cell dysfunction, and cytokine release.  As a key signal mol., PI3Kδ interacts with the lipid binding domain of a variety of cellular proteins as a secondary messenger, ultimately affecting a series of significant cellular pathways in disease pathol.  Therefore, many research organizations and pharmaceutical companies have studied it to develop effectively selective PI3Kδ inhibitors as therapeutics.  This review summarizes research advances in varying chem. classes of selective PI3Kδ inhibitors and the structure-activity relationship, and it mainly focuses on the propeller- vs. flat-type class of inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ4GqJhaS2erVg90H21EOLACvtfcHk0lhsOmCZQZVa0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Cqs7fO&md5=b5f66fba4412dd592b34e803ae2d6edb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127457%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.-Q.%26aulast%3DXin%26aufirst%3DM.%26atitle%3DResearch%2520Advances%2520on%2520Selective%2520Phosphatidylinositol%25203%2520Kinase%2520%25CE%25B4%2520%2528PI3K%25CE%25B4%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127457%26doi%3D10.1016%2Fj.bmcl.2020.127457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soujon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitzmann-Kolbe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keng Magdalene, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span> <span> </span><span class="NLM_article-title">Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-dependent and -Independent Activation of NF-kB and AKT</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.ccell.2016.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=28073005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=64-78&author=J.+Paulauthor=M.+Soujonauthor=A.+M.+Wengnerauthor=S.+Zitzmann-Kolbeauthor=A.+Sturzauthor=K.+Haikeauthor=K.+H.+Keng+Magdaleneauthor=S.+H.+Tanauthor=M.+Langeauthor=S.+Y.+Tanauthor=D.+Mumbergauthor=S.+T.+Limauthor=K.+Ziegelbauerauthor=N.+Liu&title=Simultaneous+Inhibition+of+PI3K%CE%B4+and+PI3K%CE%B1+Induces+ABC-DLBCL+Regression+by+Blocking+BCR-dependent+and+-Independent+Activation+of+NF-kB+and+AKT&doi=10.1016%2Fj.ccell.2016.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT</span></div><div class="casAuthors">Paul, Juliane; Soujon, Maurice; Wengner, Antje M.; Zitzmann-Kolbe, Sabine; Sturz, Andrea; Haike, Katja; Keng Magdalene, Koh Hui; Tan, Sze Huey; Lange, Martin; Tan, Soo Yong; Mumberg, Dominik; Lim, Soon Thye; Ziegelbauer, Karl; Liu, Ningshu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-78</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Compared with follicular lymphoma, high PI3Kα expression was more prevalent in diffuse large B cell lymphoma (DLBCL), although both tumor types expressed substantial PI3Kδ.  Simultaneous inhibition of PI3Kα and PI3Kδ dramatically enhanced the anti-tumor profile in ABC-DLBCL models compared with selective inhibition of PI3Kδ, PI3Kα, or BTK.  The anti-tumor activity was assocd. with suppression of p-AKT and a mechanism of blocking nuclear factor-κB activation driven by CD79mut, CARD11mut, TNFAIP3mut, or MYD88mut.  Inhibition of PI3Kα/δ resulted in tumor regression in an ibrutinib-resistant CD79BWT/MYD88mut patient-derived ABC-DLBCL model.  Furthermore, rebound activation of BTK and AKT was identified as a mechanism limiting CD79Bmut-ABC-DLBCL to show a robust response to PI3K and BTK inhibitor monotherapies.  A combination of ibrutinib with the PI3Kα/δ inhibitor copanlisib produced a sustained complete response in vivo in CD79Bmut/MYD88mut ABC-DLBCL models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyz2h-CoWtgLVg90H21EOLACvtfcHk0liYN9ccn5ik5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlKnsA%253D%253D&md5=6d8a64b0b75fdd0dc0519fdb19d71574</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DSoujon%26aufirst%3DM.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DZitzmann-Kolbe%26aufirst%3DS.%26aulast%3DSturz%26aufirst%3DA.%26aulast%3DHaike%26aufirst%3DK.%26aulast%3DKeng%2BMagdalene%26aufirst%3DK.%2BH.%26aulast%3DTan%26aufirst%3DS.%2BH.%26aulast%3DLange%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DS.%2BY.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DLim%26aufirst%3DS.%2BT.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DN.%26atitle%3DSimultaneous%2520Inhibition%2520of%2520PI3K%25CE%25B4%2520and%2520PI3K%25CE%25B1%2520Induces%2520ABC-DLBCL%2520Regression%2520by%2520Blocking%2520BCR-dependent%2520and%2520-Independent%2520Activation%2520of%2520NF-kB%2520and%2520AKT%26jtitle%3DCancer%2520Cell%26date%3D2017%26volume%3D31%26spage%3D64%26epage%3D78%26doi%3D10.1016%2Fj.ccell.2016.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vočková, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuskova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanska, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwammbach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapukhlyak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staiger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdel, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruzalegui, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trneny, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span> <span> </span><span class="NLM_article-title">Sensitivity to PI3K and AKT Inhibitors is Mediated by Divergent Molecular Mechanisms in Subtypes of DLBCL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-12-758599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2016-12-758599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=28202458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aqsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=310-322&author=T.+Erdmannauthor=P.+Klenerauthor=J.+T.+Lynchauthor=M.+Grauauthor=P.+Vo%C4%8Dkov%C3%A1author=J.+Molinskyauthor=D.+Tuskovaauthor=K.+Hudsonauthor=U.+M.+Polanskaauthor=M.+Grondineauthor=M.+Mayoauthor=B.+Daiauthor=M.+Pfeiferauthor=K.+Erdmannauthor=D.+Schwammbachauthor=M.+Zapukhlyakauthor=A.+M.+Staigerauthor=G.+Ottauthor=W.+E.+Berdelauthor=B.+R.+Daviesauthor=F.+Cruzaleguiauthor=M.+Trnenyauthor=P.+Lenzauthor=S.+T.+Barryauthor=G.+Lenz&title=Sensitivity+to+PI3K+and+AKT+Inhibitors+is+Mediated+by+Divergent+Molecular+Mechanisms+in+Subtypes+of+DLBCL&doi=10.1182%2Fblood-2016-12-758599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity to pi3k and akt inhibitors is mediated by divergent molecular mechanisms in subtypes of dlbcl</span></div><div class="casAuthors">Erdmann, Tabea; Klener, Pavel; Lynch, James T.; Grau, Michael; Vockova, Petra; Molinsky, Jan; Tuskova, Diana; Hudson, Kevin; Polanska, Urszula M.; Grondine, Michael; Mayo, Michele; Dai, Beiying; Pfeifer, Matthias; Erdmann, Kristian; Schwammbach, Daniela; Zapukhlyak, Myroslav; Staiger, Annette M.; Ott, German; Berdel, Wolfgang E.; Davies, Barry R.; Cruzalegui, Francisco; Trneny, Marek; Lenz, Peter; Barry, Simon T.; Lenz, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">310-322</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activated B-cell-like (ABC) and germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL) represent the 2 major mol. DLBCL subtypes.  They are characterized by differences in clin. course and by divergent addiction to oncogenic pathways.  To det. activity of novel compds. in these 2 subtypes, we conducted an unbiased pharmacol. in vitro screen.  The phosphatidylinositol-3-kinase (PI3K) α/δ (PI3Kα/δ) inhibitor AZD8835 showed marked potency in ABC DLBCL models, whereas the protein kinase B (AKT) inhibitor AZD5363 induced apoptosis in PTEN-deficient DLBCLs irresp. of their mol. subtype.  These in vitro results were confirmed in various cell line xenograft and patient-derived xenograft mouse models in vivo.  Treatment with AZD8835 induced inhibition of nuclear factor kB signaling, prompting us to combine AZD8835 with the Bruton's tyrosine kinase inhibitor ibrutinib.  This combination was synergistic and effective both in vitro and in vivo.  In contrast, the AKT inhibitor AZD5363 was effective in PTEN-deficient DLBCLs through downregulation of the oncogenic transcription factor MYC.  Collectively, our data suggest that patients should be stratified according to their oncogenic dependencies when treated with PI3K and AKT inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob70la9gAU37Vg90H21EOLACvtfcHk0liYN9ccn5ik5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aqsrbF&md5=fafbe3848dac87502bb52d580c90b8d5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-12-758599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-12-758599%26sid%3Dliteratum%253Aachs%26aulast%3DErdmann%26aufirst%3DT.%26aulast%3DKlener%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DJ.%2BT.%26aulast%3DGrau%26aufirst%3DM.%26aulast%3DVo%25C4%258Dkov%25C3%25A1%26aufirst%3DP.%26aulast%3DMolinsky%26aufirst%3DJ.%26aulast%3DTuskova%26aufirst%3DD.%26aulast%3DHudson%26aufirst%3DK.%26aulast%3DPolanska%26aufirst%3DU.%2BM.%26aulast%3DGrondine%26aufirst%3DM.%26aulast%3DMayo%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DB.%26aulast%3DPfeifer%26aufirst%3DM.%26aulast%3DErdmann%26aufirst%3DK.%26aulast%3DSchwammbach%26aufirst%3DD.%26aulast%3DZapukhlyak%26aufirst%3DM.%26aulast%3DStaiger%26aufirst%3DA.%2BM.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DCruzalegui%26aufirst%3DF.%26aulast%3DTrneny%26aufirst%3DM.%26aulast%3DLenz%26aufirst%3DP.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DLenz%26aufirst%3DG.%26atitle%3DSensitivity%2520to%2520PI3K%2520and%2520AKT%2520Inhibitors%2520is%2520Mediated%2520by%2520Divergent%2520Molecular%2520Mechanisms%2520in%2520Subtypes%2520of%2520DLBCL%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D310%26epage%3D322%26doi%3D10.1182%2Fblood-2016-12-758599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000AdminCorres.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000AdminCorres.pdf</a> (accessed Oct 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2018%2F211155Orig1Orig2s000AdminCorres.pdf+%28accessed+Oct+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D. J.</span>; <span class="NLM_string-name">O’Farrell, M.</span>; <span class="NLM_string-name">Ventura, R.</span>; <span class="NLM_string-name">Brown, S. D.</span>; <span class="NLM_string-name">Tai, A.</span></span> <i>Discovery of PI3K Delta Inhibitors for the Treatment of Inflammatory and Autoimmune Disease</i>; <span class="NLM_publisher-name">New York Academy of Sciences</span>, <span class="NLM_year">2012</span>, Meeting Poster.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+J.+Matthews&author=M.+O%E2%80%99Farrell&author=R.+Ventura&author=S.+D.+Brown&author=A.+Tai&title=Discovery+of+PI3K+Delta+Inhibitors+for+the+Treatment+of+Inflammatory+and+Autoimmune+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DD.%2BJ.%26btitle%3DDiscovery%2520of%2520PI3K%2520Delta%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520and%2520Autoimmune%2520Disease%26pub%3DNew%2520York%2520Academy%2520of%2520Sciences%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit30c"><span><span class="NLM_label">(c) </span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205858Orig1s000Approv.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205858Orig1s000Approv.pdf</a> (accessed July 23, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2014%2F205858Orig1s000Approv.pdf+%28accessed+July+23%2C+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Villieras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, M.</span></span> <span> </span><span class="NLM_article-title">La reaction de wittig-horner en milieu heterogene VI1. Selectivite de la reaction sur des composes bifonctionnels</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(00)98464-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2FS0040-4039%2800%2998464-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADyaL2MXhvVCrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1985&pages=53-56&author=J.+Villierasauthor=M.+Rambaudauthor=M.+Graff&title=La+reaction+de+wittig-horner+en+milieu+heterogene+VI1.+Selectivite+de+la+reaction+sur+des+composes+bifonctionnels&doi=10.1016%2Fs0040-4039%2800%2998464-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">Wittig-Horner reaction in a heterogeneous medium.  VI.  Selectivity of the reaction on bifunctional compounds</span></div><div class="casAuthors">Villieras, Jean; Rambaud, Monique; Graff, Micheline</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-6</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">Heterogeneous liq.-liq. (K2CO3-H2O) or solid-liq. (K2CO3-PhMe) media of low basicity allow the Wittig-Horner reaction of fragile aldehydes and unprotected hydroxy, nitro and keto aldehydes to take place with excellent yields.  The reaction is applied to the synthesis of royal jelly acid [HO(CH2)7CH:CHCO2H] and queen substance of honey bee [MeCO(CH2)5CH:CHCO2H].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQktw9krQ97Vg90H21EOLACvtfcHk0lhdoK8HgLRrtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXhvVCrtL0%253D&md5=654dea0b03731ff3b1ede3eed0689a1d</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2998464-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252998464-8%26sid%3Dliteratum%253Aachs%26aulast%3DVillieras%26aufirst%3DJ.%26aulast%3DRambaud%26aufirst%3DM.%26aulast%3DGraff%26aufirst%3DM.%26atitle%3DLa%2520reaction%2520de%2520wittig-horner%2520en%2520milieu%2520heterogene%2520VI1.%2520Selectivite%2520de%2520la%2520reaction%2520sur%2520des%2520composes%2520bifonctionnels%26jtitle%3DTetrahedron%2520Lett.%26date%3D1985%26volume%3D26%26spage%3D53%26epage%3D56%26doi%3D10.1016%2Fs0040-4039%2800%2998464-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ammetto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loreto, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardella, P. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Functionalized Spiroaziridine-oxindoles from 3-Ylideneoxindoles An Easy Route to 3-(Aminoalkyl)oxindoles</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_fpage">6189</span>– <span class="NLM_lpage">6197</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200900891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1002%2Fejoc.200900891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2msrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=6189-6197&author=I.+Ammettoauthor=T.+Gasperiauthor=M.+A.+Loretoauthor=A.+Miglioriniauthor=F.+Palmarelliauthor=P.+A.+Tardella&title=Synthesis+of+Functionalized+Spiroaziridine-oxindoles+from+3-Ylideneoxindoles+An+Easy+Route+to+3-%28Aminoalkyl%29oxindoles&doi=10.1002%2Fejoc.200900891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Functionalized Spiroaziridine-oxindoles from 3-Ylideneoxindoles: An Easy Route to 3-(Aminoalkyl)oxindoles</span></div><div class="casAuthors">Ammetto, I.; Gasperi, T.; Loreto, M. Antonietta; Migliorini, A.; Palmarelli, F.; Tardella, P. Antonio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6189-6197</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1434-193X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Novel potentially bioactive spiroaziridine-oxindoles, e.g., I, have been prepd. by treatment of easily accessible 3-ylideneoxindoles with N-{[(4-nitrophenyl)sulfonyl]oxy}carbamate (NsONHCO2Et) in the presence of CaO.  These compds. gave new 3-(aminoalkyl)oxindole derivs., e.g., II,through easy and regioselective reductive aziridine ring-opening reactions.  (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNnTyW-g9azLVg90H21EOLACvtfcHk0lhdoK8HgLRrtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2msrfJ&md5=529e6a3eb981bd69f5db94f4e7eabb47</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200900891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200900891%26sid%3Dliteratum%253Aachs%26aulast%3DAmmetto%26aufirst%3DI.%26aulast%3DGasperi%26aufirst%3DT.%26aulast%3DLoreto%26aufirst%3DM.%2BA.%26aulast%3DMigliorini%26aufirst%3DA.%26aulast%3DPalmarelli%26aufirst%3DF.%26aulast%3DTardella%26aufirst%3DP.%2BA.%26atitle%3DSynthesis%2520of%2520Functionalized%2520Spiroaziridine-oxindoles%2520from%25203-Ylideneoxindoles%2520An%2520Easy%2520Route%2520to%25203-%2528Aminoalkyl%2529oxindoles%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2009%26spage%3D6189%26epage%3D6197%26doi%3D10.1002%2Fejoc.200900891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gau, W.</span></span> <span> </span><span class="NLM_article-title">Annelation Reactions of N-Heterocycles to Condensed Pyridones with Bridgehead Nitrogen</span>. <i>Liebigs Ann. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>1980</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1002/jlac.198019800408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1002%2Fjlac.198019800408" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1980&publication_year=1980&pages=542-556&author=S.+Linkeauthor=J.+Kurzauthor=D.+Lipinskiauthor=W.+Gau&title=Annelation+Reactions+of+N-Heterocycles+to+Condensed+Pyridones+with+Bridgehead+Nitrogen&doi=10.1002%2Fjlac.198019800408"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjlac.198019800408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlac.198019800408%26sid%3Dliteratum%253Aachs%26aulast%3DLinke%26aufirst%3DS.%26aulast%3DKurz%26aufirst%3DJ.%26aulast%3DLipinski%26aufirst%3DD.%26aulast%3DGau%26aufirst%3DW.%26atitle%3DAnnelation%2520Reactions%2520of%2520N-Heterocycles%2520to%2520Condensed%2520Pyridones%2520with%2520Bridgehead%2520Nitrogen%26jtitle%3DLiebigs%2520Ann.%2520Chem.%26date%3D1980%26volume%3D1980%26spage%3D542%26epage%3D556%26doi%3D10.1002%2Fjlac.198019800408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norimine, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenaka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonaga, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10584</span>– <span class="NLM_lpage">10600</span>, <span class="refDoi"> DOI: 10.1021/jm301268u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301268u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslalu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10584-10600&author=S.+Hibiauthor=K.+Uenoauthor=S.+Nagatoauthor=K.+Kawanoauthor=K.+Itoauthor=Y.+Norimineauthor=O.+Takenakaauthor=T.+Hanadaauthor=M.+Yonaga&title=Discovery+of+2-%282-Oxo-1-phenyl-5-pyridin-2-yl-1%2C2-dihydropyridin-3-yl%29benzonitrile+%28Perampanel%29%3A+A+Novel%2C+Noncompetitive+%CE%B1-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic+Acid+%28AMPA%29+Receptor+Antagonist&doi=10.1021%2Fjm301268u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist</span></div><div class="casAuthors">Hibi, Shigeki; Ueno, Koshi; Nagato, Satoshi; Kawano, Koki; Ito, Koichi; Norimine, Yoshihiko; Takenaka, Osamu; Hanada, Takahisa; Yonaga, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10584-10600</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunction of glutamatergic neurotransmission has been implicated in the pathogenesis of epilepsy and numerous other neurol. diseases.  Here the authors describe the discovery of a series of 1,3,5-triaryl-1H-pyridin-2-one derivs. as noncompetitive antagonists of AMPA-type ionotropic glutamate receptors.  The structure-activity relationships for this series of compds. were investigated by manipulating individual arom. rings located at positions 1, 3, and 5 of the pyridone ring.  This culminated in the discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel), a novel, noncompetitive AMPA receptor antagonist that showed potent activity in an in vitro AMPA-induced Ca2+ influx assay (IC50 = 60 nM) and in an in vivo AMPA-induced seizure model (min. ED of 2 mg/kg po).  Perampanel is currently in regulatory submission for partial-onset seizures assocd. with epilepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlLIreWFyx27Vg90H21EOLACvtfcHk0lhdoK8HgLRrtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslalu7%252FJ&md5=713a950868f1e68001db5cb4d824d533</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm301268u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301268u%26sid%3Dliteratum%253Aachs%26aulast%3DHibi%26aufirst%3DS.%26aulast%3DUeno%26aufirst%3DK.%26aulast%3DNagato%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DNorimine%26aufirst%3DY.%26aulast%3DTakenaka%26aufirst%3DO.%26aulast%3DHanada%26aufirst%3DT.%26aulast%3DYonaga%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%25282-Oxo-1-phenyl-5-pyridin-2-yl-1%252C2-dihydropyridin-3-yl%2529benzonitrile%2520%2528Perampanel%2529%253A%2520A%2520Novel%252C%2520Noncompetitive%2520%25CE%25B1-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic%2520Acid%2520%2528AMPA%2529%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10584%26epage%3D10600%26doi%3D10.1021%2Fjm301268u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achmatowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zigterman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colyer, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiVirgilio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crockett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correll, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagapudi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allgeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, R. D.</span></span> <span> </span><span class="NLM_article-title">Development of a Practical Synthesis of a Pyrazolopyridinone-Based p38 MAP Kinase Inhibitor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1021/op100205s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op100205s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=31-43&author=R.+R.+Milburnauthor=O.+R.+Thielauthor=M.+Achmatowiczauthor=X.+Wangauthor=J.+Zigtermanauthor=C.+Bernardauthor=J.+T.+Colyerauthor=E.+DiVirgilioauthor=R.+Crockettauthor=T.+L.+Correllauthor=K.+Nagapudiauthor=K.+Ranganathanauthor=S.+J.+Hedleyauthor=A.+Allgeierauthor=R.+D.+Larsen&title=Development+of+a+Practical+Synthesis+of+a+Pyrazolopyridinone-Based+p38+MAP+Kinase+Inhibitor&doi=10.1021%2Fop100205s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Practical Synthesis of a Pyrazolopyridinone-Based p38 MAP Kinase Inhibitor</span></div><div class="casAuthors">Milburn, Robert R.; Thiel, Oliver R.; Achmatowicz, Michal; Wang, Xiang; Zigterman, Jamie; Bernard, Charles; Colyer, John T.; DiVirgilio, Evan; Crockett, Rich; Correll, Tiffany L.; Nagapudi, Karthik; Ranganathan, Kumar; Hedley, Simon J.; Allgeier, Alan; Larsen, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-43</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical synthesis of the pyrazolopyridinone-based p38 MAP kinase inhibitor (4) was required for an ongoing program.  The synthesis of a key pyrazolopyridinone building block was refined and optimized to provide kilogram quantities of 10 without chromatog. or extractive workups.  An efficient building-block strategy was employed to give optimal control of the key quality attributes, and in situ Raman spectroscopy was used to monitor and understand the complex solid-state properties of 4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwjN3D-xMsLVg90H21EOLACvtfcHk0lhy1Zz7hN9sFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksLzN&md5=59655e7b4a7b34767fe9736ee1abe137</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fop100205s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop100205s%26sid%3Dliteratum%253Aachs%26aulast%3DMilburn%26aufirst%3DR.%2BR.%26aulast%3DThiel%26aufirst%3DO.%2BR.%26aulast%3DAchmatowicz%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZigterman%26aufirst%3DJ.%26aulast%3DBernard%26aufirst%3DC.%26aulast%3DColyer%26aufirst%3DJ.%2BT.%26aulast%3DDiVirgilio%26aufirst%3DE.%26aulast%3DCrockett%26aufirst%3DR.%26aulast%3DCorrell%26aufirst%3DT.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DRanganathan%26aufirst%3DK.%26aulast%3DHedley%26aufirst%3DS.%2BJ.%26aulast%3DAllgeier%26aufirst%3DA.%26aulast%3DLarsen%26aufirst%3DR.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520Practical%2520Synthesis%2520of%2520a%2520Pyrazolopyridinone-Based%2520p38%2520MAP%2520Kinase%2520Inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2011%26volume%3D15%26spage%3D31%26epage%3D43%26doi%3D10.1021%2Fop100205s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Enantiomerically Pure N-tert-Butanesulfinyl Imines (tert-Butanesulfinimines) by the Direct Condensation of tert-Butanesulfinamide with Aldehydes and Ketones</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1278</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1021/jo982059i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo982059i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADyaK1MXns1SisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=1278-1284&author=G.+Liuauthor=D.+A.+Coganauthor=T.+D.+Owensauthor=T.+P.+Tangauthor=J.+A.+Ellman&title=Synthesis+of+Enantiomerically+Pure+N-tert-Butanesulfinyl+Imines+%28tert-Butanesulfinimines%29+by+the+Direct+Condensation+of+tert-Butanesulfinamide+with+Aldehydes+and+Ketones&doi=10.1021%2Fjo982059i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Enantiomerically Pure N-tert-Butanesulfinyl Imines (tert-Butanesulfinimines) by the Direct Condensation of tert-Butanesulfinamide with Aldehydes and Ketones</span></div><div class="casAuthors">Liu, Guangcheng; Cogan, Derek A.; Owens, Timothy D.; Tang, Tony P.; Ellman, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1278-1284</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Exptl. details for the first general methods for the one-step prepn. of N-tert-butanesulfinyl imines (tert-butanesulfinimines) from aldehydes and ketones is described.  To effect the condensations of tert-butanesulfinamide with aldehydes, the Lewis acidic dehydrating agents MgSO4, CuSO4, or Ti(OEt)4 are employed.  Aldehyde condensations mediated by MgSO4 proceed in high yields (84-96%) when an excess of aldehyde is used.  In contrast, only a slight excess of aldehyde (1.1 equiv) relative to tert-butanesulfinamide provides sulfinimines in high yields when the more Lewis acidic dehydrating agent CuSO4 is used.  The CuSO4-mediated procedure is effective for a wide range of aldehydes, including sterically demanding aldehydes, such as isobutyraldehyde (90%), and electron-rich aldehydes, such as p-anisaldehyde (81%).  The still more Lewis acidic Ti(OEt)4 and Ti(O-i-Pr)4 also afford N-tert-butanesulfinyl aldimines from esp. unreactive aldehydes, such as pivaldehyde (82%).  In addn., Ti(OEt)4 is effective for the condensation of tert-butanesulfinamide with ketones to afford a wide range of N-tert-butanesulfinyl ketimines in good yields (77-91%).  For sulfinyl ketimines derived from Me or n-alkyl Ph ketones and Me or n-alkyl iso-Pr ketones, only the E isomer is detected by 1H and 13C NMR in CDCl3.  For those cases where the difference in steric demand about the imine is very small, such as for 2-hexanone, high E/Z ratios are still obsd. (5:1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0W1xhdv6lw7Vg90H21EOLACvtfcHk0lhy1Zz7hN9sFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1SisQ%253D%253D&md5=7085bf46cbe5336791da58653679aa33</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo982059i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo982059i%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCogan%26aufirst%3DD.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DTang%26aufirst%3DT.%2BP.%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520of%2520Enantiomerically%2520Pure%2520N-tert-Butanesulfinyl%2520Imines%2520%2528tert-Butanesulfinimines%2529%2520by%2520the%2520Direct%2520Condensation%2520of%2520tert-Butanesulfinamide%2520with%2520Aldehydes%2520and%2520Ketones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D1278%26epage%3D1284%26doi%3D10.1021%2Fjo982059i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colyer, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedrow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faul, M. M.</span></span> <span> </span><span class="NLM_article-title">Reversal of Diastereofacial Selectivity in Hydride Reductions of N-tert-Butanesulfinyl Imines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">6859</span>– <span class="NLM_lpage">6862</span>, <span class="refDoi"> DOI: 10.1021/jo0609834</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0609834" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvFOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=6859-6862&author=J.+T.+Colyerauthor=N.+G.+Andersenauthor=J.+S.+Tedrowauthor=T.+S.+Soukupauthor=M.+M.+Faul&title=Reversal+of+Diastereofacial+Selectivity+in+Hydride+Reductions+of+N-tert-Butanesulfinyl+Imines&doi=10.1021%2Fjo0609834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of Diastereofacial Selectivity in Hydride Reductions of N-tert-Butanesulfinyl Imines</span></div><div class="casAuthors">Colyer, John T.; Andersen, Neil G.; Tedrow, Jason S.; Soukup, Troy S.; Faul, Margaret M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6859-6862</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A variety of N-tert-butanesulfinylimines were reduced with NaBH4 in THF contg. 2% water to provide the secondary sulfinamides in high yield and diastereoselectivity.  By using the same sulfinylimine starting materials and changing the reductant to L-Selectride, the stereoselectivity could be efficiently reversed to afford the opposite product diastereomer in high yield and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMmvwxbtaEErVg90H21EOLACvtfcHk0lhy1Zz7hN9sFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvFOnsr0%253D&md5=d8014c6087c6389243020efe55f1f753</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjo0609834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0609834%26sid%3Dliteratum%253Aachs%26aulast%3DColyer%26aufirst%3DJ.%2BT.%26aulast%3DAndersen%26aufirst%3DN.%2BG.%26aulast%3DTedrow%26aufirst%3DJ.%2BS.%26aulast%3DSoukup%26aufirst%3DT.%2BS.%26aulast%3DFaul%26aufirst%3DM.%2BM.%26atitle%3DReversal%2520of%2520Diastereofacial%2520Selectivity%2520in%2520Hydride%2520Reductions%2520of%2520N-tert-Butanesulfinyl%2520Imines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26spage%3D6859%26epage%3D6862%26doi%3D10.1021%2Fjo0609834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30a','cit30b','cit30c'],'ref31':['cit31a','cit31b'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of known PI3Kδ inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Docking studies of compounds <b>11</b>, <b>20</b>, and <b>34</b> with PI3Kδ (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a>). (a) Compound <b>11</b> docked to the ATP site of PI3Kδ. (b) Docking mode of compound <b>20</b> with C-1 phenyl substituent depicting the occupancy of the unexplored hydrophobic area of the protein. (c) Binding mode of compound <b>34</b> exhibiting the complete occupancy of the ATP binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Bar graphs showing % inhibition ± SEM of cell viability achieved by compound <b>34</b> and CAL-101 in SUDHL-6, OCI-Ly10, and TMD-8 cell lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. <i>In vivo</i> efficacy of compound 34 in xenograft models of OCI-Ly10 (A), TMD-8 (B), and SUDHL-6 (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>4–19</b>, <b>46</b>, and <b>26</b>, <b>30–34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) K<sub>2</sub>CO<sub>3</sub>, ethyl 3-(diethoxyphosphoryl)-4-oxopentanoate, THF, and water, 45 °C, 4 h; (ii) <i>p</i>-TsOH and xylene, 140 °C; (iii) LiOH, THF/methanol/water (2:2:1), RT, 2 h; (iv) EDC·HCl, TEA and DMF, RT, 18 h; (v) NBS and DMF, 0 °C, 1 h; (vi) arylboronic acid, Na<sub>2</sub>CO<sub>3</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub> and ethanol/toluene/water (2:2:1), 85 °C, 12 h; (vii) (<i>S</i>)-2-methylpropane-2-sulfinamide, Ti(O<i>i</i>Pr)<sub>4</sub> and toluene, 95 °C, 9 h; (viii) NaBH<sub>4</sub> and THF, 45 °C, 1.5 h; (ix) methanolic HCl and methanol, RT, 0.5 h; (x) halo heterocycle, DIPEA and DMF, 100 °C, 30 h. (xi) NBS, DMF, 0 °C, 1 h; and (xii) aliphatic or aryl boronic acid, Pd(amphos)Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub> and dioxane, 90 °C, 36 h.</p></p></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>20–25</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) NIS and DMF, RT, 2.5 h; (ii) (<i>S</i>)-2-methylpropane-2-sulfinamide, Ti(O<i>i</i>Pr)<sub>4</sub>, and toluene, 95 °C, 9 h; (iii) NaBH<sub>4</sub> and THF, 45 °C, 1.5 h; (iv) methanolic HCl and methanol, RT, 0.5 h; (v) Na<sub>2</sub>CO<sub>3</sub>, Boc-anhydride, and THF/water (12:2), 40 °C, 2 h; (vi) NBS and DMF, 0 °C, 1 h; (vii) NaBH<sub>4</sub> and IPA, 45 °C, 30 min; (viii) arylboronic acid, Na<sub>2</sub>CO<sub>3,</sub>Pd(PPh<sub>3</sub>)<sub>4</sub>, and ethanol/toluene/water (2:2:1), 90 °C, 8 h; (ix) TFA, 60 °C, 30 min; and (x) halo heterocycle, DIPEA, and DMF, 80 °C, 8 h.</p></p></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/medium/jm0c01264_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>27–29</b> and <b>35–36</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01264/20201203/images/large/jm0c01264_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01264&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions; (i) aliphatic or arylboronic acid, Pd(amphos)Cl<sub>2</sub>, NaOtBu, CsF, and dioxane, 85 °C, 15 h; (ii) NBS and DMF, 0–25 °C, 30 min; (iii) aryl boronic acid, Na<sub>2</sub>CO<sub>3</sub>, Pd(amphos)Cl<sub>2</sub>, CsF, and dioxane, 85 °C, 4 h; (iv) TFA and DCM, 50 °C, 1 h. (v) Halo heterocycle, DIPEA and DMF, 80 °C, 12 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i175">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Koehrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span> <span> </span><span class="NLM_article-title">B-cell Receptor Signaling in Chronic Lymphocytic Leukemia and other B-cell Malignancies</span>. <i>Clin. Adv. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">65</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=27057669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BC28fotFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=55-65&author=S.+Koehrerauthor=J.+A.+Burger&title=B-cell+Receptor+Signaling+in+Chronic+Lymphocytic+Leukemia+and+other+B-cell+Malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies</span></div><div class="casAuthors">Koehrer Stefan; Burger Jan A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical advances in hematology & oncology : H&O</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-65</span>
        ISSN:<span class="NLM_cas:issn">1543-0790</span>.
    </div><div class="casAbstract">B-cell receptor (BCR) signaling has emerged as a key pathway for the expansion of neoplastic B-cell clones in several B-cell malignancies.  The mechanisms that activate BCR signaling differ substantially among subtypes of B-cell lymphoma and leukemia.  These include BCR stimulation by foreign or self-antigens, or the acquisition of mutations in components of the BCR pathway that result in autonomous or enhanced antigen-induced BCR signaling.  Targeting BCR signaling with selective inhibitors of the BCR-associated kinases Bruton's tyrosine kinase, spleen tyrosine kinase, and phosphoinositide 3-kinase delta induces high response rates in patients with chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom macroglobulinemia, and diffuse large B-cell lymphoma of the activated B-cell-like subtype and is currently transforming the therapeutic landscape in these diseases.  Here we review the mechanisms of BCR activation that govern growth and survival of malignant B cells.  We also summarize recent clinical trials of BCR inhibitors, with a focus on the most clinically advanced agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk0cFTqP-4v8zK395ZObgVfW6udTcc2ebQxZuo4lz00bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28fotFCnsA%253D%253D&md5=e4c1cffc4441352f099de4bf034b3f10</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKoehrer%26aufirst%3DS.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26atitle%3DB-cell%2520Receptor%2520Signaling%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%2520and%2520other%2520B-cell%2520Malignancies%26jtitle%3DClin.%2520Adv.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D14%26spage%3D55%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Myklebust, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brody, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrt, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolstad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czerwinski, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wälchli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trøen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liestøl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beiske, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delabie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irish, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, R.</span></span> <span> </span><span class="NLM_article-title">Distinct Patterns of B-cell Receptor Signaling in Non-Hodgkin Lymphomas Identified by Single-cell Profiling</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">770</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-05-718494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2016-05-718494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=28011673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFaqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=759-770&author=J.+H.+Myklebustauthor=J.+Brodyauthor=H.+E.+Kohrtauthor=A.+Kolstadauthor=D.+K.+Czerwinskiauthor=S.+W%C3%A4lchliauthor=M.+R.+Greenauthor=G.+Tr%C3%B8enauthor=K.+Liest%C3%B8lauthor=K.+Beiskeauthor=R.+Houotauthor=J.+Delabieauthor=A.+A.+Alizadehauthor=J.+M.+Irishauthor=R.+Levy&title=Distinct+Patterns+of+B-cell+Receptor+Signaling+in+Non-Hodgkin+Lymphomas+Identified+by+Single-cell+Profiling&doi=10.1182%2Fblood-2016-05-718494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling</span></div><div class="casAuthors">Myklebust, June H.; Brody, Joshua; Kohrt, Holbrook E.; Kolstad, Arne; Czerwinski, Debra K.; Walchli, Sebastien; Green, Michael R.; Troeen, Gunhild; Liestoel, Knut; Beiske, Klaus; Houot, Roch; Delabie, Jan; Alizadeh, Ash A.; Irish, Jonathan M.; Levy, Ronald</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">129</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">759-770</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Kinases downstream of B-cell antigen receptor (BCR) represent attractive targets for therapy in non-Hodgkin lymphoma (NHL).  As clin. responses vary, improved knowledge regarding activation and regulation of BCR signaling in individual patients is needed.  Here, using phosphospecific flow cytometry to obtain malignant B-cell signaling profiles from 95 patients representing 4 types of NHL revealed a striking contrast between chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) tumors.  Lymphoma cells from diffuse large B cell lymphoma patients had high basal phosphorylation levels of most measured signaling nodes, whereas follicular lymphoma cells represented the opposite pattern with no or very low basal levels.  MCL showed large inter patient variability in basal levels, and elevated levels for the phosphorylated forms of AKT, extra cellular signal-regulated kinase, p38, STAT1, and STAT5 were assocd. with poor outcome.  CLL tumors had elevated basal levels for the phosphorylated forms of BCR-signaling nodes (Src family tyrosine kinase, spleen tyrosine kinase [SYK], phospholipase Cγ), but had low α-BCR-induced signaling.  This contrasted MCL tumors, where α-BCR-induced signalling was variable, but significantly potentiated as compared with the other types.  Over expression of CD79B, combined with a gating strategy where by signalling output was directly quantified per cell as a function of CD79B levels, confirmed a direct relationship between surface CD79B, IgM (IgM), and IgM-induced signaling levels.  Furthermore, α-BCR-induced signaling strength was variable across patient samples and correlated with BCR subunit CD79B expression, but was inversely correlated with susceptibility to Bruton tyrosine kinase (BTK) and SYK inhibitors in MCL.  These individual differences in BCR levels and signaling might relate to differences in therapy responses to BCR-pathway inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoswmOzY3Fn_bVg90H21EOLACvtfcHk0lhQKPS5CG3Jug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFaqtLk%253D&md5=d0ee3513296a6120148c107755f32188</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-05-718494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-05-718494%26sid%3Dliteratum%253Aachs%26aulast%3DMyklebust%26aufirst%3DJ.%2BH.%26aulast%3DBrody%26aufirst%3DJ.%26aulast%3DKohrt%26aufirst%3DH.%2BE.%26aulast%3DKolstad%26aufirst%3DA.%26aulast%3DCzerwinski%26aufirst%3DD.%2BK.%26aulast%3DW%25C3%25A4lchli%26aufirst%3DS.%26aulast%3DGreen%26aufirst%3DM.%2BR.%26aulast%3DTr%25C3%25B8en%26aufirst%3DG.%26aulast%3DLiest%25C3%25B8l%26aufirst%3DK.%26aulast%3DBeiske%26aufirst%3DK.%26aulast%3DHouot%26aufirst%3DR.%26aulast%3DDelabie%26aufirst%3DJ.%26aulast%3DAlizadeh%26aufirst%3DA.%2BA.%26aulast%3DIrish%26aufirst%3DJ.%2BM.%26aulast%3DLevy%26aufirst%3DR.%26atitle%3DDistinct%2520Patterns%2520of%2520B-cell%2520Receptor%2520Signaling%2520in%2520Non-Hodgkin%2520Lymphomas%2520Identified%2520by%2520Single-cell%2520Profiling%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D759%26epage%3D770%26doi%3D10.1182%2Fblood-2016-05-718494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guagnano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairhurst, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbach-Weese, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruce, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aichholz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of NVP-BYL719 a Potent and Selective Phosphatidylinositol-3 Kinase Alpha Inhibitor Selected for Clinical Evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3741</span>– <span class="NLM_lpage">3748</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.05.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.bmcl.2013.05.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=23726034" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3741-3748&author=P.+Furetauthor=V.+Guagnanoauthor=R.+A.+Fairhurstauthor=P.+Imbach-Weeseauthor=I.+Bruceauthor=M.+Knappauthor=C.+Fritschauthor=F.+Blascoauthor=J.+Blanzauthor=R.+Aichholzauthor=J.+Hamonauthor=D.+Fabbroauthor=G.+Caravatti&title=Discovery+of+NVP-BYL719+a+Potent+and+Selective+Phosphatidylinositol-3+Kinase+Alpha+Inhibitor+Selected+for+Clinical+Evaluation&doi=10.1016%2Fj.bmcl.2013.05.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation</span></div><div class="casAuthors">Furet, Pascal; Guagnano, Vito; Fairhurst, Robin A.; Imbach-Weese, Patricia; Bruce, Ian; Knapp, Mark; Fritsch, Christine; Blasco, Francesca; Blanz, Joachim; Aichholz, Reiner; Hamon, Jacques; Fabbro, Doriano; Caravatti, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3741-3748</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Phosphatidylinositol-3-kinase α (PI3Kα) is a therapeutic target of high interest in anticancer drug research.  On the basis of a binding model rationalizing the high selectivity and potency of a particular series of 2-aminothiazole compds. in inhibiting PI3Kα, a medicinal chem. program has led to the discovery of the clin. candidate NVP-BYL719 I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraN93Vwrfb4bVg90H21EOLACvtfcHk0lj_FStXcQlJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFaisrY%253D&md5=a0d2d69e01e7a82a5fed04114105925e</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.007%26sid%3Dliteratum%253Aachs%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGuagnano%26aufirst%3DV.%26aulast%3DFairhurst%26aufirst%3DR.%2BA.%26aulast%3DImbach-Weese%26aufirst%3DP.%26aulast%3DBruce%26aufirst%3DI.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DBlasco%26aufirst%3DF.%26aulast%3DBlanz%26aufirst%3DJ.%26aulast%3DAichholz%26aufirst%3DR.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCaravatti%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520NVP-BYL719%2520a%2520Potent%2520and%2520Selective%2520Phosphatidylinositol-3%2520Kinase%2520Alpha%2520Inhibitor%2520Selected%2520for%2520Clinical%2520Evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3741%26epage%3D3748%26doi%3D10.1016%2Fj.bmcl.2013.05.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Fritsch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatenay-Rivauday, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Pover, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferretti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trappe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brachmann, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boehm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Echeverria, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chene, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cozens, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caravatti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Novel and Specific PI3Kalpha Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1129</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-13-0865</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1158%2F1535-7163.MCT-13-0865" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=24608574" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1117-1129&author=C.+Fritschauthor=A.+Huangauthor=C.+Chatenay-Rivaudayauthor=C.+Schnellauthor=A.+Reddyauthor=M.+Liuauthor=A.+Kauffmannauthor=D.+Guthyauthor=D.+Erdmannauthor=A.+De+Poverauthor=P.+Furetauthor=H.+Gaoauthor=S.+Ferrettiauthor=Y.+Wangauthor=J.+Trappeauthor=S.+M.+Brachmannauthor=S.-M.+Mairaauthor=C.+Wilsonauthor=M.+Boehmauthor=C.+Garcia-Echeverriaauthor=P.+Cheneauthor=M.+Wiesmannauthor=R.+Cozensauthor=J.+Leharauthor=R.+Schlegelauthor=G.+Caravattiauthor=F.+Hofmannauthor=W.+R.+Sellers&title=Characterization+of+the+Novel+and+Specific+PI3Kalpha+Inhibitor+NVP-BYL719+and+Development+of+the+Patient+Stratification+Strategy+for+Clinical+Trials&doi=10.1158%2F1535-7163.mct-13-0865"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials</span></div><div class="casAuthors">Fritsch, Christine; Huang, Alan; Chatenay-Rivauday, Christian; Schnell, Christian; Reddy, Anupama; Liu, Manway; Kauffmann, Audrey; Guthy, Daniel; Erdmann, Dirk; De Pover, Alain; Furet, Pascal; Gao, Hui; Ferretti, Stephane; Wang, Youzhen; Trappe, Joerg; Brachmann, Saskia M.; Maira, Sauveur-Michel; Wilson, Christopher; Boehm, Markus; Garcia-Echeverria, Carlos; Chene, Patrick; Wiesmann, Marion; Cozens, Robert; Lehar, Joseph; Schlegel, Robert; Caravatti, Giorgio; Hofmann, Francesco; Sellers, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1117-1129</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects assocd. with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family.  Here, we report the biol. properties of the 2-aminothiazole deriv. NVP-BYL719, a selective inhibitor of PI3Kα and its most common oncogenic mutant forms.  The compd. selectivity combined with excellent drug-like properties translates to dose- and time-dependent inhibition of PI3Kα signaling in vivo, resulting in robust therapeutic efficacy and tolerability in PIK3CA-dependent tumors.  Novel targeted therapeutics such as NVP-BYL719, designed to modulate aberrant functions elicited by cancer-specific genetic alterations upon which the disease depends, require well-defined patient stratification strategies in order to maximize their therapeutic impact and benefit for the patients.  Here, we also describe the application of the Cancer Cell Line Encyclopedia as a preclin. platform to refine the patient stratification strategy for NVP-BYL719 and found that PIK3CA mutation was the foremost pos. predictor of sensitivity while revealing addnl. pos. and neg. assocns. such as PIK3CA amplification and PTEN mutation, resp.  These patient selection determinants are being assayed in the ongoing NVP-BYL719 clin. trials.  Mol Cancer Ther; 13(5); 1117-29. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzBW6u023PF7Vg90H21EOLACvtfcHk0lj_FStXcQlJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWjsb4%253D&md5=58d9132052dd9d430361021b0f877475</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0865&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0865%26sid%3Dliteratum%253Aachs%26aulast%3DFritsch%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DChatenay-Rivauday%26aufirst%3DC.%26aulast%3DSchnell%26aufirst%3DC.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DKauffmann%26aufirst%3DA.%26aulast%3DGuthy%26aufirst%3DD.%26aulast%3DErdmann%26aufirst%3DD.%26aulast%3DDe%2BPover%26aufirst%3DA.%26aulast%3DFuret%26aufirst%3DP.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DFerretti%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DTrappe%26aufirst%3DJ.%26aulast%3DBrachmann%26aufirst%3DS.%2BM.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DWilson%26aufirst%3DC.%26aulast%3DBoehm%26aufirst%3DM.%26aulast%3DGarcia-Echeverria%26aufirst%3DC.%26aulast%3DChene%26aufirst%3DP.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DCozens%26aufirst%3DR.%26aulast%3DLehar%26aufirst%3DJ.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DCaravatti%26aufirst%3DG.%26aulast%3DHofmann%26aufirst%3DF.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520the%2520Novel%2520and%2520Specific%2520PI3Kalpha%2520Inhibitor%2520NVP-BYL719%2520and%2520Development%2520of%2520the%2520Patient%2520Stratification%2520Strategy%2520for%2520Clinical%2520Trials%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1117%26epage%3D1129%26doi%3D10.1158%2F1535-7163.mct-13-0865" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabernero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janku, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burris, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schellens, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berlin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil-Martin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rugo, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seggewiss-Bernhardt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bootle, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demanse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blumenstein, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quadt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">Phosphatidylinositol 3-Kinase a–Selective Inhibition with Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1291</span>– <span class="NLM_lpage">1299</span>, <span class="refDoi"> DOI: 10.1200/jco.2017.72.7107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1200%2FJCO.2017.72.7107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=29401002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=1291-1299&author=D.+Juricauthor=J.+Rodonauthor=J.+Taberneroauthor=F.+Jankuauthor=H.+A.+Burrisauthor=J.+H.+M.+Schellensauthor=M.+R.+Middletonauthor=J.+Berlinauthor=M.+Schulerauthor=M.+Gil-Martinauthor=H.+S.+Rugoauthor=R.+Seggewiss-Bernhardtauthor=A.+Huangauthor=D.+Bootleauthor=D.+Demanseauthor=L.+Blumensteinauthor=C.+Coughlinauthor=C.+Quadtauthor=J.+Baselga&title=Phosphatidylinositol+3-Kinase+a%E2%80%93Selective+Inhibition+with+Alpelisib+%28BYL719%29+in+PIK3CA-Altered+Solid+Tumors%3A+Results+From+the+First-in-Human+Study&doi=10.1200%2Fjco.2017.72.7107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphatidylinositol 3-Kinase α-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study</span></div><div class="casAuthors">Juric, Dejan; Rodon, Jordi; Tabernero, Josep; Janku, Filip; Burris, Howard A.; Schellens, Jan H. M.; Middleton, Mark R.; Berlin, Jordan; Schuler, Martin; Gil-Martin, Marta; Rugo, Hope S.; Seggewiss-Bernhardt, Ruth; Huang, Alan; Bootle, Douglas; Demanse, David; Blumenstein, Lars; Coughlin, Christina; Quadt, Cornelia; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1291-1299</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">1527-7755</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose We report the first-in-human phase Ia study to our knowledge (ClinicalTrials.gov identifier: NCT01219699) identifying the max. tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase α (PI3Kα)-selective inhibitor.  Patients and Methods In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule.  In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer received alpelisib 400 mg once daily.  Results One hundred thirty-four patients received treatment.  Alpelisib max. tolerated doses were established as 400mg once daily and 150mg twice daily.  Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1).  Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%).  Alpelisib was rapidly absorbed; half-life was 7.6 h at 400 mg once daily with minimal accumulation.  Objective tumor responses were obsd. at doses ≥ 270 mg once daily; overall response ratewas 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses).  Stable disease was achieved in 70 (52.2%) patients and was maintained . 24 wk in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%.  In patients with estrogen receptor-pos./human epidermal growth factor receptor 2-neg. breast cancer, median progression-free survival was 5.5 mo.  Frequently mutated genes (≥ 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%).  Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3Kα inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGps0P3SQLaDT7Vg90H21EOLACvtfcHk0lj_FStXcQlJuA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlynurbO&md5=e95593fa4359b0ae552c92f909387f5b</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.72.7107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.72.7107%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DTabernero%26aufirst%3DJ.%26aulast%3DJanku%26aufirst%3DF.%26aulast%3DBurris%26aufirst%3DH.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%2BM.%26aulast%3DMiddleton%26aufirst%3DM.%2BR.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DGil-Martin%26aufirst%3DM.%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DSeggewiss-Bernhardt%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DBootle%26aufirst%3DD.%26aulast%3DDemanse%26aufirst%3DD.%26aulast%3DBlumenstein%26aufirst%3DL.%26aulast%3DCoughlin%26aufirst%3DC.%26aulast%3DQuadt%26aufirst%3DC.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DPhosphatidylinositol%25203-Kinase%2520a%25E2%2580%2593Selective%2520Inhibition%2520with%2520Alpelisib%2520%2528BYL719%2529%2520in%2520PIK3CA-Altered%2520Solid%2520Tumors%253A%2520Results%2520From%2520the%2520First-in-Human%2520Study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26spage%3D1291%26epage%3D1299%26doi%3D10.1200%2Fjco.2017.72.7107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanhaesebroeck, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leevers, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahmadi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timms, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driscoll, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woscholski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterfield, M. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Function of 3-Phosphorylated Inositol Lipids</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">535</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.70.1.535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1146%2Fannurev.biochem.70.1.535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=11395417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=535-602&author=B.+Vanhaesebroeckauthor=S.+J.+Leeversauthor=K.+Ahmadiauthor=J.+Timmsauthor=R.+Katsoauthor=P.+C.+Driscollauthor=R.+Woscholskiauthor=P.+J.+Parkerauthor=M.+D.+Waterfield&title=Synthesis+and+Function+of+3-Phosphorylated+Inositol+Lipids&doi=10.1146%2Fannurev.biochem.70.1.535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and function of 3-phosphorylated inositol lipids</span></div><div class="casAuthors">Vanhaesebroeck, Bart; Leevers, Sally J.; Ahmadi, Khatereh; Timms, John; Katso, Roy; Driscoll, Paul C.; Woscholski, Rudiger; Parker, Peter J.; Waterfield, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">535-602</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review, with 443 refs.  The 3-phosphorylated inositol lipids fulfill roles as second messengers by interacting with the lipid binding domains of a variety of cellular proteins.  Such interactions can affect the subcellular localization and aggregation of target proteins, and through allosteric effects, their activity.  Generation of 3-phosphoinositides has been documented to influence diverse cellular pathways and hence alter a spectrum of fundamental cellular activities.  This review is focused on the 3-phosphoinositide lipids, the synthesis of which is acutely triggered by extracellular stimuli, the enzymes responsible for their synthesis and metab., and their cell biol. roles.  Much knowledge has recently been gained through structural insights into the lipid kinases, their interaction with inhibitors, and the way their 3-phosphoinositide products interact with protein targets.  This field is now moving toward a genetic dissection of 3-phosphoinositide action in a variety of model organisms.  Such approaches will reveal the true role of the 3-phosphoinositides at the organismal level in health and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpChv_q4q6cLVg90H21EOLACvtfcHk0liclmUdrXf8hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVehtL0%253D&md5=9905473d362ef35b512d038efb901d3e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.70.1.535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.70.1.535%26sid%3Dliteratum%253Aachs%26aulast%3DVanhaesebroeck%26aufirst%3DB.%26aulast%3DLeevers%26aufirst%3DS.%2BJ.%26aulast%3DAhmadi%26aufirst%3DK.%26aulast%3DTimms%26aufirst%3DJ.%26aulast%3DKatso%26aufirst%3DR.%26aulast%3DDriscoll%26aufirst%3DP.%2BC.%26aulast%3DWoscholski%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DP.%2BJ.%26aulast%3DWaterfield%26aufirst%3DM.%2BD.%26atitle%3DSynthesis%2520and%2520Function%2520of%25203-Phosphorylated%2520Inositol%2520Lipids%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2001%26volume%3D70%26spage%3D535%26epage%3D602%26doi%3D10.1146%2Fannurev.biochem.70.1.535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stark, A.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriskantharajah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hessel, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okkenhaug, K.</span></span> <span> </span><span class="NLM_article-title">PI3K Inhibitors in Inflammation, Autoimmunity and Cancer</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">91</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2015.05.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.coph.2015.05.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=26093105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2015&pages=82-91&author=A.-K.+Starkauthor=S.+Sriskantharajahauthor=E.+M.+Hesselauthor=K.+Okkenhaug&title=PI3K+Inhibitors+in+Inflammation%2C+Autoimmunity+and+Cancer&doi=10.1016%2Fj.coph.2015.05.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K inhibitors in inflammation, autoimmunity and cancer</span></div><div class="casAuthors">Stark, Anne-Katrien; Sriskantharajah, Srividya; Hessel, Edith M.; Okkenhaug, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-91</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The healthy immune system protects against infection and malignant transformation without causing significant damage to host tissues.  Immune dysregulation results in diverse pathologies including autoimmune disease, chronic inflammatory disorders, allergies as well as immune deficiencies and cancer.  Phosphoinositide 3-kinase (PI3K) signalling has been shown to be a key pathway in the regulation of the immune response and continues to be the focus of intense research.  In recent years we have gained detailed understanding of PI3K signalling, and saw the development of potent and highly selective small mol. inhibitors, of which several are currently in clin. trials for the treatment of immune-related disorders and cancer.  The role of PI3K signalling in the immune response has been the subject of detailed reviews; here we focus on relevant recent progress in pre-clin. and clin. development of PI3K inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNWPQZuO9fE7Vg90H21EOLACvtfcHk0liclmUdrXf8hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWqs7%252FM&md5=382eb159c8ec5e3a4bc14f71f54dd295</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2015.05.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2015.05.017%26sid%3Dliteratum%253Aachs%26aulast%3DStark%26aufirst%3DA.-K.%26aulast%3DSriskantharajah%26aufirst%3DS.%26aulast%3DHessel%26aufirst%3DE.%2BM.%26aulast%3DOkkenhaug%26aufirst%3DK.%26atitle%3DPI3K%2520Inhibitors%2520in%2520Inflammation%252C%2520Autoimmunity%2520and%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2015%26volume%3D23%26spage%3D82%26epage%3D91%26doi%3D10.1016%2Fj.coph.2015.05.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulhati, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampy, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rychahou, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, H. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B. M.</span></span> <span> </span><span class="NLM_article-title">Novel Expression Patterns of PI3K/AKT/mTOR Signaling Pathway</span>. <i>J. Am. Coll. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>210</i></span>,  <span class="NLM_fpage">767</span>– <span class="NLM_lpage">778</span>, <span class="refDoi"> DOI: 10.1016/j.jamcollsurg.2009.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.jamcollsurg.2009.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=20421047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BC3c3ptV2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=210&publication_year=2010&pages=767-778&author=S.+M.+Johnsonauthor=P.+Gulhatiauthor=B.+A.+Rampyauthor=Y.+Hanauthor=P.+G.+Rychahouauthor=H.+Q.+Doanauthor=H.+L.+Weissauthor=B.+M.+Evers&title=Novel+Expression+Patterns+of+PI3K%2FAKT%2FmTOR+Signaling+Pathway&doi=10.1016%2Fj.jamcollsurg.2009.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer</span></div><div class="casAuthors">Johnson Sara M; Gulhati Pat; Rampy Bill A; Han Yimei; Rychahou Piotr G; Doan Hung Q; Weiss Heidi L; Evers B Mark</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American College of Surgeons</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">210</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">767-76, 776-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway plays a critical role in the growth and progression of colorectal cancer (CRC).  The purpose of our study was 2-fold: (1) to determine the expression levels of several key components of this pathway, including p85alpha, Akt1, Akt2, p-mTOR(Ser2448), and p-p70S6K(Thr389) in CRCs; and (2) to correlate the expression of these proteins with cancer stage and location (left versus right side).  STUDY DESIGN:  Immunohistochemistry for p85alpha, Akt1, Akt2, p-mTOR(Ser2448), and p-p70S6K(Thr389) was performed on normal colon and CRCs from 154 patients.  RESULTS:  All proteins investigated were significantly overexpressed in CRCs compared with matched normal colonic tissue from the same patient (p < 0.0001).  PI3K pathway component proteins were moderately correlated across normal and malignant colon tissues; correlations tended to be stronger in normal tissues as compared with the same correlations in cancers.  Expression levels of p85alpha were significantly higher in stage IV cancers than in stage I to III cancers (p = 0.0005). p85alpha expression was also significantly increased in the adjacent normal colonic mucosa of patients with stage IV CRC compared with earlier stages (p = 0.003).  Finally, expression of Akt1, Akt2, and p-p70S6K(Thr389) was higher in left-sided CRCs compared with CRCs in the right colon (p = 0.007, p = 0.0008, and p = 0.04, respectively).  CONCLUSIONS:  The PI3K/Akt/mTOR pathway components, p85alpha, Akt1, Akt2, p-mTOR(Ser2448), and p-p70S6K(Thr389) are highly overexpressed in CRCs, providing the rationale for targeting this pathway therapeutically in CRC patients.  The increased expression of p85alpha in the adjacent normal mucosa of stage IV patients suggests an important field defect, which may contribute to the growth and progression of these cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB4mmWCyEtHfh3YQQtAhNufW6udTcc2ebZ7snVbyHtKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c3ptV2mtw%253D%253D&md5=d9589b687ab20567c42ade1869da7fc1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.jamcollsurg.2009.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jamcollsurg.2009.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DS.%2BM.%26aulast%3DGulhati%26aufirst%3DP.%26aulast%3DRampy%26aufirst%3DB.%2BA.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DRychahou%26aufirst%3DP.%2BG.%26aulast%3DDoan%26aufirst%3DH.%2BQ.%26aulast%3DWeiss%26aufirst%3DH.%2BL.%26aulast%3DEvers%26aufirst%3DB.%2BM.%26atitle%3DNovel%2520Expression%2520Patterns%2520of%2520PI3K%252FAKT%252FmTOR%2520Signaling%2520Pathway%26jtitle%3DJ.%2520Am.%2520Coll.%2520Surg.%26date%3D2010%26volume%3D210%26spage%3D767%26epage%3D778%26doi%3D10.1016%2Fj.jamcollsurg.2009.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">591, A Novel Specific Pan-PI3K Inhibitor, Preferentially Targets Cancer Stem Cells</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">3371</span>– <span class="NLM_lpage">3386</span>, <span class="refDoi"> DOI: 10.1038/s41388-018-0674-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1038%2Fs41388-018-0674-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30635656" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVGgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=3371-3386&author=H.+Zhouauthor=C.+Yuauthor=L.+Kongauthor=X.+Xuauthor=J.+Yanauthor=Y.+Liauthor=T.+Anauthor=L.+Gongauthor=Y.+Gongauthor=H.+Zhuauthor=H.+Zhangauthor=X.+Yangauthor=Y.+Li&title=591%2C+A+Novel+Specific+Pan-PI3K+Inhibitor%2C+Preferentially+Targets+Cancer+Stem+Cells&doi=10.1038%2Fs41388-018-0674-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells</span></div><div class="casAuthors">Zhou, Hongyu; Yu, Chunlei; Kong, Lingmei; Xu, Xiaoliang; Yan, Juming; Li, Yingchao; An, Tao; Gong, Liang; Gong, Yaxiao; Zhu, Huifang; Zhang, Hongbin; Yang, Xiaodong; Li, Yan</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">3371-3386</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer stem cells (CSCs) have been implicated in metastasis, relapse, and therapeutic resistance of cancer, so successful cancer therapy may therefore require the development of drugs against CSCs or combining anti-CSCs drugs with conventional therapies.  The phosphoinositide 3-kinase (PI3K) signaling pathway is one of the most frequently activated signaling pathways in human cancer, playing a central role in tumorigenesis as well as the maintenance of CSCs.  Here, we designed and identified B591, a dihydrobenzofuran-imidazolium salt, as a novel specific pan-PI3K inhibitor with potent inhibitory activity against class I PI3K isoforms, which showed effective inhibition of cellular PI3K/mTOR signaling pathway and robust antitumor activity in a set of cancer cell lines.  Notably, compared with bulk tumor cell populations, B591 exhibited more potency in suppressing CSCs survival and inducing CSCs apoptosis, and presence of B591 effectively eliminated paclitaxel-enriched CSCs.  B591 diminished self-renewal capacity and decreased the expression of epithelial-mesenchymal transition (EMT) markers of CSCs.  In vivo, B591 preferentially decreased CSCs levels in mouse xenograft model of human breast cancer as evidenced esp. by remarkable redn. of tumor-initiating ability.  Consistent with the preferential targeting of CSCs, B591 effectively inhibited breast tumor metastasis and delayed tumor regrowth following paclitaxel treatment.  Taken together, our findings establish B591, a novel PI3K inhibitor, as a strong candidate for clin. evaluation as a CSCs targeting agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgpgRnXOUhGrVg90H21EOLACvtfcHk0ljFnpeNw3PC5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVGgsb4%253D&md5=33f993c90d89c82d0d42554dde49afcd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fs41388-018-0674-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-018-0674-5%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DKong%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DT.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26atitle%3D591%252C%2520A%2520Novel%2520Specific%2520Pan-PI3K%2520Inhibitor%252C%2520Preferentially%2520Targets%2520Cancer%2520Stem%2520Cells%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26spage%3D3371%26epage%3D3386%26doi%3D10.1038%2Fs41388-018-0674-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K in Cancer: Mechanisms and Advances in Clinical Trials</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-0954-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1186%2Fs12943-019-0954-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30782187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=26&author=J.+Yangauthor=J.+Nieauthor=X.+Maauthor=Y.+Weiauthor=Y.+Pengauthor=X.+Wei&title=Targeting+PI3K+in+Cancer%3A+Mechanisms+and+Advances+in+Clinical+Trials&doi=10.1186%2Fs12943-019-0954-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span></div><div class="casAuthors">Yang Jing; Nie Ji; Ma Xuelei; Wei Yuquan; Peng Yong; Wei Xiawei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer.  Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of which are currently employed in clinical trials evaluation, and it is becoming increasingly clear that PI3K inhibitors are effective in inhibiting tumor progression.  PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and isoform-specific inhibitors.  In this review, we performed a critical review to summarize the role of the PI3K pathway in tumor development, recent PI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGm3fFMcHFSMScOqQTSkOffW6udTcc2eZgHKGNrvpVALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D&md5=4267e4df49544ebe11ab4255e69e5bbe</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-0954-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-0954-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DX.%26atitle%3DTargeting%2520PI3K%2520in%2520Cancer%253A%2520Mechanisms%2520and%2520Advances%2520in%2520Clinical%2520Trials%26jtitle%3DMol.%2520Canc.%26date%3D2019%26volume%3D18%26spage%3D26%26doi%3D10.1186%2Fs12943-019-0954-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepherd, P.</span></span> <span> </span><span class="NLM_article-title">Review For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI3-Kinase Inhibitors</span>. <i>Biomolecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">402</span>, <span class="refDoi"> DOI: 10.3390/biom9090402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.3390%2Fbiom9090402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVCis73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=402&author=C.+Buchananauthor=K.+Leeauthor=P.+Shepherd&title=Review+For+Better+or+Worse%3A+The+Potential+for+Dose+Limiting+the+On-Target+Toxicity+of+PI3-Kinase+Inhibitors&doi=10.3390%2Fbiom9090402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">For better or worse: the potential for dose limiting the on-target toxicity of PI 3-kinase inhibitors</span></div><div class="casAuthors">Buchanan, Christina M.; Lee, Kate L.; Shepherd, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecules</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">402</span>CODEN:
                <span class="NLM_cas:coden">BIOMHC</span>;
        ISSN:<span class="NLM_cas:issn">2218-273X</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The hyper-activation of the phosphoinositide (PI) 3-kinase signaling pathway is a hallmark of many cancers and overgrowth syndromes, and as a result, there has been intense interest in the development of drugs that target the various isoforms of PI 3-kinase.  Given the key role PI 3-kinases play in many normal cell functions, there is significant potential for the disruption of essential cellular functions by PI 3-kinase inhibitors in normal tissues; so-called on-target drug toxicity.  It is, therefore, no surprise that progress within the clin. development of PI 3-kinase inhibitors as single-agent anti-cancer therapies has been slowed by the difficulty of identifying a therapeutic window.  The aim of this review is to place the cellular, tissue and whole-body effects of PI 3-kinase inhibition in the context of understanding the potential for dose limiting on-target toxicities and to introduce possible strategies to overcome these.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQp6wQLF91B7Vg90H21EOLACvtfcHk0ljFnpeNw3PC5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVCis73L&md5=ec582298d9e45e53f1fd839b63108cc9</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3390%2Fbiom9090402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiom9090402%26sid%3Dliteratum%253Aachs%26aulast%3DBuchanan%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DShepherd%26aufirst%3DP.%26atitle%3DReview%2520For%2520Better%2520or%2520Worse%253A%2520The%2520Potential%2520for%2520Dose%2520Limiting%2520the%2520On-Target%2520Toxicity%2520of%2520PI3-Kinase%2520Inhibitors%26jtitle%3DBiomolecules%26date%3D2019%26volume%3D9%26spage%3D402%26doi%3D10.3390%2Fbiom9090402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faia, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brophy, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pink, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proctor, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lussier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyt, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillotson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacDougall, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rommel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Changelian, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutok, J. L.</span></span> <span> </span><span class="NLM_article-title">PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Supresses Activity in Autoimmune and Inflammatory Disease Models</span>. <i>Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1364</span>– <span class="NLM_lpage">1374</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2013.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.chembiol.2013.09.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1364-1374&author=D.+G.+Winklerauthor=K.+L.+Faiaauthor=J.+P.+DiNittoauthor=J.+A.+Aliauthor=K.+F.+Whiteauthor=E.+E.+Brophyauthor=M.+M.+Pinkauthor=J.+L.+Proctorauthor=J.+Lussierauthor=C.+M.+Martinauthor=J.+G.+Hoytauthor=B.+Tillotsonauthor=E.+L.+Murphyauthor=A.+R.+Limauthor=B.+D.+Thomasauthor=J.+R.+MacDougallauthor=P.+Renauthor=Y.+Liuauthor=L.-S.+Liauthor=K.+A.+Jessenauthor=C.+C.+Fritzauthor=J.+L.+Dunbarauthor=J.+R.+Porterauthor=C.+Rommelauthor=V.+J.+Palombellaauthor=P.+S.+Changelianauthor=J.+L.+Kutok&title=PI3K-%CE%B4+and+PI3K-%CE%B3+Inhibition+by+IPI-145+Abrogates+Immune+Responses+and+Supresses+Activity+in+Autoimmune+and+Inflammatory+Disease+Models&doi=10.1016%2Fj.chembiol.2013.09.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2013.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2013.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DWinkler%26aufirst%3DD.%2BG.%26aulast%3DFaia%26aufirst%3DK.%2BL.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DAli%26aufirst%3DJ.%2BA.%26aulast%3DWhite%26aufirst%3DK.%2BF.%26aulast%3DBrophy%26aufirst%3DE.%2BE.%26aulast%3DPink%26aufirst%3DM.%2BM.%26aulast%3DProctor%26aufirst%3DJ.%2BL.%26aulast%3DLussier%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DC.%2BM.%26aulast%3DHoyt%26aufirst%3DJ.%2BG.%26aulast%3DTillotson%26aufirst%3DB.%26aulast%3DMurphy%26aufirst%3DE.%2BL.%26aulast%3DLim%26aufirst%3DA.%2BR.%26aulast%3DThomas%26aufirst%3DB.%2BD.%26aulast%3DMacDougall%26aufirst%3DJ.%2BR.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.-S.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DFritz%26aufirst%3DC.%2BC.%26aulast%3DDunbar%26aufirst%3DJ.%2BL.%26aulast%3DPorter%26aufirst%3DJ.%2BR.%26aulast%3DRommel%26aufirst%3DC.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DKutok%26aufirst%3DJ.%2BL.%26atitle%3DPI3K-%25CE%25B4%2520and%2520PI3K-%25CE%25B3%2520Inhibition%2520by%2520IPI-145%2520Abrogates%2520Immune%2520Responses%2520and%2520Supresses%2520Activity%2520in%2520Autoimmune%2520and%2520Inflammatory%2520Disease%2520Models%26jtitle%3DComput.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D1364%26epage%3D1374%26doi%3D10.1016%2Fj.chembiol.2013.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahana, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korenchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundaresan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberwein, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span> <span> </span><span class="NLM_article-title">Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">225</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-08-1253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1158%2F1078-0432.CCR-08-1253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=19118049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1ektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=217-225&author=M.-C.+Crouthamelauthor=J.+A.+Kahanaauthor=S.+Korenchukauthor=S.-Y.+Zhangauthor=G.+Sundaresanauthor=D.+J.+Eberweinauthor=K.+K.+Brownauthor=R.+Kumar&title=Mechanism+and+Management+of+AKT+Inhibitor-Induced+Hyperglycemia&doi=10.1158%2F1078-0432.ccr-08-1253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia</span></div><div class="casAuthors">Crouthamel, Ming-Chih; Kahana, Jason A.; Korenchuk, Susan; Zhang, Shu-Yun; Sundaresan, Gobalakrishnan; Eberwein, Derek J.; Brown, Kathleen K.; Kumar, Rakesh</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">217-225</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insulin-like growth factor-I receptor and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathways are among the most active areas of drug discovery in cancer research.  However, due to their integral roles in insulin signaling, inhibitors targeting these pathways often lead to hyperglycemia and hyperinsulinemia.  We investigated the mechanism of hyperglycemia induced by GSK690693, a pan-AKT kinase inhibitor in clin. development, as well as methods to ameliorate these side effects.  The effect of GSK690693 on blood glucose, insulin, and glucagon levels was characterized in mice.  We then evaluated the effects of commonly prescribed antidiabetic agents on GSK690693-induced hyperglycemia.  The mechanism of blood glucose increase was evaluated using fasting and tracer uptake studies and by measuring liver glycogen levels.  Finally, approaches to manage AKT inhibitor-induced hyperglycemia were designed using fasting and low carbohydrate diet.  We report that treatment with antidiabetic agents does not significantly affect GSK690693-induced hyperglycemia in rodents.  However, administration of GSK690693 in mice significantly reduces liver glycogen (∼90%), suggesting that GSK690693 may inhibit glycogen synthesis and/or activate glycogenolysis.  Consistent with this observation, fasting before drug administration reduces baseline liver glycogen levels and attenuates hyperglycemia.  Further, GSK690693 also inhibits peripheral glucose uptake and introduction of a low-carbohydrate (7%) or 0% carbohydrate diet after GSK690693 administration effectively reduces diet-induced hyperglycemia in mice.  The mechanism of GSK690693-induced hyperglycemia is related to peripheral insulin resistance, increased gluconeogenesis, and/or hepatic glycogenolysis.  A combination of fasting and low carbohydrate diet can reduce the magnitude of hyperglycemia induced by an AKT inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrleTZ-otQBbrVg90H21EOLACvtfcHk0liK849HX-n24A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1ektQ%253D%253D&md5=ae0e0287caad7b6d4de979a73dc3cc2d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-1253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-1253%26sid%3Dliteratum%253Aachs%26aulast%3DCrouthamel%26aufirst%3DM.-C.%26aulast%3DKahana%26aufirst%3DJ.%2BA.%26aulast%3DKorenchuk%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DS.-Y.%26aulast%3DSundaresan%26aufirst%3DG.%26aulast%3DEberwein%26aufirst%3DD.%2BJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DKumar%26aufirst%3DR.%26atitle%3DMechanism%2520and%2520Management%2520of%2520AKT%2520Inhibitor-Induced%2520Hyperglycemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D217%26epage%3D225%26doi%3D10.1158%2F1078-0432.ccr-08-1253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rihawi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bodla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morganstein, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banerji, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molife, L. R.</span></span> <span> </span><span class="NLM_article-title">Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">855</span>– <span class="NLM_lpage">860</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.2015-0248</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1634%2Ftheoncologist.2015-0248" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=27151652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFGnur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=855-860&author=K.+H.+Khanauthor=M.+Wongauthor=K.+Rihawiauthor=S.+Bodlaauthor=D.+Morgansteinauthor=U.+Banerjiauthor=L.+R.+Molife&title=Hyperglycemia+and+Phosphatidylinositol+3-Kinase%2FProtein+Kinase+B%2FMammalian+Target+of+Rapamycin+%28PI3K%2FAKT%2FmTOR%29+Inhibitors+in+Phase+I+Trials%3A+Incidence%2C+Predictive+Factors%2C+and+Management&doi=10.1634%2Ftheoncologist.2015-0248"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperglycemia and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitors in phase I trials: incidence, predictive factors, and management</span></div><div class="casAuthors">Khan, Khurum H.; Wong, Mabel; Rihawi, Karim; Bodla, Shankar; Morganstein, Daniel; Banerji, Udai; Molife, Lulama R.</div><div class="citationInfo"><span class="NLM_cas:title">Oncologist</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">855-860</span>CODEN:
                <span class="NLM_cas:coden">OCOLF6</span>;
        ISSN:<span class="NLM_cas:issn">1083-7159</span>.
    
            (<span class="NLM_cas:orgname">AlphaMed Press</span>)
        </div><div class="casAbstract">Dysregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is implicated in human cancer growth and progression.  Agents targeting this pathway are assocd. with hyperglycemia due to interaction with the insulin-glucose regulatory axis.  Identifying the predictive factors for hyperglycemia in patients treated with these agents may help direct future management.  Clin. characteristics and outcomes of patients treated consecutively with PI3K, AKT, or mTOR inhibitors in the Drug Development Unit, The Royal Marsden (RM) National Health Service (NHS) Foundation Trust, between 2007 and 2012 were recorded.  Baseline variables and their assocn. with grade 3 hyperglycemia (Common Terminol. Criteria for Adverse Events, version 3.0) were analyzed by using the chi-square test and Fisher exact test for categorical variables and binary logistic regression for continuous variables.  A total of 341 patients were treated in 12 phase I trials of PI3K/AKT/mTOR inhibitors, and 298 patients (87.4%) developed hyperglycemia.  Hyperglycemia was grade 1 in 217 (72.8%) and grade 2 in 61 (20.5%) patients, resp.  Grade ≥3 hyperglycemia was seen in 6.7% of patients (n = 20).  According to the chi-square test, age <65 years (p =.03), history of diabetes (p =.003), and treatment with AKT and dual PI3K/mTOR inhibitors (p <.0005) predicted the occurrence of grade 3 hyperglycemia.  Of 24 patients requiring intervention, 20 received metformin, 2 dietary advice, 1 insulin, and 1 both metformin and insulin.  One patient required dose redn.  There were no permanent drug discontinuations, and no hyperglycemia-related dose-limiting toxicities were obsd.; thus, the recommended phase II dose was not affected by the hyperglycemia obsd. in our cohort.  Hyperglycemia is common in patients treated with PI3K/AKT/mTOR inhibitors; however, it is manageable with conventional treatment.  Predictive factors of age, history of diabetes, and administration of AKT and dual PI3K/mTOR inhibitors warrant prospective validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp82LfubcEXBrVg90H21EOLACvtfcHk0liK849HX-n24A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFGnur7M&md5=3adadb9070a419e2179c830dbc711390</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2015-0248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2015-0248%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DK.%2BH.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DRihawi%26aufirst%3DK.%26aulast%3DBodla%26aufirst%3DS.%26aulast%3DMorganstein%26aufirst%3DD.%26aulast%3DBanerji%26aufirst%3DU.%26aulast%3DMolife%26aufirst%3DL.%2BR.%26atitle%3DHyperglycemia%2520and%2520Phosphatidylinositol%25203-Kinase%252FProtein%2520Kinase%2520B%252FMammalian%2520Target%2520of%2520Rapamycin%2520%2528PI3K%252FAKT%252FmTOR%2529%2520Inhibitors%2520in%2520Phase%2520I%2520Trials%253A%2520Incidence%252C%2520Predictive%2520Factors%252C%2520and%2520Management%26jtitle%3DOncologist%26date%3D2016%26volume%3D21%26spage%3D855%26epage%3D860%26doi%3D10.1634%2Ftheoncologist.2015-0248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pauls, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafarge, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landego, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. J.</span></span> <span> </span><span class="NLM_article-title">The Phosphoinositide 3-Kinase Signaling Pathway in Normal and Malignant B Cells: Activation Mechanisms, Regulation and Impact on Cellular Functions</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">224</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2012.00224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.3389%2Ffimmu.2012.00224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=22908014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BC38fpvFaqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=224&author=S.+D.+Paulsauthor=S.+T.+Lafargeauthor=I.+Landegoauthor=T.+Zhangauthor=A.+J.+Marshall&title=The+Phosphoinositide+3-Kinase+Signaling+Pathway+in+Normal+and+Malignant+B+Cells%3A+Activation+Mechanisms%2C+Regulation+and+Impact+on+Cellular+Functions&doi=10.3389%2Ffimmu.2012.00224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions</span></div><div class="casAuthors">Pauls Samantha D; Lafarge Sandrine T; Landego Ivan; Zhang Tingting; Marshall Aaron J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">224</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K) pathway is a central signal transduction axis controlling normal B cell homeostasis and activation in humoral immunity.  The p110δ PI3K catalytic subunit has emerged as a critical mediator of multiple B cell functions.  The activity of this pathway is regulated at multiple levels, with inositol phosphatases PTEN and SHIP both playing critical roles.  When deregulated, the PI3K pathway can contribute to B cell malignancies and autoantibody production.  This review summarizes current knowledge on key mechanisms that activate and regulate the PI3K pathway and influence normal B cell functional responses including the development of B cell subsets, antigen presentation, immunoglobulin isotype switch, germinal center responses, and maintenance of B cell anergy.  We also discuss PI3K pathway alterations reported in select B cell malignancies and highlight studies indicating the functional significance of this pathway in malignant B cell survival and growth within tissue microenvironments.  Finally, we comment on early clinical trial results, which support PI3K inhibition as a promising treatment of chronic lymphocytic leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6PU49jJBvRNyzdcP07UmufW6udTcc2eb9BAK7u2TxtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fpvFaqtg%253D%253D&md5=2521d7033f7bc2781aeee853ec033e5f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2012.00224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2012.00224%26sid%3Dliteratum%253Aachs%26aulast%3DPauls%26aufirst%3DS.%2BD.%26aulast%3DLafarge%26aufirst%3DS.%2BT.%26aulast%3DLandego%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DMarshall%26aufirst%3DA.%2BJ.%26atitle%3DThe%2520Phosphoinositide%25203-Kinase%2520Signaling%2520Pathway%2520in%2520Normal%2520and%2520Malignant%2520B%2520Cells%253A%2520Activation%2520Mechanisms%252C%2520Regulation%2520and%2520Impact%2520on%2520Cellular%2520Functions%26jtitle%3DFront.%2520Immunol.%26date%3D2012%26volume%3D3%26spage%3D224%26doi%3D10.3389%2Ffimmu.2012.00224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Przepiorka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Claro, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shord, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehrotra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminskas, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farrell, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma</span>. <i>Clin. Canc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1529</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-14-2522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1158%2F1078-0432.CCR-14-2522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1525-1529&author=B.+W.+Millerauthor=D.+Przepiorkaauthor=R.+A.+de+Claroauthor=K.+Leeauthor=L.+Nieauthor=N.+Simpsonauthor=R.+Gudiauthor=H.+Saberauthor=S.+Shordauthor=J.+Bullockauthor=D.+Maratheauthor=N.+Mehrotraauthor=L.+S.+Hsiehauthor=D.+Ghoshauthor=J.+Brownauthor=R.+C.+Kaneauthor=R.+Justiceauthor=E.+Kaminskasauthor=A.+T.+Farrellauthor=R.+Pazdur&title=FDA+Approval%3A+Idelalisib+Monotherapy+for+the+Treatment+of+Patients+with+Follicular+Lymphoma+and+Small+Lymphocytic+Lymphoma&doi=10.1158%2F1078-0432.ccr-14-2522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma</span></div><div class="casAuthors">Miller, Barry W.; Przepiorka, Donna; Angelo de Claro, R.; Lee, Kyung; Nie, Lei; Simpson, Natalie; Gudi, Ramadevi; Saber, Haleh; Shord, Stacy; Bullock, Julie; Marathe, Dhananjay; Mehrotra, Nitin; Hsieh, Li Shan; Ghosh, Debasis; Brown, Janice; Kane, Robert C.; Justice, Robert; Kaminskas, Edvardas; Farrell, Ann T.; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1525-1529</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">On July 23, 2014, the FDA granted accelerated approval to idelalisib (Zydelig tablets; Gilead Sciences, Inc.) for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma or relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.  In a multicenter, single-arm trial, 123 patients with relapsed indolent non-Hodgkin lymphomas received idelalisib, 150 mg orally twice daily.  In patients with follicular lymphoma, the overall response rate (ORR) was 54%, and the median duration of response (DOR) was not evaluable; median follow-up was 8.1 mo.  In patients with SLL, the ORR was 58% and the median DOR was 11.9 mo.  One-half of patients experienced a serious adverse reaction of pneumonia, pyrexia, sepsis, febrile neutropenia, diarrhea, or pneumonitis.  Other common adverse reactions were abdominal pain, nausea, fatigue, cough, dyspnea, and rash.  Common treatment-emergent lab. abnormalities were elevations in alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, abs. lymphocytes, and triglycerides.  Continued approval may be contingent upon verification of clin. benefit in confirmatory trials.  Clin Cancer Res; 21(7); 1525-9. cpr2015 AACR.  See related article by Gandhi et al., p.  1537.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbi_gkmWnf7rVg90H21EOLACvtfcHk0lgpZkQF-OjP7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahsro%253D&md5=1c8a5a577c05e3ff995368c55fd7607d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2522%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DB.%2BW.%26aulast%3DPrzepiorka%26aufirst%3DD.%26aulast%3Dde%2BClaro%26aufirst%3DR.%2BA.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DNie%26aufirst%3DL.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DGudi%26aufirst%3DR.%26aulast%3DSaber%26aufirst%3DH.%26aulast%3DShord%26aufirst%3DS.%26aulast%3DBullock%26aufirst%3DJ.%26aulast%3DMarathe%26aufirst%3DD.%26aulast%3DMehrotra%26aufirst%3DN.%26aulast%3DHsieh%26aufirst%3DL.%2BS.%26aulast%3DGhosh%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DKane%26aufirst%3DR.%2BC.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DKaminskas%26aufirst%3DE.%26aulast%3DFarrell%26aufirst%3DA.%2BT.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520Approval%253A%2520Idelalisib%2520Monotherapy%2520for%2520the%2520Treatment%2520of%2520Patients%2520with%2520Follicular%2520Lymphoma%2520and%2520Small%2520Lymphocytic%2520Lymphoma%26jtitle%3DClin.%2520Canc.%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1525%26epage%3D1529%26doi%3D10.1158%2F1078-0432.ccr-14-2522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barr, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saylors, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenwald, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liem, A. K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLntyre, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abella-Dominicis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreiling, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedberg, J. W.</span></span> <span> </span><span class="NLM_article-title">Phase 2 Study of Idelalisib and Entospletinib: Pneumonitis Limits Combination Therapy in Relapsed Refractory CLL and NHL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">2411</span>– <span class="NLM_lpage">2415</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-12-683516</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2015-12-683516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=26968534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ent7jP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2411-2415&author=P.+M.+Barrauthor=G.+B.+Saylorsauthor=S.+E.+Spurgeonauthor=B.+D.+Chesonauthor=D.+R.+Greenwaldauthor=S.+M.+O%E2%80%99Brienauthor=A.+K.+D.+Liemauthor=R.+E.+McLntyreauthor=A.+Joshiauthor=E.+Abella-Dominicisauthor=M.+J.+Hawkinsauthor=A.+Reddyauthor=J.+Di+Paoloauthor=H.+Leeauthor=J.+Heauthor=J.+Huauthor=L.+K.+Dreilingauthor=J.+W.+Friedberg&title=Phase+2+Study+of+Idelalisib+and+Entospletinib%3A+Pneumonitis+Limits+Combination+Therapy+in+Relapsed+Refractory+CLL+and+NHL&doi=10.1182%2Fblood-2015-12-683516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL</span></div><div class="casAuthors">Barr, Paul M.; Saylors, Gene B.; Spurgeon, Stephen E.; Cheson, Bruce D.; Greenwald, Daniel R.; O'Brien, Susan M.; Liem, Andre K. D.; Mclntyre, Rosemary E.; Joshi, Adarsh; Abella-Dominicis, Esteban; Hawkins, Michael J.; Reddy, Anita; Paolo, Julie Di; Lee, Hank; He, Joyce; Hu, Jing; Dreiling, Lyndah K.; Friedberg, Jonathan W.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2411-2415</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Although agents targeting B-cell receptor signaling have provided practice-changing results in relapsed chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), they require prolonged administration and provide incomplete responses.  Given synergis- tic preclin. activity with phosphatidylinositol 3-kinase d and spleen tyrosine kinase inhibition, this phase 2 study evaluated the safety and efficacy of the combination of idelalisib and entospletinib.  Eligible patients with relapsed or refractory CLL or NHL under- went intrapatient dose escalation with each agent.  With a median treatment exposure of 10 wk, 60% and 36% of patients with CLL or follicular lymphoma, resp., achieved objective responses.  However, the study was terminated early because of treatment- emergent pneumonitis in 18% of patients (severe in 11 of 12 cases).  Although most patients recovered with supportive measures and systemic steroids, 2 fatalities occurred and were attributed to treatment-emergent pneumonitis.  Increases of interferon-g and interleukins 6, 7, and 8 occurred over time in patients who developed pneumonitis.  Future studies of novel combinations should employ conservative designs that incorporate pharmacodynamics/biomarker monitoring.  These investigations should also prospectively evaluate plasma cytokine/chemokine levels in an attempt to validate biomarkers predictive of response and toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGlEOcr0eY7Vg90H21EOLACvtfcHk0lgpZkQF-OjP7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ent7jP&md5=46d9b9095074f93cb5e8a743b05316e5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-12-683516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-12-683516%26sid%3Dliteratum%253Aachs%26aulast%3DBarr%26aufirst%3DP.%2BM.%26aulast%3DSaylors%26aufirst%3DG.%2BB.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DCheson%26aufirst%3DB.%2BD.%26aulast%3DGreenwald%26aufirst%3DD.%2BR.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%2BM.%26aulast%3DLiem%26aufirst%3DA.%2BK.%2BD.%26aulast%3DMcLntyre%26aufirst%3DR.%2BE.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DAbella-Dominicis%26aufirst%3DE.%26aulast%3DHawkins%26aufirst%3DM.%2BJ.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DDreiling%26aufirst%3DL.%2BK.%26aulast%3DFriedberg%26aufirst%3DJ.%2BW.%26atitle%3DPhase%25202%2520Study%2520of%2520Idelalisib%2520and%2520Entospletinib%253A%2520Pneumonitis%2520Limits%2520Combination%2520Therapy%2520in%2520Relapsed%2520Refractory%2520CLL%2520and%2520NHL%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2411%26epage%3D2415%26doi%3D10.1182%2Fblood-2015-12-683516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lampson, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kasar, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matos, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassenti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnason, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Idelalisib given Front-line for Treatment of Chronic Lymphocytic Leukemia causes Frequent Immune-mediated Hepatotoxicity</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-03-707133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2016-03-707133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=27247136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2016&pages=195-203&author=B.+L.+Lampsonauthor=S.+N.+Kasarauthor=T.+R.+Matosauthor=E.+A.+Morganauthor=L.+Rassentiauthor=M.+S.+Davidsauthor=D.+C.+Fisherauthor=A.+S.+Freedmanauthor=C.+A.+Jacobsonauthor=P.+Armandauthor=J.+S.+Abramsonauthor=J.+E.+Arnasonauthor=T.+J.+Kippsauthor=J.+Feinauthor=S.+Fernandesauthor=J.+Hannaauthor=J.+Ritzauthor=H.+T.+Kimauthor=J.+R.+Brown&title=Idelalisib+given+Front-line+for+Treatment+of+Chronic+Lymphocytic+Leukemia+causes+Frequent+Immune-mediated+Hepatotoxicity&doi=10.1182%2Fblood-2016-03-707133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity</span></div><div class="casAuthors">Lampson, Benjamin L.; Kasar, Siddha N.; Matos, Tiago R.; Morgan, Elizabeth A.; Rassenti, Laura; Davids, Matthew S.; Fisher, David C.; Freedman, Arnold S.; Jacobson, Caron A.; Armand, Philippe; Abramson, Jeremy S.; Arnason, Jon E.; Kipps, Thomas J.; Fein, Joshua; Fernandes, Stacey; Hanna, John; Ritz, Jerome; Kim, Haesook T.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-203</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Idelalisib is a small-mol. inhibitor of PI3Kδ with demonstrated efficacy for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL).  To evaluate idelalisib as front-line therapy, we enrolled 24 subjects in a phase 2 study consisting of 2 mo of idelalisib monotherapy followed by 6 mo of combination therapy with idelalisib and the anti-CD20 antibody ofatumumab.  After a median follow-up period of 14.7 mo, hepatotoxicity was found to be a frequent and often severe adverse event.  A total of 19 subjects (79%) experienced either grade ≥1 ALT or AST elevation during the study, and 13 subjects (54%) experienced grade ≥3 transaminitis.  The median time to development of transaminitis was 28 days, occurring before ofatumumab introduction.  Younger age and mutated Ig heavy chain status were significant risk factors for the development of hepatotoxicity.  Multiple lines of evidence suggest that this hepatotoxicity was immune mediated.  A lymphocytic infiltrate was seen on liver biopsy specimens taken from 2 subjects with transaminitis, and levels of the proinflammatory cytokines CCL-3 and CCL-4 were higher in subjects experiencing hepatotoxicity.  All cases of transaminitis resolved either by holding the drug, initiating immunosuppressants, or both, and rates of recurrent toxicity were lower in patients taking steroids when idelalisib was reinitiated.  A decrease in peripheral blood regulatory T cells was seen in patients experiencing toxicity on therapy, which is consistent with an immune-mediated mechanism.  These results suggest that caution should be taken as drugs within this class are developed for CLL, particularly in younger patients who have not received prior disease-specific therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFWd0SBaN9E7Vg90H21EOLACvtfcHk0ljY_7mtcwlHYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1egtrfK&md5=eec3c52d470b0b70266f7ecc3f7d8de0</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-03-707133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-03-707133%26sid%3Dliteratum%253Aachs%26aulast%3DLampson%26aufirst%3DB.%2BL.%26aulast%3DKasar%26aufirst%3DS.%2BN.%26aulast%3DMatos%26aufirst%3DT.%2BR.%26aulast%3DMorgan%26aufirst%3DE.%2BA.%26aulast%3DRassenti%26aufirst%3DL.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DFisher%26aufirst%3DD.%2BC.%26aulast%3DFreedman%26aufirst%3DA.%2BS.%26aulast%3DJacobson%26aufirst%3DC.%2BA.%26aulast%3DArmand%26aufirst%3DP.%26aulast%3DAbramson%26aufirst%3DJ.%2BS.%26aulast%3DArnason%26aufirst%3DJ.%2BE.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DFein%26aufirst%3DJ.%26aulast%3DFernandes%26aufirst%3DS.%26aulast%3DHanna%26aufirst%3DJ.%26aulast%3DRitz%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIdelalisib%2520given%2520Front-line%2520for%2520Treatment%2520of%2520Chronic%2520Lymphocytic%2520Leukemia%2520causes%2520Frequent%2520Immune-mediated%2520Hepatotoxicity%26jtitle%3DBlood%26date%3D2016%26volume%3D128%26spage%3D195%26epage%3D203%26doi%3D10.1182%2Fblood-2016-03-707133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foss, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horwitz, S.</span></span> <span> </span><span class="NLM_article-title">Duvelisib, a Novel Oral Dual Inhibitor of PI3K-delta, Gamma, is Clinically Active in Advanced Hematologic Malignancies</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">877</span>– <span class="NLM_lpage">887</span>, <span class="refDoi"> DOI: 10.1182/blood-2017-05-786566</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2017-05-786566" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=29191916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12ks7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2018&pages=877-887&author=I.+W.+Flinnauthor=S.+O%E2%80%99Brienauthor=B.+Kahlauthor=M.+Patelauthor=Y.+Okiauthor=F.+F.+Fossauthor=P.+Porcuauthor=J.+Jonesauthor=J.+A.+Burgerauthor=N.+Jainauthor=V.+M.+Kellyauthor=K.+Allenauthor=M.+Douglasauthor=J.+Sweeneyauthor=P.+Kellyauthor=S.+Horwitz&title=Duvelisib%2C+a+Novel+Oral+Dual+Inhibitor+of+PI3K-delta%2C+Gamma%2C+is+Clinically+Active+in+Advanced+Hematologic+Malignancies&doi=10.1182%2Fblood-2017-05-786566"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies</span></div><div class="casAuthors">Flinn, Ian W.; O'Brien, Susan; Kahl, Brad; Patel, Manish; Oki, Yasuhiro; Foss, Francine F.; Porcu, Pierluigi; Jones, Jeffrey; Burger, Jan A.; Jain, Nitin; Kelly, Virginia M.; Allen, Kerstin; Douglas, Mark; Sweeney, Jennifer; Kelly, Patrick; Horwitz, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">877-887</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase-δ (PI3K-δ) and PI3K-γ in late stage clin. development for hematol. malignancy treatment.  This phase 1 study evaluated max. tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib in 210 patients with advanced hematol. malignancies.  In the dose escalation phase (n531), duvelisib 8 to 100 mg twice daily was administered, with MTD detd. as 75 mg twice daily.  In the expansion phase (n 5 179), patients with indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemia (CLL), or T-cell lymphoma(TCL) were treated with 25 or 75 mg duvelisib twice daily continuously.  Single-dose duvelisib was rapidly absorbed (time to max. concn., 1-2 h), with a half-life of 5.2 to 10.9 h.  PD results showed inhibition of phospho-AKT (S473) in CLL tumor cells following a single dose and near-complete inhibition of CLL proliferation (Ki-67) by cycle 2.  Clin. responses were seen across a range of doses and disease subtypes: iNHL overall response rate, 58% (n 5 31) with 6 complete responses (CRs); relapsed/refractory CLL, 56% (n 5 55) with 1 CR; peripheral TCL, 50%(n5 16)with 3 CR; and cutaneous TCL, 32% (n 5 19).  Median time to response was ∼1.8 mo.  Severe (grade ≥3) adverse events occurred in 84% of patients: neutropenia (32%), alanine transaminase increase (20%), aspartate transaminase increase (15%), anemia and thrombocytopenia (each 14%), diarrhea (11%), and pneumonia (10%).  These data support further investigation of duvelisib in phase 2 and 3 studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIqIxR4vd3fbVg90H21EOLACvtfcHk0ljY_7mtcwlHYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12ks7rL&md5=74e4dd8f900cbd0a29dcfc0eae9689a9</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1182%2Fblood-2017-05-786566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2017-05-786566%26sid%3Dliteratum%253Aachs%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DKahl%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DOki%26aufirst%3DY.%26aulast%3DFoss%26aufirst%3DF.%2BF.%26aulast%3DPorcu%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DJain%26aufirst%3DN.%26aulast%3DKelly%26aufirst%3DV.%2BM.%26aulast%3DAllen%26aufirst%3DK.%26aulast%3DDouglas%26aufirst%3DM.%26aulast%3DSweeney%26aufirst%3DJ.%26aulast%3DKelly%26aufirst%3DP.%26aulast%3DHorwitz%26aufirst%3DS.%26atitle%3DDuvelisib%252C%2520a%2520Novel%2520Oral%2520Dual%2520Inhibitor%2520of%2520PI3K-delta%252C%2520Gamma%252C%2520is%2520Clinically%2520Active%2520in%2520Advanced%2520Hematologic%2520Malignancies%26jtitle%3DBlood%26date%3D2018%26volume%3D131%26spage%3D877%26epage%3D887%26doi%3D10.1182%2Fblood-2017-05-786566" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nastoupil, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunning, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vose, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreeder, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sportelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Purdom, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span> <span> </span><span class="NLM_article-title">Tolerability and Activity of Ublituximab, Umbralisib, and Ibrutinib in Patients with Chronic Lymphocytic Leukaemia and Non-hodgkin Lymphoma: a Phase 1 Dose Escalation and Expansion Trial</span>. <i>Lancet Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">e100</span>– <span class="NLM_lpage">e109</span>, <span class="refDoi"> DOI: 10.1016/s2352-3026(18)30216-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2FS2352-3026%2818%2930216-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30709431" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2019&pages=e100-e109&author=L.+J.+Nastoupilauthor=M.+A.+Lunningauthor=J.+M.+Voseauthor=M.+T.+Schreederauthor=T.+Siddiqiauthor=C.+R.+Flowersauthor=J.+B.+Cohenauthor=J.+A.+Burgerauthor=W.+G.+Wierdaauthor=S.+O%E2%80%99Brienauthor=P.+Sportelliauthor=H.+P.+Miskinauthor=M.+A.+Purdomauthor=M.+S.+Weissauthor=N.+H.+Fowler&title=Tolerability+and+Activity+of+Ublituximab%2C+Umbralisib%2C+and+Ibrutinib+in+Patients+with+Chronic+Lymphocytic+Leukaemia+and+Non-hodgkin+Lymphoma%3A+a+Phase+1+Dose+Escalation+and+Expansion+Trial&doi=10.1016%2Fs2352-3026%2818%2930216-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS2352-3026%2818%2930216-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2352-3026%252818%252930216-3%26sid%3Dliteratum%253Aachs%26aulast%3DNastoupil%26aufirst%3DL.%2BJ.%26aulast%3DLunning%26aufirst%3DM.%2BA.%26aulast%3DVose%26aufirst%3DJ.%2BM.%26aulast%3DSchreeder%26aufirst%3DM.%2BT.%26aulast%3DSiddiqi%26aufirst%3DT.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DCohen%26aufirst%3DJ.%2BB.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DSportelli%26aufirst%3DP.%26aulast%3DMiskin%26aufirst%3DH.%2BP.%26aulast%3DPurdom%26aufirst%3DM.%2BA.%26aulast%3DWeiss%26aufirst%3DM.%2BS.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26atitle%3DTolerability%2520and%2520Activity%2520of%2520Ublituximab%252C%2520Umbralisib%252C%2520and%2520Ibrutinib%2520in%2520Patients%2520with%2520Chronic%2520Lymphocytic%2520Leukaemia%2520and%2520Non-hodgkin%2520Lymphoma%253A%2520a%2520Phase%25201%2520Dose%2520Escalation%2520and%2520Expansion%2520Trial%26jtitle%3DLancet%2520Haematol.%26date%3D2019%26volume%3D6%26spage%3De100%26epage%3De109%26doi%3D10.1016%2Fs2352-3026%2818%2930216-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lunning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vose, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nastoupil, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreeder, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sportelli, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskin, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Ublituximab and Umbralisib in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">1811</span>– <span class="NLM_lpage">1820</span>, <span class="refDoi"> DOI: 10.1182/blood.2019002118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood.2019002118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=31558467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BB3MnisVyksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2019&pages=1811-1820&author=M.+Lunningauthor=J.+Voseauthor=L.+Nastoupilauthor=N.+Fowlerauthor=J.+A.+Burgerauthor=W.+G.+Wierdaauthor=M.+T.+Schreederauthor=T.+Siddiqiauthor=C.+R.+Flowersauthor=J.+B.+Cohenauthor=P.+Sportelliauthor=H.+P.+Miskinauthor=M.+S.+Weissauthor=S.+O%E2%80%99Brien&title=Ublituximab+and+Umbralisib+in+Relapsed%2FRefractory+B-cell+Non-Hodgkin+Lymphoma+and+Chronic+Lymphocytic+Leukemia&doi=10.1182%2Fblood.2019002118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia</span></div><div class="casAuthors">Lunning Matthew; Vose Julie; Nastoupil Loretta; Fowler Nathan; Burger Jan A; Wierda William G; Schreeder Marshall T; Siddiqi Tanya; Flowers Christopher R; Cohen Jonathon B; Sportelli Peter; Miskin Hari P; Weiss Michael S; O'Brien Susan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1811-1820</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Targeting both CD20 and phosphatidylinositol 3-kinase (PI3K), a protein that is critically involved in B-cell maturation, could be an efficacious strategy for treating B-cell malignancies.  The safety of the next-generation compounds umbralisib, a PI3K-δ inhibitor, plus ublituximab, an anti-CD20 monoclonal antibody (combination referred to as U2), was evaluated in patients with chronic lymphocytic lymphoma (CLL) or non-Hodgkin lymphoma (NHL) in this phase 1/1b study.  Phase 1 dose escalation was performed with a 3 + 3 design to establish the maximum tolerated dose.  In this portion, ublituximab was given intravenously (NHL, 900 mg; CLL, 600 or 900 mg) for 12 cycles.  Umbralisib was given orally once daily at 800 or 1200 mg (initial formulation) or 400 to 1200 mg (micronized formulation) in the phase 1 dose escalation portion, and at 800 to 1200 mg in the phase 1b portion until progression, toxicity, or study removal.  The maximum tolerated dose was not reached in either the CLL or NHL cohort, and only 1 dose-limiting toxicity was observed.  U2 had low instances of grade 3 or higher diarrhea (8%), pneumonia (8%), or hepatic toxicity (4%).  Treatment discontinuation due to adverse events occurred in 13% of patients, and umbralisib dose reductions occurred in 15% of patients.  The overall response rate for all patients was 46% with 17% complete responses.  The median duration of response was 20 months (95% confidence interval, 11.3-not reached).  U2 was well tolerated, and no new safety signals were observed over single-agent umbralisib.  Preliminary efficacy with this combination is promising and warrants further investigation.  This study was registered at www.clinicaltrials.gov as #NCT02006485.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS8ka8B-cMxyEwlCcfExbvbfW6udTcc2ebF-GfRtkNX6bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnisVyksg%253D%253D&md5=f2984ca33f2a3690331ab1c0a79966a4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1182%2Fblood.2019002118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.2019002118%26sid%3Dliteratum%253Aachs%26aulast%3DLunning%26aufirst%3DM.%26aulast%3DVose%26aufirst%3DJ.%26aulast%3DNastoupil%26aufirst%3DL.%26aulast%3DFowler%26aufirst%3DN.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DSchreeder%26aufirst%3DM.%2BT.%26aulast%3DSiddiqi%26aufirst%3DT.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DCohen%26aufirst%3DJ.%2BB.%26aulast%3DSportelli%26aufirst%3DP.%26aulast%3DMiskin%26aufirst%3DH.%2BP.%26aulast%3DWeiss%26aufirst%3DM.%2BS.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DUblituximab%2520and%2520Umbralisib%2520in%2520Relapsed%252FRefractory%2520B-cell%2520Non-Hodgkin%2520Lymphoma%2520and%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DBlood%26date%3D2019%26volume%3D134%26spage%3D1811%26epage%3D1820%26doi%3D10.1182%2Fblood.2019002118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Careddu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Consonni, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viswanadha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakkalanka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagna, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allavena, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sica, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlo-Stella, C.</span></span> <span> </span><span class="NLM_article-title">Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3K δ / γ Inhibitor RP6530</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1112</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-18-1133</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1158%2F1078-0432.CCR-18-1133" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30352904" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Kntr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=1098-1112&author=S.+L.+Locatelliauthor=G.+Caredduauthor=S.+Serioauthor=F.+M.+Consonniauthor=A.+Maedaauthor=S.+Viswanadhaauthor=S.+Vakkalankaauthor=L.+Castagnaauthor=A.+Santoroauthor=P.+Allavenaauthor=A.+Sicaauthor=C.+Carlo-Stella&title=Targeting+Cancer+Cells+and+Tumor+Microenvironment+in+Preclinical+and+Clinical+Models+of+Hodgkin+Lymphoma+Using+the+Dual+PI3K+%CE%B4+%2F+%CE%B3+Inhibitor+RP6530&doi=10.1158%2F1078-0432.ccr-18-1133"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530</span></div><div class="casAuthors">Locatelli, Silvia L.; Careddu, Giuseppa; Serio, Simone; Consonni, Francesca M.; Maeda, Akihiro; Viswanadha, Srikant; Vakkalanka, Swaroop; Castagna, Luca; Santoro, Armando; Allavena, Paola; Sica, Antonio; Carlo-Stella, Carmelo</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1098-1112</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Tumor-assocd. macrophages (TAMs) and the hyperactivation of the PI3K/AKT pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease outcome.  Because the δ and γ isoforms of PI3K are overexpressed in Hodgkin/Reed-Sternberg (HRS) cells and the tumor microenvironment (TME), we propose that the PI3Kδ/γ inhibitor RP6530 might affect both HRS cells and TME, ultimately leading to an enhanced antitumor response.  Exptl. Design: Hodgkin lymphoma cell lines (L-540, KM-H2, and L-428) and primary human macrophages were used to investigate the activity of RP6530 in vitro and in vivo in Hodgkin lymphoma cell line xenografts.  Results:In vitro, RP6530 besides killing and inhibiting the proliferation of Hodgkin lymphoma cells, downregulated lactic acid metab., switching the activation of macrophages from an immunosuppressive M2-like phenotype to a more inflammatory M1-like state.  By RNA sequencing, we define tumor glycolysis as a specific PI3Kδ/γ-dependent pathway implicated in the metabolic reprogramming of cancer cells.  We identify the metabolic regulator pyruvate kinase M2 as the main mediator of tumor-induced immunosuppressive phenotype of macrophages.  Furthermore, we show in human tumor xenografts that RP6530 repolarizes TAMs into proinflammatory macrophages and inhibits tumor vasculature, leading to tumor regression.  Interestingly, patients with Hodgkin lymphoma experiencing objective responses (complete response and partial response) in a phase I trial using RP6530 showed a significant inhibition of circulating myeloid-derived suppressor cells and an av. mean redn. in serum thymus and activation-regulated chemokine levels of 40% (range, 4%-76%).  Conclusions: Our results support PI3Kδ/γ inhibition as a novel therapeutic strategy that targets both malignant cells and the TME to treat patients with Hodgkin lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAqk8NCT8DkbVg90H21EOLACvtfcHk0lhEz-r9yzkwuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Kntr7E&md5=9f612e6aa256af3ef9c542855312d6b9</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1133%26sid%3Dliteratum%253Aachs%26aulast%3DLocatelli%26aufirst%3DS.%2BL.%26aulast%3DCareddu%26aufirst%3DG.%26aulast%3DSerio%26aufirst%3DS.%26aulast%3DConsonni%26aufirst%3DF.%2BM.%26aulast%3DMaeda%26aufirst%3DA.%26aulast%3DViswanadha%26aufirst%3DS.%26aulast%3DVakkalanka%26aufirst%3DS.%26aulast%3DCastagna%26aufirst%3DL.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DAllavena%26aufirst%3DP.%26aulast%3DSica%26aufirst%3DA.%26aulast%3DCarlo-Stella%26aufirst%3DC.%26atitle%3DTargeting%2520Cancer%2520Cells%2520and%2520Tumor%2520Microenvironment%2520in%2520Preclinical%2520and%2520Clinical%2520Models%2520of%2520Hodgkin%2520Lymphoma%2520Using%2520the%2520Dual%2520PI3K%2520%25CE%25B4%2520%252F%2520%25CE%25B3%2520Inhibitor%2520RP6530%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D1098%26epage%3D1112%26doi%3D10.1158%2F1078-0432.ccr-18-1133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobinai, K.</span></span> <span> </span><span class="NLM_article-title">Development of New Agents for Peripheral T-cell Lymphoma</span>. <i>Expet Opin. Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">209</span>, <span class="refDoi"> DOI: 10.1080/14712598.2019.1572746</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1080%2F14712598.2019.1572746" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=30658046" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=197-209&author=Y.+Itoauthor=S.+Makitaauthor=K.+Tobinai&title=Development+of+New+Agents+for+Peripheral+T-cell+Lymphoma&doi=10.1080%2F14712598.2019.1572746"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F14712598.2019.1572746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14712598.2019.1572746%26sid%3Dliteratum%253Aachs%26aulast%3DIto%26aufirst%3DY.%26aulast%3DMakita%26aufirst%3DS.%26aulast%3DTobinai%26aufirst%3DK.%26atitle%3DDevelopment%2520of%2520New%2520Agents%2520for%2520Peripheral%2520T-cell%2520Lymphoma%26jtitle%3DExpet%2520Opin.%2520Biol.%2520Ther.%26date%3D2019%26volume%3D19%26spage%3D197%26epage%3D209%26doi%3D10.1080%2F14712598.2019.1572746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cushing, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duquette, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Lopez
de Turiso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henne, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hungate, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattaropong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettus, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichelt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzasa, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seganish, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tasker, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wannberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whoriskey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalameda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, D. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and In Vivo Evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG 319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">480</span>– <span class="NLM_lpage">511</span>, <span class="refDoi"> DOI: 10.1021/jm501624r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501624r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegur%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=480-511&author=T.+D.+Cushingauthor=X.+Haoauthor=Y.+Shinauthor=K.+Andrewsauthor=M.+Brownauthor=M.+Cardozoauthor=Y.+Chenauthor=J.+Duquetteauthor=B.+Fisherauthor=F.+Gonzalez-Lopez%0Ade+Turisoauthor=X.+Heauthor=K.+R.+Henneauthor=Y.-L.+Huauthor=R.+Hungateauthor=M.+G.+Johnsonauthor=R.+C.+Kellyauthor=B.+Lucasauthor=J.+D.+McCarterauthor=L.+R.+McGeeauthor=J.+C.+Medinaauthor=T.+San+Miguelauthor=D.+Mohnauthor=V.+Pattaropongauthor=L.+H.+Pettusauthor=A.+Reicheltauthor=R.+M.+Rzasaauthor=J.+Seganishauthor=A.+S.+Taskerauthor=R.+C.+Wahlauthor=S.+Wannbergauthor=D.+A.+Whittingtonauthor=J.+Whoriskeyauthor=G.+Yuauthor=L.+Zalamedaauthor=D.+Zhangauthor=D.+P.+Metz&title=Discovery+and+In+Vivo+Evaluation+of+%28S%29-N-%281-%287-fluoro-2-%28pyridin-2-yl%29quinolin-3-yl%29ethyl%29-9H-purin-6-amine+%28AMG+319%29+and+Related+PI3K%CE%B4+Inhibitors+for+Inflammation+and+Autoimmune+Disease&doi=10.1021%2Fjm501624r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and in Vivo Evaluation of (S)-N-(1-(7-Fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and Related PI3Kδ Inhibitors for Inflammation and Autoimmune Disease</span></div><div class="casAuthors">Cushing, Timothy D.; Hao, Xiaolin; Shin, Youngsook; Andrews, Kristin; Brown, Matthew; Cardozo, Mario; Chen, Yi; Duquette, Jason; Fisher, Ben; Gonzalez-Lopez de Turiso, Felix; He, Xiao; Henne, Kirk R.; Hu, Yi-Ling; Hungate, Randall; Johnson, Michael G.; Kelly, Ron C.; Lucas, Brian; McCarter, John D.; McGee, Lawrence R.; Medina, Julio C.; San Miguel, Tisha; Mohn, Deanna; Pattaropong, Vatee; Pettus, Liping H.; Reichelt, Andreas; Rzasa, Robert M.; Seganish, Jennifer; Tasker, Andrew S.; Wahl, Robert C.; Wannberg, Sharon; Whittington, Douglas A.; Whoriskey, John; Yu, Gang; Zalameda, Leeanne; Zhang, Dawei; Metz, Daniela P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">480-511</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The development and optimization of a series of quinolinylpurines as potent and selective PI3Kδ kinase inhibitors with excellent physicochem. properties are described.  This medicinal chem. effort led to the identification of I (AMG319), a compd. with an IC50 of 16 nM in a human whole blood assay (HWB), excellent selectivity over a large panel of protein kinases, and a high level of in vivo efficacy as measured by two rodent disease models of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt3BtsoY7G2rVg90H21EOLACvtfcHk0lg5nOrJ4aYKEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegur%252FL&md5=08af48a5c6208d6f61bea77e9ad840aa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm501624r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501624r%26sid%3Dliteratum%253Aachs%26aulast%3DCushing%26aufirst%3DT.%2BD.%26aulast%3DHao%26aufirst%3DX.%26aulast%3DShin%26aufirst%3DY.%26aulast%3DAndrews%26aufirst%3DK.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DDuquette%26aufirst%3DJ.%26aulast%3DFisher%26aufirst%3DB.%26aulast%3DGonzalez-Lopez%2Bde%2BTuriso%26aufirst%3DF.%26aulast%3DHe%26aufirst%3DX.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DHu%26aufirst%3DY.-L.%26aulast%3DHungate%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DM.%2BG.%26aulast%3DKelly%26aufirst%3DR.%2BC.%26aulast%3DLucas%26aufirst%3DB.%26aulast%3DMcCarter%26aufirst%3DJ.%2BD.%26aulast%3DMcGee%26aufirst%3DL.%2BR.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DMohn%26aufirst%3DD.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DPettus%26aufirst%3DL.%2BH.%26aulast%3DReichelt%26aufirst%3DA.%26aulast%3DRzasa%26aufirst%3DR.%2BM.%26aulast%3DSeganish%26aufirst%3DJ.%26aulast%3DTasker%26aufirst%3DA.%2BS.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWannberg%26aufirst%3DS.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWhoriskey%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DG.%26aulast%3DZalameda%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DMetz%26aufirst%3DD.%2BP.%26atitle%3DDiscovery%2520and%2520In%2520Vivo%2520Evaluation%2520of%2520%2528S%2529-N-%25281-%25287-fluoro-2-%2528pyridin-2-yl%2529quinolin-3-yl%2529ethyl%2529-9H-purin-6-amine%2520%2528AMG%2520319%2529%2520and%2520Related%2520PI3K%25CE%25B4%2520Inhibitors%2520for%2520Inflammation%2520and%2520Autoimmune%2520Disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D480%26epage%3D511%26doi%3D10.1021%2Fjm501624r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, L.-h.</span></span> <span> </span><span class="NLM_article-title">PI3K Isoform-selective Inhibitors: Next-generation Targeted Cancer Therapies</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1170</span>– <span class="NLM_lpage">1176</span>, <span class="refDoi"> DOI: 10.1038/aps.2015.71</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1038%2Faps.2015.71" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=26364801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Wls7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=1170-1176&author=X.+Wangauthor=J.+Dingauthor=L.-h.+Meng&title=PI3K+Isoform-selective+Inhibitors%3A+Next-generation+Targeted+Cancer+Therapies&doi=10.1038%2Faps.2015.71"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K isoform-selective inhibitors: next-generation targeted cancer therapies</span></div><div class="casAuthors">Wang, Xiang; Ding, Jian; Meng, Ling-hua</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1170-1176</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pivotal roles of phosphatidylinositol 3-kinases (PI3Ks) in human cancers have inspired active development of small mols. to inhibit these lipid kinases.  However, the first-generation pan-PI3K and dual-PI3K/mTOR inhibitors have encountered problems in clin. trials, with limited efficacies as a monotherapeutic agent as well as a relatively high rate of side effects.  It is increasingly recognized that different PI3K isoforms play non-redundant roles in particular tumor types, which has prompted the development of isoform-selective inhibitors for pre-selected patients with the aim for improving efficacy while decreasing undesirable side effects.  The success of PI3K isoform-selective inhibitors is represented by CAL101 (Idelalisib), a first-in-class PI3Kδ-selective small-mol. inhibitor that has been approved by the FDA for the treatment of chronic lymphocytic leukemia, indolent B-cell non-Hodgkin's lymphoma and relapsed small lymphocytic lymphoma.  Inhibitors targeting other PI3K isoforms are also being extensively developed.  This review focuses on the recent progress in development of PI3K isoform-selective inhibitors for cancer therapy.  A deeper understanding of the action modes of novel PI3K isoform-selective inhibitors will provide valuable information to further validate the concept of targeting specific PI3K isoforms, while the identification of biomarkers to stratify patients who are likely to benefit from the therapy will be essential for the success of these agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwF2MuL2qax7Vg90H21EOLACvtfcHk0lg5nOrJ4aYKEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Wls7jN&md5=1cad476e2913a827be1d9c4a0294e519</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Faps.2015.71&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Faps.2015.71%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DL.-h.%26atitle%3DPI3K%2520Isoform-selective%2520Inhibitors%253A%2520Next-generation%2520Targeted%2520Cancer%2520Therapies%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2015%26volume%3D36%26spage%3D1170%26epage%3D1176%26doi%3D10.1038%2Faps.2015.71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenwell, I. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, J. B.</span></span> <span> </span><span class="NLM_article-title">PI3K Inhibitors: Understanding Toxicity Mechanisms and Management</span>. <i>Oncology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">828</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=29179250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ltlGntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=821-828&author=I.+B.+Greenwellauthor=A.+Ipauthor=J.+B.+Cohen&title=PI3K+Inhibitors%3A+Understanding+Toxicity+Mechanisms+and+Management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">PI3K Inhibitors: Understanding Toxicity Mechanisms and Management</span></div><div class="casAuthors">Greenwell I Brian; Ip Andrew; Cohen Jonathon B</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">821-8</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K) pathway has attracted immense interest as a therapeutic target for cancer treatment.  Idelalisib was the first PI3K inhibitor approved by the US Food and Drug Administration and is utilized in the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma.  Copanlisib has subsequently been approved for relapsed follicular lymphoma in patients who have received at least two prior systemic therapies.  There are multiple other PI3K agents currently in development; these target various combinations of PI3K isoforms.  Despite the therapeutic benefit, there have been concerns about the severe and sometimes fatal adverse effects of this class of drug.  Several side effects are unusual and have poorly understood mechanisms; these include autoimmune dysfunction, opportunistic infections, skin toxicity, hypertension, and hyperglycemia.  An understanding of these unusual toxicities, as well as a good grasp of management principles, will be important as more PI3K inhibitors are approved and become incorporated into routine practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5yvT6h5ErjpQHPYJuLg8TfW6udTcc2eYa1VNjyXk6ILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ltlGntA%253D%253D&md5=6c477dd4ae70ee2393283cd0b43ec885</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwell%26aufirst%3DI.%2BB.%26aulast%3DIp%26aufirst%3DA.%26aulast%3DCohen%26aufirst%3DJ.%2BB.%26atitle%3DPI3K%2520Inhibitors%253A%2520Understanding%2520Toxicity%2520Mechanisms%2520and%2520Management%26jtitle%3DOncology%26date%3D2017%26volume%3D31%26spage%3D821%26epage%3D828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Safina, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisconte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrera, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flagella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heald, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nonomiya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seward, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherlin, D. P.</span></span> <span> </span><span class="NLM_article-title">Identification of GNE-293, a Potent and Selective PI3K delta Inhibitor: Navigating In Vitro Genotoxicity while Improving Potency and Selectivity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4953</span>– <span class="NLM_lpage">4959</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.bmcl.2013.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=23867164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4953-4959&author=B.+S.+Safinaauthor=Z.+K.+Sweeneyauthor=J.+Liauthor=B.+K.+Chanauthor=A.+Bisconteauthor=D.+Carreraauthor=G.+Castanedoauthor=M.+Flagellaauthor=R.+Healdauthor=C.+Lewisauthor=J.+M.+Murrayauthor=J.+Nonomiyaauthor=J.+Pangauthor=S.+Priceauthor=K.+Reifauthor=L.+Salphatiauthor=E.+M.+Sewardauthor=B.+Weiauthor=D.+P.+Sutherlin&title=Identification+of+GNE-293%2C+a+Potent+and+Selective+PI3K+delta+Inhibitor%3A+Navigating+In+Vitro+Genotoxicity+while+Improving+Potency+and+Selectivity&doi=10.1016%2Fj.bmcl.2013.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GNE-293, a potent and selective PI3Kδ inhibitor: Navigating in vitro genotoxicity while improving potency and selectivity</span></div><div class="casAuthors">Safina, Brian S.; Sweeney, Zachary K.; Li, Jun; Chan, Bryan K.; Bisconte, Angelina; Carrera, Diane; Castanedo, Georgette; Flagella, Michael; Heald, Robert; Lewis, Cristina; Murray, Jeremy M.; Nonomiya, Jim; Pang, Jodie; Price, Steve; Reif, Karin; Salphati, Laurent; Seward, Eileen M.; Wei, Binqing; Sutherlin, Daniel P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4953-4959</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In an effort to identify potent and isoform selective inhibitors of PI3Kδ, GNE-293 was identified.  Inhibitor 2 was found to induce micronuclei formation in both the MNT and HCA in vitro assays.  Compds. testing neg. for genotoxicity were successfully identified through modifications of the 2-benzimidazole substituent and the methylene moiety to disrupt planarity.  A variety of heteroatom linkers were explored to examine their effect on potency and isoform selectivity by restricting torsional angles to favor ligand interactions with PI3Kδ's Trp 760.  These modifications also resulted in an improved in vivo pharmacokinetic profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeYyeZOKH5CrVg90H21EOLACvtfcHk0ljXKMugeD2-EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltLbO&md5=c1aac13409cb5f33390cf98d689dabc3</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DSafina%26aufirst%3DB.%2BS.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DB.%2BK.%26aulast%3DBisconte%26aufirst%3DA.%26aulast%3DCarrera%26aufirst%3DD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DLewis%26aufirst%3DC.%26aulast%3DMurray%26aufirst%3DJ.%2BM.%26aulast%3DNonomiya%26aufirst%3DJ.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSeward%26aufirst%3DE.%2BM.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DSutherlin%26aufirst%3DD.%2BP.%26atitle%3DIdentification%2520of%2520GNE-293%252C%2520a%2520Potent%2520and%2520Selective%2520PI3K%2520delta%2520Inhibitor%253A%2520Navigating%2520In%2520Vitro%2520Genotoxicity%2520while%2520Improving%2520Potency%2520and%2520Selectivity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4953%26epage%3D4959%26doi%3D10.1016%2Fj.bmcl.2013.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forseth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashishian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koppenol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">Discovery of Orally Efficacious Phosphoinositide 3-Kinaseδ Inhibitors with Improved Metabolic Stability</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9228</span>– <span class="NLM_lpage">9242</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01169</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01169" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGrs7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9228-9242&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=K.+Forsethauthor=A.+C.+Haranauthor=C.+Ipauthor=A.+Kashishianauthor=M.+Kimauthor=D.+Koditekauthor=S.+Koppenolauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=S.+Perreaultauthor=K.+D.+Puriauthor=A.+G.+Villase%C3%B1orauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=J.+Therrienauthor=J.+Treibergauthor=G.+Phillips&title=Discovery+of+Orally+Efficacious+Phosphoinositide+3-Kinase%CE%B4+Inhibitors+with+Improved+Metabolic+Stability&doi=10.1021%2Facs.jmedchem.6b01169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability</span></div><div class="casAuthors">Patel, Leena; Chandrasekhar, Jayaraman; Evarts, Jerry; Forseth, Kristen; Haran, Aaron C.; Ip, Carmen; Kashishian, Adam; Kim, Musong; Koditek, David; Koppenol, Sandy; Lad, Latesh; Lepist, Eve-Irene; McGrath, Mary E.; Perreault, Stephane; Puri, Kamal D.; Villasenor, Armando G.; Somoza, John R.; Steiner, Bart H.; Therrien, Joseph; Treiberg, Jennifer; Phillips, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9228-9242</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant signaling of phosphoinositide-3-kinase delta (PI3K-delta) has been implicated in numerous pathologies including hematol. malignancies and rheumatoid arthritis.  Described in this manuscript is the discovery, optimization and in vivo evaluation of a novel series of pyridine-contg. PI3K-delta inhibitors.  This work led to the discovery of I, a highly selective inhibitor of PI3K-delta which displays an excellent pharmacokinetic profile and is efficacious in a rodent model of rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LgrP9YV8frVg90H21EOLACvtfcHk0ljXKMugeD2-EQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGrs7rF&md5=6d9dff0ec5270aab250fcb4800d8635a</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01169%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DForseth%26aufirst%3DK.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKashishian%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DKoppenol%26aufirst%3DS.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Orally%2520Efficacious%2520Phosphoinositide%25203-Kinase%25CE%25B4%2520Inhibitors%2520with%2520Improved%2520Metabolic%2520Stability%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9228%26epage%3D9242%26doi%3D10.1021%2Facs.jmedchem.6b01169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandrasekhar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evarts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haran, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ip, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koditek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lad, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepist, E.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novikov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perreault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Therrien, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villaseñor, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillips, G.</span></span> <span> </span><span class="NLM_article-title">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">3532</span>– <span class="NLM_lpage">3548</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00213</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00213" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC28Xkt1CgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=3532-3548&author=L.+Patelauthor=J.+Chandrasekharauthor=J.+Evartsauthor=A.+C.+Haranauthor=C.+Ipauthor=J.+A.+Kaplanauthor=M.+Kimauthor=D.+Koditekauthor=L.+Ladauthor=E.-I.+Lepistauthor=M.+E.+McGrathauthor=N.+Novikovauthor=S.+Perreaultauthor=K.+D.+Puriauthor=J.+R.+Somozaauthor=B.+H.+Steinerauthor=J.+Therrienauthor=J.+Treibergauthor=A.+G.+Villase%C3%B1orauthor=A.+Yeungauthor=G.+Phillipsauthor=A.+Yeungauthor=G.+Phillips&title=2%2C4%2C6-Triaminopyrimidine+as+a+Novel+Hinge+Binder+in+a+Series+of+PI3K%CE%B4+Selective+Inhibitors&doi=10.1021%2Facs.jmedchem.6b00213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">2,4,6-Triaminopyrimidine as a Novel Hinge Binder in a Series of PI3Kδ Selective Inhibitors</span></div><div class="casAuthors">Patel, Leena; Chandrasekhar, Jayaraman; Evarts, Jerry; Haran, Aaron C.; Ip, Carmen; Kaplan, Joshua A.; Kim, Musong; Koditek, David; Lad, Latesh; Lepist, Eve-Irene; McGrath, Mary E.; Novikov, Nikolai; Perreault, Stephane; Puri, Kamal D.; Somoza, John R.; Steiner, Bart H.; Stevens, Kirk L.; Therrien, Joseph; Treiberg, Jennifer; Villasenor, Armando G.; Yeung, Arthur; Phillips, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3532-3548</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of phosphoinositide 3-kinase δ (PI3Kδ) is an appealing target for several hematol. malignancies and inflammatory diseases.  Herein, we describe the discovery and optimization of a series of propeller shaped PI3Kδ inhibitors comprising a novel triaminopyrimidine hinge binder.  Combinations of electronic and structural strategies were employed to mitigate aldehyde oxidase mediated metab.  This medicinal chem. effort culminated in the identification of 52, a potent and highly selective inhibitor of PI3Kδ that demonstrates efficacy in a rat model of arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpygPlHbWp_TLVg90H21EOLACvtfcHk0lhgRdnuDfgnwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xkt1CgtL4%253D&md5=9e01fff097eccd127a9b9284d725d7e1</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00213%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DL.%26aulast%3DChandrasekhar%26aufirst%3DJ.%26aulast%3DEvarts%26aufirst%3DJ.%26aulast%3DHaran%26aufirst%3DA.%2BC.%26aulast%3DIp%26aufirst%3DC.%26aulast%3DKaplan%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DKoditek%26aufirst%3DD.%26aulast%3DLad%26aufirst%3DL.%26aulast%3DLepist%26aufirst%3DE.-I.%26aulast%3DMcGrath%26aufirst%3DM.%2BE.%26aulast%3DNovikov%26aufirst%3DN.%26aulast%3DPerreault%26aufirst%3DS.%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSteiner%26aufirst%3DB.%2BH.%26aulast%3DTherrien%26aufirst%3DJ.%26aulast%3DTreiberg%26aufirst%3DJ.%26aulast%3DVillase%25C3%25B1or%26aufirst%3DA.%2BG.%26aulast%3DYeung%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26aulast%3DYeung%26aufirst%3DA.%26aulast%3DPhillips%26aufirst%3DG.%26atitle%3D2%252C4%252C6-Triaminopyrimidine%2520as%2520a%2520Novel%2520Hinge%2520Binder%2520in%2520a%2520Series%2520of%2520PI3K%25CE%25B4%2520Selective%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D3532%26epage%3D3548%26doi%3D10.1021%2Facs.jmedchem.6b00213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, M. W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdulai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mogemark, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valastro, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westin Eriksson, A.</span></span> <span> </span><span class="NLM_article-title">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4783</span>– <span class="NLM_lpage">4814</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFOrsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4783-4814&author=M.+W.+D.+Perryauthor=R.+Abdulaiauthor=M.+Mogemarkauthor=J.+Petersenauthor=M.+J.+Thomasauthor=B.+Valastroauthor=A.+Westin+Eriksson&title=Evolution+of+PI3K%CE%B3+and+%CE%B4+Inhibitors+for+Inflammatory+and+Autoimmune+Diseases&doi=10.1021%2Facs.jmedchem.8b01298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases</span></div><div class="casAuthors">Perry, Matthew W. D.; Abdulai, Raolat; Mogemark, Mickael; Petersen, Jens; Thomas, Matthew J.; Valastro, Barbara; Westin Eriksson, Annika</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4783-4814</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositol 3-kinases (PI3Ks) γ and δ are key enzymes in hematopoietic cells and have been seen as high-value targets for the treatment of diseases with inflammatory and immunomodulatory components since their discovery and the identification of their roles.  In this Perspective we review progress in the application of inhibitors of PI3Kγ and δ to inflammatory and immunol. conditions over the past 6 years.  We consider progress in the understanding of the roles of PI3Kγ and PI3Kδ in immunol. and inflammation, the experience from clin. trials where inhibitors have been tested, and what has been learned about the safety of their use.  The extensive medicinal chem. efforts to discover both isoform selective and dual PI3Kγδ inhibitors are analyzed and detailed.  Developments in understanding the structural chem. of the PI3K enzymes and the factors that govern isoform selectivity are discussed.  The effects obsd. with the known inhibitor compds. in animal models are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5tJy6u73_7bVg90H21EOLACvtfcHk0lhgRdnuDfgnwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFOrsr7O&md5=2b5cdec8135ee6ebd94624b9a675c889</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01298%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DM.%2BW.%2BD.%26aulast%3DAbdulai%26aufirst%3DR.%26aulast%3DMogemark%26aufirst%3DM.%26aulast%3DPetersen%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DM.%2BJ.%26aulast%3DValastro%26aufirst%3DB.%26aulast%3DWestin%2BEriksson%26aufirst%3DA.%26atitle%3DEvolution%2520of%2520PI3K%25CE%25B3%2520and%2520%25CE%25B4%2520Inhibitors%2520for%2520Inflammatory%2520and%2520Autoimmune%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4783%26epage%3D4814%26doi%3D10.1021%2Facs.jmedchem.8b01298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span> <span> </span><span class="NLM_article-title">Research Advances on Selective Phosphatidylinositol 3 Kinase δ (PI3Kδ) Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127457</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.bmcl.2020.127457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=32755681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Cqs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127457&author=J.+Sunauthor=Y.+Fengauthor=Y.+Huangauthor=S.-Q.+Zhangauthor=M.+Xin&title=Research+Advances+on+Selective+Phosphatidylinositol+3+Kinase+%CE%B4+%28PI3K%CE%B4%29+Inhibitors&doi=10.1016%2Fj.bmcl.2020.127457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Research advances on selective phosphatidylinositol 3 kinase δ (PI3Kδ) inhibitors</span></div><div class="casAuthors">Sun, Jiajia; Feng, Yifan; Huang, Yuan; Zhang, San-Qi; Xin, Minhang</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">127457</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">PI3Kδ in B cells mediates antigen receptor signaling and promote neutrophil chemotaxis.  The activation of PI3Kδ can cause mast cell maturation and degranulation, myeloid cell dysfunction, and cytokine release.  As a key signal mol., PI3Kδ interacts with the lipid binding domain of a variety of cellular proteins as a secondary messenger, ultimately affecting a series of significant cellular pathways in disease pathol.  Therefore, many research organizations and pharmaceutical companies have studied it to develop effectively selective PI3Kδ inhibitors as therapeutics.  This review summarizes research advances in varying chem. classes of selective PI3Kδ inhibitors and the structure-activity relationship, and it mainly focuses on the propeller- vs. flat-type class of inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ4GqJhaS2erVg90H21EOLACvtfcHk0lims8ihiumsRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Cqs7fO&md5=b5f66fba4412dd592b34e803ae2d6edb</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127457%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.-Q.%26aulast%3DXin%26aufirst%3DM.%26atitle%3DResearch%2520Advances%2520on%2520Selective%2520Phosphatidylinositol%25203%2520Kinase%2520%25CE%25B4%2520%2528PI3K%25CE%25B4%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127457%26doi%3D10.1016%2Fj.bmcl.2020.127457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paul, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soujon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wengner, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitzmann-Kolbe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haike, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keng Magdalene, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mumberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziegelbauer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span> <span> </span><span class="NLM_article-title">Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-dependent and -Independent Activation of NF-kB and AKT</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">64</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.12.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2Fj.ccell.2016.12.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=28073005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2017&pages=64-78&author=J.+Paulauthor=M.+Soujonauthor=A.+M.+Wengnerauthor=S.+Zitzmann-Kolbeauthor=A.+Sturzauthor=K.+Haikeauthor=K.+H.+Keng+Magdaleneauthor=S.+H.+Tanauthor=M.+Langeauthor=S.+Y.+Tanauthor=D.+Mumbergauthor=S.+T.+Limauthor=K.+Ziegelbauerauthor=N.+Liu&title=Simultaneous+Inhibition+of+PI3K%CE%B4+and+PI3K%CE%B1+Induces+ABC-DLBCL+Regression+by+Blocking+BCR-dependent+and+-Independent+Activation+of+NF-kB+and+AKT&doi=10.1016%2Fj.ccell.2016.12.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT</span></div><div class="casAuthors">Paul, Juliane; Soujon, Maurice; Wengner, Antje M.; Zitzmann-Kolbe, Sabine; Sturz, Andrea; Haike, Katja; Keng Magdalene, Koh Hui; Tan, Sze Huey; Lange, Martin; Tan, Soo Yong; Mumberg, Dominik; Lim, Soon Thye; Ziegelbauer, Karl; Liu, Ningshu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-78</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Compared with follicular lymphoma, high PI3Kα expression was more prevalent in diffuse large B cell lymphoma (DLBCL), although both tumor types expressed substantial PI3Kδ.  Simultaneous inhibition of PI3Kα and PI3Kδ dramatically enhanced the anti-tumor profile in ABC-DLBCL models compared with selective inhibition of PI3Kδ, PI3Kα, or BTK.  The anti-tumor activity was assocd. with suppression of p-AKT and a mechanism of blocking nuclear factor-κB activation driven by CD79mut, CARD11mut, TNFAIP3mut, or MYD88mut.  Inhibition of PI3Kα/δ resulted in tumor regression in an ibrutinib-resistant CD79BWT/MYD88mut patient-derived ABC-DLBCL model.  Furthermore, rebound activation of BTK and AKT was identified as a mechanism limiting CD79Bmut-ABC-DLBCL to show a robust response to PI3K and BTK inhibitor monotherapies.  A combination of ibrutinib with the PI3Kα/δ inhibitor copanlisib produced a sustained complete response in vivo in CD79Bmut/MYD88mut ABC-DLBCL models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyz2h-CoWtgLVg90H21EOLACvtfcHk0lims8ihiumsRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlKnsA%253D%253D&md5=6d8a64b0b75fdd0dc0519fdb19d71574</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.12.003%26sid%3Dliteratum%253Aachs%26aulast%3DPaul%26aufirst%3DJ.%26aulast%3DSoujon%26aufirst%3DM.%26aulast%3DWengner%26aufirst%3DA.%2BM.%26aulast%3DZitzmann-Kolbe%26aufirst%3DS.%26aulast%3DSturz%26aufirst%3DA.%26aulast%3DHaike%26aufirst%3DK.%26aulast%3DKeng%2BMagdalene%26aufirst%3DK.%2BH.%26aulast%3DTan%26aufirst%3DS.%2BH.%26aulast%3DLange%26aufirst%3DM.%26aulast%3DTan%26aufirst%3DS.%2BY.%26aulast%3DMumberg%26aufirst%3DD.%26aulast%3DLim%26aufirst%3DS.%2BT.%26aulast%3DZiegelbauer%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DN.%26atitle%3DSimultaneous%2520Inhibition%2520of%2520PI3K%25CE%25B4%2520and%2520PI3K%25CE%25B1%2520Induces%2520ABC-DLBCL%2520Regression%2520by%2520Blocking%2520BCR-dependent%2520and%2520-Independent%2520Activation%2520of%2520NF-kB%2520and%2520AKT%26jtitle%3DCancer%2520Cell%26date%3D2017%26volume%3D31%26spage%3D64%26epage%3D78%26doi%3D10.1016%2Fj.ccell.2016.12.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klener, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vočková, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinsky, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuskova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polanska, U. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfeifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdmann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwammbach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapukhlyak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staiger, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdel, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruzalegui, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trneny, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, G.</span></span> <span> </span><span class="NLM_article-title">Sensitivity to PI3K and AKT Inhibitors is Mediated by Divergent Molecular Mechanisms in Subtypes of DLBCL</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">310</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-12-758599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1182%2Fblood-2016-12-758599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=28202458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1aqsrbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2017&pages=310-322&author=T.+Erdmannauthor=P.+Klenerauthor=J.+T.+Lynchauthor=M.+Grauauthor=P.+Vo%C4%8Dkov%C3%A1author=J.+Molinskyauthor=D.+Tuskovaauthor=K.+Hudsonauthor=U.+M.+Polanskaauthor=M.+Grondineauthor=M.+Mayoauthor=B.+Daiauthor=M.+Pfeiferauthor=K.+Erdmannauthor=D.+Schwammbachauthor=M.+Zapukhlyakauthor=A.+M.+Staigerauthor=G.+Ottauthor=W.+E.+Berdelauthor=B.+R.+Daviesauthor=F.+Cruzaleguiauthor=M.+Trnenyauthor=P.+Lenzauthor=S.+T.+Barryauthor=G.+Lenz&title=Sensitivity+to+PI3K+and+AKT+Inhibitors+is+Mediated+by+Divergent+Molecular+Mechanisms+in+Subtypes+of+DLBCL&doi=10.1182%2Fblood-2016-12-758599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sensitivity to pi3k and akt inhibitors is mediated by divergent molecular mechanisms in subtypes of dlbcl</span></div><div class="casAuthors">Erdmann, Tabea; Klener, Pavel; Lynch, James T.; Grau, Michael; Vockova, Petra; Molinsky, Jan; Tuskova, Diana; Hudson, Kevin; Polanska, Urszula M.; Grondine, Michael; Mayo, Michele; Dai, Beiying; Pfeifer, Matthias; Erdmann, Kristian; Schwammbach, Daniela; Zapukhlyak, Myroslav; Staiger, Annette M.; Ott, German; Berdel, Wolfgang E.; Davies, Barry R.; Cruzalegui, Francisco; Trneny, Marek; Lenz, Peter; Barry, Simon T.; Lenz, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">310-322</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Activated B-cell-like (ABC) and germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL) represent the 2 major mol. DLBCL subtypes.  They are characterized by differences in clin. course and by divergent addiction to oncogenic pathways.  To det. activity of novel compds. in these 2 subtypes, we conducted an unbiased pharmacol. in vitro screen.  The phosphatidylinositol-3-kinase (PI3K) α/δ (PI3Kα/δ) inhibitor AZD8835 showed marked potency in ABC DLBCL models, whereas the protein kinase B (AKT) inhibitor AZD5363 induced apoptosis in PTEN-deficient DLBCLs irresp. of their mol. subtype.  These in vitro results were confirmed in various cell line xenograft and patient-derived xenograft mouse models in vivo.  Treatment with AZD8835 induced inhibition of nuclear factor kB signaling, prompting us to combine AZD8835 with the Bruton's tyrosine kinase inhibitor ibrutinib.  This combination was synergistic and effective both in vitro and in vivo.  In contrast, the AKT inhibitor AZD5363 was effective in PTEN-deficient DLBCLs through downregulation of the oncogenic transcription factor MYC.  Collectively, our data suggest that patients should be stratified according to their oncogenic dependencies when treated with PI3K and AKT inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob70la9gAU37Vg90H21EOLACvtfcHk0lims8ihiumsRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1aqsrbF&md5=fafbe3848dac87502bb52d580c90b8d5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-12-758599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-12-758599%26sid%3Dliteratum%253Aachs%26aulast%3DErdmann%26aufirst%3DT.%26aulast%3DKlener%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DJ.%2BT.%26aulast%3DGrau%26aufirst%3DM.%26aulast%3DVo%25C4%258Dkov%25C3%25A1%26aufirst%3DP.%26aulast%3DMolinsky%26aufirst%3DJ.%26aulast%3DTuskova%26aufirst%3DD.%26aulast%3DHudson%26aufirst%3DK.%26aulast%3DPolanska%26aufirst%3DU.%2BM.%26aulast%3DGrondine%26aufirst%3DM.%26aulast%3DMayo%26aufirst%3DM.%26aulast%3DDai%26aufirst%3DB.%26aulast%3DPfeifer%26aufirst%3DM.%26aulast%3DErdmann%26aufirst%3DK.%26aulast%3DSchwammbach%26aufirst%3DD.%26aulast%3DZapukhlyak%26aufirst%3DM.%26aulast%3DStaiger%26aufirst%3DA.%2BM.%26aulast%3DOtt%26aufirst%3DG.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DDavies%26aufirst%3DB.%2BR.%26aulast%3DCruzalegui%26aufirst%3DF.%26aulast%3DTrneny%26aufirst%3DM.%26aulast%3DLenz%26aufirst%3DP.%26aulast%3DBarry%26aufirst%3DS.%2BT.%26aulast%3DLenz%26aufirst%3DG.%26atitle%3DSensitivity%2520to%2520PI3K%2520and%2520AKT%2520Inhibitors%2520is%2520Mediated%2520by%2520Divergent%2520Molecular%2520Mechanisms%2520in%2520Subtypes%2520of%2520DLBCL%26jtitle%3DBlood%26date%3D2017%26volume%3D130%26spage%3D310%26epage%3D322%26doi%3D10.1182%2Fblood-2016-12-758599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000AdminCorres.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211155Orig1Orig2s000AdminCorres.pdf</a> (accessed Oct 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2018%2F211155Orig1Orig2s000AdminCorres.pdf+%28accessed+Oct+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, D. J.</span>; <span class="NLM_string-name">O’Farrell, M.</span>; <span class="NLM_string-name">Ventura, R.</span>; <span class="NLM_string-name">Brown, S. D.</span>; <span class="NLM_string-name">Tai, A.</span></span> <i>Discovery of PI3K Delta Inhibitors for the Treatment of Inflammatory and Autoimmune Disease</i>; <span class="NLM_publisher-name">New York Academy of Sciences</span>, <span class="NLM_year">2012</span>, Meeting Poster.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=D.+J.+Matthews&author=M.+O%E2%80%99Farrell&author=R.+Ventura&author=S.+D.+Brown&author=A.+Tai&title=Discovery+of+PI3K+Delta+Inhibitors+for+the+Treatment+of+Inflammatory+and+Autoimmune+Disease"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DD.%2BJ.%26btitle%3DDiscovery%2520of%2520PI3K%2520Delta%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520and%2520Autoimmune%2520Disease%26pub%3DNew%2520York%2520Academy%2520of%2520Sciences%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit30c"><span><span class="NLM_label">(c) </span><a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205858Orig1s000Approv.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205858Orig1s000Approv.pdf</a> (accessed July 23, 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2014%2F205858Orig1s000Approv.pdf+%28accessed+July+23%2C+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Villieras, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rambaud, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, M.</span></span> <span> </span><span class="NLM_article-title">La reaction de wittig-horner en milieu heterogene VI1. Selectivite de la reaction sur des composes bifonctionnels</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(00)98464-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1016%2FS0040-4039%2800%2998464-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADyaL2MXhvVCrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1985&pages=53-56&author=J.+Villierasauthor=M.+Rambaudauthor=M.+Graff&title=La+reaction+de+wittig-horner+en+milieu+heterogene+VI1.+Selectivite+de+la+reaction+sur+des+composes+bifonctionnels&doi=10.1016%2Fs0040-4039%2800%2998464-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31aR"><div class="casContent"><span class="casTitleNuber">31a</span><div class="casTitle"><span class="NLM_cas:atitle">Wittig-Horner reaction in a heterogeneous medium.  VI.  Selectivity of the reaction on bifunctional compounds</span></div><div class="casAuthors">Villieras, Jean; Rambaud, Monique; Graff, Micheline</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">53-6</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    </div><div class="casAbstract">Heterogeneous liq.-liq. (K2CO3-H2O) or solid-liq. (K2CO3-PhMe) media of low basicity allow the Wittig-Horner reaction of fragile aldehydes and unprotected hydroxy, nitro and keto aldehydes to take place with excellent yields.  The reaction is applied to the synthesis of royal jelly acid [HO(CH2)7CH:CHCO2H] and queen substance of honey bee [MeCO(CH2)5CH:CHCO2H].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgQktw9krQ97Vg90H21EOLACvtfcHk0lhWKFxWCJLgQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXhvVCrtL0%253D&md5=654dea0b03731ff3b1ede3eed0689a1d</span></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2998464-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252998464-8%26sid%3Dliteratum%253Aachs%26aulast%3DVillieras%26aufirst%3DJ.%26aulast%3DRambaud%26aufirst%3DM.%26aulast%3DGraff%26aufirst%3DM.%26atitle%3DLa%2520reaction%2520de%2520wittig-horner%2520en%2520milieu%2520heterogene%2520VI1.%2520Selectivite%2520de%2520la%2520reaction%2520sur%2520des%2520composes%2520bifonctionnels%26jtitle%3DTetrahedron%2520Lett.%26date%3D1985%26volume%3D26%26spage%3D53%26epage%3D56%26doi%3D10.1016%2Fs0040-4039%2800%2998464-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ammetto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loreto, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliorini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmarelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tardella, P. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Functionalized Spiroaziridine-oxindoles from 3-Ylideneoxindoles An Easy Route to 3-(Aminoalkyl)oxindoles</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_fpage">6189</span>– <span class="NLM_lpage">6197</span>, <span class="refDoi"> DOI: 10.1002/ejoc.200900891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1002%2Fejoc.200900891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsV2msrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=6189-6197&author=I.+Ammettoauthor=T.+Gasperiauthor=M.+A.+Loretoauthor=A.+Miglioriniauthor=F.+Palmarelliauthor=P.+A.+Tardella&title=Synthesis+of+Functionalized+Spiroaziridine-oxindoles+from+3-Ylideneoxindoles+An+Easy+Route+to+3-%28Aminoalkyl%29oxindoles&doi=10.1002%2Fejoc.200900891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31bR"><div class="casContent"><span class="casTitleNuber">31b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Functionalized Spiroaziridine-oxindoles from 3-Ylideneoxindoles: An Easy Route to 3-(Aminoalkyl)oxindoles</span></div><div class="casAuthors">Ammetto, I.; Gasperi, T.; Loreto, M. Antonietta; Migliorini, A.; Palmarelli, F.; Tardella, P. Antonio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">6189-6197</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1434-193X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Novel potentially bioactive spiroaziridine-oxindoles, e.g., I, have been prepd. by treatment of easily accessible 3-ylideneoxindoles with N-{[(4-nitrophenyl)sulfonyl]oxy}carbamate (NsONHCO2Et) in the presence of CaO.  These compds. gave new 3-(aminoalkyl)oxindole derivs., e.g., II,through easy and regioselective reductive aziridine ring-opening reactions.  (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNnTyW-g9azLVg90H21EOLACvtfcHk0lgTD8CLKRWmTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsV2msrfJ&md5=529e6a3eb981bd69f5db94f4e7eabb47</span></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=10.1002%2Fejoc.200900891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.200900891%26sid%3Dliteratum%253Aachs%26aulast%3DAmmetto%26aufirst%3DI.%26aulast%3DGasperi%26aufirst%3DT.%26aulast%3DLoreto%26aufirst%3DM.%2BA.%26aulast%3DMigliorini%26aufirst%3DA.%26aulast%3DPalmarelli%26aufirst%3DF.%26aulast%3DTardella%26aufirst%3DP.%2BA.%26atitle%3DSynthesis%2520of%2520Functionalized%2520Spiroaziridine-oxindoles%2520from%25203-Ylideneoxindoles%2520An%2520Easy%2520Route%2520to%25203-%2528Aminoalkyl%2529oxindoles%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2009%26spage%3D6189%26epage%3D6197%26doi%3D10.1002%2Fejoc.200900891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Linke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipinski, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gau, W.</span></span> <span> </span><span class="NLM_article-title">Annelation Reactions of N-Heterocycles to Condensed Pyridones with Bridgehead Nitrogen</span>. <i>Liebigs Ann. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>1980</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">556</span>, <span class="refDoi"> DOI: 10.1002/jlac.198019800408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=10.1002%2Fjlac.198019800408" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1980&publication_year=1980&pages=542-556&author=S.+Linkeauthor=J.+Kurzauthor=D.+Lipinskiauthor=W.+Gau&title=Annelation+Reactions+of+N-Heterocycles+to+Condensed+Pyridones+with+Bridgehead+Nitrogen&doi=10.1002%2Fjlac.198019800408"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fjlac.198019800408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjlac.198019800408%26sid%3Dliteratum%253Aachs%26aulast%3DLinke%26aufirst%3DS.%26aulast%3DKurz%26aufirst%3DJ.%26aulast%3DLipinski%26aufirst%3DD.%26aulast%3DGau%26aufirst%3DW.%26atitle%3DAnnelation%2520Reactions%2520of%2520N-Heterocycles%2520to%2520Condensed%2520Pyridones%2520with%2520Bridgehead%2520Nitrogen%26jtitle%3DLiebigs%2520Ann.%2520Chem.%26date%3D1980%26volume%3D1980%26spage%3D542%26epage%3D556%26doi%3D10.1002%2Fjlac.198019800408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagato, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norimine, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takenaka, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yonaga, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10584</span>– <span class="NLM_lpage">10600</span>, <span class="refDoi"> DOI: 10.1021/jm301268u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301268u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslalu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10584-10600&author=S.+Hibiauthor=K.+Uenoauthor=S.+Nagatoauthor=K.+Kawanoauthor=K.+Itoauthor=Y.+Norimineauthor=O.+Takenakaauthor=T.+Hanadaauthor=M.+Yonaga&title=Discovery+of+2-%282-Oxo-1-phenyl-5-pyridin-2-yl-1%2C2-dihydropyridin-3-yl%29benzonitrile+%28Perampanel%29%3A+A+Novel%2C+Noncompetitive+%CE%B1-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic+Acid+%28AMPA%29+Receptor+Antagonist&doi=10.1021%2Fjm301268u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist</span></div><div class="casAuthors">Hibi, Shigeki; Ueno, Koshi; Nagato, Satoshi; Kawano, Koki; Ito, Koichi; Norimine, Yoshihiko; Takenaka, Osamu; Hanada, Takahisa; Yonaga, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10584-10600</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysfunction of glutamatergic neurotransmission has been implicated in the pathogenesis of epilepsy and numerous other neurol. diseases.  Here the authors describe the discovery of a series of 1,3,5-triaryl-1H-pyridin-2-one derivs. as noncompetitive antagonists of AMPA-type ionotropic glutamate receptors.  The structure-activity relationships for this series of compds. were investigated by manipulating individual arom. rings located at positions 1, 3, and 5 of the pyridone ring.  This culminated in the discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel), a novel, noncompetitive AMPA receptor antagonist that showed potent activity in an in vitro AMPA-induced Ca2+ influx assay (IC50 = 60 nM) and in an in vivo AMPA-induced seizure model (min. ED of 2 mg/kg po).  Perampanel is currently in regulatory submission for partial-onset seizures assocd. with epilepsy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlLIreWFyx27Vg90H21EOLACvtfcHk0lgTD8CLKRWmTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslalu7%252FJ&md5=713a950868f1e68001db5cb4d824d533</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm301268u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301268u%26sid%3Dliteratum%253Aachs%26aulast%3DHibi%26aufirst%3DS.%26aulast%3DUeno%26aufirst%3DK.%26aulast%3DNagato%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DK.%26aulast%3DNorimine%26aufirst%3DY.%26aulast%3DTakenaka%26aufirst%3DO.%26aulast%3DHanada%26aufirst%3DT.%26aulast%3DYonaga%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25202-%25282-Oxo-1-phenyl-5-pyridin-2-yl-1%252C2-dihydropyridin-3-yl%2529benzonitrile%2520%2528Perampanel%2529%253A%2520A%2520Novel%252C%2520Noncompetitive%2520%25CE%25B1-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic%2520Acid%2520%2528AMPA%2529%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10584%26epage%3D10600%26doi%3D10.1021%2Fjm301268u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, O. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Achmatowicz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zigterman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colyer, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiVirgilio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crockett, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correll, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagapudi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranganathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allgeier, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, R. D.</span></span> <span> </span><span class="NLM_article-title">Development of a Practical Synthesis of a Pyrazolopyridinone-Based p38 MAP Kinase Inhibitor</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1021/op100205s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op100205s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=31-43&author=R.+R.+Milburnauthor=O.+R.+Thielauthor=M.+Achmatowiczauthor=X.+Wangauthor=J.+Zigtermanauthor=C.+Bernardauthor=J.+T.+Colyerauthor=E.+DiVirgilioauthor=R.+Crockettauthor=T.+L.+Correllauthor=K.+Nagapudiauthor=K.+Ranganathanauthor=S.+J.+Hedleyauthor=A.+Allgeierauthor=R.+D.+Larsen&title=Development+of+a+Practical+Synthesis+of+a+Pyrazolopyridinone-Based+p38+MAP+Kinase+Inhibitor&doi=10.1021%2Fop100205s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Practical Synthesis of a Pyrazolopyridinone-Based p38 MAP Kinase Inhibitor</span></div><div class="casAuthors">Milburn, Robert R.; Thiel, Oliver R.; Achmatowicz, Michal; Wang, Xiang; Zigterman, Jamie; Bernard, Charles; Colyer, John T.; DiVirgilio, Evan; Crockett, Rich; Correll, Tiffany L.; Nagapudi, Karthik; Ranganathan, Kumar; Hedley, Simon J.; Allgeier, Alan; Larsen, Robert D.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-43</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A practical synthesis of the pyrazolopyridinone-based p38 MAP kinase inhibitor (4) was required for an ongoing program.  The synthesis of a key pyrazolopyridinone building block was refined and optimized to provide kilogram quantities of 10 without chromatog. or extractive workups.  An efficient building-block strategy was employed to give optimal control of the key quality attributes, and in situ Raman spectroscopy was used to monitor and understand the complex solid-state properties of 4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXwjN3D-xMsLVg90H21EOLACvtfcHk0li5cB5v52iysw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksLzN&md5=59655e7b4a7b34767fe9736ee1abe137</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fop100205s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop100205s%26sid%3Dliteratum%253Aachs%26aulast%3DMilburn%26aufirst%3DR.%2BR.%26aulast%3DThiel%26aufirst%3DO.%2BR.%26aulast%3DAchmatowicz%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZigterman%26aufirst%3DJ.%26aulast%3DBernard%26aufirst%3DC.%26aulast%3DColyer%26aufirst%3DJ.%2BT.%26aulast%3DDiVirgilio%26aufirst%3DE.%26aulast%3DCrockett%26aufirst%3DR.%26aulast%3DCorrell%26aufirst%3DT.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DRanganathan%26aufirst%3DK.%26aulast%3DHedley%26aufirst%3DS.%2BJ.%26aulast%3DAllgeier%26aufirst%3DA.%26aulast%3DLarsen%26aufirst%3DR.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520Practical%2520Synthesis%2520of%2520a%2520Pyrazolopyridinone-Based%2520p38%2520MAP%2520Kinase%2520Inhibitor%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2011%26volume%3D15%26spage%3D31%26epage%3D43%26doi%3D10.1021%2Fop100205s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cogan, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Enantiomerically Pure N-tert-Butanesulfinyl Imines (tert-Butanesulfinimines) by the Direct Condensation of tert-Butanesulfinamide with Aldehydes and Ketones</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">1278</span>– <span class="NLM_lpage">1284</span>, <span class="refDoi"> DOI: 10.1021/jo982059i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo982059i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADyaK1MXns1SisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=1278-1284&author=G.+Liuauthor=D.+A.+Coganauthor=T.+D.+Owensauthor=T.+P.+Tangauthor=J.+A.+Ellman&title=Synthesis+of+Enantiomerically+Pure+N-tert-Butanesulfinyl+Imines+%28tert-Butanesulfinimines%29+by+the+Direct+Condensation+of+tert-Butanesulfinamide+with+Aldehydes+and+Ketones&doi=10.1021%2Fjo982059i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Enantiomerically Pure N-tert-Butanesulfinyl Imines (tert-Butanesulfinimines) by the Direct Condensation of tert-Butanesulfinamide with Aldehydes and Ketones</span></div><div class="casAuthors">Liu, Guangcheng; Cogan, Derek A.; Owens, Timothy D.; Tang, Tony P.; Ellman, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1278-1284</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Exptl. details for the first general methods for the one-step prepn. of N-tert-butanesulfinyl imines (tert-butanesulfinimines) from aldehydes and ketones is described.  To effect the condensations of tert-butanesulfinamide with aldehydes, the Lewis acidic dehydrating agents MgSO4, CuSO4, or Ti(OEt)4 are employed.  Aldehyde condensations mediated by MgSO4 proceed in high yields (84-96%) when an excess of aldehyde is used.  In contrast, only a slight excess of aldehyde (1.1 equiv) relative to tert-butanesulfinamide provides sulfinimines in high yields when the more Lewis acidic dehydrating agent CuSO4 is used.  The CuSO4-mediated procedure is effective for a wide range of aldehydes, including sterically demanding aldehydes, such as isobutyraldehyde (90%), and electron-rich aldehydes, such as p-anisaldehyde (81%).  The still more Lewis acidic Ti(OEt)4 and Ti(O-i-Pr)4 also afford N-tert-butanesulfinyl aldimines from esp. unreactive aldehydes, such as pivaldehyde (82%).  In addn., Ti(OEt)4 is effective for the condensation of tert-butanesulfinamide with ketones to afford a wide range of N-tert-butanesulfinyl ketimines in good yields (77-91%).  For sulfinyl ketimines derived from Me or n-alkyl Ph ketones and Me or n-alkyl iso-Pr ketones, only the E isomer is detected by 1H and 13C NMR in CDCl3.  For those cases where the difference in steric demand about the imine is very small, such as for 2-hexanone, high E/Z ratios are still obsd. (5:1).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0W1xhdv6lw7Vg90H21EOLACvtfcHk0li5cB5v52iysw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXns1SisQ%253D%253D&md5=7085bf46cbe5336791da58653679aa33</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjo982059i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo982059i%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DCogan%26aufirst%3DD.%2BA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DTang%26aufirst%3DT.%2BP.%26aulast%3DEllman%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520of%2520Enantiomerically%2520Pure%2520N-tert-Butanesulfinyl%2520Imines%2520%2528tert-Butanesulfinimines%2529%2520by%2520the%2520Direct%2520Condensation%2520of%2520tert-Butanesulfinamide%2520with%2520Aldehydes%2520and%2520Ketones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1999%26volume%3D64%26spage%3D1278%26epage%3D1284%26doi%3D10.1021%2Fjo982059i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colyer, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tedrow, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soukup, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faul, M. M.</span></span> <span> </span><span class="NLM_article-title">Reversal of Diastereofacial Selectivity in Hydride Reductions of N-tert-Butanesulfinyl Imines</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">6859</span>– <span class="NLM_lpage">6862</span>, <span class="refDoi"> DOI: 10.1021/jo0609834</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0609834" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvFOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=6859-6862&author=J.+T.+Colyerauthor=N.+G.+Andersenauthor=J.+S.+Tedrowauthor=T.+S.+Soukupauthor=M.+M.+Faul&title=Reversal+of+Diastereofacial+Selectivity+in+Hydride+Reductions+of+N-tert-Butanesulfinyl+Imines&doi=10.1021%2Fjo0609834"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of Diastereofacial Selectivity in Hydride Reductions of N-tert-Butanesulfinyl Imines</span></div><div class="casAuthors">Colyer, John T.; Andersen, Neil G.; Tedrow, Jason S.; Soukup, Troy S.; Faul, Margaret M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6859-6862</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A variety of N-tert-butanesulfinylimines were reduced with NaBH4 in THF contg. 2% water to provide the secondary sulfinamides in high yield and diastereoselectivity.  By using the same sulfinylimine starting materials and changing the reductant to L-Selectride, the stereoselectivity could be efficiently reversed to afford the opposite product diastereomer in high yield and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMmvwxbtaEErVg90H21EOLACvtfcHk0lipunz_s0fHYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvFOnsr0%253D&md5=d8014c6087c6389243020efe55f1f753</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjo0609834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0609834%26sid%3Dliteratum%253Aachs%26aulast%3DColyer%26aufirst%3DJ.%2BT.%26aulast%3DAndersen%26aufirst%3DN.%2BG.%26aulast%3DTedrow%26aufirst%3DJ.%2BS.%26aulast%3DSoukup%26aufirst%3DT.%2BS.%26aulast%3DFaul%26aufirst%3DM.%2BM.%26atitle%3DReversal%2520of%2520Diastereofacial%2520Selectivity%2520in%2520Hydride%2520Reductions%2520of%2520N-tert-Butanesulfinyl%2520Imines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26spage%3D6859%26epage%3D6862%26doi%3D10.1021%2Fjo0609834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0','PDB','4XE0'); return false;">PDB: 4XE0</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i172"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01264">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_80676"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01264?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01264</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Analytical data; methods and conditions for separation of enantiomers (compounds <b>4–9</b>) by preparative chiral HPLC and comprehensive kinase profile of compound <b>34</b> (Table S2) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" href="#tbl1">Table <a class="ref showTableEvent internalNav" href="#tbl1">1</a></a>) that are the subject of this publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_003.csv">CSV</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" href="#tbl2">Table <a class="ref showTableEvent internalNav" href="#tbl2">2</a></a>) that are the subject of this publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_004.csv">CSV</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" href="#tbl3">Table <a class="ref showTableEvent internalNav" href="#tbl3">3</a></a>) that are the subject of this publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_005.csv">CSV</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" href="#tbl4">Table <a class="ref showTableEvent internalNav" href="#tbl4">4</a></a>) that are the subject of this publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_006.csv">CSV</a>)</p></li><li><p class="inline">SMILES strings for the compounds (<a class="ref showTableEvent internalNav" href="#tbl5">Table <a class="ref showTableEvent internalNav" href="#tbl5">5</a></a>) that are the subject of this publication (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_007.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_001.pdf">jm0c01264_si_001.pdf (7.73 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_003.csv">jm0c01264_si_003.csv (1.42 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_004.csv">jm0c01264_si_004.csv (1.67 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_005.csv">jm0c01264_si_005.csv (1.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_006.csv">jm0c01264_si_006.csv (1.29 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01264/suppl_file/jm0c01264_si_007.csv">jm0c01264_si_007.csv (0.72 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01264&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01264%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01264" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c072ee393d4e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
